The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALECENSA	NNP	O
is	VBZ	O
600	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
with	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

(	(	O
9	CD	O
)	)	O
Patient	NNP	O
alarm	NN	O
device	NN	O
:	:	O
An	DT	O
alarm	NN	O
device	NN	O
within	IN	O
the	DT	O
UVA	NNP	O
irradiator	NN	O
chamber	NN	O
should	MD	O
be	VB	O
accessible	JJ	O
to	TO	O
the	DT	O
patient	NN	O
for	IN	O
emergency	NN	O
activation	NN	O
.	.	O

100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
10	CD	I-DUR
days	NNS	O-DUR
.	.	O

Limit	NNP	O
the	DT	O
use	NN	O
of	IN	O
ABSTRAL	NNP	O
to	TO	O
treat	VB	O
four	CD	O
or	CC	O
fewer	JJR	O
episodes	NNS	O
of	IN	O
breakthrough	NN	O
pain	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

Each	DT	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
mixed	JJ	O
under	IN	O
sterile	JJ	O
conditions	NNS	O
with	IN	O
832	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
Dextrose	NNP	O
70	CD	O
%	NN	O
will	MD	O
provide	VB	O
a	DT	O
solution	NN	O
of	IN	O
1.95	CD	O
%	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
in	IN	O
44	CD	O
%	NN	O
dextrose	NN	O
.	.	O

Clinical	JJ	O
trial	NN	O
and	CC	O
postmarketing	VBG	O
experience	NN	O
suggest	VBP	O
that	IN	O
debilitated	JJ	B-WHO
patients	NNS	I-WHO
or	CC	I-WHO
patients	NNS	I-WHO
taking	VBG	I-WHO
additional	JJ	I-WHO
medications	NNS	I-WHO
that	WDT	I-WHO
decrease	VBP	I-WHO
gastrointestinal	JJ	I-WHO
motility	NN	O-WHO
may	MD	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
serious	JJ	O
complications	NNS	O
of	IN	O
constipation	NN	O
.	.	O

If	IN	O
you	PRP	O
stop	VBP	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
,	,	O
continue	VBP	O
with	IN	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
program	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACCOLATE	NNP	O
in	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

In	IN	O
adults	NNS	B-WHO
,	,	O
hypertonic	JJ	O
mixtures	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	VB	O
may	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
by	IN	O
continuous	JJ	O
infusion	NN	O
through	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
with	IN	O
the	DT	O
tip	NN	O
located	VBN	O
in	IN	O
the	DT	O
vena	NN	O
cava	NN	O
.	.	O

Once	RB	O
a	DT	O
stable	JJ	O
dose	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
monitor	VB	O
trough	IN	O
concentrations	NNS	O
every	DT	B-FREQ
3	CD	O-FREQ
to	TO	O
6	CD	B-FREQ
months	NNS	O-FREQ
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
changing	VBG	I-WHO
body	NN	I-WHO
surface	JJ	I-WHO
area	NN	O-WHO
or	CC	O
every	DT	B-FREQ
6	CD	O-FREQ
to	TO	O
12	CD	B-FREQ
months	NNS	O-FREQ
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
stable	JJ	I-WHO
body	NN	I-WHO
surface	JJ	I-WHO
area	NN	O-WHO
for	IN	O
the	DT	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

More	JJR	O
than	IN	O
two	CD	B-DOS
5	CD	O-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
of	IN	O
amiloride	JJ	O
HCl	NNP	O
daily	RB	B-FREQ
usually	RB	O
are	VBP	O
not	RB	O
needed	VBN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
little	JJ	O
controlled	JJ	O
experience	NN	O
with	IN	O
such	JJ	O
doses	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AROMASIN	NNP	O
in	IN	O
early	JJ	O
and	CC	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
is	VBZ	O
one	CD	B-DOS
25	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
once	IN	B-FREQ
daily	JJ	O-FREQ
after	IN	O
a	DT	O
meal	NN	O
.	.	O

See	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
:	:	O
1	CD	O
)	)	O
by	IN	O
incremental	JJ	O
injection	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
adjunct	NN	O
to	TO	O
anesthesia	VB	O
with	IN	O
barbiturate	JJ	O
/	NNS	O
nitrous	JJ	O
oxide	IN	O
/	NNP	O
oxygen	NN	O
for	IN	O
short	JJ	O
surgical	JJ	O
procedures	NNS	O
(	(	O
expected	VBN	O
duration	NN	O
of	IN	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
by	IN	O
continuous	JJ	O
infusion	NN	O
as	IN	O
a	DT	O
maintenance	NN	O
analgesic	JJ	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NNP	O
oxygen	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
in	IN	O
anesthetic	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
with	IN	O
a	DT	O
minimum	NN	O
expected	VBN	O
duration	NN	O
of	IN	O
45	CD	O
minutes	NNS	O
;	:	O
and	CC	O
4	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
as	IN	O
the	DT	O
analgesic	JJ	O
component	NN	O
for	IN	O
monitored	JJ	O
anesthesia	NN	O
care	NN	O
(	(	O
MAC	NNP	O
)	)	O
.	.	O

NIASPAN	NNP	O
must	MD	O
be	VB	O
titrated	VBN	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	B-DOS
mg	JJ	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2000	CD	B-DOS
mg	NN	B-UNIT
a	DT	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ADDYI	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

Administer	NNP	O
intravenously	RB	O
25	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
within	IN	O
5	CD	O
minutes	NNS	O
and	CC	O
then	RB	O
0.15	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	FW	O
(	(	O
or	CC	O
0.075	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
≤60	NNP	I-WHO
mL	NN	O-WHO
/	NNP	O
min	NN	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
18	CD	O
hours	NNS	O
.	.	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
<	VBP	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
weighing	VBG	I-WHO
≥	$	I-WHO
70	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	B-DOS
mCi	NN	B-UNIT
(	(	O
370	CD	B-DOS
MBq	NNP	B-UNIT
)	)	O
[	VBD	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Such	JJ	O
infusates	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
dilutions	NNS	O
of	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
prepare	VB	O
isotonic	JJ	O
or	CC	O
slightly	RB	O
hypertonic	JJ	O
solutions	NNS	O
for	IN	O
peripheral	JJ	O
infusion	NN	O
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
gram	NN	B-UNIT
of	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
will	MD	O
meet	VB	O
the	DT	O
requirements	NNS	O
of	IN	O
the	DT	O
majority	NN	O
of	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
,	,	O
up	RB	O
to	TO	O
4.4	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Example	NN	O
:	:	O
UPAH	NNP	O
=	VBZ	O
8.0	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
mL	NN	O

The	DT	O
dose	NN	O
of	IN	O
ADCETRIS	NNP	O
should	MD	O
be	VB	O
held	VBN	O
for	IN	O
Grade	NNP	O
3	CD	O
or	CC	O
4	CD	O
neutropenia	NN	O
until	IN	O
resolution	NN	O
to	TO	O
baseline	VB	O
or	CC	O
Grade	VB	O
2	CD	O
or	CC	O
lower	JJR	O
.	.	O

When	WRB	O
improvement	NN	O
is	VBZ	O
noted	VBN	O
,	,	O
dosage	NN	O
should	MD	O
be	VB	O
gradually	RB	O
reduced	VBN	O
to	TO	O
maintenance	NN	O
levels	NNS	O
ranging	VBG	O
from	IN	O
125	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
500	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

Once	RB	O
an	DT	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
established	VBN	O
,	,	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
conveniently	RB	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
bedtime	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

Patients	NNS	B-WHO
requiring	VBG	I-WHO
reductions	NNS	I-WHO
in	IN	I-WHO
LDL	NNP	I-WHO
cholesterol	NN	O-WHO
of	IN	O
20	CD	O
%	NN	O
or	CC	O
more	JJR	O
to	TO	O
achieve	VB	O
their	PRP$	O
goal	NN	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
)	)	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
of	IN	O
lovastatin	NN	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	B-DOS
,	,	O
0.5	CD	B-DOS
and	CC	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
PRESTALIA	NNP	O
is	VBZ	O
3.5	CD	B-DOS
/	JJ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
in	IN	O
elderly	JJ	B-WHO
patients	NNS	I-WHO
(	(	I-WHO
age	NN	I-WHO
≥	VBZ	I-WHO
65	CD	I-WHO
years	NNS	I-WHO
)	)	O-WHO
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
CARDURA	NNP	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
either	CC	O
in	IN	O
the	DT	O
morning	NN	O
or	CC	O
evening	NN	O
.	.	O

Congestive	JJ	O
Heart	NNP	O
Failure	NN	O
:	:	O
For	IN	O
diuresis	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
usually	RB	O
250	CD	B-DOS
to	TO	O
375	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
(	(	O
5	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
)	)	O
.	.	O

Thereafter	RB	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
over	IN	O
the	DT	O
next	JJ	O
several	JJ	B-DUR
weeks	NNS	O-DUR
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
250	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

Using	VBG	O
the	DT	O
transfer	NN	O
device	NN	O
provided	VBD	O
,	,	O
reconstitute	NN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
accompanying	VBG	O
100	CD	B-DOS
mL	JJ	B-UNIT
vial	NN	O-UNIT
of	IN	O
SWFI	NNP	O
to	TO	O
the	DT	O
100	CD	B-DOS
mg	JJ	B-UNIT
vial	NN	O-UNIT
of	IN	O
Activase	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
(	(	O
37.5	CD	B-DOS
mg	NN	B-UNIT
)	)	O
daily	RB	B-FREQ
,	,	O
as	IN	O
prescribed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
,	,	O
administered	VBN	O
before	IN	O
breakfast	NN	O
or	CC	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
.	.	O

A	DT	O
syringe	NN	O
,	,	O
filled	VBN	O
with	IN	O
fluorescein	NN	O
,	,	O
is	VBZ	O
attached	VBN	O
to	TO	O
transparent	VB	O
tubing	NN	O
and	CC	O
a	DT	O
25	CD	O
gauge	NN	O
scalp	NN	O
vein	NN	O
needle	NN	O
for	IN	O
injection	NN	O
.	.	O

Aseptically	RB	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
by	IN	O
injecting	VBG	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
mild	JJ	I-WHO
to	TO	I-WHO
moderate	VB	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
and	CC	O
a	DT	O
1	CD	B-DOS
-	:	O
mg	NN	B-UNIT
starting	VBG	O
dose	NN	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Mitchell2	NNP	O
has	VBZ	O
shown	VBN	O
that	IN	O
particles	VBZ	O
less	JJR	O
than	IN	O
10	CD	O
microns	NNS	O
should	MD	O
be	VB	O
retained	VBN	O
in	IN	O
the	DT	O
respiratory	NN	O
tract	JJ	O
satisfactorily	RB	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
and	CC	O
electrolytes	VBZ	O
needed	VBN	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	B-FREQ
losses	NNS	O
.	.	O

When	WRB	O
acetaZOLAMIDE	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
anticonvulsants	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
250	CD	B-DOS
mg	JJ	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
existing	VBG	O
medications	NNS	O
.	.	O

Using	VBG	O
a	DT	O
new	JJ	O
needle	NN	O
and	CC	O
syringe	NN	O
,	,	O
withdraw	JJ	O
0.5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
reconstituted	JJ	O
vaccine	NN	O
and	CC	O
administer	NN	O
intramuscularly	RB	O
.	.	O

The	DT	O
dose	JJ	O
increase	NN	O
increment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
0.5	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
any	DT	O
one	CD	B-DUR
week	NN	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
troche	NN	B-UNIT
five	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
fourteen	JJ	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
ALDACTONE	NNP	O
25	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
if	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
potassium	NN	O
is	VBZ	O
≤	JJ	O
5	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
≤	JJ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TRADJENTA	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Avoid	IN	O
the	DT	O
use	NN	O
of	IN	O
concomitant	NN	O
strong	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
,	,	O
clarithromycin	NN	O
,	,	O
atazanavir	NN	O
,	,	O
nefazodone	NN	O
,	,	O
saquinavir	NN	O
,	,	O
telithromycin	NN	O
,	,	O
ritonavir	NN	O
,	,	O
indinavir	NN	O
,	,	O
nelfinavir	RB	O
,	,	O
voriconazole	NN	O
)	)	O
in	IN	O
patients	NNS	B-WHO
receiving	VBG	I-WHO
AFINITOR	NNP	I-WHO
Tablets	NNPS	O-WHO
or	CC	O
AFINITOR	NNP	O
DISPERZ	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

A	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
no	DT	O
greater	JJR	O
than	IN	O
6	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
mL	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

To	TO	O
ensure	VB	O
the	DT	O
precise	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
small	JJ	O
volumes	NNS	O
of	IN	O
fluid	NN	O
necessary	JJ	O
for	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
in	IN	O
infants	NNS	B-WHO
,	,	O
accurately	RB	O
calibrated	VBN	O
and	CC	O
reliable	JJ	O
infusion	NN	O
systems	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

When	WRB	O
high	JJ	O
dose	NN	O
therapy	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
A	NNP	O
-	:	O
Methapred	NNP	O
(	(	O
methylprednisolone	CD	O
sodium	NN	O
succinate	NN	O
)	)	O
sterile	NN	O
powder	NN	O
is	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
.	.	O

ALDACTONE	NNP	O
in	IN	O
a	DT	O
dosage	NN	O
ranging	VBG	O
from	IN	O
25	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
is	VBZ	O
useful	JJ	O
in	IN	O
treating	VBG	O
a	DT	O
diuretic	JJ	O
-	:	O
induced	JJ	O
hypokalemia	NN	O
,	,	O
when	WRB	O
oral	JJ	O
potassium	NN	O
supplements	NNS	O
or	CC	O
other	JJ	O
potassium	NN	O
-	:	O
sparing	NN	O
regimens	NNS	O
are	VBP	O
considered	VBN	O
inappropriate	JJ	O
.	.	O

Narcolepsy	NNP	O
seldom	NN	O
occurs	VBZ	O
in	IN	O
children	NNS	B-WHO
under	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
;	:	O
however	RB	O
,	,	O
when	WRB	O
it	PRP	O
does	VBZ	O
,	,	O
dextroamphetamine	VB	O
sulfate	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
total	JJ	O
radiation	NN	O
exposure	NN	O
from	IN	O
Amyvid	NNP	O
administration	NN	O
and	CC	O
subsequent	JJ	O
scan	NN	O
on	IN	O
a	DT	O
PET	NNP	O
/	NNP	O
CT	NNP	O
scanner	NN	O
is	VBZ	O
estimated	VBN	O
to	TO	O
be	VB	O
9	CD	O
mSv	NN	O
.	.	O

The	DT	O
maximum	JJ	O
daily	JJ	B-FREQ
dose	NN	O
is	VBZ	O
63	CD	B-DOS
mg	NN	B-UNIT
(	(	O
four	CD	B-DOS
doses	NNS	B-UNIT
)	)	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	FW	O
hydrochloride	NN	O
)	)	O
should	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
titrated	VBN	O
to	TO	O
the	DT	O
desired	JJ	O
effect	NN	O
in	IN	O
each	DT	O
patient	NN	O
according	VBG	O
to	TO	O
body	NN	O
weight	NN	O
,	,	O
physical	JJ	O
status	NN	O
,	,	O
underlying	VBG	O
pathological	JJ	O
condition	NN	O
,	,	O
use	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
and	CC	O
type	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgical	JJ	O
procedure	NN	O
and	CC	O
anesthesia	NN	O
.	.	O

Consider	VB	O
titrating	VBG	O
to	TO	O
dosages	VB	O
higher	JJR	O
than	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
if	IN	O
tolerated	VBN	O
,	,	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
smoke	VBP	O-WHO
.	.	O

The	DT	O
suggested	VBN	O
intravenous	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
(	(	O
10	CD	B-DOS
mL	NN	B-UNIT
)	)	O
for	IN	O
every	DT	O
12.5	CD	B-DOS
g	NN	B-UNIT
(	(	O
179	CD	B-DOS
mL	NN	B-UNIT
)	)	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
7	CD	O
%	NN	O
administered	VBN	O
(	(	O
see	VB	O
package	NN	O
insert	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
tolerated	VBN	I-WHO
AGRYLIN	NNP	O-WHO
therapy	NN	O
for	IN	O
one	CD	B-DUR
week	NN	O-DUR
may	MD	O
have	VB	O
their	PRP$	O
dose	NN	O
increased	VBN	O
.	.	O

After	IN	O
reconstitution	NN	O
with	IN	O
saline	JJ	O
diluent	NN	O
(	(	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
)	)	O
,	,	O
ActHIB	NNP	O
vaccine	NN	O
should	MD	O
be	VB	O
administered	VBN	O
promptly	RB	O
or	CC	O
stored	VBN	O
refrigerated	VBN	O
between	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
35°	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
administered	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AMARYL	NNP	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
2	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	B-DOS
mM	NN	B-UNIT
.	.	O

Heart	NNP	O
Failure	NNP	O
Post	NNP	O
Myocardial	NNP	O
Infarction	NN	O
:	:	O
For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
heart	NN	I-WHO
failure	NN	I-WHO
and	CC	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	B-DOS
mg	NN	B-UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

It	PRP	O
should	MD	O
not	RB	O
be	VB	O
less	JJR	O
than	IN	O
0.5	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
kg	NN	O
every	DT	B-FREQ
24	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

In	IN	O
both	DT	B-WHO
adults	NNS	I-WHO
and	CC	I-WHO
children	NNS	O-WHO
,	,	O
the	DT	O
daily	JJ	B-FREQ
dose	NN	O
can	MD	O
be	VB	O
given	VBN	O
as	IN	O
single	JJ	B-DOS
infusion	NN	B-UNIT
or	CC	O
in	IN	O
equally	RB	O
divided	JJ	O
infusions	NNS	O
at	IN	O
6	CD	O
-	:	O
,	,	O
8	CD	O
-	:	O
,	,	O
or	CC	O
12	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
at	IN	O
the	DT	O
recommended	JJ	O
final	JJ	O
concentration	NN	O
of	IN	O
not	RB	O
greater	JJR	O
than	IN	O
6	CD	B-DOS
mg	JJ	B-UNIT
/	NN	O
mL	NN	O
(	(	O
see	VB	O
Preparation	NNP	O
of	IN	O
Solution	NNP	O
)	)	O
.	.	O

Stability	NN	O
in	IN	O
IV	NNP	O
Fluids	NNP	O
:	:	O
Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	B-DUR
hours	NNS	O-DUR
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5.0	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

Patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
score	NN	I-WHO
ranging	VBG	I-WHO
from	IN	I-WHO
5	CD	I-WHO
to	TO	I-WHO
8	CD	O-WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
of	IN	O
450	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
and	CC	O
patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
score	NN	I-WHO
ranging	VBG	I-WHO
from	IN	I-WHO
9	CD	I-WHO
to	TO	I-WHO
12	CD	O-WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
of	IN	O
300	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Hepatic	JJ	O
Insufficiency	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
,	,	I-WHO
children	NNS	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
infants	NNS	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
divided	VBD	O
into	IN	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
equal	JJ	B-UNIT
doses	NNS	O-UNIT
administered	VBN	O
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
,	,	O
i.e	NN	O
,	,	O
7.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
q12h	NN	O
or	CC	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
q8h	NN	O
.	.	O

One	CD	B-DOS
drop	NN	B-UNIT
instilled	VBD	O
into	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	PRP	O
)	)	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Table	JJ	O
2	CD	O
:	:	O
3	CD	O
-	:	O
hour	NN	O
Infusion	NNP	O
Weight	NNP	O
-	:	O
Based	VBD	O
Doses	NNS	O
for	IN	O
Patients	NNS	B-WHO
with	IN	I-WHO
AMI	NNP	O-WHO

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Amyvid	NNP	O
is	VBZ	O
370	CD	B-DOS
MBq	NNP	B-UNIT
(	(	O
10	CD	B-DOS
mCi	NN	B-UNIT
)	)	O
,	,	O
maximum	JJ	O
50	CD	O
μg	JJ	O
mass	NN	O
dose	NN	O
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
bolus	NN	O-UNIT
in	IN	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
10	CD	B-DOS
mL	NN	B-UNIT
or	CC	O
less	JJR	O
.	.	O

Combination	NNP	O
therapy	NN	O
with	IN	O
NIASPAN	NNP	O
and	CC	O
lovastatin	NN	O
should	MD	O
not	RB	O
exceed	VB	O
doses	NNS	O
of	IN	O
2000	CD	B-DOS
mg	NN	B-UNIT
and	CC	O
40	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
,	,	O
respectively	RB	O
.	.	O

For	IN	O
recurrence	NN	O
of	IN	O
severe	JJ	O
neutropenia	NN	O
or	CC	O
severe	JJ	O
sensory	NN	O
neuropathy	NN	O
,	,	O
additional	JJ	O
dose	NN	O
reduction	NN	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
180	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²	NN	O
.	.	O

If	IN	O
the	DT	O
migraine	NN	O
returns	NNS	O
or	CC	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
only	RB	O
partial	JJ	O
response	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
repeated	VBN	O
once	RB	O
after	IN	O
4	CD	O
hours	NNS	O
,	,	O
for	IN	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
in	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
.	.	O

AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
and	CC	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
on	IN	O
a	DT	O
milligram	JJ	O
-	:	O
per	IN	O
-	:	O
milligram	JJ	O
basis	NN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

Continuous	JJ	O
maintenance	NN	O
therapy	NN	O
with	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
is	VBZ	O
instituted	VBN	O
when	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
4000	CD	O
cells	NNS	O
/	JJ	O
mcL	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
100000	CD	O
cells	NNS	O
/	JJ	O
mcL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

An	DT	O
initial	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
100	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
ALDACTONE	NNP	O
administered	VBD	O
in	IN	O
either	DT	O
single	JJ	B-DOS
or	CC	O
divided	JJ	B-UNIT
doses	NNS	O-UNIT
is	VBZ	O
recommended	VBN	O
,	,	O
but	CC	O
may	MD	O
range	VB	O
from	IN	O
25	CD	B-DOS
to	TO	O
200	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
0.05	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
or	CC	O
less	JJR	O
and	CC	O
is	VBZ	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
blood	NN	O
count	NN	O
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitor	NN	O
,	,	O
reduce	VB	O
the	DT	O
AFINITOR	NNP	O
dose	NN	O
to	TO	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bleeding	NN	O
syndromes	NNS	O
due	JJ	O
to	TO	O
elevated	JJ	O
fibrinolytic	JJ	O
activity	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
5	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNPS	O-UNIT
or	CC	O
10	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNP	O-UNIT
(	(	O
5	CD	B-DOS
g	NN	B-UNIT
)	)	O
or	CC	O
20	CD	B-DOS
milliliter	NN	B-UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
5	CD	B-DOS
g	NN	B-UNIT
)	)	O
be	VB	O
administered	VBN	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuing	VBG	O
rate	NN	O
of	IN	O
1	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	B-DOS
mg	JJ	B-UNIT
Tablet	NNP	O-UNIT
or	CC	O
2	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNP	O-UNIT
(	(	O
1	CD	B-DOS
g	NN	B-UNIT
)	)	O
or	CC	O
5	CD	B-DOS
milliliter	NN	B-UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
1.25	CD	B-DOS
g	NN	B-UNIT
)	)	O
per	IN	O
hour	NN	O
.	.	O

The	DT	O
suggested	VBN	O
intravenous	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
(	(	O
10	CD	B-DOS
mL	NN	B-UNIT
)	)	O
for	IN	O
every	DT	O
12.5	CD	B-DOS
g	NN	B-UNIT
(	(	O
125	CD	B-DOS
mL	NN	B-UNIT
)	)	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
10	CD	O
%	NN	O
administered	VBN	O
(	(	O
see	VB	O
package	NN	O
insert	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
.	.	O

The	DT	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
dose	VB	O
was	VBD	O
not	RB	O
shown	VBN	O
to	TO	O
be	VB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
the	DT	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
dose	VB	O
.	.	O

To	TO	O
facilitate	VB	O
delivery	NN	O
to	TO	O
the	DT	O
stomach	NN	O
,	,	O
Actonel	NNP	O
should	MD	O
be	VB	O
swallowed	VBN	O
while	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
in	IN	O
an	DT	O
upright	JJ	O
position	NN	O
and	CC	O
with	IN	O
a	DT	O
full	JJ	O
glass	NN	O
of	IN	O
plain	JJ	O
water	NN	O
(	(	O
6	CD	B-DOS
to	TO	O
8	CD	B-DOS
oz	NN	B-UNIT
)	)	O
.	.	O

In	IN	O
depleted	VBN	B-WHO
and	CC	I-WHO
severely	RB	I-WHO
traumatized	JJ	I-WHO
patients	NNS	I-WHO
such	JJ	I-WHO
as	IN	I-WHO
burned	JJ	I-WHO
patients	NNS	I-WHO
or	CC	I-WHO
patients	NNS	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
received	VBN	I-WHO
major	JJ	I-WHO
surgery	NN	I-WHO
with	IN	I-WHO
complications	NNS	O-WHO
,	,	O
the	DT	O
requirements	NNS	O
for	IN	O
nutrients	NNS	O
and	CC	O
fluids	NNS	O
may	MD	O
be	VB	O
significantly	RB	O
higher	JJR	O
.	.	O

Onset	NNP	O
of	IN	O
significant	JJ	O
relief	NN	O
of	IN	O
nasal	NN	O
symptoms	NNS	O
was	VBD	O
seen	VBN	O
within	IN	O
two	CD	B-DUR
days	NNS	O-DUR
after	IN	O
starting	VBG	O
treatment	NN	O
at	IN	O
400	CD	B-DOS
mcg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Reconstituted	VBN	O
ABRAXANE	NNP	O
in	IN	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
refrigerated	VBN	O
at	IN	O
2°C	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°F	CD	O
to	TO	O
46°F	CD	O
)	)	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
24	CD	O
hours	NNS	O
if	IN	O
necessary	JJ	O
.	.	O

Dose	JJ	O
adjustments	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
should	MD	O
occur	VB	O
gradually	RB	O
,	,	O
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	B-DUR
week	NN	O-DUR
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

The	DT	O
dosage	NN	O
to	TO	O
be	VB	O
administered	VBN	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
(	(	O
1	CD	B-DOS
mcg	NN	B-UNIT
corticorelin	NN	O
/	NNP	O
kg	NN	O
)	)	O
.	.	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
lyophilized	VBN	O
material	NN	O
are	VBP	O
to	TO	O
be	VB	O
stored	VBN	O
at	IN	O
temperatures	NNS	O
up	RB	O
to	TO	O
25°	CD	O
C	NNP	O
(	(	O
77°	CD	O
F	NNP	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
pregnancy	NN	O
increases	NNS	O
with	IN	O
each	DT	O
active	JJ	O
(	(	O
pink	NN	O
)	)	O
tablet	NN	O
missed	VBN	O
.	.	O

After	IN	O
reaching	VBG	O
a	DT	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
2	CD	B-DOS
mg	NN	B-UNIT
,	,	O
further	RB	O
dose	JJ	O
increases	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
or	CC	O
2	CD	B-DOS
mg	NNS	B-UNIT
based	VBN	O
upon	IN	O
the	DT	O
patient	NN	O
's	POS	O
glycemic	JJ	O
response	NN	O
.	.	O

Such	JJ	O
a	DT	O
solution	NN	O
given	VBN	O
at	IN	O
the	DT	O
rate	NN	O
of	IN	O
145	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	JJ	B-FREQ
day	NN	O-FREQ
provides	VBZ	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

As	IN	O
an	DT	O
alternate	NN	O
single	JJ	O
visit	NN	O
dose	NN	O
,	,	O
administer	RB	O
300	CD	B-DOS
mg	NN	B-UNIT
stat	NN	O
followed	VBD	O
in	IN	O
one	CD	O
hour	NN	O
by	IN	O
a	DT	O
second	JJ	O
300	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

For	IN	O
adults	NNS	B-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosages	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
hypotension	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	B-DOS
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
.	.	O

Start	NNP	O
all	DT	B-WHO
patients	NNS	O-WHO
with	IN	O
a	DT	O
single	JJ	B-DOS
100	CD	O-DOS
mcg	JJ	B-UNIT
tablet	NN	O-UNIT
.	.	O

Calculate	VB	O
the	DT	O
exact	JJ	O
total	JJ	O
dosing	NN	O
volume	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	JJ	O
suspension	NN	O
required	VBN	O
for	IN	O
the	DT	O
patient	NN	O
and	CC	O
slowly	RB	O
withdraw	VB	O
the	DT	O
dosing	NN	O
volume	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
suspension	NN	O
from	IN	O
the	DT	O
vial	NN	O
(	(	O
s	NN	O
)	)	O
into	IN	O
a	DT	O
syringe	NN	O
:	:	O
Dosing	NN	O
volume	NN	O
(	(	O
mL	NN	O
)	)	O
=Total	NN	O
dose	NN	O
(	(	O
mg	NN	B-UNIT
)	)	O
/	VBZ	O
5	CD	B-DOS
(	(	O
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
asthma	NNS	I-WHO
aged	VBN	I-WHO
4	CD	I-WHO
to	TO	I-WHO
11	CD	I-WHO
years	NNS	I-WHO
who	WP	I-WHO
are	VBP	I-WHO
not	RB	I-WHO
controlled	VBN	I-WHO
on	IN	I-WHO
an	DT	I-WHO
inhaled	JJ	I-WHO
corticosteroid	NN	O-WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
inhalation	NN	B-UNIT
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
100	CD	O
/	VBD	O
50	CD	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postoperative	JJ	O
inflammation	NN	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
have	VBP	I-WHO
undergone	VBN	I-WHO
cataract	JJ	I-WHO
extraction	NN	O-WHO
,	,	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
ACULAR®	NNP	O
ophthalmic	JJ	O
solution	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
cataract	NN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
class	NN	I-WHO
C	NNP	I-WHO
)	)	I-WHO
or	CC	I-WHO
requiring	VBG	I-WHO
moderate	JJ	I-WHO
CYP3A4	NNP	I-WHO
/	NNP	I-WHO
PgP	NNP	I-WHO
inhibitors	NNS	O-WHO
is	VBZ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
[	NNP	O
see	VBP	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypoproteinemia	NN	O
,	,	O
200	CD	B-DOS
to	TO	O
300	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
reduce	VB	O
edema	NN	O
and	CC	O
to	TO	O
bring	VB	O
serum	JJ	O
protein	NN	O
values	NNS	O
to	TO	O
normal	JJ	O
.	.	O

To	TO	O
administer	VB	O
1.25	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
0.63	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
albuterol	NN	O
,	,	O
use	VBP	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
one	CD	B-DOS
unit	NN	B-UNIT
-	:	O
dose	JJ	O
vial	JJ	O
(	(	O
3	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
or	CC	O
0.63	CD	B-DOS
mg	JJ	B-UNIT
inhalation	NN	O
solution	NN	O
)	)	O
by	IN	O
nebulization	NN	O
.	.	O

If	IN	O
the	DT	O
dose	NN	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	B-DOS
vial	NN	B-UNIT
,	,	O
use	VB	O
a	DT	O
separate	JJ	O
,	,	O
unused	JJ	O
Mix2Vial®	NNP	O
transfer	NN	O
set	NN	O
for	IN	O
each	DT	O
product	NN	O
vial	NN	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
keep	VB	O
the	DT	O
wick	NN	O
in	IN	O
for	IN	O
at	IN	B-DUR
least	JJS	I-DUR
24	CD	I-DUR
hours	NNS	O-DUR
and	CC	O
to	TO	O
keep	VB	O
it	PRP	O
moist	JJ	O
by	IN	O
adding	VBG	O
3	CD	B-DOS
to	TO	O
5	CD	B-DOS
drops	NNS	B-UNIT
of	IN	O
Acetic	NNP	O
Acid	NNP	O
Otic	NNP	O
Solution	NNP	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

Patients	NNS	O
must	MD	O
also	RB	O
receive	VB	O
one	CD	B-DOS
(	(	O
1	CD	B-DOS
)	)	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
vitamin	JJ	O
B12	NNP	O
during	IN	O
the	DT	O
week	NN	B-DUR
preceding	VBG	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
and	CC	O
every	DT	O
3	CD	O
cycles	NNS	O
thereafter	RB	O
.	.	O

Depending	VBG	O
upon	IN	O
tolerance	NN	O
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
week	NN	B-DUR
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
80	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Oral	JJ	O
:	:	O
One	CD	B-DOS
tablet	NN	B-UNIT
one	CD	B-FREQ
to	TO	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTIMMUNE	NNP	O
administered	VBD	O
subcutaneously	RB	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
CGD	NNP	I-WHO
and	CC	I-WHO
SMO	NNP	O-WHO
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
:	:	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
interdigital	JJ	O
tinea	NN	O
pedis	NN	O
,	,	O
ERTACZO	NNP	O
cream	NN	O
,	,	O
2	CD	O
%	NN	O
,	,	O
should	MD	O
be	VB	O
applied	VBN	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
for	IN	O
4	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

Patients	NNS	O
receiving	VBG	O
30	CD	B-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
should	MD	O
receive	VB	O
25	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
the	DT	O
solution	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

0	CD	B-DOS
-	:	O
0.03PPM	CD	B-DOS

The	DT	O
rate	NN	O
of	IN	O
IV	NNP	O
injection	NN	O
for	IN	O
adults	NNS	B-WHO
should	MD	O
not	RB	O
exceed	VB	O
50	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
min	NN	O
to	TO	O
prevent	VB	O
sleep	NN	O
or	CC	O
sudden	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
induction	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
0.3	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
,	,	O
injected	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
to	TO	O
60	CD	O
seconds	NNS	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
underlying	JJ	I-WHO
cardiac	NNS	I-WHO
or	CC	I-WHO
respiratory	JJ	I-WHO
compromise	NN	I-WHO
and	CC	I-WHO
weighing	VBG	I-WHO
up	RB	I-WHO
to	TO	I-WHO
30	CD	I-WHO
kg	NNS	O-WHO
,	,	O
physicians	NNS	O
may	MD	O
consider	VB	O
diluting	VBG	O
ALDURAZYME	NNP	O
in	IN	O
a	DT	O
volume	NN	O
of	IN	O
100	CD	B-DOS
mL	NNS	B-UNIT
and	CC	O
administering	VBG	O
at	IN	O
a	DT	O
decreased	JJ	O
infusion	NN	O
rate	NN	O
[	NNP	O
see	VBP	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
below	IN	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Addition	NN	O
of	IN	O
iron	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	B-WHO
infant	NN	O-WHO
than	IN	O
the	DT	B-WHO
adult	NN	O-WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
for	IN	O
the	DT	O
growing	VBG	O
infant	NN	O
.	.	O

Bottles	NNS	O
of	IN	O
60	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
158	CD	O
-	:	O
60	CD	O
Bottles	NNS	O
of	IN	O
180	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
158	CD	O
-	:	O
18	CD	O

For	IN	O
patients	NNS	B-WHO
aged	VBN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

0.1	CD	B-DOS
to	TO	O
0.2	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
(	(	O
0.045	CD	B-DOS
to	TO	O
0.09	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
pound	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
initiate	VB	O
dosing	VBG	O
24	CD	O
to	TO	O
28	CD	O
hours	NNS	O
before	IN	O
ascent	NN	O
and	CC	O
to	TO	O
continue	VB	O
for	IN	O
48	CD	B-DUR
hours	NNS	O-DUR
while	IN	O
at	IN	O
high	JJ	O
altitude	NN	O
,	,	O
or	CC	O
longer	RB	O
as	IN	O
necessary	JJ	O
to	TO	O
control	VB	O
symptoms	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
without	IN	I-WHO
congestive	JJ	I-WHO
heart	NN	I-WHO
failure	NN	O-WHO
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
30	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	B-DOS
to	TO	O
15	CD	B-DOS
mM	NNS	B-UNIT
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderately	RB	I-WHO
impaired	JJ	I-WHO
hepatic	JJ	I-WHO
function	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
Class	NNP	I-WHO
B	NNP	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
16	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hyperchloremic	JJ	I-WHO
or	CC	I-WHO
other	JJ	I-WHO
metabolic	JJ	I-WHO
acidoses	NNS	O-WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
precursor	NN	O
.	.	O

The	DT	O
patient	NN	O
may	MD	O
be	VB	O
kept	VBN	O
on	IN	O
his	PRP$	O
schedule	NN	O
until	IN	O
again	RB	O
95	CD	O
percent	NN	O
clear	JJ	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
ADVATE	NN	O
Dosing	VBG	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O
in	IN	O
Adults	NNP	B-WHO
and	CC	I-WHO
Children	NNP	O-WHO

For	IN	O
adults	NNS	B-WHO
,	,	O
an	DT	O
initial	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
50	CD	B-DOS
to	TO	O
100	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
ALDACTONE	NNP	O
administered	VBD	O
in	IN	O
either	DT	O
single	JJ	B-DOS
or	CC	O
divided	JJ	B-UNIT
doses	NNS	O-UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
have	VBP	I-WHO
not	RB	I-WHO
had	VBN	I-WHO
adequate	JJ	I-WHO
control	NN	O-WHO
of	IN	O
IBS	NNP	O
symptoms	NNS	O
after	IN	O
4	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
treatment	NN	O
with	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
are	VBP	O
at	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
propylene	NN	O
glycol	NN	O
-	:	O
associated	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

In	IN	O
some	DT	O
acute	JJ	O
cases	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
more	JJR	O
satisfactory	JJ	O
to	TO	O
administer	VB	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
500	CD	B-DOS
mg	NN	B-UNIT
followed	VBN	O
by	IN	O
125	CD	B-DOS
or	CC	O
250	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
.	.	O

ACCOLATE	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatitis	NN	O-WHO
or	CC	O
in	IN	O
long	JJ	O
-	:	O
term	NN	O
studies	NNS	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
cirrhosis	NN	O-WHO
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
2	CD	B-DOS
g	NNS	B-UNIT
in	IN	O
two	CD	B-DOS
to	TO	O
four	CD	B-DOS
doses	NNS	B-UNIT
.	.	O

Since	IN	O
such	JJ	O
patients	NNS	O
usually	RB	O
have	VBP	O
approximately	RB	O
normal	JJ	O
blood	NN	O
volume	NN	O
,	,	O
doses	NNS	O
of	IN	O
more	JJR	O
than	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
faster	JJR	O
than	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
in	IN	O
30	CD	O
to	TO	O
45	CD	O
minutes	NNS	O
to	TO	O
avoid	VB	O
circulatory	JJ	O
embarrassment	NN	O
.	.	O

Acute	NNP	O
epididymo	SYM	O
-	:	O
orchitis	NN	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
10	CD	I-DUR
days	NNS	O-DUR
.	.	O

To	TO	O
measure	VB	O
ERPF	NNP	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
PAH	NNP	O
in	IN	O
the	DT	O
plasma	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
at	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
,	,	O
which	WDT	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
a	DT	O
priming	VBG	O
dose	NN	O
of	IN	O
6	CD	B-DOS
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
and	CC	O
an	DT	O
infusion	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
to	TO	O
24	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
min	NN	O
.	.	O

The	DT	O
drug	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
infusion	NN	B-UNIT
over	IN	O
15	CD	O
to	TO	O
20	CD	O
minutes	NNS	O
.	.	O

Acute	NNP	O
epididymo	SYM	O
-	:	O
orchitis	NN	O
caused	VBN	O
by	IN	O
N.	NNP	O
gonorrhoeae	NN	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
10	CD	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
cisplatin	NN	O
is	VBZ	O
75	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
infused	VBD	O
over	IN	O
2	CD	O
hours	NNS	O
beginning	VBG	O
approximately	RB	O
30	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
ALIMTA	NNP	O
administration	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
applicatorful	NN	B-UNIT
,	,	O
administered	VBN	O
intravaginally	RB	O
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
8.5	CD	O
%	NN	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
with	IN	O
electrolytes	NNS	O
)	)	O
WITH	NNP	O
ELECTROLYTES	NNP	O
is	VBZ	O
designed	VBN	O
to	TO	O
supply	VB	O
necessary	JJ	O
electrolytes	NNS	O
to	TO	O
patients	NNS	B-WHO
in	IN	I-WHO
a	DT	I-WHO
stable	JJ	I-WHO
metabolic	JJ	I-WHO
state	NN	O-WHO
(	(	O
about	IN	O
three	CD	O
-	:	O
fourths	NNS	O
of	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
on	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
)	)	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
respond	VB	I-WHO
adequately	RB	O-WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
4	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
doses	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

Apply	NNP	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
,	,	O
for	IN	O
3	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
,	,	O
then	RB	O
withhold	VBD	O
use	NN	O
for	IN	O
4	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

A	DT	O
separate	JJ	O
sterile	JJ	O
syringe	NN	O
and	CC	O
needle	JJ	O
must	MD	O
be	VB	O
used	VBN	O
for	IN	O
each	DT	O
injection	NN	O
to	TO	O
prevent	VB	O
transmission	NN	O
of	IN	O
infectious	JJ	O
agents	NNS	O
from	IN	O
one	CD	O
person	NN	O
to	TO	O
another	DT	O
.	.	O

Patients	NNS	O
should	MD	O
discontinue	VB	O
therapy	NN	O
if	IN	O
Grade	NNP	O
3	CD	O
or	CC	O
4	CD	O
neurotoxicity	NN	O
is	VBZ	O
experienced	VBN	O
.	.	O

(	(	O
2	CD	O
)	)	O
Protective	NNP	O
shielding	NN	O
of	IN	O
lamps	NNS	O
:	:	O
The	DT	O
patient	NN	O
should	MD	O
not	RB	O
be	VB	O
able	JJ	O
to	TO	O
come	VB	O
in	IN	O
contact	NN	O
with	IN	O
the	DT	O
bare	NN	O
lamps	VBZ	O
.	.	O

For	IN	O
smaller	JJR	B-WHO
patients	NNS	I-WHO
(	(	I-WHO
<	JJ	I-WHO
65	CD	I-WHO
kg	NN	I-WHO
)	)	O-WHO
,	,	O
a	DT	O
dose	NN	O
of	IN	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NNS	O
administered	VBN	O
over	IN	O
3	CD	O
hours	NNS	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

However	RB	O
,	,	O
older	JJR	B-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
of	IN	O
AKYNZEO	NNP	O
approximately	RB	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
with	IN	O
dexamethasone	NN	O
12	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
chemotherapy	VB	O
on	IN	O
day	NN	O
1	CD	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	B-DOS
g	NNS	B-UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

Withdraw	JJ	O
0.6	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
or	CC	O
Tripedia	NNP	O
vaccine	NN	O
as	IN	O
indicated	JJ	O
.	.	O

If	IN	O
potential	JJ	O
allergy	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
an	DT	O
intradermal	JJ	O
skin	JJ	O
test	NN	O
may	MD	O
be	VB	O
performed	VBN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
,	,	O
i.e	FW	O
,	,	O
0.05	CD	B-DOS
mL	NN	B-UNIT
injection	NN	O-UNIT
intradermally	RB	O
to	TO	O
be	VB	O
evaluated	VBN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
following	VBG	O
injection	NN	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
400	CD	B-DOS
mcg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
may	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	B-WHO
when	WRB	I-WHO
starting	VBG	I-WHO
therapy	NN	I-WHO
with	IN	I-WHO
AllerNaze	NNP	O-WHO
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
in	IN	O
cases	NNS	O
where	WRB	O
a	DT	O
faster	RBR	O
onset	NN	O
of	IN	O
relief	NN	O
is	VBZ	O
desirable	JJ	O
.	.	O

Apply	NNP	O
and	CC	O
gently	RB	O
massage	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
FINACEA	NNP	O
Gel	NNP	O
into	IN	O
the	DT	O
affected	JJ	O
areas	NNS	O
on	IN	O
the	DT	O
face	NN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
.	.	O

Figure	NN	O
1	CD	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
is	VBZ	O
2.5	CD	B-DOS
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

AVITA®	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
.	.	O

Alternatively	RB	O
,	,	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
D30	NNP	O
or	CC	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
D50	NNP	O
once	RB	B-FREQ
daily	JJ	O-FREQ
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Dosage	NN	O
is	VBZ	O
adjusted	VBN	O
to	TO	O
between	IN	O
1	CD	B-DOS
and	CC	O
3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
depending	VBG	O
upon	IN	O
the	DT	O
hematological	JJ	O
response	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
8	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

A	DT	O
dose	NN	O
of	IN	O
one	CD	B-DOS
tablet	NN	B-UNIT
once	IN	B-FREQ
daily	JJ	O-FREQ
is	VBZ	O
recommended	VBN	O
as	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
decreased	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
VPRIV	NNP	O
dosage	NN	O
in	IN	O
naïve	JJ	B-WHO
adults	NNS	I-WHO
and	CC	I-WHO
naïve	JJ	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
4	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
60	CD	B-DOS
Units	NNS	B-UNIT
/	VBP	O
kg	NN	O
administered	VBN	O
every	DT	B-FREQ
other	JJ	I-FREQ
week	NN	O-FREQ
as	IN	O
a	DT	O
60	CD	B-DOS
-	:	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

Syncope	NN	O
in	IN	O
older	JJR	B-WHO
patients	NNS	O-WHO
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
an	DT	O
increased	VBN	O
sensitivity	NN	O
and	CC	O
advanced	VBD	O
arteriosclerotic	JJ	O
vascular	JJ	O
disease	NN	O
.	.	O

If	IN	O
such	JJ	O
circumstances	NNS	O
are	VBP	O
suspected	VBN	O
to	TO	O
be	VB	O
present	JJ	O
,	,	O
initiate	JJ	O
dosing	NN	O
at	IN	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

After	IN	O
the	DT	O
first	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
injection	NN	O
,	,	O
administer	RB	O
oral	JJ	O
aripiprazole	NN	O
(	(	O
10	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
)	)	O
for	IN	O
14	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
to	TO	O
achieve	VB	O
therapeutic	JJ	O
aripiprazole	JJ	O
concentrations	NNS	O
during	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
200	CD	B-DOS
mg	NN	B-UNIT
and	CC	O
160	CD	B-DOS
mg	NN	B-UNIT
dosage	NN	O
adjustments	NNS	O
are	VBP	O
obtained	VBN	O
only	RB	O
by	IN	O
using	VBG	O
the	DT	O
300	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
400	CD	B-DOS
mg	JJ	B-UNIT
strength	NN	O
vials	NNS	O
.	.	O

PEGANONE	NNP	O
(	(	O
ethotoin	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
administered	VBN	O
orally	RB	O
in	IN	O
4	CD	B-DOS
to	TO	O
6	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
daily	RB	B-FREQ
.	.	O

100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
7	CD	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	B-DOS
mg	NN	B-UNIT
vial	NN	O-UNIT
to	TO	O
100	CD	B-DOS
or	CC	O
200	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
other	JJ	O
compatible	JJ	O
solution	NN	O
.	.	O

ALDACTONE	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
400	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
three	CD	B-DUR
to	TO	O
four	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
250	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
used	VBD	O
dose	JJ	O
schedule	NN	O
when	WRB	O
used	VBN	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
is	VBZ	O
60	CD	B-DOS
to	TO	O
75	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m2	NN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
injection	NN	O-UNIT
administered	VBD	O
at	IN	O
21	CD	O
-	:	O
day	NN	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AFINITOR	NNP	O
Tablets	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
,	,	O
to	TO	O
be	VB	O
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	B-FREQ
day	NN	O-FREQ
.	.	O

In	IN	O
those	DT	O
patients	NNS	B-WHO
with	IN	I-WHO
an	DT	I-WHO
intact	JJ	I-WHO
uterus	NN	I-WHO
who	WP	I-WHO
are	VBP	I-WHO
not	RB	I-WHO
using	VBG	I-WHO
concomitant	JJ	I-WHO
progestin	NN	I-WHO
therapy	NN	O-WHO
,	,	O
Alora	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
on	IN	O
a	DT	O
cyclic	JJ	O
schedule	NN	O
(	(	O
e.g	NN	O
,	,	O
3	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
followed	VBN	O
by	IN	O
1	CD	B-DUR
week	NN	O-DUR
without	IN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	NN	O
symptoms	NNS	O
.	.	O

Figure	NN	O
9	CD	O

For	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
,	,	O
half	JJ	B-DOS
tablet	NN	B-UNIT
(	(	O
18.75	CD	B-DOS
mg	NN	B-UNIT
)	)	O
daily	NN	B-FREQ
may	MD	O
be	VB	O
adequate	JJ	O
,	,	O
while	IN	O
in	IN	O
some	DT	O
cases	NNS	O
it	PRP	O
may	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
give	VB	O
half	NN	B-DOS
tablets	NNS	B-UNIT
(	(	O
18.75	CD	B-DOS
mg	NN	B-UNIT
)	)	O
two	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
effective	JJ	O
dose	NN	O
is	VBZ	O
1	CD	B-DOS
-	:	O
2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
but	CC	O
higher	JJR	O
doses	NNS	O
may	MD	O
be	VB	O
required	VBN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	B-WHO
or	CC	I-WHO
debilitated	JJ	I-WHO
patients	NNS	O-WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
2	CD	B-DUR
months	NNS	O-DUR
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
require	VBP	I-WHO
treatment	NN	I-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
CYP3A4	NNP	O-WHO
/	NNP	O
PgP	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
amprenavir	NN	O
,	,	O
fosamprenavir	NN	O
,	,	O
aprepitant	NN	O
,	,	O
erythromycin	NN	O
,	,	O
fluconazole	NN	O
,	,	O
verapamil	NN	O
,	,	O
diltiazem	NN	O
)	)	O
:	:	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	B-DOS
to	TO	O
250	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	B-DOS
mL	NN	B-UNIT
,	,	O
administered	VBN	O
from	IN	O
bottles	NNS	O
containing	VBG	O
250	CD	B-DOS
or	CC	O
500	CD	B-DOS
mL	NN	B-UNIT
.	.	O

(	(	O
Use	NNP	O
only	RB	O
one	CD	B-DOS
filter	NN	B-UNIT
per	IN	O
vial	NN	O
of	IN	O
AmBisome	NNP	O
.	.	O
)	)	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	B-DOS
mg	NN	B-UNIT
vial	NN	O-UNIT
to	TO	O
100	CD	B-DOS
or	CC	O
200	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
of	IN	O
the	DT	O
compatible	JJ	O
solutions	NNS	O
listed	VBN	O
below	IN	O
.	.	O

AEROSPAN	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
in	IN	O
asthmatic	JJ	B-WHO
patients	NNS	I-WHO
aged	VBN	I-WHO
6	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
.	.	O

ABSTRAL	NNP	O
is	VBZ	O
not	RB	O
equivalent	JJ	O
on	IN	O
a	DT	O
mcg	NN	O
per	IN	O
mcg	JJ	O
basis	NN	O
with	IN	O
all	DT	O
other	JJ	O
fentanyl	NN	O
products	NNS	O
,	,	O
therefore	RB	O
,	,	O
do	VBP	O
not	RB	O
switch	VB	O
patients	NNS	O
on	IN	O
a	DT	O
mcg	NN	O
per	IN	O
mcg	JJ	O
basis	NN	O
from	IN	O
any	DT	O
other	JJ	O
fentanyl	JJ	O
product	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	B-DUR
to	TO	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
20	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
daily	JJ	O-FREQ
before	IN	O
meals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
for	IN	O
overweight	NN	B-WHO
adults	NNS	I-WHO
18	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
1	CD	B-DOS
60	CD	O-DOS
-	:	O
mg	NN	B-UNIT
capsule	NN	O-UNIT
with	IN	O
each	DT	O
meal	NN	O
containing	VBG	O
fat	NN	O
.	.	O

Estimated	VBN	O
Increment	NNP	O
of	IN	O
Factor	NNP	O
VIII	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	B-DOS
(	(	O
IU	NNP	O
/	NNP	O
dL	NN	O
per	IN	O
IU	NNP	O
/	NNP	O
kg	NN	O
)	)	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
rheumatoid	JJ	I-WHO
arthritis	NN	O-WHO
(	(	O
RA	NNP	O
)	)	O
,	,	O
psoriatic	JJ	O
arthritis	NN	O
(	(	O
PsA	NNP	O
)	)	O
,	,	O
or	CC	O
ankylosing	VBG	O
spondylitis	NN	O
(	(	O
AS	IN	O
)	)	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
every	DT	B-FREQ
other	JJ	I-FREQ
week	NN	O-FREQ
.	.	O

Dosage	NN	O
is	VBZ	O
usually	RB	O
prescribed	VBN	O
on	IN	O
a	DT	O
g	NN	O
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
basis	NN	O
and	CC	O
patient	JJ	O
age	NN	O
as	IN	O
follows	VBZ	O
:	:	O
infants	NNS	B-WHO
,	,	O
2	CD	B-DOS
to	TO	O
3	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
1	CD	I-WHO
to	TO	I-WHO
3	CD	I-WHO
years	NNS	O-WHO
,	,	O
2	CD	B-DOS
to	TO	O
2.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
4	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	O-WHO
,	,	O
2	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
13	CD	I-WHO
to	TO	I-WHO
15	CD	I-WHO
years	NNS	O-WHO
,	,	O
1.7	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
16	CD	I-WHO
and	CC	I-WHO
above	RB	O-WHO
,	,	O
1.5	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hyperchloremic	JJ	I-WHO
or	CC	I-WHO
other	JJ	I-WHO
metabolic	JJ	I-WHO
acidosis	NN	O-WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
or	CC	O
lactate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
alternates	NNS	O
.	.	O

A	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
maintenance	NN	O
dosage	NN	O
is	VBZ	O
usually	RB	O
4	CD	B-DOS
to	TO	O
8	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

Storage	NN	O
:	:	O
Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
BLOCADREN	NNP	O
(	(	O
timolol	NN	O
)	)	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
.	.	O

Image	NN	O
reconstruction	NN	O
should	MD	O
include	VB	O
attenuation	NN	O
correction	NN	O
with	IN	O
resulting	VBG	O
transaxial	JJ	O
pixel	NN	O
sizes	NNS	O
between	IN	O
2	CD	O
and	CC	O
3	CD	O
mm	NN	O
.	.	O

Given	VBN	O
the	DT	O
possibility	NN	O
of	IN	O
extravasation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
closely	RB	O
monitor	VB	O
the	DT	O
infusion	NN	O
site	NN	O
for	IN	O
possible	JJ	O
infiltration	NN	O
during	IN	O
drug	NN	O
administration	NN	O
.	.	O

Children	NNS	B-WHO
:	:	O
weighing	VBG	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
100	CD	I-WHO
pounds	NNS	I-WHO
(	(	I-WHO
45	CD	I-WHO
kg	NN	I-WHO
)	)	O-WHO
:	:	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
lb	NN	O
(	(	O
2.2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
.	.	O

Examples	NNS	O
of	IN	O
cartridge	NN	O
combinations	NNS	O
for	IN	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
24	CD	B-DOS
units	NNS	B-UNIT
are	VBP	O
shown	VBN	O
in	IN	O
Figure	NNP	O
1	CD	O
.	.	O

If	IN	O
immediate	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
possible	JJ	O
,	,	O
the	DT	O
diluted	JJ	O
solution	NN	O
should	MD	O
be	VB	O
stored	VBN	O
refrigerated	VBN	O
at	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
for	IN	O
up	IN	O
to	TO	O
36	CD	O
hours	NNS	O
.	.	O

Use	NNP	O
of	IN	O
NIASPAN	NNP	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	O-WHO
or	CC	O
hepatic	JJ	O
insufficiency	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

A	DT	O
patient	NN	B-WHO
who	WP	I-WHO
becomes	VBZ	I-WHO
hypotensive	VBP	I-WHO
at	IN	I-WHO
this	DT	I-WHO
dose	NN	O-WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
and	CC	O
after	IN	O
one	CD	B-DUR
week	NN	O-DUR
at	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
then	RB	O
be	VB	O
titrated	VBN	O
(	(	O
if	IN	O
tolerated	VBN	O
)	)	O
toward	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
with	IN	O
dosage	NN	O
increases	NNS	O
being	VBG	O
about	IN	O
3	CD	B-DUR
weeks	NNS	O-DUR
apart	RB	O
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	B-WHO
-	:	O
a	DT	O
single	JJ	B-DOS
0.075	CD	O-DOS
mg	NN	B-UNIT
intravenous	JJ	I-UNIT
dose	NN	O-UNIT
administered	VBD	O
over	IN	O
10	CD	O
seconds	NNS	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
recommended	VBD	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
should	MD	O
be	VB	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
15,000	CD	B-DOS
mg	NNS	B-UNIT
infused	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
one	CD	O
hour	NN	O
followed	VBN	O
by	IN	O
a	DT	O
first	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
5,000	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
4	CD	O
hours	NNS	O
and	CC	O
a	DT	O
second	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
10,000	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
16	CD	O
hours	NNS	O
(	(	O
See	VB	O
Table	NNP	O
3	CD	O
)	)	O
.	.	O

Administer	RB	O
ABLAVAR	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injection	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
0.03	CD	B-DOS
mmol	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
up	IN	O
to	TO	O
30	CD	O
seconds	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
25	CD	B-DOS
-	:	O
30	CD	B-DOS
mL	NN	B-UNIT
normal	JJ	O
saline	JJ	O
flush	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
1.25	CD	B-DOS
mg	NN	B-UNIT
b.i.d	NN	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	B-DOS
mg	JJ	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
Hepatic	JJ	I-WHO
Impairment	NN	O-WHO
:	:	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
failure	NN	O-WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
strong	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inducer	NN	O
,	,	O
consider	VB	O
doubling	VBG	O
the	DT	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
AFINITOR	NNP	O
using	VBG	O
increments	NNS	O
of	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
less	JJR	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	B-DOS
-	:	O
60	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
single	JJ	B-DOS
doses	NNS	B-UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Doses	NNS	O
of	IN	O
ADVICOR	NNP	O
greater	JJR	O
than	IN	O
2000	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
40	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

AMEVIVE®	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
the	DT	O
counts	NNS	O
remain	VBP	O
below	IN	O
250	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
µL	NNP	O
for	IN	O
one	CD	B-DUR
month	NN	O-DUR
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

With	IN	O
one	CD	O
hand	NN	O
,	,	O
grasp	VBP	O
the	DT	O
AFSTYLA	NNP	O
side	NN	O
of	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
and	CC	O
with	IN	O
the	DT	O
other	JJ	O
hand	NN	O
grasp	VBD	O
the	DT	O
blue	JJ	O
diluent	NN	O
-	:	O
side	NN	O
of	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
,	,	O
and	CC	O
unscrew	VBD	O
the	DT	O
set	VBN	O
into	IN	O
two	CD	O
pieces	NNS	O
.	.	O

100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

Aldara	NNP	O
Cream	NNP	O
is	VBZ	O
packaged	VBN	O
in	IN	O
single	JJ	B-DOS
-	:	O
use	NN	O
packets	NNS	O
,	,	O
with	IN	O
12	CD	B-DOS
packets	NNS	B-UNIT
supplied	VBN	O
per	IN	O
box	NN	O
.	.	O

A	DT	O
single	JJ	B-DOS
vaccine	NN	B-UNIT
dose	NN	O-UNIT
is	VBZ	O
administered	VBN	O
orally	RB	O
as	IN	O
two	CD	B-DOS
tablets	NNS	B-UNIT
:	:	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
4	CD	O
and	CC	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
7	CD	O
.	.	O

Titration	NN	O
Steps	NNS	O
:	:	O
If	IN	O
adequate	JJ	O
analgesia	NN	O
was	VBD	O
not	RB	O
obtained	VBN	O
with	IN	O
the	DT	O
first	JJ	O
100	CD	B-DOS
mcg	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
continue	VBP	O
dose	JJ	O
escalation	NN	O
in	IN	O
a	DT	O
stepwise	NN	O
manner	NN	O
over	IN	O
consecutive	JJ	O
breakthrough	NN	O
episodes	NNS	O
until	IN	O
adequate	JJ	O
analgesia	NNS	O
with	IN	O
tolerable	JJ	O
side	NN	O
effects	NNS	O
is	VBZ	O
achieved	VBN	O
.	.	O

Following	VBG	O
an	DT	O
anesthetic	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
-	:	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
maintenance	NN	O
.	.	O

Regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ACCURETIC	NNP	O
need	MD	O
not	RB	O
take	VB	O
account	NN	O
of	IN	O
renal	JJ	O
function	NN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
>	JJ	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	B-DOS
m²	NN	B-UNIT
(	(	O
serum	JJ	O
creatinine	NN	O
roughly	RB	O
≤	$	O
3	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
or	CC	O
265	CD	B-DOS
μmol	JJ	B-UNIT
/	NNP	O
L	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CHOLBAM	NNP	O
is	VBZ	O
10	CD	B-DOS
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NNS	O
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
or	CC	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
,	,	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
and	CC	I-WHO
in	IN	I-WHO
adults	NNS	O-WHO
.	.	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1.0	CD	B-DOS
Joule	NNP	B-UNIT
/	NNP	O
cm²	NN	B-UNIT
at	IN	O
each	DT	O
treatment	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

0.140	CD	B-DOS
(	(	O
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
)	)	O
x	FW	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
/	FW	O
Adenoscan	JJ	O
concentration	NN	O
(	(	O
3mg	CD	B-DOS
/	NNP	O
mL	NN	O
)	)	O
=	VBZ	O
Infusion	NNP	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
min	NN	O
)	)	O

Each	DT	O
vial	NN	O
of	IN	O
ALDURAZYME	NNP	O
provides	VBZ	O
2.9	CD	B-DOS
milligrams	NNS	B-UNIT
(	(	O
mg	NN	B-UNIT
)	)	O
of	IN	O
laronidase	NN	O
in	IN	O
5.0	CD	B-DOS
milliliters	NNS	B-UNIT
(	(	O
mL	NN	O
)	)	O
of	IN	O
solution	NN	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
begin	VB	O
a	DT	O
new	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
unless	IN	O
the	DT	O
ANC	NNP	O
is	VBZ	O
≥	JJ	O
1500	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm³	NN	O
,	,	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
>	JJ	O
100,000	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm³	NN	O
,	,	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
≥	JJ	O
45	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
1,200	CD	B-DOS
mg	NN	B-UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	B-DOS
50	CD	O-DOS
-	:	O
mg	NN	B-UNIT
capsules	NNS	O-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Osserman	NNP	O
and	CC	O
Takatsuki	NNP	O
have	VBP	O
used	VBN	O
an	DT	O
initial	JJ	O
course	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
to	TO	O
10	CD	B-DUR
days	NNS	O-DUR
.	.	O

This	DT	O
process	NN	O
should	MD	O
continue	VB	O
until	IN	O
sinus	JJ	O
rhythm	NN	O
is	VBZ	O
established	VBN	O
or	CC	O
a	DT	O
maximum	JJ	O
single	JJ	B-DOS
dose	NN	B-UNIT
of	IN	O
0.3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
is	VBZ	O
used	VBN	O
.	.	O

Direct	JJ	O
Instillation	NN	O
:	:	O
When	WRB	O
used	VBN	O
by	IN	O
direct	JJ	O
instillation	NN	O
,	,	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
a	DT	O
10	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
as	RB	O
often	RB	O
as	IN	O
every	DT	B-FREQ
hour	NN	O-FREQ
.	.	O

An	DT	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
activity	NN	I-WHO
who	WP	I-WHO
is	VBZ	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	O-WHO
,	,	O
requires	VBZ	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
used	VBD	O
dose	NN	O
of	IN	O
oral	JJ	O
folic	JJ	O
acid	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
was	VBD	O
400	CD	B-DOS
mcg	JJ	B-UNIT
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
,	,	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
when	WRB	O
initiating	VBG	O
Adempas	NNP	O
in	IN	O
patients	NNS	B-WHO
receiving	VBG	I-WHO
strong	JJ	I-WHO
cytochrome	NN	I-WHO
P450	NNP	O-WHO
(	(	O
CYP	NNP	O
)	)	O
and	CC	O
P	NNP	O
-	:	O
glycoprotein	NN	O
/	JJ	O
breast	NN	O
cancer	NN	O
resistance	NN	O
protein	NN	O
(	(	O
P	NNP	O
-	:	O
gp	NN	O
/	NNP	O
BCRP	NNP	O
)	)	O
inhibitors	NNS	O
such	JJ	O
as	IN	O
azole	JJ	O
antimycotics	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
)	)	O
or	CC	O
HIV	NNP	O
protease	NN	O
inhibitors	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ritonavir	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
for	IN	O
adult	NN	B-WHO
schizophrenic	JJ	I-WHO
patients	NNS	O-WHO
is	VBZ	O
50	CD	B-DOS
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
with	IN	O
a	DT	O
gradual	JJ	O
increment	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
800	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
if	IN	O
necessary	JJ	O
.	.	O

No	DT	O
data	NN	O
are	VBP	O
available	JJ	O
on	IN	O
more	JJR	O
than	IN	O
1	CD	O
course	NN	O
of	IN	O
retreatment	NN	O
.	.	O

Adacel	NNP	O
vaccine	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
intramuscular	JJ	O
injection	NN	O
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INVEGA®	NNP	O
(	(	O
paliperidone	NN	O
)	)	O
Extended	VBD	O
-	:	O
Release	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

If	IN	O
a	DT	O
tent	NN	O
or	CC	O
Croupette	NNP	O
must	MD	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
the	DT	O
volume	NN	O
of	IN	O
acetylcysteine	NN	O
(	(	O
using	VBG	O
10	CD	O
or	CC	O
20	CD	O
%	NN	O
)	)	O
that	WDT	O
will	MD	O
maintain	VB	O
a	DT	O
very	RB	O
heavy	JJ	O
mist	NN	O
in	IN	O
the	DT	O
tent	NN	O
or	CC	O
Croupette	NNP	O
for	IN	O
the	DT	O
desired	JJ	O
period	NN	O
.	.	O

IU	NNP	O
/	NNP	O
dL	NN	O
(	(	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	B-DOS
[	NNP	O
IU	NNP	O
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	VBD	O
]	NN	O

Rapidly	RB	O
make	VB	O
15	CD	O
jabs	NN	O
of	IN	O
the	DT	O
needle	JJ	O
perpendicular	NN	O
to	TO	O
the	DT	O
skin	NN	O
through	IN	O
the	DT	O
vaccine	NN	O
droplet	NN	O
to	TO	O
puncture	VB	O
the	DT	O
skin	NN	O
,	,	O
within	IN	O
a	DT	O
diameter	NN	O
of	IN	O
about	IN	O
5	CD	O
mm	NNS	O
.	.	O

While	IN	O
Recommended	VBN	O
Dietary	NNP	O
Allowances	NNPS	O
for	IN	O
oral	JJ	O
protein	NNS	O
are	VBP	O
approximately	RB	O
0.8	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
for	IN	O
the	DT	O
healthy	JJ	B-WHO
adult	NN	O-WHO
,	,	O
protein	NN	O
and	CC	O
caloric	JJ	O
requirements	NNS	O
in	IN	O
traumatized	JJ	B-WHO
or	CC	I-WHO
maInourished	JJ	I-WHO
patients	NNS	O-WHO
may	MD	O
be	VB	O
substantially	RB	O
increased	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
NAFTIN	NNP	O
Cream	NNP	O
once	RB	B-FREQ
-	:	O
daily	NN	B-FREQ
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
plus	CC	O
a	DT	O
½	JJ	O
inch	NN	O
margin	NN	O
of	IN	O
healthy	JJ	O
surrounding	VBG	O
skin	NN	O
for	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
AGRYLIN	NNP	O
is	VBZ	O
0.5	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

A	DT	O
-	:	O
Methapred	NNP	O
(	(	O
methylprednisolone	CD	O
sodium	NN	O
succinate	NN	O
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
or	CC	O
intramuscular	JJ	O
injection	NN	O
or	CC	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
,	,	O
the	DT	O
preferred	JJ	O
method	NN	O
for	IN	O
initial	JJ	O
emergency	NN	O
use	NN	O
being	VBG	O
intravenous	JJ	O
injection	NN	O
.	.	O

(	(	O
6	CD	O
)	)	O
Non	NNP	O
-	:	O
skid	NN	O
floor	NN	O
:	:	O
The	DT	O
floor	NN	O
should	MD	O
be	VB	O
of	IN	O
a	DT	O
non	JJ	O
-	:	O
skid	JJ	O
nature	NN	O
.	.	O

There	EX	O
are	VBP	O
inadequate	JJ	O
data	NNS	O
to	TO	O
make	VB	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
patients	NNS	B-WHO
below	IN	I-WHO
the	DT	I-WHO
age	NN	I-WHO
of	IN	I-WHO
ten	NN	I-WHO
(	(	I-WHO
10	CD	I-WHO
)	)	I-WHO
years	NNS	O-WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Clearance	NN	O
measurements	NNS	O
using	VBG	O
single	JJ	B-DOS
injection	NN	B-UNIT
techniques	NNS	O
are	VBP	O
generally	RB	O
inaccurate	JJ	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ERPF	NNP	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PIPRACIL	NNP	O
(	(	O
piperacillin	JJ	O
sodium	NN	O
)	)	O
for	IN	O
serious	JJ	O
infections	NNS	O
is	VBZ	O
3	CD	B-DOS
to	TO	O
4	CD	B-DOS
g	NNS	B-UNIT
given	VBN	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
a	DT	O
-	:	O
20	CD	O
to	TO	O
30	CD	O
-	:	O
minute	NN	O
infusion	NN	O
.	.	O

Recommended	VBN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
other	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
adenocarcinoma	NN	O-WHO
of	IN	O
the	DT	O
pancreas	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
.	.	O

Vials	NNS	O
of	IN	O
Accretropin™	NNP	O
(	(	O
somatropin	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
should	MD	O
be	VB	O
stored	VBN	O
in	IN	O
the	DT	O
refrigerator	NN	O
[	VBD	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
]	NN	O
.	.	O

Before	IN	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
,	,	O
administer	RB	O
Potassium	NNP	O
Iodide	NNP	O
Oral	NNP	O
Solution	NNP	O
or	CC	O
Lugol	NNP	O
's	POS	O
Solution	NNP	O
(	(	O
equivalent	JJ	O
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
iodide	RB	O
for	IN	O
adults	NNS	B-WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	B-WHO
)	)	O
or	CC	O
potassium	NN	O
perchlorate	NN	O
(	(	O
400	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
adults	NNS	B-WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	B-WHO
)	)	O
to	TO	O
block	VB	O
uptake	NN	O
of	IN	O
iodine	NN	O
123	CD	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
thyroid	NN	O
.	.	O

For	IN	O
immunocompromised	JJ	B-WHO
patients	NNS	I-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
clear	JJ	I-WHO
parasites	NNS	I-WHO
or	CC	I-WHO
who	WP	I-WHO
experience	VBP	I-WHO
relapses	NNS	O-WHO
,	,	O
expert	JJ	O
advice	NN	O
regarding	VBG	O
further	JJ	O
treatment	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
<	VBD	O-WHO
40	CD	B-DOS
ml	NN	B-UNIT
/	NNP	O
min	NN	O
/	NN	O
1.73m2	CD	O
(	(	O
serum	JJ	O
creatinine	NN	O
approximately	RB	O
>	JJ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dl	NN	O
)	)	O
doses	VBZ	O
only	RB	O
25	CD	O
%	NN	O
of	IN	O
those	DT	O
normally	NNS	O
used	VBN	O
should	MD	O
be	VB	O
expected	VBN	O
to	TO	O
induce	VB	O
full	JJ	O
therapeutic	JJ	O
levels	NNS	O
of	IN	O
ramiprilat	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
5.25	CD	B-DOS
to	TO	O
15	CD	B-DOS
mg.	NN	B-UNIT
No	NNP	O
additional	JJ	O
benefit	NN	O
was	VBD	O
demonstrated	VBN	O
for	IN	O
15	CD	B-DOS
mg	NNS	B-UNIT
compared	VBN	O
to	TO	O
9.75	CD	B-DOS
mg.	NN	B-UNIT
A	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
5.25	CD	B-DOS
mg	NN	B-UNIT
may	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
clinical	JJ	O
factors	NNS	O
warrant	VBP	O
.	.	O

Withdraw	IN	O
the	DT	O
appropriate	JJ	O
dose	NN	O
of	IN	O
ABELCET®	NNP	O
(	(	O
amphotericin	IN	O
b	NN	O
)	)	O
from	IN	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
vials	NNS	O
into	IN	O
one	CD	O
or	CC	O
more	JJR	O
sterile	JJ	O
syringes	NNS	O
using	VBG	O
an	DT	O
18	CD	O
-	:	O
gauge	NN	O
needle	NN	O
.	.	O

AmBisome	NNP	O
must	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

AMERGE	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
:	:	O
<	JJ	O
15	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
because	IN	O
of	IN	O
decreased	JJ	O
clearance	NN	O
of	IN	O
the	DT	O
drug	NN	O
[	NNP	O
see	NN	O
CONTRAINDICATIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

One	CD	B-DOS
or	CC	O
two	CD	B-DOS
drops	NNS	B-UNIT
instilled	VBD	O
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
may	MD	I-WHO
not	RB	I-WHO
tolerate	VB	I-WHO
the	DT	I-WHO
hypotensive	JJ	I-WHO
effect	NN	I-WHO
of	IN	I-WHO
Adempas	NNP	O-WHO
,	,	O
consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
AFREZZA	NNP	O
doses	VBZ	O
exceeding	VBG	O
12	CD	B-DOS
units	NNS	B-UNIT
,	,	O
inhalations	NNS	O
from	IN	O
multiple	JJ	O
cartridges	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

The	DT	O
initial	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
Sandimmune	NNP	O
(	(	O
cyclosporine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
4	CD	O
to	TO	O
12	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
transplantation	NN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
of	IN	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

Limited	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
regarding	VBG	O
the	DT	O
dosing	NN	O
requirements	NNS	O
of	IN	O
patients	NNS	B-WHO
that	WDT	I-WHO
weigh	VBP	I-WHO
more	JJR	I-WHO
than	IN	I-WHO
100	CD	I-WHO
kg	NN	O-WHO
.	.	O

If	IN	O
deficiencies	NNS	O
of	IN	O
ASS	NNP	O
or	CC	O
ASL	NNP	O
are	VBP	O
excluded	VBN	O
as	IN	O
diagnostic	JJ	O
possibilities	NNS	O
,	,	O
the	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
arginine	JJ	O
HCl	NNP	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
2	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
Arginine	NNP	O
HCl	NNP	O
Injection	NNP	O
10	CD	O
%	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
of	IN	O
ADVAIR	NNP	O
HFA	NNP	O
230	CD	O
/	VBD	O
21	CD	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
2000	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

b	NN	O
)	)	O
Rotate	NNP	O
sites	NNS	O
of	IN	O
injections	NNS	O
between	IN	O
the	DT	O
two	CD	O
deltoid	NN	O
or	CC	O
gluteal	NN	O
muscles	NNS	O
.	.	O

Inspect	VB	O
the	DT	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
vial	NN	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

For	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
3	CD	I-WHO
years	NNS	I-WHO
old	JJ	O-WHO
,	,	O
the	DT	O
volume	NN	O
of	IN	O
a	DT	O
single	JJ	O
clysis	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
200	CD	B-DOS
mL	NN	B-UNIT
;	:	O
and	CC	O
in	IN	O
premature	JJ	B-WHO
infants	NNS	O-WHO
or	CC	O
during	IN	O
the	DT	O
neonatal	JJ	O
period	NN	O
,	,	O
the	DT	O
daily	JJ	B-FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
25	CD	B-DOS
mL	JJ	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
administration	NN	O
should	MD	O
not	RB	O
be	VB	O
greater	JJR	O
than	IN	O
2	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
minute	NN	O
.	.	O

To	TO	O
satisfy	VB	O
protein	NN	O
needs	NNS	O
and	CC	O
promote	VB	O
positive	JJ	O
nitrogen	NN	O
balance	NN	O
,	,	O
the	DT	O
daily	JJ	B-FREQ
dosage	NN	O
level	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
for	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
adequate	JJ	I-WHO
caloric	NNS	I-WHO
intake	VBP	O-WHO
is	VBZ	O
approximately	RB	O
1.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	B-FREQ
dose	NN	O
ranges	VBZ	O
from	IN	O
300	CD	B-DOS
to	TO	O
600	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
,	,	O
Sulfite	NNP	O
-	:	O
Free	JJ	O
,	,	O
(	(	O
an	DT	O
amino	NN	O
acid	NN	O
injection	NN	O
—	NNP	O
renal	JJ	O
formula	NN	O
)	)	O
equivalent	NN	O
to	TO	O
2.4	CD	B-DOS
to	TO	O
4.7	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
in	IN	O
15.7	CD	B-DOS
to	TO	O
31	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
.	.	O

Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Increase	NNP	O
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
based	VBN	O
upon	IN	O
individual	JJ	O
tolerability	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Doses	NNS	O
of	IN	O
AEROSPAN	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
Note	NN	O
:	:	O
In	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
titrate	VB	O
to	TO	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
once	RB	O
asthma	JJ	O
stability	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

A	DT	O
mixture	NN	O
containing	VBG	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
HBC	$	O
7	CD	O
%	NN	O
with	IN	O
500	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
concentrated	JJ	O
dextrose	NN	O
supplemented	VBN	O
with	IN	O
electrolytes	NNS	O
,	,	O
trace	NN	O
metals	NNS	O
and	CC	O
vitamins	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
8	CD	O
hours	NNS	O
.	.	O

Although	IN	O
occasional	JJ	B-WHO
patients	NNS	O-WHO
have	VBP	O
responded	VBN	O
to	TO	O
higher	JJR	O
doses	NNS	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	B-FREQ
dosage	NN	O
is	VBZ	O
3	CD	B-DOS
g.	NN	B-UNIT
Once	NNP	O
an	DT	O
effective	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
a	DT	O
smooth	JJ	O
blood	NN	O
pressure	NN	O
response	NN	O
occurs	VBZ	O
in	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
in	IN	O
12	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
single	JJ	B-DOS
100	CD	O-DOS
-	:	O
mg	NN	B-UNIT
tablet	NN	O-UNIT
of	IN	O
TROVAN	NNP	O
and	CC	O
a	DT	O
single	JJ	B-DOS
1	CD	O-DOS
-	:	O
gram	NN	B-UNIT
(	(	O
1000	CD	B-DOS
mg	NN	B-UNIT
)	)	O
dose	NN	B-UNIT
of	IN	O
ZITHROMAX	NNP	O
for	IN	O
oral	JJ	O
suspension	NN	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
14	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	B-DOS
hrs	NNS	B-UNIT

Prepare	NNP	O
ALDURAZYME	NNP	O
using	VBG	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	NN	O
containers	NNS	O
and	CC	O
administer	NN	O
with	IN	O
a	DT	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	NN	O
infusion	NN	O
set	VBN	O
equipped	VBN	O
with	IN	O
an	DT	O
in	IN	O
-	:	O
line	NN	O
,	,	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	VBG	O
0.2	CD	B-DOS
micrometer	NN	B-UNIT
(	(	O
μm	NNP	O
)	)	O
filter	NN	O
.	.	O

ALBENZA	NNP	O
chewable	JJ	O
tablets	NNS	O
are	VBP	O
also	RB	O
available	JJ	O
for	IN	O
children	NNS	B-WHO
and	CC	I-WHO
patients	NNS	O-WHO
who	WP	O
may	MD	O
experience	VB	O
swallowing	VBG	O
difficulties	NNS	O
.	.	O

When	WRB	O
the	DT	O
drug	NN	O
is	VBZ	O
used	VBN	O
chronically	RB	O
at	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
periodically	RB	O
for	IN	O
effects	NNS	O
on	IN	O
the	DT	O
hypothalamic	JJ	O
-	:	O
pituitary	JJ	O
-	:	O
adrenal	NN	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
.	.	O

This	DT	O
12	CD	B-DOS
mg	NNS	B-UNIT
dose	NN	O-UNIT
may	MD	O
be	VB	O
repeated	VBN	O
a	DT	O
second	JJ	O
time	NN	O
if	IN	O
required	VBN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
is	VBZ	O
the	DT	O
lowest	JJS	O
dose	NN	O
that	WDT	O
produces	VBZ	O
maximal	JJ	O
cortisol	NN	O
responses	NNS	O
and	CC	O
significant	JJ	O
(	(	O
though	IN	O
apparently	RB	O
sub	JJ	O
-	:	O
maximal	NN	O
)	)	O
ACTH	NNP	O
responses	NNS	O
.	.	O

If	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
remains	VBZ	O
greater	JJR	O
than	IN	O
95	CD	O
mmHg	NN	O
and	CC	O
the	DT	O
patient	NN	O
has	VBZ	O
no	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
hypotension	NN	O
,	,	O
up	RB	O
-	:	O
titrate	VB	O
the	DT	O
dose	NN	O
by	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
taken	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

A	DT	O
4.25	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
one	CD	I-WHO
year	NN	I-WHO
old	JJ	O-WHO
,	,	O
who	WP	O
generally	RB	O
receive	VBP	O
a	DT	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
titration	NN	O
should	MD	O
proceed	VB	O
over	IN	O
a	DT	O
7	CD	B-DUR
-	:	O
14	CD	B-DUR
day	NN	O-DUR
period	NN	O
starting	VBG	O
with	IN	O
30	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
,	,	O
administer	RB	O
0.01	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBD	O
or	CC	O
0.3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m2	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
subcutaneously	RB	O
,	,	O
repeated	VBD	O
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
if	IN	O
required	VBN	O
.	.	O

In	IN	O
children	NNS	B-WHO
from	IN	I-WHO
3	CD	I-WHO
to	TO	I-WHO
5	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
start	VBP	O
with	IN	O
2.5	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
;	:	O
daily	JJ	B-FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
2.5	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
;	:	O
daily	JJ	B-FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
10	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

Clearance	NN	O
measurements	NNS	O
using	VBG	O
single	JJ	B-DOS
injection	NN	B-UNIT
techniques	NNS	O
are	VBP	O
generally	RB	O
inaccurate	JJ	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ERPF	NNP	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ADVICOR	NNP	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
(	(	O
based	VBN	O
on	IN	O
the	DT	O
NIASPAN	NNP	O
component	NN	O
)	)	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

Note	NN	O
:	:	O
The	DT	O
Adrenalin®	NNP	O
30	CD	B-DOS
mL	NN	B-UNIT
multiple	JJ	O
-	:	O
dose	JJ	O
vial	NN	O
is	VBZ	O
not	RB	O
for	IN	O
ophthalmic	JJ	O
use	NN	O
.	.	O

Prescott	NNP	O
LF	NNP	O
,	,	O
J	NNP	O
Pharm	NNP	O
Pharmacol	NNP	O
1971	CD	O
,	,	O
23	CD	O
(	(	O
10	CD	O
)	)	O
:807	SYM	O
-	:	O
808	CD	O
(	(	O
October	NNP	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
infused	JJ	O
dextrose	NN	O
provides	VBZ	O
3.4	CD	O
kcal	JJ	O
;	:	O
each	DT	O
gram	NN	O
of	IN	O
infused	JJ	O
fat	NN	O
provides	VBZ	O
9	CD	O
kcal	NN	O
.	.	O

Total	JJ	O
dosage	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
should	MD	O
not	RB	O
exceed	VB	O
12	CD	B-DOS
inhalations	NNS	B-UNIT
.	.	O

Use	NNP	O
another	DT	O
rabeprazole	NN	O
formulation	NN	O
for	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
1	CD	I-WHO
year	NN	I-WHO
to	TO	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
10	CD	B-DOS
-	:	O
60	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
single	JJ	B-DOS
doses	NNS	B-UNIT
.	.	O

If	IN	O
the	DT	O
6.25	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
is	VBZ	O
not	RB	O
effective	JJ	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
12.5	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
as	IN	O
monotherapy	NN	O
and	CC	O
10	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
as	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
lithium	NN	O
or	CC	O
valproate	NN	O
.	.	O

Three	CD	B-DUR
weeks	NNS	O-DUR
constitutes	VBZ	O
an	DT	O
adequate	JJ	O
period	NN	O
of	IN	O
trial	NN	O
providing	NN	O
dosage	NN	O
has	VBZ	O
reached	VBN	O
300	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
(	(	O
or	CC	O
lower	JJR	O
level	NN	O
of	IN	O
tolerance	NN	O
)	)	O
for	IN	O
at	IN	B-DUR
least	JJS	I-DUR
two	CD	I-DUR
weeks	NNS	O-DUR
.	.	O

One	CD	B-DOS
pink	NN	B-UNIT
tablet	NN	O-UNIT
should	MD	O
be	VB	O
taken	VBN	O
daily	RB	B-FREQ
for	IN	O
21	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
,	,	O
followed	VBN	O
by	IN	O
one	CD	B-DOS
light	NN	B-UNIT
-	:	O
green	JJ	B-UNIT
inert	JJ	I-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
for	IN	O
7	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

Single	NNP	B-DOS
Dose	NNP	B-UNIT
-	:	O
Actidose®	NNP	O
-	:	O
Aqua	NN	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
have	VBP	I-WHO
never	RB	I-WHO
taken	VBN	I-WHO
aripiprazole	NN	O-WHO
,	,	O
establish	VB	O
tolerability	NN	O
with	IN	O
oral	JJ	O
aripiprazole	JJ	O
prior	NN	O
to	TO	O
initiating	VBG	O
treatment	NN	O
with	IN	O
ABILIFY	NNP	O
MAINTENA	NNP	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
,	,	O
as	IN	O
needed	VBN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Dovonex®	NNP	O
(	(	O
calcipotriene	JJ	O
ointment	NN	O
)	)	O
ointment	NN	O
once	RB	B-FREQ
or	CC	O
twice	JJ	B-FREQ
daily	JJ	O-FREQ
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
and	CC	O
completely	RB	O
.	.	O

Acetaminophen	NNP	O
Assays	NNP	O
-	:	O
Interpretation	NN	O
and	CC	O
Methodology	NN	O
:	:	O
The	DT	O
acute	JJ	O
ingestion	NN	O
of	IN	O
acetaminophen	NN	O
in	IN	O
quantities	NNS	O
of	IN	O
150	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
or	CC	O
greater	JJR	O
may	MD	O
result	VB	O
in	IN	O
hepatic	JJ	O
toxicity	NN	O
.	.	O

Instill	NNP	O
1	CD	B-DOS
drop	NN	B-UNIT
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
for	IN	O
5	CD	B-DOS
to	TO	O
7	CD	B-DOS
doses	NNS	B-UNIT
.	.	O

No	DT	O
more	JJR	O
than	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
of	IN	O
ABSTRAL	NNP	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
treat	VB	O
an	DT	O
episode	NN	O
of	IN	O
breakthrough	NN	O
pain	NN	O
.	.	O

When	WRB	O
given	VBN	O
as	IN	O
the	DT	O
sole	JJ	O
agent	NN	O
for	IN	O
diuresis	NN	O
,	,	O
ALDACTONE	NNP	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
at	IN	B-DUR
least	JJS	I-DUR
five	CD	I-DUR
days	NNS	O-DUR
at	IN	O
the	DT	O
initial	JJ	O
dosage	NN	O
level	NN	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
may	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
optimal	JJ	O
therapeutic	JJ	O
or	CC	O
maintenance	NN	O
level	NN	O
administered	VBN	O
in	IN	O
either	DT	O
single	JJ	B-DOS
or	CC	O
divided	JJ	O
daily	JJ	B-FREQ
doses	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
4	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
15	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
before	IN	O
exercise	NN	O
.	.	O

men	NNS	B-WHO
675	CD	B-DOS
±	$	O
150	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NNP	O
women	NNS	B-WHO
595	CD	B-DOS
±	JJ	O
125	CD	B-DOS
mL	NN	B-UNIT
/	CD	O
min	NN	O

Although	IN	O
100	CD	B-DOS
to	TO	O
150	CD	B-DOS
mg	NNS	B-UNIT
daily	JJ	B-FREQ
may	MD	O
be	VB	O
adequate	JJ	O
for	IN	O
many	JJ	B-WHO
elderly	JJ	I-WHO
patients	NNS	O-WHO
,	,	O
some	DT	O
may	MD	O
require	VB	O
higher	JJR	O
dosage	NN	O
.	.	O

Pentacel	NNP	O
vaccine	NN	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
4	CD	B-DOS
dose	JJ	B-UNIT
series	NN	O-UNIT
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
15	CD	O
-	:	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
180	CD	O
and	CC	O
pseudoephendrine	VB	O
hcl	NN	O
240	CD	O
)	)	O
Extended	VBN	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
(	(	O
37.5	CD	B-DOS
mg	NN	B-UNIT
)	)	O
daily	RB	B-FREQ
as	IN	O
prescribed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
,	,	O
administered	VBN	O
before	IN	O
breakfast	NN	O
or	CC	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
for	IN	O
appetite	JJ	O
control	NN	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
10	CD	O
%	NN	O
is	VBZ	O
up	RB	O
to	TO	O
2.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
infants	NNS	B-WHO
up	RB	I-WHO
to	TO	I-WHO
10	CD	I-WHO
kg	NNS	O-WHO
.	.	O

ERPF	NNP	O
=	VBD	O
8	CD	O
x	JJ	O
1.5	CD	O
/	JJ	O
0.02	CD	O
=	JJ	O
600	CD	B-DOS
mL	NN	B-UNIT
/	CD	O
min	NN	O

In	IN	O
many	JJ	B-WHO
patients	NNS	O-WHO
,	,	O
provision	NN	O
of	IN	O
adequate	JJ	O
calories	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
hypertonic	JJ	O
dextrose	NN	O
may	MD	O
require	VB	O
the	DT	O
administration	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
to	TO	O
prevent	VB	O
hyperglycemia	NN	O
and	CC	O
glycosuria	NN	O
.	.	O

Increase	VB	O
the	DT	O
dose	JJ	O
by	IN	O
100	CD	B-DOS
mcg	NNS	B-UNIT
multiples	VBZ	O
up	IN	O
to	TO	O
400	CD	B-DOS
mcg	NNS	B-UNIT
as	IN	O
needed	VBN	O
.	.	O

ALINIA	NNP	O
tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
pediatric	VB	B-WHO
patients	NNS	I-WHO
11	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
younger	JJR	O-WHO
because	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
contains	VBZ	O
a	DT	O
greater	JJR	O
amount	NN	O
of	IN	O
nitazoxanide	NN	O
than	IN	O
the	DT	O
recommended	JJ	O
dosing	NN	O
in	IN	O
this	DT	O
pediatric	JJ	O
age	NN	O
group	NN	O
.	.	O

The	DT	O
benzyl	NN	O
alcohol	NN	O
in	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
may	MD	O
cause	VB	O
serious	JJ	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
premature	NN	B-WHO
or	CC	I-WHO
low	JJ	I-WHO
birth	NN	I-WHO
-	:	I-WHO
weight	NN	I-WHO
infants	NNS	O-WHO
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Treat	NNP	O
single	JJ	O
lesions	NNS	O
or	CC	O
an	DT	O
entire	JJ	O
field	NN	O
affected	VBN	O
by	IN	O
multiple	JJ	O
lesions	NNS	O
with	IN	O
AMELUZ	NNP	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
red	JJ	O
light	JJ	O
photodynamic	JJ	O
therapy	NN	O
(	(	O
PDT	NNP	O
)	)	O
.	.	O

Patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
opioid	JJ	I-WHO
tolerant	NN	O-WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	B-DUR
week	NN	O-DUR
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	B-DOS
mg	JJ	B-UNIT
oral	JJ	O
morphine	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
25	CD	B-DOS
mcg	NN	B-UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	B-DOS
mg	JJ	B-UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
8	CD	B-DOS
mg	JJ	B-UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
25	CD	B-DOS
mg	JJ	B-UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
60	CD	B-DOS
mg	JJ	B-UNIT
oral	JJ	O
hydrocodone	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

Scabies	NNS	O
rarely	RB	O
infests	VBZ	O
the	DT	O
scalp	NN	O
of	IN	O
adults	NNS	B-WHO
,	,	O
although	IN	O
the	DT	O
hairline	NN	O
,	,	O
neck	NN	O
,	,	O
temple	NN	O
,	,	O
and	CC	O
forehead	NN	O
may	MD	O
be	VB	O
infested	VBN	O
in	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
geriatric	JJ	I-WHO
patients	NNS	O-WHO
.	.	O

Use	NNP	O
sufficient	JJ	O
amount	NN	O
of	IN	O
gel	NN	O
to	TO	O
cover	VB	O
the	DT	O
single	JJ	O
lesions	NNS	O
or	CC	O
if	IN	O
multiple	JJ	O
lesions	NNS	O
,	,	O
the	DT	O
entire	JJ	O
area	NN	O
.	.	O

Intramuscular	JJ	O
Administration	NNP	O
for	IN	O
Patients	NNPS	B-WHO
with	IN	I-WHO
Normal	NNP	I-WHO
Renal	NNP	I-WHO
Function	NN	O-WHO
:	:	O
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
,	,	I-WHO
children	NNS	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
infants	NNS	O-WHO
(	(	O
see	VB	O
DESCRIPTION	NNP	O
:	:	O
WARNINGS	JJ	O
With	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
divided	VBD	O
into	IN	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
equal	JJ	B-UNIT
doses	NNS	O-UNIT
administered	VBN	O
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
i.e	VBP	O
,	,	O
7.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
q12h	NN	O
or	CC	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
q8h	NN	O
.	.	O

During	IN	O
dialysis	NN	O
,	,	O
perindopril	NN	O
is	VBZ	O
removed	VBN	O
with	IN	O
the	DT	O
same	JJ	O
clearance	NN	O
as	IN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
normal	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
.	.	O

The	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	O-WHO
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
infusion	NN	B-UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
schedule	NN	O
is	VBZ	O
10	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
15	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
second	JJ	O
dose	NN	O
,	,	O
and	CC	O
20	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
third	JJ	O
dose	NN	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
for	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
children	NNS	O-WHO
but	CC	O
should	MD	O
be	VB	O
governed	VBN	O
more	JJR	O
by	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
and	CC	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
than	IN	O
by	IN	O
age	NN	O
or	CC	O
size	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
women	NNS	B-WHO
and	CC	O
either	DT	O
5	CD	B-DOS
or	CC	O
10	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
men	NNS	B-WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
night	NN	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7–8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

Adults	NNS	B-WHO
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
of	IN	O
doxycycline	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
.	.	O

Continuous	JJ	O
Infusion	NN	O
:	:	O
0.5	CD	B-DOS
to	TO	O
3	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
administered	VBN	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NN	O
oxygen	NN	O
in	IN	O
patients	NNS	B-WHO
undergoing	VBG	I-WHO
general	JJ	I-WHO
surgery	NN	O-WHO
.	.	O

Subcutaneously	RB	O
or	CC	O
intramuscularly	RB	O
-	:	O
0.2	CD	B-DOS
to	TO	O
1	CD	B-DOS
mL	NN	B-UNIT
(	(	O
mg	NN	B-UNIT
)	)	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
of	IN	O
ACCURETIC	NNP	O
,	,	O
the	DT	O
average	JJ	O
change	NN	O
in	IN	O
serum	NN	O
potassium	NN	O
was	VBD	O
near	JJ	O
zero	NN	O
in	IN	O
subjects	NNS	B-WHO
who	WP	I-WHO
received	VBD	I-WHO
HCTZ	NNP	O-WHO
6.25	CD	B-DOS
mg	NN	B-UNIT
in	IN	O
the	DT	O
combination	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
subject	NN	O
who	WP	O
received	VBD	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
/	NNS	O
12.5	CD	B-DOS
to	TO	O
25	CD	B-DOS
mg	NNS	B-UNIT
experienced	VBD	O
a	DT	O
milder	NN	O
reduction	NN	O
in	IN	O
serum	NN	O
potassium	NN	O
than	IN	O
that	DT	O
experienced	VBN	O
by	IN	O
the	DT	O
average	JJ	O
subject	JJ	O
receiving	VBG	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
hydrochlorothiazide	JJ	O
monotherapy	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
Extended	NNP	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
mild	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
CrCl	NNP	O
51	CD	B-DOS
–	VBD	O
80	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
AMPYRA	NNP	O
plasma	NN	O
levels	NNS	O
may	MD	O
approach	VB	O
those	DT	O
seen	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
15	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
a	DT	O
dose	NN	O
that	WDT	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
seizures	NNS	O
.	.	O

The	DT	O
average	JJ	O
intramuscular	JJ	O
dose	NN	O
ranges	VBZ	O
from	IN	O
65	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
0.5	CD	B-DOS
g.	NNS	B-UNIT
A	DT	O
volume	NN	O
of	IN	O
5	CD	B-DOS
mL	NN	B-UNIT
(	(	O
irrespective	JJ	O
of	IN	O
concentration	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
at	IN	O
any	DT	O
one	CD	O
site	NN	O
because	IN	O
of	IN	O
possible	JJ	O
tissue	NN	O
irritation	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
adhered	VBN	O
to	TO	O
the	DT	O
prescribed	VBN	O
schedule	NN	O
(	(	O
missed	JJ	O
one	CD	B-DOS
or	CC	O
more	JJR	O
tablets	NNS	O
or	CC	O
started	VBD	O
taking	VBG	O
them	PRP	O
on	IN	O
a	DT	O
day	NN	O
later	RB	O
than	IN	O
she	PRP	O
should	MD	O
have	VB	O
)	)	O
,	,	O
the	DT	O
probability	NN	O
of	IN	O
pregnancy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
first	JJ	O
missed	JJ	O
period	NN	O
and	CC	O
appropriate	JJ	O
diagnostic	JJ	O
measures	NNS	O
taken	VBN	O
.	.	O

IPLEX	NNP	O
(	(	O
mecasermin	JJ	O
rinfabate	NN	O
[	NNP	O
rdna	NN	O
origin	NN	O
]	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
,	,	O
to	TO	O
be	VB	O
increased	VBN	O
into	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
range	NN	O
of	IN	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
,	,	O
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Intraspinal	JJ	O
use	NN	O
(	(	O
Amp	NNP	O
88	CD	O
)	)	O
-	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
0.2	CD	B-DOS
to	TO	O
0.4	CD	B-DOS
mL	NN	B-UNIT
(	(	O
0.2	CD	B-DOS
to	TO	O
0.4	CD	B-DOS
mg	NN	B-UNIT
)	)	O
added	VBD	O
to	TO	O
anesthetic	JJ	O
spinal	JJ	O
fluid	NN	O
mixture	NN	O
(	(	O
may	MD	O
prolong	VB	O
anesthetic	JJ	O
action	NN	O
by	IN	O
limiting	VBG	O
absorption	NN	O
)	)	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Examples	NNS	O
of	IN	O
Amyvid	NNP	O
negative	JJ	O
scans	NNS	O
(	(	O
top	JJ	O
two	CD	O
rows	NNS	O
)	)	O
and	CC	O
positive	JJ	O
scans	NNS	O
(	(	O
bottom	JJ	O
two	CD	O
rows	NNS	O
)	)	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
respond	VB	I-WHO
to	TO	I-WHO
AIRDUO	NNP	I-WHO
RESPICLICK	NNP	O-WHO
55	CD	B-DOS
/	VBD	O
14	CD	B-DOS
mcg	NN	B-UNIT
after	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
,	,	O
increasing	VBG	O
the	DT	O
dose	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

When	WRB	O
AZILECT	NNP	O
is	VBZ	O
prescribed	VBN	O
as	IN	O
monotherapy	NN	O
or	CC	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	B-WHO
not	RB	I-WHO
taking	VBG	I-WHO
levodopa	NN	O-WHO
,	,	O
patients	NNS	O
may	MD	O
start	VB	O
AZILECT	NNP	O
at	IN	O
the	DT	O
recommended	JJ	O
dose	NN	O
of	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	B-DOS
to	TO	O
120	CD	B-DOS
g	NN	B-UNIT
of	IN	O
amino	NN	O
acids	NNS	O
(	(	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
g	NN	B-UNIT
of	IN	O
nitrogen	NN	O
)	)	O
as	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BONIVA	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
is	VBZ	O
3	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
3	CD	I-FREQ
months	NNS	O-FREQ
administered	VBN	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
15	CD	O
to	TO	O
30	CD	O
seconds	NNS	O
.	.	O

Adults	NNS	B-WHO
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
doxycycline	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	$	O
12.5	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

A	DT	O
10	CD	O
-	:	O
minute	NN	O
PET	NNP	O
image	NN	O
should	MD	O
be	VB	O
acquired	VBN	O
starting	VBG	O
30	CD	O
to	TO	O
50	CD	O
minutes	NNS	O
after	IN	O
Amyvid	NNP	O
intravenous	JJ	O
injection	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
taking	VBG	I-WHO
danazol	NN	I-WHO
,	,	I-WHO
diltiazem	NN	I-WHO
,	,	I-WHO
or	CC	I-WHO
verapamil	NNS	I-WHO
concomitantly	RB	I-WHO
with	IN	I-WHO
lovastatin	NN	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
lovastatin	NN	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Upper	NNP	O
GI	NNP	O
X	NNP	O
-	:	O
rays	NNS	O
are	VBP	O
desirable	JJ	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
an	DT	I-WHO
ulcer	JJ	I-WHO
history	NN	I-WHO
or	CC	I-WHO
significant	JJ	I-WHO
dyspepsia	NN	O-WHO
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	B-WHO
21	CD	I-WHO
kg	NN	I-WHO
to	TO	I-WHO
40	CD	I-WHO
kg	NNS	O-WHO

After	IN	O
one	CD	B-DUR
week	NN	O-DUR
at	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
increase	NN	O
dose	NN	O
(	(	O
if	IN	O
tolerated	VBN	O
)	)	O
toward	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
with	IN	O
dosage	NN	O
increases	NNS	O
being	VBG	O
about	IN	O
3	CD	B-DUR
weeks	NNS	O-DUR
apart	RB	O
.	.	O

Syphilis	NN	O
of	IN	O
more	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
(	(	O
except	IN	O
neurosyphilis	RB	O
)	)	O
,	,	O
500	CD	B-DOS
mg	NN	B-UNIT
q.i.d	NN	O
.	.	O

Administer	NNP	O
HYQVIA	NNP	O
at	IN	O
300	CD	B-DOS
to	TO	O
600	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
at	IN	O
3	CD	B-DUR
to	TO	O
4	CD	B-DUR
week	NN	O-DUR
intervals	NNS	O
,	,	O
after	IN	O
initial	JJ	O
ramp	NN	O
-	:	O
up	RB	O
.	.	O

Pediatric	JJ	B-WHO
Patients	NNS	O-WHO
:	:	O
For	IN	O
adolescents	NNS	B-WHO
(	(	I-WHO
13	CD	I-WHO
to	TO	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
1,200	CD	B-DOS
mg	NN	B-UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	B-DOS
50	CD	O-DOS
-	:	O
mg	NN	B-UNIT
capsules	NNS	O-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
in	IN	O
elderly	JJ	B-WHO
patients	NNS	O-WHO
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
followed	VBN	O
by	IN	O
titration	NN	O
(	(	O
as	IN	O
described	VBN	O
above	IN	O
)	)	O
to	TO	O
the	DT	O
optimal	JJ	O
response	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
40	CD	I-WHO
kg	NNS	O-WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
(	(	O
see	VB	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
.	.	O

0.25	CD	B-DOS
mg	NN	B-UNIT

Adding	VBG	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
54	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
60.1	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

When	WRB	O
used	VBN	O
for	IN	O
the	DT	O
routine	JJ	O
nursing	NN	O
care	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
tracheostomy	NN	O-WHO
,	,	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
a	DT	O
10	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
by	IN	O
instillation	NN	O
into	IN	O
the	DT	O
tracheostomy	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
1000	CD	B-DOS
mg	NN	B-UNIT
daily	RB	B-FREQ
,	,	O
in	IN	O
divided	JJ	O
doses	NNS	O
using	VBG	O
tablets	NNS	O
or	CC	O
sustained	VBN	O
-	:	O
release	NN	O
capsules	NNS	O
as	IN	O
appropriate	NN	O
.	.	O

Average	JJ	O
daily	JJ	B-FREQ
adult	NN	B-WHO
fluid	NN	O
requirements	NNS	O
are	VBP	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
higher	JJR	O
with	IN	O
losses	NNS	O
from	IN	O
fistula	JJ	O
drainage	NN	O
or	CC	O
severe	JJ	O
burns	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Estimated	VBN	O
Absorbed	NNP	O
Radiation	NNP	O
Dose	NNP	O
from	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O

However	RB	O
,	,	O
for	IN	O
patients	NNS	B-WHO
converting	VBG	I-WHO
from	IN	I-WHO
Actiq	NNP	O-WHO
,	,	O
see	VBP	O
Table	JJ	O
1	CD	O
:	:	O
Initial	JJ	O
Dosing	NNP	O
Recommendations	NNP	O
for	IN	O
Patients	NNPS	B-WHO
on	IN	I-WHO
ACTIQ	NNP	O-WHO
.	.	O

The	DT	O
recommended	VBN	O
AMJEVITA	NNP	O
dose	JJ	O
regimen	NNS	O
for	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
ulcerative	JJ	I-WHO
colitis	NN	O-WHO
(	(	O
UC	NNP	O
)	)	O
is	VBZ	O
160	CD	B-DOS
mg	NN	B-UNIT
initially	RB	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
given	VBN	O
as	IN	O
four	CD	B-DOS
40	CD	O-DOS
mg	NN	B-UNIT
injections	NNS	O-UNIT
in	IN	O
one	CD	B-DUR
day	NN	O-DUR
or	CC	O
as	IN	O
two	CD	B-DOS
40	CD	O-DOS
mg	NNS	B-UNIT
injections	NNS	O-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
for	IN	O
two	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
)	)	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	B-DOS
mg	NNS	B-UNIT
two	CD	B-DUR
weeks	NNS	O-DUR
later	RB	O
(	(	O
Day	NNP	O
15	CD	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
large	JJ	O
bore	NN	O
needle	NN	O
(	(	O
e.g	UH	O
,	,	O
18	CD	O
gauge	NN	O
)	)	O
and	CC	O
a	DT	O
syringe	NN	O
,	,	O
reconstitute	NN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
accompanying	VBG	O
50	CD	B-DOS
mL	JJ	B-UNIT
vial	NN	O-UNIT
of	IN	O
SWFI	NNP	O
to	TO	O
the	DT	O
50	CD	B-DOS
mg	JJ	B-UNIT
vial	NN	O-UNIT
of	IN	O
Activase	NNP	O
,	,	O
directing	VBG	O
the	DT	O
SWFI	NNP	O
stream	NN	O
into	IN	O
the	DT	O
lyophilized	JJ	O
cake	NN	O
.	.	O

Each	DT	O
filter	NN	O
needle	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
filter	VB	O
the	DT	O
contents	NNS	O
of	IN	O
up	IN	O
to	TO	O
four	CD	B-DOS
100	CD	O-DOS
mg	NN	B-UNIT
vials	NNS	O
.	.	O

Immediately	RB	O
after	IN	O
removing	VBG	O
occlusion	NN	O
and	CC	O
any	DT	O
remaining	VBG	O
gel	NN	O
,	,	O
illuminate	VB	O
the	DT	O
treatment	NN	O
area	NN	O
with	IN	O
BF	NNP	O
-	:	O
RhodoLED®	NNP	O
,	,	O
a	DT	O
red	JJ	O
light	NN	O
credit	NN	O
with	IN	O
a	DT	O
narrow	JJ	O
spectrum	NN	O
around	IN	O
635	CD	O
nm	NNS	O
that	IN	O
delivers	VBZ	O
a	DT	O
light	JJ	O
dose	NN	O
of	IN	O
approximately	RB	O
37	CD	B-DOS
J	NNP	B-UNIT
/	NNP	O
cm²	NN	B-UNIT
within	IN	O
10	CD	O
minutes	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
congestive	JJ	I-WHO
heart	NN	I-WHO
failure	NN	O-WHO
(	(	O
NYHA	NNP	O
Class	NNP	O
I	PRP	O
or	CC	O
II	NNP	O
)	)	O
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

1	CD	O

Further	JJ	O
increases	NNS	O
of	IN	O
5	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	B-FREQ
week	NN	O-FREQ
may	MD	O
be	VB	O
necessary	JJ	O
,	,	O
but	CC	O
a	DT	O
maximum	JJ	O
single	JJ	B-DOS
dose	NN	B-UNIT
of	IN	O
30	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	NN	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Begin	NNP	O
whole	JJ	O
body	NN	O
planar	JJ	O
scintigraphy	NN	O
imaging	VBG	O
24	CD	O
±	JJ	O
6	CD	O
hours	NNS	O
following	VBG	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	B-WHO
-	:	O
a	DT	O
single	JJ	B-DOS
0.075	CD	O-DOS
mg	NN	B-UNIT
intravenous	JJ	I-UNIT
dose	NN	O-UNIT
administered	VBD	O
over	IN	O
10	CD	O
seconds	NNS	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
gram	NN	B-UNIT
administered	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
every	DT	O
8	CD	O
to	TO	O
12	CD	O
hours	NNS	O
.	.	O

Pediatric	JJ	B-WHO
patients	NNS	O-WHO
should	MD	O
administer	VB	O
this	DT	O
product	NN	O
under	IN	O
adult	JJ	B-WHO
supervision	NN	O
.	.	O

If	IN	O
,	,	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
,	,	O
blood	NN	O
glucose	NN	O
control	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
with	IN	O
increased	JJ	O
AFREZZA	NNP	O
doses	NNS	O
,	,	O
consider	VB	O
use	NN	O
of	IN	O
subcutaneous	JJ	O
mealtime	JJ	O
insulin	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
should	MD	O
occur	VB	O
gradually	RB	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	B-DUR
week	NN	O-DUR
.	.	O

A	DT	O
previously	RB	B-WHO
unvaccinated	JJ	I-WHO
child	NN	I-WHO
15	CD	I-WHO
months	NNS	I-WHO
through	IN	I-WHO
5	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
should	MD	O
receive	VB	O
one	CD	B-DOS
dose	NN	B-UNIT
of	IN	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Teflaro	NNP	O
is	VBZ	O
600	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
by	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
over	IN	O
5	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	B-WHO
≥	JJ	I-WHO
18	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

Evidence	NN	O
is	VBZ	O
available	JJ	O
that	IN	O
in	IN	O
some	DT	O
types	NNS	O
of	IN	O
neoplastic	JJ	O
disease	NN	O
combination	NN	O
chemotherapy	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
single	JJ	O
agents	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
acceptable	JJ	O
in	IN	O
pediatrics	NNS	O
to	TO	O
start	VB	O
with	IN	O
a	DT	O
nutritional	JJ	O
solution	NN	O
of	IN	O
half	JJ	O
strength	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
about	IN	O
60	CD	B-DOS
to	TO	O
70	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
gonorrhea	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
seven	CD	B-DUR
days	NNS	O-DUR
.	.	O

If	IN	O
a	DT	O
flare	NN	O
occurs	VBZ	O
less	JJR	O
than	IN	O
6	CD	B-DUR
weeks	NNS	O-DUR
after	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
,	,	O
25	CD	O
percent	NN	O
of	IN	O
the	DT	O
maximum	JJ	O
exposure	NN	O
received	VBD	O
during	IN	O
the	DT	O
clearing	NN	O
phase	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
and	CC	O
then	RB	O
proceed	VB	O
with	IN	O
the	DT	O
clearing	NN	O
schedule	NN	O
previously	RB	O
followed	VBD	O
for	IN	O
this	DT	O
patient	NN	O
.	.	O

Patients	NNS	B-WHO
who	WP	I-WHO
experience	VBP	I-WHO
severe	JJ	I-WHO
neutropenia	NN	O-WHO
(	(	O
neutrophils	VBZ	O
less	JJR	O
than	IN	O
500	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm³	NN	O
for	IN	O
a	DT	O
week	NN	B-DUR
or	CC	O
longer	JJR	O
)	)	O
or	CC	O
severe	JJ	O
sensory	JJ	O
neuropathy	JJ	O
during	IN	O
ABRAXANE	NNP	O
therapy	NN	O
should	MD	O
have	VB	O
dosage	NN	O
reduced	VBN	O
to	TO	O
220	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²	NN	O
for	IN	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
ABRAXANE	NNP	O
.	.	O

If	IN	O
potential	JJ	O
allergy	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
an	DT	O
intradermal	JJ	O
skin	JJ	O
test	NN	O
may	MD	O
be	VB	O
performed	VBN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
,	,	O
i.e	FW	O
,	,	O
0.05	CD	B-DOS
mL	NN	B-UNIT
injection	NN	O-UNIT
intradermally	RB	O
to	TO	O
be	VB	O
evaluated	VBN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
following	VBG	O
injection	NN	O
.	.	O

Recommended	VBN	O
dosage	NN	O
is	VBZ	O
250	CD	B-DOS
to	TO	O
375	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
acetaZOLAMIDE	NN	O
once	IN	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
one	CD	B-DUR
or	CC	O
two	CD	B-DUR
days	NNS	O-DUR
,	,	O
alternating	VBG	O
with	IN	O
a	DT	O
day	NN	O
of	IN	O
rest	NN	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
suspected	JJ	O
massive	JJ	O
overdose	NN	O
,	,	O
or	CC	O
with	IN	O
concomitant	JJ	O
ingestion	NN	O
of	IN	O
other	JJ	O
substances	NNS	O
,	,	O
or	CC	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
preexisting	VBG	I-WHO
liver	JJ	I-WHO
disease	NN	O-WHO
,	,	O
the	DT	O
absorption	NN	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
acetaminophen	NN	O
may	MD	O
be	VB	O
prolonged	VBN	O
,	,	O
in	IN	O
such	JJ	O
cases	NNS	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
infusion	NN	O
of	IN	O
N	NNP	O
-	:	O
acetylcysteine	NN	O
beyond	IN	O
21	CD	O
hours	NNS	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
NIASPAN	NNP	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	B-DOS
mg	NNS	B-UNIT
in	IN	O
any	DT	O
4	CD	B-DUR
-	:	O
week	NN	B-DUR
period	NN	O
.	.	O

Usual	JJ	O
regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ALTACE	NNP	O
may	MD	O
be	VB	O
followed	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
estimated	VBN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
>	VBD	O-WHO
40	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

The	DT	O
usual	JJ	O
single	JJ	O
dose	NN	O
is	VBZ	O
two	CD	B-DOS
to	TO	O
three	CD	B-DOS
inhalations	NNS	B-UNIT
.	.	O

Give	VB	O
first	JJ	O
dose	NN	O
on	IN	O
awakening	VBG	O
;	:	O
additional	JJ	O
doses	NNS	O
(	(	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
)	)	O
at	IN	O
intervals	NNS	O
of	IN	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

If	IN	O
CD4+	NNP	O
T	NNP	O
lymphocyte	NN	O
counts	NNS	O
are	VBP	O
below	IN	O
250	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
µL	NNP	O
,	,	O
AMEVIVE®	NNP	O
dosing	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
and	CC	O
weekly	JJ	B-FREQ
monitoring	NN	O
instituted	VBN	O
.	.	O

Fluid	NNP	O
intake	NN	O
for	IN	O
the	DT	B-WHO
infant	NN	I-WHO
receiving	VBG	I-WHO
central	JJ	I-WHO
venous	JJ	I-WHO
TPN	NNP	O-WHO
should	MD	O
be	VB	O
approximately	RB	O
125	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
range	NN	O
:	:	O
100	CD	B-DOS
to	TO	O
175	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
for	IN	O
patients	NNS	B-WHO
2	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
is	VBZ	O
1.25	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
0.63	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
AccuNeb	NNP	O
(	(	O
albuterol	JJ	O
sulfate	NN	O
inhalation	NN	O
solution	NN	O
)	)	O
administered	VBD	O
3	CD	B-FREQ
or	CC	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
,	,	O
as	IN	O
needed	VBN	O
,	,	O
by	IN	O
nebulization	NN	O
.	.	O

In	IN	O
the	DT	O
management	NN	O
of	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
(	(	O
particularly	RB	O
chronic	JJ	O
infections	NNS	O
of	IN	O
the	DT	O
urinary	JJ	O
tract	NN	O
)	)	O
,	,	O
100	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

A	DT	O
0.5	CD	B-DOS
mL	NN	B-UNIT
dose	NN	O-UNIT
of	IN	O
ActHIB	NNP	O
is	VBZ	O
approved	VBN	O
for	IN	O
intramuscular	JJ	O
administration	NN	O
in	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
children	NNS	O-WHO
,	,	O
2	CD	O
months	NNS	O
through	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
as	IN	O
a	DT	O
4	CD	B-DOS
-	:	O
dose	JJ	O
series	NN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

A	DT	O
mixture	NN	O
of	IN	O
Aminosyn	NNP	O
II	NNP	O
and	CC	O
dextrose	RB	O
diluted	VBN	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
and	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
administration	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
fat	JJ	O
provides	VBZ	O
9	CD	O
kcal	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
that	WDT	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
24	CD	O
hours	NNS	O
is	VBZ	O
two	CD	B-DOS
doses	NNS	B-UNIT
of	IN	O
ALSUMA	NNP	O
separated	VBN	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
6.25	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NN	B-UNIT
may	MD	O
be	VB	O
considered	VBN	O
for	IN	O
patients	NNS	B-WHO
requiring	VBG	I-WHO
smaller	JJR	I-WHO
reductions	NNS	O-WHO
.	.	O

For	IN	O
patients	NNS	B-WHO
aged	VBN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
3	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Normal	JJ	O
Dosage	NNP	O
at	IN	O
Prolonged	NNP	O
Intervals	NNS	O
:	:	O
If	IN	O
the	DT	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
is	VBZ	O
stable	JJ	O
,	,	O
a	DT	O
dosage	NN	O
interval	NN	O
in	IN	O
hours	NNS	O
for	IN	O
the	DT	O
normal	JJ	O
dose	NN	O
can	MD	O
be	VB	O
calculated	VBN	O
by	IN	O
multiplying	VBG	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
by	IN	O
9	CD	O
,	,	O
e.g	NN	O
,	,	O
if	IN	O
the	DT	O
serum	NN	O
creatinine	NN	O
concentration	NN	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
100	CD	B-DOS
mL	NN	B-UNIT
,	,	O
the	DT	O
recommended	VBN	O
single	JJ	B-DOS
dose	NN	B-UNIT
(	(	O
7.5mg	CD	B-DOS
/	NNP	O
kg	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	B-FREQ
18	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

The	DT	O
starting	NN	O
dosage	NN	O
for	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
based	VBN	O
upon	IN	O
patients	NNS	B-WHO
'	POS	I-WHO
asthma	JJ	I-WHO
severity	NN	O-WHO
.	.	O

To	TO	O
minimize	VB	O
radiation	NN	O
dose	NN	O
to	TO	O
the	DT	O
bladder	NN	O
,	,	O
prior	RB	O
to	TO	O
and	CC	O
following	VBG	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
administration	NN	O
,	,	O
encourage	VB	O
hydration	NN	O
to	TO	O
permit	VB	O
frequent	JJ	O
voiding	NN	O
.	.	O

The	DT	O
dose	JJ	O
increment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
0.5	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
any	DT	O
one	CD	B-DUR
week	NN	O-DUR
.	.	O

If	IN	O
there	EX	O
are	VBP	O
adverse	JJ	O
reactions	NNS	O
with	IN	O
the	DT	O
400	CD	B-DOS
mg	NN	B-UNIT
dosage	NN	O
,	,	O
consider	VB	O
reducing	VBG	O
the	DT	O
dosage	NN	O
to	TO	O
300	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
monthly	RB	O-FREQ
.	.	O

The	DT	O
daily	JJ	B-FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
,	,	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	I-WHO
,	,	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
and	CC	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1.0	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
total	NN	O
doses	NNS	O
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
is	VBZ	O
based	VBN	O
on	IN	O
patient	JJ	O
weight	NN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
100	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
selected	VBN	O
administration	NN	O
regimen	NNS	O
(	(	O
accelerated	VBD	O
or	CC	O
3	CD	O
hour	NN	O
,	,	O
described	VBN	O
below	IN	O
)	)	O
.	.	O

However	RB	O
,	,	O
older	JJR	B-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
can	MD	O
tolerate	VB	O
amino	JJ	O
acids	NNS	O
in	IN	O
concentrations	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
%	NN	O
.	.	O

After	IN	O
failure	NN	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
for	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
or	CC	O
relapse	NN	O
within	IN	O
6	CD	O
months	NNS	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
the	DT	O
recommended	JJ	O
regimen	NNS	O
for	IN	O
ABRAXANE	NNP	O
is	VBZ	O
260	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
30	CD	O
minutes	NNS	O
every	DT	B-FREQ
3	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

Since	IN	O
the	DT	O
doses	NNS	O
of	IN	O
epinephrine	NN	O
delivered	VBN	O
from	IN	O
Adrenaclick	NNP	O
are	VBP	O
fixed	VBN	O
,	,	O
consider	VB	O
using	VBG	O
other	JJ	O
forms	NNS	O
of	IN	O
injectable	JJ	O
epinephrine	NN	O
if	IN	O
doses	NNS	O
lower	JJR	O
than	IN	O
0.15	CD	B-DOS
mg	NNS	B-UNIT
are	VBP	O
deemed	VBN	O
necessary	JJ	O
.	.	O

In	IN	O
patients	NNS	B-WHO
taking	VBG	I-WHO
amiodarone	NN	I-WHO
or	CC	I-WHO
verapamil	NN	I-WHO
concomitantly	RB	I-WHO
with	IN	I-WHO
ALTOCORTM	NNP	O-WHO
,	,	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Mypoathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
,	,	O
Other	JJ	O
Drug	NNP	O
Interactions	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
Bumex	NNP	O
(	(	O
bumetanide	NN	O
)	)	O
is	VBZ	O
0.5	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
2	CD	B-DOS
mg	NNS	B-UNIT
and	CC	O
in	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
is	VBZ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
.	.	O

See	NNP	O
also	RB	O
Section	NNP	O
titled	VBD	O
Volume	NN	O
Adjustment	NN	O
:	:	O
Patients	NNS	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
40	CD	I-WHO
kg	NNS	I-WHO
and	CC	I-WHO
Requiring	VBG	I-WHO
Fluid	NNP	I-WHO
Restriction	NN	O-WHO

They	PRP	O
may	MD	O
be	VB	O
restarted	VBN	O
at	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
Amikacin	NNP	O
Sulfate	NNP	O
Injection	NNP	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

or	CC	O
250	CD	B-DOS
mg	JJ	B-UNIT
q.i.d	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bleeding	NN	O
syndromes	NNS	O
due	JJ	O
to	TO	O
elevated	JJ	O
fibrinolytic	JJ	O
activity	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
5	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNPS	O-UNIT
or	CC	O
10	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNP	O-UNIT
(	(	O
5	CD	B-DOS
g	NN	B-UNIT
)	)	O
or	CC	O
20	CD	B-DOS
milliliter	NN	B-UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
5	CD	B-DOS
g	NN	B-UNIT
)	)	O
be	VB	O
administered	VBN	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuing	VBG	O
rate	NN	O
of	IN	O
1	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	B-DOS
mg	JJ	B-UNIT
Tablet	NNP	O-UNIT
or	CC	O
2	CD	B-DOS
AMICAR	NNP	B-UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	B-DOS
mg	JJ	B-UNIT
Tablets	NNP	O-UNIT
(	(	O
1	CD	B-DOS
g	NN	B-UNIT
)	)	O
or	CC	O
5	CD	B-DOS
milliliter	NN	B-UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
1.25	CD	B-DOS
g	NN	B-UNIT
)	)	O
per	IN	O
hour	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
100	CD	B-DOS
to	TO	O
200	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
MINTEZOL	NNP	O
(	(	O
thiabendazole	NN	O
)	)	O
is	VBZ	O
3	CD	B-DOS
grams	NNS	B-UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
COPD	NNP	O-WHO
is	VBZ	O
1	CD	B-DOS
inhalation	NN	B-UNIT
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
250	CD	O
/	VBD	O
50	CD	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

Figure	NN	O
16	CD	O

If	IN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
patients	NNS	B-WHO
receiving	VBG	I-WHO
the	DT	I-WHO
lowest	JJS	I-WHO
available	JJ	I-WHO
strength	NN	O-WHO
,	,	O
administer	NN	O
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
.	.	O

In	IN	O
adults	NNS	B-WHO
with	IN	I-WHO
ADHD	NNP	I-WHO
who	WP	I-WHO
are	VBP	I-WHO
either	DT	I-WHO
starting	VBG	I-WHO
treatment	NN	I-WHO
for	IN	I-WHO
the	DT	I-WHO
first	JJ	I-WHO
time	NN	I-WHO
or	CC	I-WHO
switching	VBG	I-WHO
from	IN	I-WHO
another	DT	I-WHO
medication	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Administer	NNP	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

Changes	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
that	WDT	O
indicate	VBP	O
a	DT	O
response	NN	O
to	TO	O
surgical	JJ	O
stress	NN	O
or	CC	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
may	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
4	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
and	CC	O
/	NN	O
or	CC	O
administration	NN	O
of	IN	O
bolus	JJ	O
doses	NNS	O
of	IN	O
7	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

For	IN	O
new	JJ	B-WHO
or	CC	I-WHO
worsening	VBG	I-WHO
Grade	JJ	I-WHO
2	CD	I-WHO
or	CC	I-WHO
3	CD	I-WHO
neuropathy	JJ	O-WHO
,	,	O
dosing	VBG	O
should	MD	O
be	VB	O
held	VBN	O
until	IN	O
neuropathy	JJ	O
improves	NNS	O
to	TO	O
Grade	VB	O
1	CD	O
or	CC	O
baseline	NN	O
and	CC	O
then	RB	O
restarted	VBD	O
at	IN	O
1.2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
.	.	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
<	VBP	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
weighing	VBG	I-WHO
<	$	I-WHO
70	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
should	MD	O
be	VB	O
calculated	VBN	O
according	VBG	O
to	TO	O
patient	NN	O
body	NN	O
weight	VBD	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
[	NN	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AmBisome	NNP	O
for	IN	O
each	DT	O
indication	NN	O
for	IN	O
adult	NN	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	FW	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
supplied	VBN	O
in	IN	O
individually	RB	O
sealed	VBN	O
dosage	NN	O
forms	NNS	O
which	WDT	O
pose	VBP	O
no	DT	O
known	VBN	O
risk	NN	O
to	TO	O
health	NN	O
-	:	O
care	NN	O
providers	NNS	O
having	VBG	O
incidental	JJ	O
contact	NN	O
.	.	O

Titrate	NNP	O
GRALISE	NNP	O
to	TO	O
an	DT	O
1800	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

AGRIFLUshould	RB	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
intramuscular	JJ	O
injection	NN	B-UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
region	NN	O
of	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Adding	VBG	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
53	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
54.7	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

Patients	NNS	B-WHO
6	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
with	IN	I-WHO
more	RBR	I-WHO
severe	JJ	I-WHO
asthma	NN	O-WHO
(	(	O
baseline	JJ	O
FEV1	NNP	O
less	JJR	O
than	IN	O
60	CD	O
%	NN	O
predicted	VBN	O
)	)	O
,	,	O
weight	VBD	B-WHO
>	$	I-WHO
40	CD	I-WHO
kg	NN	I-WHO
,	,	I-WHO
or	CC	I-WHO
patients	NNS	I-WHO
11	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
may	MD	O
achieve	VB	O
a	DT	O
better	JJR	O
initial	JJ	O
response	NN	O
with	IN	O
the	DT	O
1.25	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

The	DT	O
highest	JJS	O
recommended	VBD	O
dose	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
232	CD	B-DOS
/	JJ	O
14	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	O
is	VBZ	O
about	IN	O
1000	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
of	IN	O
therapy	NN	O
,	,	O
delivered	VBN	O
by	IN	O
the	DT	O
following	JJ	O
infusion	NN	O
regimen	NNS	O
:	:	O

Due	JJ	O
to	TO	O
incompletely	RB	O
developed	JJ	O
renal	JJ	O
function	NN	O
affecting	VBG	O
elimination	NN	O
of	IN	O
amoxicillin	NN	O
in	IN	O
this	DT	O
age	NN	O
group	NN	O
,	,	O
the	DT	O
recommended	VBN	O
upper	JJ	O
dose	NN	O
of	IN	O
AMOXIL	NNP	O
is	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
divided	VBD	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Patients	NNS	B-WHO
already	RB	I-WHO
receiving	VBG	I-WHO
a	DT	I-WHO
stable	JJ	I-WHO
dose	NN	I-WHO
of	IN	I-WHO
lovastatin	NN	I-WHO
who	WP	I-WHO
require	VBP	I-WHO
further	JJ	I-WHO
TG	NNP	O-WHO
-	:	O
lowering	NN	O
or	CC	O
HDL	NNP	O
-	:	O
raising	NN	O
(	(	O
e.g	UH	O
,	,	O
to	TO	O
achieve	VB	O
NCEP	NNP	O
non	SYM	O
-	:	O
HDL	NNP	O
-	:	O
C	NNP	O
goals	NNS	O
)	)	O
,	,	O
may	MD	O
receive	VB	O
concomitant	JJ	O
dosage	NN	O
titration	NN	O
with	IN	O
NIASPAN	NNP	O
per	IN	O
NIASPAN	NNP	O
recommended	VBD	O
initial	JJ	O
titration	NN	O
schedule	NN	O
(	(	O
see	VB	O
Table	NNP	O
10	CD	O
,	,	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
section	NN	O
)	)	O
.	.	O

To	TO	O
prepare	VB	O
TriHIBit	NNP	O
vaccine	NN	O
,	,	O
thoroughly	RB	O
agitate	VBP	O
the	DT	O
vial	NN	O
of	IN	O
Sanofi	NNP	O
Pasteur	NNP	O
Inc.	NNP	O
Tripedia	NNP	O
vaccine	NN	O
then	RB	O
withdraw	VBZ	O
0.6	CD	B-DOS
mL	NN	B-UNIT
and	CC	O
inject	NN	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

In	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
,	,	O
serum	JJ	O
amikacin	JJ	O
concentrations	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
to	TO	O
assure	VB	O
accurate	JJ	O
administration	NN	O
of	IN	O
amikacin	NNS	O
and	CC	O
to	TO	O
avoid	VB	O
concentrations	NNS	O
above	IN	O
35	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

One	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
Isopto®	NNP	O
Carpine	NNP	O
1	CD	O
%	NN	O
,	,	O
2	CD	O
%	NN	O
or	CC	O
4	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
in	IN	O
the	DT	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
up	IN	O
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Peak	JJ	O
concentrations	NNS	O
(	(	O
30	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
after	IN	O
injection	NN	O
)	)	O
above	IN	O
35	CD	B-DOS
µg	NNS	B-UNIT
per	IN	O
mL	NN	O
and	CC	O
trough	JJ	O
concentrations	NNS	O
(	(	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
next	JJ	O
dose	NN	O
)	)	O
above	IN	O
10	CD	B-DOS
µg	NNS	B-UNIT
per	IN	O
mL	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Apply	NNP	O
twice	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
3	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
,	,	O
then	RB	O
discontinue	NN	O
for	IN	O
4	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ADLYXIN	NNP	O
is	VBZ	O
10	CD	B-DOS
mcg	NN	B-UNIT
subcutaneously	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
14	CD	B-DUR
days	NNS	O-DUR
.	.	O

DUTREBIS	NNP	O
is	VBZ	O
a	DT	O
fixed	JJ	O
-	:	O
dose	JJ	O
combination	NN	O
product	NN	O
containing	VBG	O
150	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
lamivudine	NN	O
and	CC	O
300	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
raltegravir	NN	O
.	.	O

Flushing	VBG	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
may	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
frequency	NN	O
or	CC	O
severity	NN	O
by	IN	O
pretreatment	NN	O
with	IN	O
aspirin	NN	O
up	RB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
325	CD	B-DOS
mg	NN	B-UNIT
(	(	O
taken	VBN	O
up	RP	O
to	TO	O
approximately	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
ADVICOR	NNP	O
dose	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
older	JJR	B-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
.	.	O

Iron	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	B-WHO
child	NN	O-WHO
than	IN	O
the	DT	B-WHO
adult	NN	O-WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
by	IN	O
the	DT	O
growing	VBG	O
child	NN	O
.	.	O

Part	NN	O
of	IN	O
the	DT	O
nonprotein	JJ	O
caloric	JJ	O
requirement	NN	O
may	MD	O
be	VB	O
provided	VBN	O
as	IN	O
lipid	JJ	O
emulsion	NN	O
administered	VBD	O
concurrently	RB	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
daily	JJ	B-FREQ
calories	NNS	O
at	IN	O
a	DT	O
dose	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	B-DOS
g	JJ	B-UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

USE	NNP	O
ONLY	NNP	O
THE	NNP	O
ADRENALIN	NNP	O
1	CD	B-DOS
ML	NNP	B-UNIT
SINGLE	NNP	O
-	:	O
USE	NN	O
VIAL	NNP	O
FOR	NNP	O
OPHTHALMIC	NNP	O
USE	NNP	O
.	.	O

The	DT	O
maximum	JJ	O
radiant	JJ	O
exposure	NN	O
or	CC	O
irradiance	NN	O
(	(	O
within	IN	O
±15	NNP	O
percent	NN	O
)	)	O
of	IN	O
UVA	NNP	O
(	(	O
320	CD	B-DOS
–	RB	O
400	CD	B-DOS
nm	NNS	B-UNIT
)	)	O
delivered	VBN	O
to	TO	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
using	VBG	O
an	DT	O
appropriate	JJ	O
radiometer	NN	O
calibrated	VBD	O
to	TO	O
be	VB	O
read	VBN	O
in	IN	O
Joules	NNP	B-UNIT
/	NNP	O
cm²	NN	B-UNIT
or	CC	O
mW	NN	B-UNIT
/	JJ	O
cm²	NN	B-UNIT
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
ACTOS	NNP	O
is	VBZ	O
15	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
when	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
gemfibrozil	NN	O
or	CC	O
other	JJ	O
strong	JJ	O
CYP2C8	NNP	O
inhibitors	NNS	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

If	IN	O
no	DT	O
response	NN	O
is	VBZ	O
seen	VBN	O
at	IN	O
300	CD	B-DOS
mg	NN	B-UNIT
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
,	,	O
depending	VBG	O
upon	IN	O
tolerance	NN	O
,	,	O
up	RB	O
to	TO	O
400	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

Elderly	RB	B-WHO
or	CC	I-WHO
debilitated	VBN	I-WHO
patients	NNS	O-WHO
may	MD	O
be	VB	O
especially	RB	O
sensitive	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
zolpidem	NN	O
tartrate	NN	O
.	.	O

The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
.	.	O

ACIPHEX	NNP	O
Sprinkle	NNP	O
is	VBZ	O
recommended	VBN	O
for	IN	O
up	RB	B-DUR
to	TO	I-DUR
12	CD	I-DUR
weeks	NNS	O-DUR
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
1	CD	I-WHO
to	TO	I-WHO
11	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
and	CC	O
is	VBZ	O
dosed	VBN	O
by	IN	O
body	NN	O
weight	NN	O
:	:	O

In	IN	O
elderly	JJ	B-WHO
patients	NNS	I-WHO
(	(	I-WHO
greater	JJR	I-WHO
than	IN	I-WHO
70	CD	I-WHO
years	NNS	I-WHO
)	)	O-WHO
,	,	O
ACEON	NNP	O
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
2	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
first	JJ	O
week	NN	B-DUR
,	,	O
followed	VBN	O
by	IN	O
4	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
second	JJ	O
week	NN	B-DUR
and	CC	O
8	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
maintenance	NN	O
dose	NN	O
if	IN	O
tolerated	VBN	O
.	.	O

Figure	NN	O
10	CD	O

Usual	JJ	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
200	CD	B-DOS
to	TO	O
300	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
suspension	NN	O
for	IN	O
infusion	NN	O
when	WRB	O
prepared	VBN	O
as	IN	O
recommended	VBN	O
in	IN	O
an	DT	O
infusion	NN	O
bag	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
refrigerated	VBN	O
at	IN	O
2°C	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°F	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
protected	VBN	O
from	IN	O
bright	JJ	O
light	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	B-WHO
41	CD	I-WHO
kg	NN	I-WHO
to	TO	I-WHO
100	CD	I-WHO
kg	NNS	O-WHO

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
syphilis	NN	O
in	IN	O
patients	NNS	B-WHO
allergic	JJ	I-WHO
to	TO	I-WHO
penicillin	VB	O-WHO
,	,	O
the	DT	O
following	JJ	O
dosage	NN	O
of	IN	O
Achromycin	NNP	O
V	NNP	O
(	(	O
Tetracycline	NNP	O
HCl	NNP	O
Capsules	NNP	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
recommended	VBN	O
:	:	O
early	JJ	O
syphilis	NN	O
(	(	O
less	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
)	)	O
,	,	O
500	CD	B-DOS
mg	NN	B-UNIT
q.i.d	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
as	IN	O
50	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Nebulization	NNP	O
-	:	O
Face	NN	O
Mask	NNP	O
,	,	O
Mouthpiece	NNP	O
,	,	O
Tracheostomy	NNP	O
:	:	O
When	WRB	O
nebulized	VBN	O
into	IN	O
a	DT	O
face	NN	O
mask	NN	O
,	,	O
mouthpiece	NN	O
,	,	O
or	CC	O
tracheostomy	NN	O
,	,	O
1	CD	B-DOS
to	TO	O
10	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
2	CD	B-DOS
to	TO	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	O
2	CD	O
to	TO	O
6	CD	O
hours	NNS	O
;	:	O
the	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
is	VBZ	O
3	CD	B-DOS
to	TO	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
6	CD	B-DOS
to	TO	O
10	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
three	CD	O
to	TO	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Control	NNP	O
and	CC	O
Prevention	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
doses	NNS	O
higher	JJR	O
than	IN	O
800	CD	B-DOS
mcg	NNS	B-UNIT
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
in	IN	O
patients	NNS	B-WHO
.	.	O

May	NNP	O
be	VB	O
administered	VBN	O
by	IN	O
needle	JJ	O
and	CC	O
syringe	NN	O
(	(	O
5	CD	B-DOS
years	NNS	B-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
)	)	O-WHO
or	CC	O
PharmaJet	NNP	O
Stratis	NNP	O
Needle	NNP	O
-	:	O
Free	JJ	O
Injection	NN	O
System	NNP	O
(	(	O
18	CD	B-WHO
through	IN	I-WHO
64	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
only	RB	I-WHO
)	)	O-WHO
.	.	O

In	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
,	,	O
the	DT	O
higher	JJR	O
morning	NN	O
blood	NN	O
levels	NNS	O
following	VBG	O
use	NN	O
of	IN	O
the	DT	O
12.5	CD	B-DOS
mg	NN	B-UNIT
dose	JJ	O-UNIT
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
next	JJ	O
day	NN	O
impairment	NN	O
of	IN	O
driving	NN	O
and	CC	O
other	JJ	O
activities	NNS	O
that	WDT	O
require	VBP	O
full	JJ	O
alertness	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Treatment	NN	O
with	IN	O
Anafranil	NNP	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
25	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
and	CC	O
gradually	RB	O
increased	VBD	O
,	,	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
approximately	RB	O
100	CD	B-DOS
mg	NNS	B-UNIT
during	IN	O
the	DT	O
first	JJ	O
2	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

Acetylcysteine	NNP	O
Solution	NNP	O
,	,	O
USP	NNP	O
(	(	O
n	JJ	O
-	:	O
acetyl	NN	O
-	:	O
l	NN	O
-	:	O
cysteine	NN	O
)	)	O
is	VBZ	O
available	JJ	O
in	IN	O
rubber	NN	O
stoppered	JJ	O
glass	NN	O
vials	NNS	O
containing	VBG	O
10	CD	B-DOS
mL	NN	B-UNIT
or	CC	O
30	CD	B-DOS
mL	NN	B-UNIT
.	.	O

Uncomplicated	VBN	O
urethral	JJ	O
,	,	O
endocervical	JJ	O
,	,	O
or	CC	O
rectal	JJ	O
infection	NN	O
caused	VBN	O
by	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

(	(	O
c	NN	O
)	)	O
Slowly	RB	O
inject	VBP	O
the	DT	O
recommended	JJ	O
volume	NN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
intramuscular	JJ	O
injection	NN	B-UNIT
into	IN	O
the	DT	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
muscle	NN	O
.	.	O

If	IN	O
patients	NNS	B-WHO
develop	VBP	I-WHO
nonhematologic	JJ	I-WHO
toxicities	NNS	O-WHO
(	(	O
excluding	VBG	O
neurotoxicity	NN	O
)	)	O
>	NN	O
Grade	NNP	O
3	CD	O
,	,	O
treatment	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
until	IN	O
resolution	NN	O
to	TO	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
pre	JJ	O
-	:	O
therapy	NN	O
value	NN	O
.	.	O

Administer	NNP	O
only	RB	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
within	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
uncomplicated	JJ	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
250	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
may	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
as	IN	O
adjunctive	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	B-WHO
already	RB	I-WHO
taking	VBG	I-WHO
an	DT	I-WHO
antidepressant	NN	O-WHO
is	VBZ	O
2	CD	B-DOS
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

A	DT	O
normal	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
is	VBZ	O
15	CD	B-DUR
–	JJ	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
solution	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
adults	NNS	B-WHO
over	IN	O
a	DT	O
30	CD	O
to	TO	O
60	CD	O
minute	JJ	O
period	NN	O
.	.	O

Caregivers	NNS	O
of	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
receiving	VBG	I-WHO
doxorubicin	NN	O-WHO
should	MD	O
be	VB	O
counseled	VBN	O
to	TO	O
take	VB	O
precautions	NNS	O
(	(	O
such	JJ	O
as	IN	O
wearing	VBG	O
latex	JJ	O
gloves	NNS	O
)	)	O
to	TO	O
prevent	VB	O
contact	NN	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
urine	NN	O
and	CC	O
other	JJ	O
body	NN	O
fluids	NNS	O
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
5	CD	I-DUR
days	NNS	O-DUR
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
0.25	CD	O
percent	NN	O
Preservative	NNP	O
-	:	O
free	JJ	O
TIMOPTIC	NNP	O
in	IN	O
OCUDOSE	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
administered	VBD	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
mild	JJ	I-WHO
or	CC	I-WHO
moderate	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
and	CC	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
,	,	O
and	CC	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
sterile	JJ	O
solution	NN	O
containing	VBG	O
50	CD	B-DOS
mcg	JJ	B-UNIT
corticorelin	NN	O
/	NNP	O
mL	NN	O
is	VBZ	O
then	RB	O
ready	JJ	O
for	IN	O
injection	NN	O
by	IN	O
the	DT	O
intravenous	JJ	O
route	NN	O
.	.	O

Fat	NNP	O
emulsion	NN	O
may	MD	O
comprise	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
daily	JJ	B-FREQ
caloric	JJ	O
intake	NN	O
at	IN	O
a	DT	O
dosage	NN	O
level	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	B-DOS
g	JJ	B-UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

There	EX	O
are	VBP	O
two	CD	B-DOS
Activase	NNP	B-UNIT
dose	NN	O-UNIT
regimens	NNS	O
(	(	O
accelerated	VBN	O
and	CC	O
3	CD	O
-	:	O
hour	NN	O
)	)	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
AMI	NNP	O
;	:	O
there	EX	O
are	VBP	O
no	DT	O
controlled	JJ	O
studies	NNS	O
to	TO	O
compare	VB	O
clinical	JJ	O
outcomes	NNS	O
with	IN	O
these	DT	O
regimens	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

For	IN	O
patients	NNS	B-WHO
converting	VBG	I-WHO
from	IN	I-WHO
Actiq	NNP	I-WHO
doses	VBZ	O-WHO
400	CD	B-DOS
mcg	NN	B-UNIT
and	CC	O
below	IN	O
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
100	CD	B-DOS
mcg	JJ	B-UNIT
Abstral	NNP	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

Apply	NNP	O
to	TO	O
affected	VB	O
area	NN	O
3	CD	B-FREQ
to	TO	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

â€¢	JJ	O
Increase	NNP	O
the	DT	O
dose	NN	O
to	TO	O
the	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
20	CD	B-DOS
mcg	NNS	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
starting	VBG	O
on	IN	O
Day	NNP	O
15	CD	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1.0	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
after	IN	O
one	CD	B-DUR
week	NN	O-DUR
if	IN	O
ADHD	NNP	O
symptoms	NNS	O
are	VBP	O
not	RB	O
adequately	RB	O
controlled	VBN	O
.	.	O

Reconstituted	VBN	O
AFSTYLA	NNP	O
may	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
hours	NNS	O
.	.	O

Amphadase®	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
small	JJ	O
volumes	NNS	O
of	IN	O
solution	NN	O
(	(	O
up	IN	O
to	TO	O
200	CD	B-DOS
mL	NN	B-UNIT
)	)	O
,	,	O
such	JJ	O
as	IN	O
small	JJ	O
clysis	NN	O
for	IN	O
infants	NNS	B-WHO
or	CC	O
solutions	NNS	O
of	IN	O
drugs	NNS	O
for	IN	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMERGE	NNP	O
is	VBZ	O
1	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
2.5	CD	B-DOS
mg	NN	B-UNIT
.	.	O

If	IN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
use	VB	O
amiloride	JJ	O
HCl	NNP	O
alone	RB	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
)	)	O
,	,	O
the	DT	O
starting	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
one	CD	B-DOS
5	CD	O-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
.	.	O

300	CD	B-DOS
mg	NNS	B-UNIT
a	DT	B-FREQ
day	NN	O-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
at	IN	B-DUR
least	JJ	I-DUR
10	CD	I-DUR
days	NNS	O-DUR
.	.	O

Two	CD	B-DOS
to	TO	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
then	RB	O
be	VB	O
instilled	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
syringe	NN	O
connected	VBN	O
to	TO	O
the	DT	O
catheter	NN	O
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	B-DOS
to	TO	O
250	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	B-DOS
mL	NN	B-UNIT
,	,	O
administered	VBN	O
from	IN	O
containers	NNS	O
containing	VBG	O
250	CD	B-DOS
or	CC	O
500	CD	B-DOS
mL	NN	B-UNIT
.	.	O

In	IN	O
a	DT	O
large	JJ	O
randomized	VBN	O
study	NN	O
(	(	O
NSABP	NNP	O
B	NNP	O
-	:	O
15	CD	O
)	)	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
early	JJ	I-WHO
breast	NN	I-WHO
cancer	NN	I-WHO
involving	VBG	I-WHO
axillary	JJ	I-WHO
lymph	NN	I-WHO
nodes	NNS	O-WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Clinical	NNP	O
Studies	NNPS	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
,	,	O
Adverse	NNP	O
Reactions	NNP	O
in	IN	O
Patients	NNPS	B-WHO
with	IN	I-WHO
Early	JJ	I-WHO
Breast	NNP	I-WHO
Cancer	NNP	I-WHO
Receiving	NNP	I-WHO
Doxorubicin	NNP	O-WHO
-	:	O
Containing	VBG	O
Adjuvant	NNP	O
Therapy	NNP	O
)	)	O
,	,	O
the	DT	O
combination	NN	O
dosage	NN	O
regimen	NNS	O
of	IN	O
AC	NNP	O
(	(	O
doxorubicin	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
and	CC	O
cyclophosphamide	VB	O
600	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
treatment	NN	O
cycle	NN	O
.	.	O

After	IN	O
a	DT	O
period	NN	O
of	IN	O
2	CD	B-DUR
months	NNS	O-DUR
or	CC	O
more	JJR	O
off	IN	O
therapy	NN	O
,	,	O
and	CC	O
if	IN	O
warranted	VBN	O
by	IN	O
persistent	NN	O
or	CC	O
recurring	VBG	O
severe	JJ	O
nodular	JJ	O
acne	NN	O
,	,	O
a	DT	O
second	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
are	VBP	O
at	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
propylene	NN	O
glycol	NN	O
-	:	O
associated	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Figure	NN	O
13	CD	O

However	RB	O
,	,	O
on	IN	O
limited	JJ	O
clinical	JJ	O
experience	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
SYPRINE	NNP	O
is	VBZ	O
500	CD	B-DOS
-	:	O
750	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
and	CC	O
750	CD	B-DOS
-	:	O
1250	CD	B-DOS
mg	NN	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
adults	NNS	B-WHO
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
two	CD	B-FREQ
,	,	O
three	CD	B-FREQ
or	CC	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Hospitalized	VBN	B-WHO
patients	NNS	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
been	VBN	I-WHO
refractory	JJ	I-WHO
to	TO	I-WHO
antidepressant	VB	I-WHO
therapy	NN	I-WHO
and	CC	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
no	DT	I-WHO
history	NN	I-WHO
of	IN	I-WHO
convulsive	JJ	I-WHO
seizures	NNS	O-WHO
may	MD	O
have	VB	O
dosage	NN	O
raised	VBN	O
cautiously	RB	O
up	IN	O
to	TO	O
600	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
opioids	NNS	O
,	,	O
the	DT	O
safety	NN	O
of	IN	O
patients	NNS	B-WHO
using	VBG	I-WHO
such	JJ	I-WHO
products	NNS	O-WHO
is	VBZ	O
dependent	JJ	O
on	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
prescribing	VBG	O
them	PRP	O
in	IN	O
strict	JJ	O
conformity	NN	O
with	IN	O
their	PRP$	O
approved	JJ	O
labeling	NN	O
with	IN	O
respect	NN	O
to	TO	O
patient	JJ	O
selection	NN	O
,	,	O
dosing	NN	O
,	,	O
and	CC	O
proper	JJ	O
conditions	NNS	O
for	IN	O
use	NN	O
.	.	O

Example	NN	O
:	:	O
UPAH	NNP	O
=	VBZ	O
8	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
mL	NN	O

Adult	NN	B-WHO
patients	NNS	I-WHO
whose	WP$	I-WHO
disease	NN	I-WHO
is	VBZ	I-WHO
very	RB	I-WHO
severe	JJ	I-WHO
with	IN	I-WHO
scarring	NN	O-WHO
or	CC	O
is	VBZ	O
primarily	RB	O
manifested	VBN	O
on	IN	O
the	DT	O
trunk	NN	O
may	MD	O
require	VB	O
dose	NN	O
adjustments	NNS	O
up	IN	O
to	TO	O
2.0	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	B-DOS
g	NNS	B-UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBN	O
in	IN	O
1000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	B-DOS
hrs	NNS	B-UNIT

ABELCET®	NNP	O
(	(	O
amphotericin	IN	O
b	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	JJ	O
h	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
of	IN	O
ALDURAZYME	NNP	O
is	VBZ	O
0.58	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
administered	VBN	O
once	RB	B-FREQ
weekly	JJ	O-FREQ
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
.	.	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
ABRAXANE	NNP	O
are	VBP	O
stable	JJ	O
until	IN	O
the	DT	O
date	NN	O
indicated	VBD	O
on	IN	O
the	DT	O
package	NN	O
when	WRB	O
stored	VBD	O
between	IN	O
20°C	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°F	CD	O
to	TO	O
77°F	CD	O
)	)	O
in	IN	O
the	DT	O
original	JJ	O
package	NN	O
.	.	O

Schnurr	NNP	O
,	,	O
E.	NNP	O
;	:	O
Lahme	NNP	O
,	,	O
W.	NNP	O
;	:	O
Kuppers	NNP	O
,	,	O
H.	NNP	O
:	:	O
Measurement	NN	O
of	IN	O
renal	JJ	O
clearance	NN	O
of	IN	O
inulin	NN	O
and	CC	O
PAH	NNP	O
in	IN	O
the	DT	O
steady	JJ	O
state	NN	O
without	IN	O
urine	JJ	O
collection	NN	O
;	:	O
Clinical	NNP	O
Nephrology	NNP	O
,	,	O
13	CD	O
(	(	O
1	CD	O
)	)	O
:	:	O
(	(	O
26	CD	O
-	:	O
29	CD	O
)	)	O
,	,	O
1980	CD	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
30	CD	B-DOS
micrograms	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
week	NN	O-FREQ
.	.	O

For	IN	O
previously	RB	B-WHO
unvaccinated	JJ	I-WHO
children	NNS	O-WHO
,	,	O
the	DT	O
number	NN	O
of	IN	O
doses	NNS	O
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
needed	VBD	O
depends	VBZ	O
on	IN	O
the	DT	O
age	NN	O
at	IN	O
which	WDT	O
the	DT	O
immunization	NN	O
series	NN	O
is	VBZ	O
begun	VBN	O
.	.	O

15	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
850	CD	B-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
:	:	O
white	JJ	O
to	TO	O
off	VB	O
-	:	O
white	JJ	O
,	,	O
oblong	JJ	O
,	,	O
film	NN	O
-	:	O
coated	VBN	O
tablet	NN	O
with	IN	O
“	JJ	O
4833M	CD	O
”	NN	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
“	$	O
15	CD	O
/	$	O
850	CD	O
”	NN	O
on	IN	O
the	DT	O
other	JJ	O
,	,	O
available	JJ	O
in	IN	O
:	:	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
dosage	NN	O
increases	NNS	O
above	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
should	MD	O
only	RB	O
be	VB	O
considered	VBN	O
if	IN	O
the	DT	O
expected	JJ	O
benefit	NN	O
exceeds	VBZ	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
myopathy	JJ	O
/	JJ	O
rhabdomyolysis	NN	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
Hepatic	JJ	I-WHO
Impairment	NN	O-WHO
:	:	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
or	CC	I-WHO
severe	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

Figure	NN	O
5	CD	O

To	TO	O
prepare	VB	O
ActHIB	NNP	O
vaccine	NN	O
,	,	O
withdraw	JJ	O
0.6	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
saline	JJ	O
diluent	NN	O
(	(	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
)	)	O
and	CC	O
inject	VB	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

Although	IN	O
there	EX	O
was	VBD	O
a	DT	O
threefold	JJ	O
increase	NN	O
in	IN	O
acetylcysteine	JJ	O
plasma	NN	O
concentrations	NNS	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
cirrhosis	NN	O-WHO
,	,	O
no	DT	O
data	NNS	O
are	VBP	O
available	JJ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
required	VBN	O
.	.	O

Note	NN	O
:	:	O
this	DT	O
0.3	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent	NN	O
is	VBZ	O
not	RB	O
the	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
diluent	JJ	O
vial	NN	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	B-DOS
hr	NNS	B-UNIT

If	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
to	TO	O
receive	VB	O
more	JJR	O
than	IN	O
one	CD	B-DOS
vial	NN	B-UNIT
of	IN	O
ADYNOVATE	NNP	O
,	,	O
the	DT	O
contents	NNS	O
of	IN	O
multiple	JJ	O
vials	NNS	O
may	MD	O
be	VB	O
drawn	VBN	O
into	IN	O
the	DT	O
same	JJ	O
syringe	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
24	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
orally	RB	O
with	IN	O
food	NN	O
and	CC	O
water	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
for	IN	O
children	NNS	B-WHO
is	VBZ	O
30	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
doses	VBZ	O
greater	JJR	O
than	IN	O
30	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
of	IN	O
ADDERALL	NNP	O
XR	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	B-WHO
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
dose	NN	O
for	IN	O
an	DT	B-WHO
adult	NN	O-WHO
is	VBZ	O
1	CD	B-DOS
g	NN	B-UNIT
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
kcal	JJ	O
.	.	O

For	IN	O
severely	RB	B-WHO
catabolic	JJ	I-WHO
,	,	I-WHO
depleted	JJ	I-WHO
patients	NNS	I-WHO
or	CC	I-WHO
those	DT	I-WHO
who	WP	I-WHO
require	VBP	I-WHO
long	JJ	I-WHO
-	:	I-WHO
term	NN	I-WHO
parenteral	JJ	I-WHO
nutrition	NN	O-WHO
,	,	O
central	JJ	O
venous	JJ	O
nutrition	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

When	WRB	O
the	DT	O
dose	NN	O
counter	NN	O
reaches	VBZ	O
20	CD	O
,	,	O
the	DT	O
color	NN	O
of	IN	O
the	DT	O
numbers	NNS	O
will	MD	O
change	VB	O
to	TO	O
red	VB	O
to	TO	O
remind	VB	O
the	DT	O
patient	NN	O
to	TO	O
contact	VB	O
their	PRP$	O
pharmacist	NN	O
for	IN	O
a	DT	O
refill	NN	O
of	IN	O
medication	NN	O
or	CC	O
consult	VB	O
their	PRP$	O
physician	NN	O
for	IN	O
a	DT	O
prescription	NN	O
refill	NN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
nebulizers	NNS	O
tested	VBN	O
will	MD	O
supply	VB	O
a	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
the	DT	O
drug	NN	O
solution	NN	O
as	IN	O
particles	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	B-DOS
microns	NNS	B-UNIT
in	IN	O
diameter	NN	O
.	.	O

If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
a	DT	O
400	CD	B-DOS
mcg	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
the	DT	O
next	JJ	O
titration	NN	O
step	NN	O
is	VBZ	O
600	CD	B-DOS
mcg	NN	B-UNIT
.	.	O

ALDACTONE	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
400	CD	B-DOS
mg	NNS	B-UNIT
for	IN	O
four	CD	B-DUR
days	NNS	O-DUR
.	.	O

Adding	VBG	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
multiple	JJ	O
electrolyte	NN	O
additive	NN	O
,	,	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
each	DT	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
solution	NN	O
and	CC	O
4	CD	B-DOS
to	TO	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
each	DT	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
40	CD	O
to	TO	O
50	CD	O
%	NN	O
dextrose	JJ	O
solution	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
appropriate	VBP	O
for	IN	O
central	JJ	O
vein	JJ	O
administration	NN	O
.	.	O

Titrate	VB	O
the	DT	O
dose	NN	O
to	TO	O
attain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	B-DOS
to	TO	O
15	CD	B-DOS
ng	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Akten™	NNP	O
(	(	O
lidocaine	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
gel	NN	O
)	)	O
is	VBZ	O
2	CD	B-DOS
drops	NNS	B-UNIT
applied	VBN	O
to	TO	O
the	DT	O
ocular	JJ	O
surface	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
planned	JJ	O
procedure	NN	O
.	.	O

Some	DT	B-WHO
patients	NNS	O-WHO
may	MD	O
require	VB	O
up	IN	O
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
,	,	O
given	VBN	O
as	IN	O
one	CD	B-DOS
(	(	O
1	CD	B-DOS
)	)	O
AMRIX	$	O
30	CD	B-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
as	IN	O
two	CD	B-DOS
(	(	O
2	CD	B-DOS
)	)	O
AMRIX	$	O
15	CD	B-DOS
mg	NN	B-UNIT
capsules	NNS	O-UNIT
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

In	IN	O
adults	NNS	B-WHO
,	,	O
in	IN	O
one	CD	O
clinical	JJ	O
trial	NN	O
,	,	O
doses	VBZ	O
over	IN	O
600	CD	B-DOS
mg	NNS	B-UNIT
a	DT	B-FREQ
day	NN	O-FREQ
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACULAR	NNP	O
LS™	NNP	O
(	(	O
ketorolac	FW	O
tromethamine	VB	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
ophthalmic	JJ	O
solution	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
in	IN	O
the	DT	O
operated	JJ	O
eye	NN	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
and	CC	O
burning	NN	O
/	NN	O
stinging	VBG	O
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
4	CD	I-DUR
days	NNS	O-DUR
following	VBG	O
corneal	JJ	O
refractive	JJ	O
surgery	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Vizamyl	NNP	O
is	VBZ	O
185	CD	B-DOS
megabecquerels	NNS	B-UNIT
(	(	O
MBq	NNP	O
)	)	O
[	VBD	O
5	CD	B-DOS
millicuries	NNS	B-UNIT
(	(	O
mCi	NN	O
)	)	O
]	NN	O
in	IN	O
a	DT	O
maximum	JJ	O
dose	JJ	O
volume	NN	O
of	IN	O
10	CD	B-DOS
mL	NNS	B-UNIT
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
bolus	NN	O-UNIT
within	IN	O
40	CD	O
seconds	NNS	O
.	.	O

Only	RB	O
in	IN	O
rare	JJ	O
cases	NNS	O
will	MD	O
it	PRP	O
be	VB	O
necessary	JJ	O
to	TO	O
exceed	VB	O
a	DT	O
total	NN	O
of	IN	O
40	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
5.6	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

A	DT	O
10	CD	O
%	NN	O
lipid	JJ	O
emulsion	NN	O
contains	VBZ	O
1.1	CD	O
kcal	JJ	O
/	NN	O
mL	NN	O
.	.	O

(	(	O
Initial	JJ	O
dosage	NN	O
of	IN	O
300	CD	B-DOS
mg	NNS	B-UNIT
daily	JJ	B-FREQ
may	MD	O
be	VB	O
given	VBN	O
,	,	O
but	CC	O
notable	JJ	O
sedation	NN	O
may	MD	O
occur	VB	O
in	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
during	IN	O
the	DT	O
first	JJ	O
few	JJ	O
days	NNS	O
of	IN	O
therapy	NN	O
at	IN	O
this	DT	O
level	NN	O
.	.	O
)	)	O

Recommended	VBN	O
starting	JJ	O
dosage	NN	O
of	IN	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
small	JJ	O
syringes	NNS	O
(	(	O
0.5	CD	B-DOS
mL	NN	B-UNIT
or	CC	O
1	CD	B-DOS
mL	NNS	B-UNIT
)	)	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
minimize	VB	O
any	DT	O
product	NN	O
loss	NN	O
.	.	O

Do	NNP	O
not	RB	O
combine	VB	O
the	DT	O
2	CD	O
dosage	NN	O
forms	NNS	O
(	(	O
AFINITOR	NNP	O
Tablets	NNP	O
and	CC	O
AFINITOR	NNP	O
DISPERZ	NNP	O
)	)	O
to	TO	O
achieve	VB	O
the	DT	O
desired	JJ	O
total	NN	O
dose	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
weighing	VBG	I-WHO
≥	JJ	I-WHO
65	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBD	O
as	IN	O
60	CD	B-DOS
mg	NN	B-UNIT
in	IN	O
the	DT	O
first	JJ	O
hour	NN	O
(	(	O
6	CD	B-DOS
-	:	O
10	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
as	IN	O
a	DT	O
bolus	NN	O
)	)	O
,	,	O
20	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
the	DT	O
second	JJ	O
hour	NN	O
,	,	O
and	CC	O
20	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
the	DT	O
third	JJ	O
hour	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AllerNaze	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
for	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
is	VBZ	O
200	CD	B-DOS
mcg	JJ	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
given	VBN	O
as	IN	O
2	CD	B-DOS
sprays	NNS	B-UNIT
(	(	O
approximately	RB	O
50	CD	B-DOS
mcg	NNS	B-UNIT
/	NNP	O
spray	NN	O
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ABRAXANE	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
dosages	NNS	O
used	VBN	O
in	IN	O
neonates	NNS	B-WHO
,	,	O
infants	NNS	B-WHO
,	,	I-WHO
children	NNS	I-WHO
and	CC	I-WHO
adolescents	NNS	I-WHO
were	VBD	I-WHO
equivalent	JJ	I-WHO
to	TO	I-WHO
those	DT	I-WHO
administered	VBN	I-WHO
to	TO	I-WHO
adults	NNS	O-WHO
on	IN	O
a	DT	O
weight	JJ	O
basis	NN	O
.	.	O

Therefore	RB	O
,	,	O
appropriate	JJ	O
caution	NN	O
and	CC	O
follow	VB	O
-	:	O
up	RP	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
alosetron	JJ	O
hydrochloride	NN	O
tablets	NNS	O
are	VBP	O
prescribed	VBN	O
for	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
.	.	O

ALIMTA	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
a	DT	O
patient	NN	B-WHO
experiences	VBZ	I-WHO
any	DT	I-WHO
hematologic	NN	I-WHO
or	CC	I-WHO
nonhematologic	JJ	I-WHO
Grade	NNP	I-WHO
3	CD	I-WHO
or	CC	I-WHO
4	CD	I-WHO
toxicity	NN	O-WHO
after	IN	O
2	CD	B-DOS
dose	JJ	B-UNIT
reductions	NNS	O-UNIT
or	CC	O
immediately	RB	O
if	IN	O
Grade	VBN	O
3	CD	O
or	CC	O
4	CD	O
neurotoxicity	NN	O
is	VBZ	O
observed	VBN	O
.	.	O

4	CD	O

Reduced	VBN	O
Dosage	NN	O
at	IN	O
Fixed	NNP	O
Time	NNP	O
Intervals	NNS	O
:	:	O
When	WRB	O
renal	JJ	O
function	NN	O
is	VBZ	O
impaired	JJ	O
and	CC	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
administer	VB	O
amikacin	NN	O
at	IN	O
a	DT	O
fixed	JJ	O
time	NN	O
interval	NN	O
,	,	O
dosage	NN	O
must	MD	O
be	VB	O
reduced	VBN	O
.	.	O

One	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
ACUVAIL®	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
beginning	VBG	O
1	CD	O
day	NN	O
prior	RB	O
to	TO	O
cataract	VB	O
surgery	NN	O
,	,	O
continued	VBD	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
,	,	O
and	CC	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

Vials	NNS	O
of	IN	O
AmBisome	NNP	O
containing	VBG	O
50	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
amphotericin	NN	O
B	NNP	O
are	VBP	O
prepared	JJ	O
as	IN	O
follows	VBZ	O
:	:	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1	CD	B-DOS
Joule	NNP	B-UNIT
/	NNP	O
cm²	NN	B-UNIT
at	IN	O
each	DT	O
treatment	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
impaired	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
either	RB	O
by	IN	O
administering	VBG	O
normal	JJ	O
doses	NNS	O
at	IN	O
prolonged	JJ	O
intervals	NNS	O
or	CC	O
by	IN	O
administering	VBG	O
reduced	JJ	O
doses	NNS	O
at	IN	O
afixed	JJ	O
interval	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
ALDACTAZIDE	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	JJ	B-UNIT
each	DT	O
of	IN	O
spironolactone	NN	O
and	CC	O
hydrochlorothiazide	JJ	O
daily	RB	B-FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
but	CC	O
may	MD	O
range	VB	O
from	IN	O
25	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
200	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
each	DT	O
component	JJ	O
daily	JJ	B-FREQ
depending	VBG	O
on	IN	O
the	DT	O
response	NN	O
to	TO	O
the	DT	O
initial	JJ	O
titration	NN	O
.	.	O

When	WRB	O
renal	JJ	O
function	NN	O
is	VBZ	O
impaired	JJ	O
and	CC	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
administer	VB	O
amikacin	NN	O
at	IN	O
a	DT	O
fixed	JJ	O
time	NN	O
interval	NN	O
,	,	O
dosage	NN	O
must	MD	O
be	VB	O
reduced	VBN	O
.	.	O

Insufficient	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
to	TO	O
warrant	VB	O
use	NN	O
in	IN	O
children	NNS	B-WHO
under	IN	I-WHO
age	NN	I-WHO
6	CD	O-WHO
.	.	O

Apply	NNP	O
Cloderm	NNP	O
(	(	O
clocortolone	NN	O
pivalate	NN	O
)	)	O
Cream	NNP	O
0.1	CD	O
%	NN	O
sparingly	RB	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
.	.	O

Most	JJS	B-WHO
patients	NNS	O-WHO
have	VBP	O
required	VBN	O
dosages	NNS	O
of	IN	O
20	CD	B-DOS
,	,	O
40	CD	B-DOS
,	,	O
or	CC	O
80	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
.	.	O

In	IN	O
hyperammonemic	JJ	B-WHO
infants	NNS	I-WHO
with	IN	I-WHO
suspected	JJ	I-WHO
,	,	I-WHO
but	CC	I-WHO
unconfirmed	JJ	I-WHO
urea	JJ	I-WHO
cycle	NN	I-WHO
disorders	NNS	O-WHO
,	,	O
intravenous	JJ	O
arginine	NN	O
should	MD	O
be	VB	O
given	VBN	O
(	(	O
6	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
Arginine	NNP	O
HCl	NNP	O
Injection	NNP	O
10	CD	O
%	NN	O
,	,	O
over	IN	O
90	CD	O
minutes	NNS	O
followed	VBN	O
by	IN	O
the	DT	O
same	JJ	O
dose	JJ	O
given	VBN	O
as	IN	O
a	DT	O
maintenance	NN	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
)	)	O
.	.	O

ACTOPLUS	NNP	O
MET	NNP	O
is	VBZ	O
available	JJ	O
in	IN	O
15	CD	B-DOS
mg	NN	B-UNIT
pioglitazone	NN	O
(	(	O
as	IN	O
the	DT	O
base	NN	O
)	)	O
/	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
metformin	NN	O
hydrochloride	NN	O
and	CC	O
15	CD	B-DOS
mg	NN	B-UNIT
pioglitazone	NN	O
(	(	O
as	IN	O
the	DT	O
base	NN	O
)	)	O
/	VBZ	O
850	CD	B-DOS
mg	NN	B-UNIT
metformin	NN	O
hydrochloride	JJ	O
tablets	NNS	O
as	IN	O
follows	VBZ	O
:	:	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

Ambien	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
and	CC	O
should	MD	O
not	RB	O
be	VB	O
readministered	VBN	O
during	IN	O
the	DT	O
same	JJ	O
night	NN	O
.	.	O

Children	NNP	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
30	CD	I-WHO
kg	NN	I-WHO
(	(	I-WHO
66	CD	I-WHO
lbs	NN	I-WHO
)	)	O-WHO
:	:	O
0.01	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
kg	NN	O
(	(	O
0.01	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
undiluted	JJ	O
Adrenalin®	NNP	O
administered	VBD	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.3	CD	B-DOS
mg	NN	B-UNIT
(	(	O
0.3	CD	B-DOS
mL	NN	B-UNIT
)	)	O
per	IN	O
injection	NN	O
,	,	O
repeated	VBN	O
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
as	IN	O
necessary	JJ	O
.	.	O

UPAH	NNP	O
=	VBD	O
9.55	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
V	NNP	O
=	VBZ	O
16.68	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
GFR	NNP	O
=	VBZ	O
120	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
PPAH	NNP	O
=	VBZ	O
0.60	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
Then	RB	O
TmPAH	NNP	O
=	NNP	O
9.55	CD	O
x	VBD	O
16.68	CD	B-DOS
–	NNP	B-UNIT
(	(	O
120	CD	O
x	RB	O
0.60	CD	O
x	JJ	O
0.83	CD	O
)	)	O
=	VBD	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

Solutions	NNS	O
containing	VBG	O
3.5	CD	O
to	TO	O
5	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
infused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ALOPRIM	NNP	O
(	(	O
allopurinol	JJ	O
sodium	NN	O
)	)	O
for	IN	O
Injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
impaired	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
to	TO	O
avoid	VB	O
accumulation	NN	O
of	IN	O
allopurinol	NN	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
:	:	O

Luminescence	NN	O
appears	VBZ	O
in	IN	O
the	DT	O
retina	NN	O
and	CC	O
choroidal	NN	O
vessels	NNS	O
in	IN	O
9	CD	O
to	TO	O
14	CD	O
seconds	NNS	O
and	CC	O
can	MD	O
be	VB	O
observed	VBN	O
by	IN	O
standard	JJ	O
viewing	VBG	O
equipment	NN	O
.	.	O

The	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
in	IN	O
children	NNS	B-WHO
and	CC	I-WHO
adults	NNS	O-WHO
is	VBZ	O
1	CD	B-DOS
-	:	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

7	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
(	(	O
e.	JJ	O
g.	NN	O
,	,	O
100	CD	B-DOS
-	:	O
125	CD	B-DOS
mcg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
a	DT	O
70	CD	B-WHO
kg	NN	I-WHO
adult	NN	O-WHO
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
by	IN	O
IV	NNP	O
infusion	NN	O
over	IN	O
2	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
total	NN	O
(	(	O
diet	JJ	O
and	CC	O
otherwise	RB	O
)	)	O
daily	RB	B-FREQ
calcium	JJ	O
intake	NN	O
in	IN	O
postmenopausal	JJ	B-WHO
women	NNS	O-WHO
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
elemental	JJ	O
calcium	NN	O
.	.	O

The	DT	O
estimated	VBN	O
absorbed	IN	O
radiation	NN	O
doses	NNS	O
to	TO	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	O-WHO
from	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
are	VBP	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
:	:	O

Estimated	VBN	O
Increment	NNP	O
of	IN	O
factor	NN	O
VIII	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	B-DOS
(	(	O
IU	NNP	O
/	NNP	O
dL	NN	O
per	IN	O
IU	NNP	O
/	NNP	O
kg	NN	O
)	)	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ARAVA	NNP	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
3	CD	B-DOS
separate	JJ	B-UNIT
doses	NNS	O-UNIT
and	CC	O
administered	VBN	O
over	IN	O
a	DT	O
total	NN	O
of	IN	O
21	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
range	NN	O
is	VBZ	O
4	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
8	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
or	CC	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
is	VBZ	O
6.3	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
range	NN	O
is	VBZ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
.	.	O

For	IN	O
patients	NNS	B-WHO
between	IN	I-WHO
4	CD	I-WHO
and	CC	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
for	IN	I-WHO
patients	NNS	I-WHO
13	CD	I-WHO
to	TO	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
with	IN	I-WHO
weight	NN	I-WHO
of	IN	I-WHO
<	$	I-WHO
50	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
twice	RB	B-FREQ
daily	RB	O-FREQ
or	CC	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBD	O
3	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
to	TO	O
a	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
2,400	CD	B-DOS
mg	NN	B-UNIT
)	)	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

If	IN	O
no	DT	O
intolerance	NN	O
is	VBZ	O
observed	VBN	O
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
week	NN	B-DUR
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Patients	NNS	B-WHO
whose	WP$	I-WHO
blood	NN	I-WHO
pressures	NNS	I-WHO
are	VBP	I-WHO
adequately	RB	I-WHO
controlled	VBN	I-WHO
with	IN	O-WHO
25	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
daily	JJ	B-FREQ
hydrochlorothiazide	NN	O
,	,	O
but	CC	O
who	WP	O
experience	VBP	O
significant	JJ	O
potassium	NN	O
loss	NN	O
with	IN	O
this	DT	O
regimen	NNS	O
,	,	O
may	MD	O
achieve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
with	IN	O
less	JJR	O
electrolyte	JJ	O
disturbance	NN	O
if	IN	O
they	PRP	O
are	VBP	O
switched	VBN	O
to	TO	O
ACCURETIC	NNP	O
10	CD	O
/	NNP	O
12.5	CD	O
or	CC	O
20	CD	O
/	JJ	O
12.5	CD	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
the	DT	O
highest	JJS	O
tolerated	JJ	O
dosage	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
2.5	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Complete	JJ	O
blood	NN	O
cell	NN	O
counts	NNS	O
,	,	O
including	VBG	O
platelet	NN	O
counts	NNS	O
,	,	O
should	MD	O
be	VB	O
performed	VBN	O
on	IN	O
all	DT	B-WHO
patients	NNS	I-WHO
receiving	VBG	I-WHO
ALIMTA	NNP	O-WHO
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
:	:	O
total	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
reduction	NN	O
of	IN	O
recommended	JJ	O
individual	JJ	O
doses	NNS	O
and	CC	O
/	NN	O
or	CC	O
by	IN	O
extending	VBG	O
time	NN	O
intervals	NNS	O
between	IN	O
doses	NNS	O
.	.	O

The	DT	O
dosage	NN	O
employed	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
simple	NN	O
(	(	O
open	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
ranges	VBZ	O
from	IN	O
250	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
1	CD	B-DOS
g	NN	B-UNIT
of	IN	O
acetaZOLAMIDE	JJ	O
per	IN	O
24	CD	O
hours	NNS	O
,	,	O
usually	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
amounts	NNS	O
over	IN	O
250	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

Usual	JJ	O
starting	VBG	O
dosage	NN	O
is	VBZ	O
50	CD	B-DOS
mg	NN	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
suggested	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
aged	VBN	I-WHO
6	CD	I-WHO
to	TO	I-WHO
12	CD	O-WHO
is	VBZ	O
5	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
;	:	O
daily	RB	B-FREQ
dose	VB	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
not	RB	I-WHO
on	IN	I-WHO
inhaled	JJ	I-WHO
corticosteroids	NNS	O-WHO
is	VBZ	O
55	CD	B-DOS
/	JJ	O
14	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
plaque	JJ	I-WHO
psoriasis	NN	O-WHO
(	(	O
Ps	NNP	O
)	)	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
80	CD	B-DOS
mg	NN	B-UNIT
,	,	O
followed	VBN	O
by	IN	O
40	CD	B-DOS
mg	NNS	B-UNIT
given	VBN	O
every	DT	B-FREQ
other	JJ	I-FREQ
week	NN	O-FREQ
starting	VBG	O
one	CD	B-DUR
week	NN	O-DUR
after	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
200	CD	B-DOS
micrograms	NNS	B-UNIT
(	(	O
mcg	NN	O
)	)	O
given	VBN	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
.	.	O

1	CD	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
upward	RB	O
until	IN	O
blood	NN	O
pressure	NN	O
is	VBZ	O
controlled	VBN	O
or	CC	O
to	TO	O
a	DT	O
maximum	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
ABSORICA	NNP	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
for	IN	O
15	CD	B-DUR
to	TO	I-DUR
20	CD	I-DUR
weeks	NNS	O-DUR
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	B-WHO
administered	VBN	I-WHO
anesthetic	JJ	O-WHO
(	(	O
induction	NN	O
)	)	O
dosages	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
that	IN	O
qualified	JJ	O
personnel	NNS	O
and	CC	O
adequate	JJ	O
facilities	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

Typically	RB	O
,	,	O
a	DT	O
hospitalized	JJ	B-WHO
patient	NN	O-WHO
may	MD	O
lose	VB	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
a	DT	B-FREQ
day	NN	O-FREQ
,	,	O
and	CC	O
in	IN	O
severe	JJ	O
trauma	VBP	O
the	DT	O
daily	JJ	B-FREQ
loss	NN	O
may	MD	O
be	VB	O
20	CD	B-DOS
to	TO	O
25	CD	B-DOS
grams	NNS	B-UNIT
or	CC	O
more	JJR	O
.	.	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
If	IN	O
AGENERASE	NNP	O
and	CC	O
ritonavir	NN	O
are	VBP	O
used	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
:	:	O
AGENERASE	$	O
1200	CD	B-DOS
mg	NN	B-UNIT
with	IN	O
ritonavir	JJ	O
200	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
AGENERASE	$	O
600	CD	B-DOS
mg	NN	B-UNIT
with	IN	O
ritonavir	JJ	O
100	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

A	DT	O
thiazide	NN	O
may	MD	O
be	VB	O
added	VBN	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
methyldopa	JJ	O
therapy	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
if	IN	O
therapy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
started	VBN	O
with	IN	O
a	DT	O
thiazide	NN	O
or	CC	O
if	IN	O
effective	JJ	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
can	MD	O
not	RB	O
be	VB	O
maintained	VBN	O
on	IN	O
2	CD	B-DOS
g	NN	B-UNIT
of	IN	O
methyldopa	JJ	O
daily	JJ	B-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
VEMLIDY	NNP	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
(	(	O
one	CD	B-DOS
tablet	NN	B-UNIT
)	)	O
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ABRAXANE	NNP	O
is	VBZ	O
125	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
-	:	O
40	CD	O
minutes	NNS	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
8	CD	O
and	CC	O
15	CD	O
of	IN	O
each	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

6	CD	O

Figure	NN	O
6	CD	O
:	:	O
Hold	CD	O
Breath	NN	O

When	WRB	O
undiluted	JJ	O
albumin	NN	O
solution	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
normal	JJ	I-WHO
blood	NN	I-WHO
volume	NN	O-WHO
,	,	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
should	MD	O
be	VB	O
slow	JJ	O
enough	RB	O
(	(	O
1	CD	B-DOS
mL	NNS	B-UNIT
per	IN	O
minute	NN	O
)	)	O
to	TO	O
prevent	VB	O
too	RB	O
rapid	JJ	O
expansion	NN	O
of	IN	O
plasma	NN	O
volume	NN	O
.	.	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
and	CC	I-WHO
patients	NNS	I-WHO
with	IN	I-WHO
cardiovascular	JJ	I-WHO
disease	NN	O-WHO
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
infusion	NN	O
concentration	NN	O
of	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

This	DT	O
solution	NN	O
is	VBZ	O
indicated	VBN	O
for	IN	O
patients	NNS	B-WHO
requiring	VBG	I-WHO
larger	JJR	I-WHO
amounts	NNS	I-WHO
of	IN	I-WHO
nitrogen	NN	O-WHO
than	IN	O
could	MD	O
otherwise	RB	O
be	VB	O
provided	VBN	O
or	CC	O
where	WRB	O
total	JJ	O
fluid	NN	O
load	NN	O
must	MD	O
be	VB	O
kept	VBN	O
to	TO	O
a	DT	O
minimum	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
failure	NN	O-WHO
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
the	DT	O
gel	NN	O
should	MD	O
be	VB	O
applied	VBN	O
,	,	O
avoiding	VBG	O
eyes	NNS	O
,	,	O
lips	NNS	O
,	,	O
and	CC	O
mucous	JJ	O
membranes	NNS	O
.	.	O

ALLZITAL	NNP	O
(	(	O
butalbital	JJ	O
and	CC	O
acetaminophen	NN	O
,	,	O
25	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
325	CD	B-DOS
mg	NN	B-UNIT
)	)	O
tablets	NNS	O
:	:	O
Two	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Olux	NNP	O
-	:	O
E	NN	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
foam	NN	O
)	)	O
Foam	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
2	CD	I-DUR
consecutive	JJ	I-DUR
weeks	NNS	O-DUR
.	.	O

Patients	NNS	B-WHO
previously	RB	I-WHO
receiving	VBG	I-WHO
niacin	JJ	I-WHO
products	NNS	I-WHO
other	JJ	I-WHO
than	IN	I-WHO
NIASPAN	NNP	O-WHO
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
NIASPAN	NNP	O
with	IN	O
the	DT	O
recommended	VBN	O
NIASPAN	NNP	O
titration	NN	O
schedule	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
response	NN	O
.	.	O

To	TO	O
combine	VB	O
two	CD	B-DOS
or	CC	O
more	JJR	O
vials	NNS	O
of	IN	O
ALPROLIX™	NNP	O
,	,	O
follow	VBP	O
the	DT	O
following	VBG	O
pooling	JJ	O
steps	NNS	O
.	.	O

The	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	B-DOS
inhalations	NNS	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
2	CD	B-DOS
mg	NN	B-UNIT
.	.	O

Both	DT	O
methods	NNS	O
are	VBP	O
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
or	CC	O
serum	JJ	O
creatinine	NN	O
values	NNS	O
since	IN	O
these	DT	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
correlate	VB	O
with	IN	O
aminoglycoside	JJ	O
half	NN	O
-	:	O
lives	NNS	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
diminished	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
bronchospasm	NN	O
or	CC	O
prevention	NN	O
of	IN	O
asthmatic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
4	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
repeated	VBD	O
every	DT	B-FREQ
4	CD	I-FREQ
to	TO	O
6	CD	B-FREQ
hours	NNS	I-FREQ
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
increments	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
subsequent	JJ	O
administrations	NNS	O
is	VBZ	O
up	IN	O
to	TO	O
4	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
IMLYGIC	NNP	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
108	CD	O
(	(	O
100	CD	O
million	CD	O
)	)	O
PFU	NNP	O
per	IN	O
mL	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Accelerated	VBN	O
Infusion	NNP	O
Weight	NNP	O
-	:	O
Based	VBD	O
Doses	NNS	O
for	IN	O
Patients	NNS	B-WHO
with	IN	I-WHO
AMI	NNP	O-WHO

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
and	CC	O
administration	NN	O
should	MD	O
begin	VB	O
within	IN	O
10	CD	O
hours	NNS	O
after	IN	O
reconstitution	NN	O
.	.	O

Actonel	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

Adult	NN	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	B-FREQ
Intake	NNP	O
(	(	O
adults	NNS	B-WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	O
approximately	RB	O
10	CD	B-DOS
IU	NNP	B-UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
avoid	VB	O
excess	JJ	O
hypotension	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Actigall	NNP	O
treatment	NN	O
of	IN	O
radiolucent	JJ	O
gallbladder	NN	O
stones	NNS	O
is	VBZ	O
8	CD	B-DOS
-	:	O
10	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

Thereafter	RB	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
over	IN	O
the	DT	O
next	JJ	O
several	JJ	B-DUR
weeks	NNS	O-DUR
up	RB	O
to	TO	O
a	DT	O
daily	JJ	B-FREQ
maximum	NN	O-FREQ
of	IN	O
3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBD	O
or	CC	O
200	CD	B-DOS
mg	NN	B-UNIT
,	,	O
whichever	WP	O
is	VBZ	O
smaller	JJR	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

(	(	O
10	CD	O
)	)	O
Danger	NNP	O
label	NN	O
:	:	O
The	DT	O
unit	NN	O
should	MD	O
have	VB	O
a	DT	O
label	NN	O
prominently	RB	O
displayed	VBD	O
which	WDT	O
reads	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
over	IN	I-WHO
100	CD	I-WHO
pounds	NNS	I-WHO
the	DT	I-WHO
usual	JJ	I-WHO
adult	NN	O-WHO
dose	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Uncomplicated	VBN	O
gonococcal	JJ	O
infections	NNS	O
in	IN	O
adults	NNS	B-WHO
(	(	O
except	IN	O
anorectal	JJ	O
infections	NNS	O
in	IN	O
men	NNS	B-WHO
)	)	O-WHO
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

Apply	NNP	O
and	CC	O
rub	NN	O
in	IN	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
NORITATE	NNP	O
(	(	O
metronidazole	NN	O
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
to	TO	O
entire	JJ	O
affected	JJ	O
area	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	B-DOS
g	NNS	B-UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
doses	NNS	O
above	IN	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
each	DT	O
maintenance	NN	O
schedule	NN	O
be	VB	O
adhered	VBN	O
to	TO	O
for	IN	O
at	IN	O
least	JJS	O
2	CD	O
treatments	NNS	O
(	(	O
unless	IN	O
erythema	NN	O
or	CC	O
psoriatic	JJ	O
flare	NN	O
occurs	VBZ	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
see	NN	O
(	(	O
2a	CD	O
)	)	O
and	CC	O
(	(	O
2b	CD	O
)	)	O
below	IN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
140	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
infused	VBD	O
for	IN	O
six	CD	O
minutes	NNS	O
(	(	O
total	JJ	O
dose	NN	O
of	IN	O
0.84	CD	B-DOS
mg	NNS	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	B-FREQ
daily	RB	O-FREQ
dose	NN	O
of	IN	O
methyldopa	NN	O
is	VBZ	O
3	CD	B-DOS
g	NN	B-UNIT
.	.	O

Based	VBN	O
on	IN	O
cross	NN	O
-	:	O
study	NN	O
comparisons	NNS	O
,	,	O
the	DT	O
clearance	NN	O
of	IN	O
zafirlukast	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
elderly	JJ	B-WHO
patients	NNS	I-WHO
(	(	I-WHO
65	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
)	)	O-WHO
,	,	O
such	JJ	O
that	IN	O
Cmax	NNP	O
and	CC	O
AUC	NNP	O
are	VBP	O
approximately	RB	O
twice	RB	O
those	DT	O
of	IN	O
younger	JJR	B-WHO
adults	NNS	O-WHO
.	.	O

The	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

However	RB	O
,	,	O
if	IN	O
ALTOCOR™	NNP	O
(	(	O
lovastatin	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
is	VBZ	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
gemfibrozil	NN	O
,	,	O
other	JJ	O
fibrates	NNS	O
,	,	O
or	CC	O
lipid	JJ	O
-	:	O
lowering	NN	O
doses	NNS	O
(	(	O
≥	$	O
1	CD	B-DOS
g	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
of	IN	O
niacin	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
ALTOCOR™	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	B-DOS
mg	NNS	B-UNIT
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
200	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	B-DOS
hr	NNS	B-UNIT

Store	NN	O
unreconstituted	JJ	O
product	NN	O
at	IN	O
20	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Single	NNP	B-DOS
dose	JJ	B-UNIT
vial	NN	O-UNIT
,	,	O
preservative	JJ	O
-	:	O
free	JJ	O
,	,	O
discard	RB	O
unused	JJ	O
portion	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Neulasta	NNP	O
is	VBZ	O
a	DT	O
single	JJ	B-DOS
subcutaneous	JJ	B-UNIT
injection	NN	O-UNIT
of	IN	O
6	CD	B-DOS
mg	NNS	B-UNIT
administered	VBN	O
once	RB	O
per	IN	O
chemotherapy	NN	O
cycle	NN	O
.	.	O

Patients	NNS	B-WHO
at	IN	I-WHO
increased	VBN	I-WHO
risk	NN	I-WHO
for	IN	I-WHO
hypoglycemia	NN	O-WHO
(	(	O
e.g	UH	O
,	,	O
the	DT	O
elderly	JJ	B-WHO
or	CC	I-WHO
patients	NNS	I-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
)	)	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
[	NNP	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Once	RB	O
a	DT	O
successful	JJ	O
dose	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
(	(	O
i.e	FW	O
,	,	O
an	DT	O
average	JJ	O
episode	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
unit	NN	O
)	)	O
,	,	O
patients	NNS	O
should	MD	O
limit	VB	O
consumption	NN	O
to	TO	O
four	CD	B-DOS
or	CC	O
fewer	JJR	B-DOS
units	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

When	WRB	O
necessary	JJ	O
,	,	O
the	DT	O
next	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
cycle	NN	O
was	VBD	O
delayed	VBN	O
until	IN	O
the	DT	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
(	(	O
ANC	NNP	O
)	)	O
was	VBD	O
≥	JJ	O
1000	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm3	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
was	VBD	O
≥	JJ	O
100	CD	B-DOS
000	CD	O-DOS
cells	NNS	B-UNIT
/	JJ	O
mm3	NN	O
and	CC	O
nonhematologic	JJ	O
toxicities	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

The	DT	O
high	JJ	O
solution	NN	O
osmolarity	NN	O
(	(	O
894	CD	B-DOS
mOsmol	NN	B-UNIT
/	NNP	O
L	NNP	O
)	)	O
will	MD	O
likely	RB	O
provoke	VB	O
vein	NNS	O
irritation	NN	O
if	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
administered	VBN	O
without	IN	O
fat	JJ	O
emulsion	NN	O
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
try	VB	O
to	TO	O
maintain	VB	O
a	DT	O
significant	JJ	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
depression	NN	O
so	RB	O
as	IN	O
to	TO	O
keep	VB	O
the	DT	O
leukocyte	NN	O
count	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
3,000	CD	B-DOS
to	TO	O
3,500	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mcL	NN	O
.	.	O

When	WRB	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
established	VBN	O
,	,	O
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	B-DOS
mg	NNS	B-UNIT
)	)	O
at	IN	O
bedtime	NN	O
.	.	O

Maintenance	NN	O
Dose	NNP	O
Every	NNP	O
12	CD	O
hours	NNS	O
=	RB	O
observed	VBD	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NNP	O
/	NNP	O
normal	JJ	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NN	O
X	NNP	O
Calculated	NNP	O
loading	VBG	O
dose	NN	O
in	IN	O
mg	NN	B-UNIT
(	(	O
CC	NNP	O
-	:	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
)	)	O

The	DT	O
recommended	JJ	O
initial	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
ACEON	NNP	O
for	IN	O
the	DT	B-WHO
elderly	JJ	O-WHO
is	VBZ	O
4	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
,	,	O
given	VBN	O
in	IN	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

Treatment	NN	O
of	IN	O
tinea	NN	O
versicolor	NN	O
:	:	O
Apply	VB	O
to	TO	O
affected	JJ	O
areas	NNS	O
and	CC	O
lather	NN	O
with	IN	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
water	NN	O
.	.	O

While	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
likelihood	NN	O
of	IN	O
ovulation	NN	O
occurring	VBG	O
if	IN	O
only	RB	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
pink	JJ	B-UNIT
tablets	NNS	O-UNIT
are	VBP	O
missed	VBN	O
,	,	O
the	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
increases	NNS	O
with	IN	O
each	DT	O
successive	JJ	O
day	NN	O
that	WDT	O
scheduled	VBD	O
pink	JJ	O
tablets	NNS	O
are	VBP	O
missed	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

(	(	O
120	CD	B-DOS
ml	NN	B-UNIT
)	)	O
of	IN	O
water	NN	O
or	CC	O
apple	NN	O
juice	NN	O
.	.	O

Butalbital	NNP	O
and	CC	O
Acetaminophen	NNP	O
,	,	O
50	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
325	CD	B-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
:	:	O
One	CD	B-DOS
or	CC	O
two	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
Pugh	NNP	I-WHO
score	VBD	I-WHO
7	CD	I-WHO
-	:	I-WHO
9	CD	I-WHO
)	)	O-WHO
start	NN	O
AGRYLIN	NNP	O
therapy	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
and	CC	O
monitor	NN	O
frequently	RB	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
[	JJ	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

One	CD	B-DOS
to	TO	O
2	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
or	CC	O
2	CD	B-DOS
to	TO	O
4	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
every	DT	B-FREQ
1	CD	I-FREQ
to	TO	O
4	CD	B-FREQ
hours	NNS	I-FREQ
may	MD	O
then	RB	O
be	VB	O
given	VBN	O
by	IN	O
a	DT	O
syringe	NN	O
attached	VBN	O
to	TO	O
the	DT	O
catheter	NN	O
.	.	O

Ordinarily	RB	O
,	,	O
an	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
65	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
0.5	CD	B-DOS
g	NN	B-UNIT
may	MD	O
be	VB	O
given	VBN	O
to	TO	O
a	DT	O
child	NN	B-WHO
6	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

The	DT	O
final	JJ	O
infusion	NN	O
concentration	NN	O
should	MD	O
be	VB	O
1	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
mL	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
Amturnide	NNP	O
is	VBZ	O
300	CD	B-DOS
/	JJ	O
10	CD	B-DOS
/	JJ	O
25	CD	B-DOS
mg	NN	B-UNIT
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
entire	JJ	O
capsule	NN	O
should	MD	O
be	VB	O
taken	VBN	O
,	,	O
and	CC	O
patients	NNS	O
should	MD	O
not	RB	O
take	VB	O
anything	NN	O
less	JJR	O
than	IN	O
one	CD	B-DOS
capsule	NN	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	B-WHO
average	NN	I-WHO
depleted	VBD	I-WHO
major	JJ	I-WHO
surgical	JJ	I-WHO
patient	NN	I-WHO
with	IN	I-WHO
complications	NNS	O-WHO
requires	VBZ	O
between	IN	O
2500	CD	O
and	CC	O
4000	CD	O
kcal	JJ	O
and	CC	O
between	IN	O
12	CD	B-DOS
and	CC	O
24	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
effective	JJ	O
dose	NN	O
resulting	VBG	O
from	IN	O
an	DT	O
administered	VBN	O
activity	NN	O
amount	NN	O
of	IN	O
10	CD	B-DOS
mCi	NN	B-UNIT
is	VBZ	O
5.07	CD	B-DOS
mSv	NN	B-UNIT
in	IN	O
an	DT	B-WHO
adult	NN	O-WHO
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dose	NN	O
is	VBZ	O
1	CD	B-DOS
gram	NN	B-UNIT
AMOXIL	NNP	O
,	,	O
500	CD	B-DOS
mg	NN	B-UNIT
clarithromycin	NN	O
,	,	O
and	CC	O
30	CD	B-DOS
mg	NN	B-UNIT
lansoprazole	NN	O
,	,	O
all	DT	O
given	VBN	O
twice	NNS	B-FREQ
daily	RB	O-FREQ
(	(	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
for	IN	O
14	CD	B-DUR
days	NNS	O-DUR
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	B-WHO
-	:	O
one	CD	B-DOS
0.5	CD	O-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
administered	VBD	O
approximately	RB	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
breakthrough	NN	O
episodes	NNS	O
of	IN	O
VF	NNP	O
or	CC	O
hemodynamically	RB	O
unstable	JJ	O
VT	NNP	O
,	,	O
150	CD	B-DOS
mg	NN	B-UNIT
supplemental	JJ	O
infusions	NNS	O
of	IN	O
amiodarone	NN	O
HCl	NNP	O
injection	NN	O
mixed	VBD	O
in	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
D5W	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
.	.	O

Take	VB	O
a	DT	O
multivitamin	NN	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
when	WRB	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
capsules	NNS	O
.	.	O

Smaller	NNP	O
increments	NNS	O
of	IN	O
intravenous	JJ	O
etomidate	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
adult	VB	B-WHO
patients	NNS	I-WHO
during	IN	I-WHO
short	JJ	I-WHO
operative	JJ	I-WHO
procedures	NNS	O-WHO
to	TO	O
supplement	VB	O
subpotent	JJ	O
anesthetic	JJ	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
nitrous	JJ	O
oxide	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
are	VBP	O
recommended	VBN	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
CYP2D6	NNP	I-WHO
poor	JJ	I-WHO
metabolizers	NNS	O-WHO
and	CC	O
in	IN	O
patients	NNS	B-WHO
taking	VBG	I-WHO
concomitant	JJ	I-WHO
CYP3A4	NNP	I-WHO
inhibitors	NNS	O-WHO
or	CC	O
CYP2D6	NNP	O
inhibitors	NNS	O
for	IN	O
greater	JJR	O
than	IN	O
14	CD	O
days	NNS	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
lesser	JJR	I-WHO
degrees	NNS	I-WHO
of	IN	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
2	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
and	CC	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
8	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Table	JJ	O
1	CD	O
shows	VBZ	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACIPHEX	NNP	O
delayed	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
in	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
adolescent	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
.	.	O

Recommended	VBN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
neutropenia	NN	O
and	CC	O
thrombocytopenia	NN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
adenocarcinoma	NN	O-WHO
of	IN	O
the	DT	O
pancreas	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
.	.	O

ACCOLATE	NN	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	I-WHO
including	VBG	I-WHO
hepatic	JJ	I-WHO
cirrhosis	NN	O-WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

The	DT	O
following	JJ	O
safety	NN	O
features	NNS	O
should	MD	O
be	VB	O
present	JJ	O
:	:	O
(	(	O
1	CD	O
)	)	O
Protection	NN	O
from	IN	O
electrical	JJ	O
hazard	NN	O
:	:	O
All	DT	O
units	NNS	O
should	MD	O
be	VB	O
grounded	VBN	O
and	CC	O
conform	VB	O
to	TO	O
applicable	JJ	O
electrical	JJ	O
codes	NNS	O
.	.	O

Avoid	NNP	O
use	NN	O
of	IN	O
AGRYLIN	NNP	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

However	RB	O
,	,	O
older	JJR	B-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
nutritional	JJ	O
management	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
liver	JJ	I-WHO
disease	NN	O-WHO
is	VBZ	O
the	DT	O
provision	NN	O
of	IN	O
sufficient	JJ	O
amino	NN	O
acid	NN	O
and	CC	O
caloric	JJ	O
support	NN	O
for	IN	O
protein	NN	O
synthesis	NN	O
without	IN	O
exacerbating	VBG	O
hepatic	JJ	O
encephalopathy	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
vial	NN	O
more	JJR	O
than	IN	O
one	CD	O
time	NN	O
.	.	O

AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
emits	VBZ	O
radiation	NN	O
and	CC	O
must	MD	O
be	VB	O
handled	VBN	O
with	IN	O
appropriate	JJ	O
safety	NN	O
measures	NNS	O
to	TO	O
minimize	VB	O
radiation	NN	O
exposure	NN	O
to	TO	O
clinical	JJ	O
personnel	NNS	O
and	CC	O
patients	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O

In	IN	O
contrast	NN	O
,	,	O
aripiprazole	JJ	O
injection	NN	O
(	(	O
9.75	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
vial	NN	O
)	)	O
is	VBZ	O
a	DT	O
short	JJ	O
-	:	O
acting	VBG	O
formulation	NN	O
indicated	VBD	O
for	IN	O
agitation	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
schizophrenia	NN	I-WHO
or	CC	I-WHO
mania	NN	O-WHO
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
exceeds	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

In	IN	O
treatment	NN	O
of	IN	O
secondary	JJ	O
glaucoma	NN	O
and	CC	O
in	IN	O
the	DT	O
preoperative	JJ	O
treatment	NN	O
of	IN	O
some	DT	O
cases	NNS	O
of	IN	O
acute	JJ	O
congestive	NN	O
(	(	O
closed	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
,	,	O
the	DT	O
preferred	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
,	,	O
although	IN	O
some	DT	O
cases	NNS	O
have	VBP	O
responded	VBN	O
to	TO	O
250	CD	B-DOS
mg	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
on	IN	O
short	JJ	O
-	:	O
term	NN	O
therapy	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
intravenous	JJ	O
infusion	NN	O
initially	RB	O
should	MD	O
be	VB	O
2	CD	B-DOS
mL	JJ	B-UNIT
/	NNP	O
min	NN	O
and	CC	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
.	.	O

See	VB	O
Table	JJ	O
1	CD	O
for	IN	O
the	DT	O
recommended	JJ	O
starting	NN	O
dosage	NN	O
.	.	O

The	DT	O
treatment	NN	O
area	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
one	CD	B-DOS
contiguous	JJ	B-UNIT
area	NN	O-UNIT
of	IN	O
approximately	RB	O
25	CD	B-DOS
cm2	NN	B-UNIT
(	(	O
e.g	UH	O
,	,	O
5	CD	B-DOS
cm	NN	B-UNIT
×	VBD	O
5	CD	B-DOS
cm	NN	B-UNIT
)	)	O
on	IN	O
the	DT	O
face	NN	O
(	(	O
e.g	JJ	O
,	,	O
forehead	JJ	O
or	CC	O
one	CD	O
cheek	NN	O
)	)	O
or	CC	O
on	IN	O
the	DT	O
scalp	NN	O
.	.	O

PPAH	NNP	O
=	VBD	O
0.02	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
mL	NN	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
ACCUPRIL	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
careful	JJ	O
medical	JJ	O
supervision	NN	O
for	IN	O
several	JJ	B-DUR
hours	NNS	O-DUR
and	CC	O
until	IN	O
blood	NN	O
pressure	NN	O
has	VBZ	O
stabilized	VBN	O
.	.	O

See	VB	O
instructions	NNS	O
for	IN	O
reconstitution	NN	O
/	NNP	O
injection	NN	O
/	NNP	O
disposal	NN	O
procedures	NNS	O
for	IN	O
1	CD	O
)	)	O
Pre	NNP	O
-	:	O
filled	VBD	O
Dual	JJ	O
Chamber	NNP	O
Syringe	NNP	O
available	JJ	O
in	IN	O
300	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
400	CD	B-DOS
mg	JJ	B-UNIT
strength	NN	O
syringes	NNS	O
[	VBP	O
see	VB	O
section	NN	O
below	IN	O
]	NNP	O
,	,	O
and	CC	O
2	CD	O
)	)	O
Single	NNP	O
-	:	O
use	NN	O
vials	NNS	O
available	JJ	O
in	IN	O
300	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
400	CD	B-DOS
mg	JJ	B-UNIT
strength	NN	O
vials	NNS	O
[	VBP	O
see	VB	O
section	NN	O
below	IN	O
]	NN	O
.	.	O

For	IN	O
diuresis	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
usually	RB	O
250	CD	B-DOS
to	TO	O
375	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
(	(	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

In	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
,	,	O
serum	JJ	O
amikacin	JJ	O
concentrations	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
to	TO	O
assure	VB	O
accurate	JJ	O
administration	NN	O
of	IN	O
amikacin	NNS	O
and	CC	O
to	TO	O
avoid	VB	O
concentrations	NNS	O
above	IN	O
35	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
and	CC	I-WHO
in	IN	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
above	IN	I-WHO
the	DT	I-WHO
age	NN	I-WHO
of	IN	I-WHO
ten	NN	I-WHO
(	(	I-WHO
10	CD	I-WHO
)	)	I-WHO
years	NNS	O-WHO
will	MD	O
vary	VB	O
between	IN	O
0.2	CD	B-DOS
and	CC	O
0.6	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
it	PRP	O
must	MD	O
be	VB	O
individualized	VBN	O
in	IN	O
each	DT	O
case	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
switching	VBG	I-WHO
to	TO	I-WHO
AIRDUO	NNP	I-WHO
RESPICLICK	NNP	I-WHO
from	IN	I-WHO
another	DT	I-WHO
inhaled	VBN	I-WHO
corticosteroid	NN	O-WHO
or	CC	O
combination	NN	O
product	NN	O
,	,	O
select	VBP	O
the	DT	O
low	JJ	O
(	(	O
55	CD	B-DOS
/	RB	O
14	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
,	,	O
medium	NN	O
(	(	O
113	CD	B-DOS
/	RB	O
14	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
or	CC	O
high	JJ	O
(	(	O
232	CD	B-DOS
/	RB	O
14	CD	B-DOS
mcg	NN	B-UNIT
)	)	O
dose	VBP	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
based	VBN	O
on	IN	O
the	DT	O
strength	NN	O
of	IN	O
the	DT	O
previous	JJ	O
inhaled	JJ	O
corticosteroid	JJ	O
product	NN	O
or	CC	O
the	DT	O
strength	NN	O
of	IN	O
the	DT	O
inhaled	JJ	O
corticosteroid	NN	O
from	IN	O
a	DT	O
combination	NN	O
product	NN	O
and	CC	O
disease	NN	O
severity	NN	O
.	.	O

Typically	RB	O
,	,	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
appropriately	RB	O
mixed	JJ	O
with	IN	O
500	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
50	CD	O
%	NN	O
dextrose	NN	O
supplemented	VBN	O
with	IN	O
electrolytes	NNS	O
and	CC	O
vitamins	NNS	O
is	VBZ	O
administered	VBN	O
over	IN	O
an	DT	O
8	CD	O
to	TO	O
12	CD	O
hour	NN	O
period	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dosage	NN	O
for	IN	O
active	JJ	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

Begin	NNP	O
steady	JJ	O
state	NN	O
imaging	NN	O
after	IN	O
dynamic	JJ	O
imaging	NN	O
has	VBZ	O
been	VBN	O
completed	VBN	O
,	,	O
generally	RB	O
5	CD	O
to	TO	O
7	CD	O
minutes	NNS	O
following	VBG	O
ABLAVAR	NNP	O
administration	NN	O
.	.	O

Figure	NN	O
2	CD	O

ONE	CD	B-DOS
APPLICATION	NNP	B-UNIT
IS	NNP	O
GENERALLY	NNP	O
CURATIVE	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
continued	VBD	O
monitoring	NN	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
clinical	JJ	O
status	NN	O
is	VBZ	O
essential	JJ	O
in	IN	O
any	DT	B-WHO
patient	NN	I-WHO
with	IN	I-WHO
a	DT	I-WHO
primary	JJ	I-WHO
immunodeficiency	NN	I-WHO
disease	NN	O-WHO
and	CC	O
should	MD	O
be	VB	O
continued	VBN	O
in	IN	O
patients	NNS	B-WHO
undergoing	VBG	I-WHO
treatment	NN	I-WHO
with	IN	I-WHO
ADAGEN®	NNP	O-WHO
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

Once	RB	O
an	DT	O
appropriate	JJ	O
dose	NN	O
for	IN	O
pain	NN	O
management	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
use	VB	O
only	RB	O
one	CD	B-DOS
ABSTRAL	NNP	B-UNIT
tablet	NN	O-UNIT
of	IN	O
the	DT	O
appropriate	JJ	O
strength	NN	O
per	IN	O
dose	NN	O
.	.	O

Higher	JJR	O
doses	NNS	O
such	JJ	O
as	IN	O
500	CD	B-DOS
mg	NN	B-UNIT
q.i.d	NN	O
.	.	O

Good	JJ	O
results	NNS	O
,	,	O
however	RB	O
,	,	O
have	VBP	O
been	VBN	O
seen	VBN	O
in	IN	O
patients	NNS	B-WHO
,	,	I-WHO
both	DT	I-WHO
children	NNS	I-WHO
and	CC	I-WHO
adults	NNS	O-WHO
,	,	O
in	IN	O
other	JJ	O
types	NNS	O
of	IN	O
seizures	NNS	O
such	JJ	O
as	IN	O
grand	JJ	O
mal	NN	O
,	,	O
mixed	JJ	O
seizure	NN	O
patterns	NNS	O
,	,	O
myoclonic	JJ	O
jerk	NN	O
patterns	NNS	O
,	,	O
etc	FW	O
.	.	O

Reductions	NNS	O
may	MD	O
be	VB	O
made	VBN	O
after	IN	O
an	DT	O
interval	NN	O
of	IN	O
one	CD	B-DUR
or	CC	O
two	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Initial	JJ	O
amino	NN	O
acid	JJ	O
dosage	NN	O
levels	NNS	O
of	IN	O
1	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
in	IN	O
increments	NNS	O
of	IN	O
0.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
to	TO	O
approximate	VB	O
desired	JJ	O
intake	NN	O
levels	NNS	O
.	.	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
newborns	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
be	VB	O
administered	VBN	O
initially	RB	O
to	TO	O
be	VB	O
followed	VBN	O
with	IN	O
7.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Available	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
about	IN	O
one	CD	O
third	NN	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	B-WHO
with	IN	I-WHO
multiple	JJ	I-WHO
myeloma	NN	O-WHO
show	NN	O
a	DT	O
favorable	JJ	O
response	NN	O
to	TO	O
oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
considered	VBN	I-WHO
unsuitable	JJ	I-WHO
for	IN	I-WHO
surgery	NN	O-WHO
,	,	O
ALDACTONE	NNP	O
may	MD	O
be	VB	O
employed	VBN	O
for	IN	O
long	JJ	O
-	:	O
term	NN	O
maintenance	NN	O
therapy	NN	O
at	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
determined	VBD	O
for	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

Total	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
12	CD	B-DOS
tablets	NNS	B-UNIT
.	.	O

The	DT	O
clearance	NN	O
of	IN	O
zafirlukast	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
stable	JJ	I-WHO
alcoholic	JJ	I-WHO
cirrhosis	NN	O-WHO
such	JJ	O
that	IN	O
the	DT	O
Cmax	NNP	O
and	CC	O
AUC	NNP	O
are	VBP	O
approximately	RB	O
50	CD	O
-	:	O
60	CD	O
%	NN	O
greater	JJR	O
than	IN	O
those	DT	O
of	IN	O
normal	JJ	B-WHO
adults	NNS	O-WHO
.	.	O

Instill	NNP	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
immediately	RB	O
before	IN	O
measurement	NN	O
.	.	O

As	IN	O
individual	JJ	O
monotherapy	NN	O
,	,	O
quinapril	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
of	IN	O
hypertension	NN	O
in	IN	O
once	RB	B-FREQ
-	:	O
daily	JJ	B-FREQ
doses	NNS	O
of	IN	O
10	CD	B-DOS
to	TO	O
80	CD	B-DOS
mg	NNS	B-UNIT
and	CC	O
hydrochlorothiazide	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
doses	NNS	O
of	IN	O
12.5	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

In	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
,	,	O
the	DT	O
higher	JJR	O
morning	NN	O
blood	NN	O
levels	NNS	O
following	VBG	O
use	NN	O
of	IN	O
the	DT	O
10	CD	B-DOS
mg	NN	B-UNIT
dose	JJ	O-UNIT
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
next	JJ	O
day	NN	O
impairment	NN	O
of	IN	O
driving	NN	O
and	CC	O
other	JJ	O
activities	NNS	O
that	WDT	O
require	VBP	O
full	JJ	O
alertness	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Occasionally	RB	O
,	,	O
the	DT	O
inactive	JJ	O
ingredients	NNS	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
may	MD	O
be	VB	O
eliminated	VBN	O
in	IN	O
the	DT	O
feces	NNS	O
in	IN	O
a	DT	O
form	NN	O
that	WDT	O
may	MD	O
resemble	VB	O
the	DT	O
original	JJ	O
tablet	NN	O
.	.	O

Begin	NNP	O
titration	NN	O
of	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
with	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
ABSTRAL	NNP	O
of	IN	O
100	CD	B-DOS
mcg	NN	B-UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
10	CD	O
minutes	NNS	O
on	IN	O
Day	NNP	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

UPAH	NNP	O
=	VBD	O
9.55	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
V	NNP	O
=	VBZ	O
16.68	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
GFR	NNP	O
=	VBZ	O
120	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
PPAH	NNP	O
=	VBZ	O
0.6	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
Then	RB	O
TmPAH	NNP	O
=	NNP	O
9.55	CD	O
x	VBD	O
16.68	CD	B-DOS
–	NNP	B-UNIT
(	(	O
120	CD	O
x	RB	O
0.6	CD	O
x	JJ	O
0.83	CD	O
)	)	O
=	VBD	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

Before	IN	O
initiating	VBG	O
AFREZZA	NNP	O
,	,	O
perform	VB	O
a	DT	O
medical	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
and	CC	O
spirometry	NN	O
(	(	O
FEV1	NNP	O
)	)	O
in	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
to	TO	O
identify	VB	O
potential	JJ	O
lung	NN	O
disease	NN	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
and	CC	O
WARNING	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

0.5	CD	B-DOS
mg	NN	B-UNIT

If	IN	O
ongoing	JJ	O
ABILIFY	NNP	O
therapy	NN	O
is	VBZ	O
clinically	RB	O
indicated	VBN	O
,	,	O
oral	JJ	O
ABILIFY	NNP	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
10	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
should	MD	O
replace	VB	O
ABILIFY	NNP	O
injection	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
[	NN	O
see	VBP	O
Schizophrenia	NNP	O
and	CC	O
Bipolar	NNP	O
I	PRP	O
Disorder	VBP	O
sections	NNS	O
above	IN	O
]	NN	O
.	.	O

Due	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
and	CC	O
individual	JJ	O
variability	NN	O
,	,	O
even	RB	O
patients	NNS	B-WHO
switching	VBG	I-WHO
from	IN	I-WHO
other	JJ	I-WHO
fentanyl	NN	I-WHO
containing	VBG	I-WHO
products	NNS	I-WHO
to	TO	I-WHO
ABSTRAL	NNP	O-WHO
must	MD	O
start	VB	O
with	IN	O
the	DT	O
100	CD	B-DOS
mcg	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
restarted	VBN	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
develop	VBP	I-WHO
ischemic	JJ	I-WHO
colitis	NN	O-WHO
.	.	O

The	DT	O
concentrated	JJ	O
solution	NN	O
for	IN	O
infusion	NN	O
must	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
a	DT	O
final	JJ	O
volume	NN	O
of	IN	O
100	CD	B-DOS
mL	NNS	B-UNIT
or	CC	O
250	CD	B-DOS
mL	NN	B-UNIT
,	,	O
using	VBG	O
aseptic	JJ	O
techniques	NNS	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
essential	JJ	I-WHO
hypertension	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
4	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

However	RB	O
,	,	O
if	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
unable	JJ	O
to	TO	O
take	VB	O
oral	JJ	O
nourishment	NN	O
for	IN	O
a	DT	O
prolonged	JJ	O
period	NN	O
of	IN	O
time	NN	O
,	,	O
institution	NN	O
of	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
with	IN	O
exogenous	JJ	O
calories	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Usually	RB	O
30	CD	B-DOS
grams	NNS	B-UNIT
is	VBZ	O
sufficient	JJ	O
for	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	O-WHO
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLECTOR	NNP	O
PATCH	NNP	O
is	VBZ	O
one	CD	B-DOS
(	(	O
1	CD	B-DOS
)	)	O
patch	NN	B-UNIT
to	TO	O
the	DT	O
most	RBS	O
painful	JJ	O
area	NN	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Admixtures	NNS	O
of	IN	O
3.5	CD	O
to	TO	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
coinfused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
1250	CD	B-DOS
mg	NN	B-UNIT
(	(	O
five	CD	B-DOS
250	CD	O-DOS
mg	NN	B-UNIT
tablets	NNS	O-UNIT
or	CC	O
two	CD	B-DOS
625	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
or	CC	O
750	CD	B-DOS
mg	NN	B-UNIT
(	(	O
three	CD	B-DOS
250	CD	O-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
)	)	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

See	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
:	:	O
1	CD	O
)	)	O
by	IN	O
incremental	JJ	O
injection	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
adjunct	NN	O
to	TO	O
anesthesia	VB	O
with	IN	O
barbiturate	JJ	O
/	NNS	O
nitrous	JJ	O
oxide	IN	O
/	NNP	O
oxygen	NN	O
for	IN	O
short	JJ	O
surgical	JJ	O
procedures	NNS	O
(	(	O
expected	VBN	O
duration	NN	O
of	IN	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
by	IN	O
continuous	JJ	O
infusion	NN	O
as	IN	O
a	DT	O
maintenance	NN	O
analgesic	JJ	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NNP	O
oxygen	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
in	IN	O
anesthetic	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
with	IN	O
a	DT	O
minimum	NN	O
expected	VBN	O
duration	NN	O
of	IN	O
45	CD	O
minutes	NNS	O
;	:	O
and	CC	O
4	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
as	IN	O
the	DT	O
analgesic	JJ	O
component	NN	O
for	IN	O
monitored	JJ	O
anesthesia	NN	O
care	NN	O
(	(	O
MAC	NNP	O
)	)	O
.	.	O

For	IN	O
the	DT	O
relief	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
or	CC	O
osteoarthritis	NN	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
400	CD	B-DOS
mg	NN	B-UNIT
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
1200	CD	B-DOS
mg	FW	B-UNIT
daily	RB	B-FREQ
)	)	O
,	,	O
preferably	RB	O
including	VBG	O
a	DT	O
dose	NN	O
on	IN	O
arising	VBG	O
and	CC	O
a	DT	O
dose	NN	O
at	IN	O
bedtime	NN	O
.	.	O

One	CD	B-DOS
suppository	NN	B-UNIT
in	IN	O
the	DT	O
rectum	NN	O
morning	NN	O
and	CC	O
night	NN	O
for	IN	O
two	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
in	IN	O
nonspecific	JJ	O
proctitis	NN	O
.	.	O

2	CD	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTEMRA	NNP	O
for	IN	O
adult	NN	B-WHO
patients	NNS	O-WHO
given	VBN	O
as	IN	O
a	DT	O
60	CD	B-DOS
-	:	O
minute	NN	O
single	JJ	O
intravenous	JJ	O
drip	NN	O
infusion	NN	O
is	VBZ	O
4	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
followed	VBN	O
by	IN	O
an	DT	O
increase	NN	O
to	TO	O
8	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
small	JJ	O
syringes	NNS	O
(	(	O
0.5	CD	B-DOS
mL	NN	B-UNIT
or	CC	O
1	CD	B-DOS
mL	NN	B-UNIT
)	)	O
be	VB	O
used	VBN	O
to	TO	O
minimize	VB	O
any	DT	O
product	NN	O
loss	NN	O
.	.	O

In	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
,	,	O
3	CD	B-DOS
to	TO	O
4	CD	B-DOS
drops	NNS	B-UNIT
may	MD	O
be	VB	O
sufficient	JJ	O
due	JJ	O
to	TO	O
the	DT	O
smaller	JJR	O
capacity	NN	O
of	IN	O
the	DT	O
ear	JJ	O
canal	NN	O
.	.	O

Renal	JJ	O
Insufficiency	NN	O
:	:	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
failure	NN	O-WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
NEXAVAR	NNP	O
is	VBZ	O
400	CD	B-DOS
mg	NN	B-UNIT
(	(	O
2	CD	B-DOS
x	RB	O
200	CD	B-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
)	)	O
taken	VBN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
without	IN	O
food	NN	O
(	(	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
25	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
meclizine	JJ	O
hydrochloride	NN	O
,	,	O
should	MD	O
be	VB	O
taken	VBN	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
travel	VB	O
for	IN	O
protection	NN	O
against	IN	O
motion	NN	O
sickness	NN	O
.	.	O

Figure	NN	O
17	CD	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
one	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
salmeterol	NN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
likelihood	NN	O
of	IN	O
hypotension	NN	O
,	,	O
the	DT	O
diuretic	NN	O
should	MD	O
,	,	O
if	IN	O
possible	JJ	O
,	,	O
be	VB	O
discontinued	VBN	O
two	CD	B-DUR
to	TO	O
three	CD	B-DUR
days	NNS	O-DUR
prior	RB	O
to	TO	O
beginning	VBG	O
therapy	NN	O
with	IN	O
ALTACE	NNP	O
.	.	O

5	CD	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
newborns	NNS	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
:	:	O
WARNINGS	VB	O
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
be	VB	O
administered	VBN	O
initially	RB	O
to	TO	O
be	VB	O
followed	VBN	O
with	IN	O
7.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Nongonococcal	JJ	O
urethritis	NN	O
(	(	O
NGU	NNP	O
)	)	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
and	CC	O
U.	NNP	O
urealyticum	NN	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Figure	NN	O
14	CD	O

In	IN	O
adults	NNS	B-WHO
,	,	O
strongly	RB	O
hypertonic	JJ	O
admixtures	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	VB	O
may	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
only	RB	O
by	IN	O
continuous	JJ	O
infusion	NN	O
through	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
with	IN	O
the	DT	O
tip	NN	O
located	VBN	O
in	IN	O
the	DT	O
superior	JJ	O
vena	NN	O
cava	NN	O
.	.	O

Typically	RB	O
,	,	O
each	DT	O
liter	NN	O
of	IN	O
central	JJ	O
vein	NNS	O
TPN	NNP	O
solution	NN	O
for	IN	O
adults	NNS	B-WHO
contains	NNS	O
42.5	CD	B-DOS
to	TO	O
50	CD	B-DOS
g	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
with	IN	O
approximately	RB	O
250	CD	B-DOS
±	JJ	O
100	CD	B-DOS
g	NN	B-UNIT
of	IN	O
dextrose	NN	O
;	:	O
supplementary	JJ	O
nonprotein	NN	O
calories	NNS	O
from	IN	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
may	MD	O
be	VB	O
prescribed	VBN	O
,	,	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

two	CD	B-DOS
tablets	NNS	B-UNIT
of	IN	O
500	CD	B-DOS
mg	NNS	B-UNIT
/	VBD	O
20	CD	B-DOS
mg	NN	B-UNIT
and	CC	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
1000	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
40	CD	B-DOS
mg	NN	B-UNIT
)	)	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
body	NN	I-WHO
weight	NN	I-WHO
of	IN	I-WHO
20	CD	I-WHO
kg	NNS	I-WHO
or	CC	I-WHO
less	JJR	O-WHO
should	MD	O
receive	VB	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
2.4	CD	B-DOS
to	TO	O
4.7	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
(	(	O
from	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
)	)	O
with	IN	O
adequate	JJ	O
calories	NNS	O
will	MD	O
maintain	VB	O
nitrogen	JJ	O
equilibrium	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
uremia	JJ	O-WHO
.	.	O

Each	DT	O
vial	NN	O
of	IN	O
ALDURAZYME	NNP	O
provides	VBZ	O
2.9	CD	B-DOS
milligrams	NNS	B-UNIT
(	(	O
mg	NN	B-UNIT
)	)	O
of	IN	O
laronidase	NN	O
in	IN	O
5	CD	B-DOS
milliliters	NNS	B-UNIT
(	(	O
mL	NN	O
)	)	O
of	IN	O
solution	NN	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
.	.	O

Monitor	NNP	O
everolimus	JJ	O
whole	JJ	O
blood	NN	O
trough	NN	O
levels	NNS	O
routinely	RB	O
in	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	FW	O
per	IN	B-FREQ
week	NN	O-FREQ
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
is	VBZ	O
switching	VBG	O
from	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
regimen	NNS	O
of	IN	O
tablets	NNS	O
,	,	O
she	PRP	O
should	MD	O
start	VB	O
her	PRP$	O
first	JJ	O
pack	NN	O
of	IN	O
ALESSE	NNP	O
(	(	O
levonorgestrel	NN	O
and	CC	O
ethinyl	VB	O
estradiol	NN	O
)	)	O
on	IN	O
the	DT	O
day	NN	O
after	IN	O
her	PRP$	O
last	JJ	O
tablet	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
chronic	JJ	I-WHO
kidney	NN	I-WHO
disease	NN	O-WHO
and	CC	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
less	JJR	O
than	IN	O
60	CD	B-DOS
mL	JJ	B-UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
VYTORIN	NNP	O
is	VBZ	O
10	CD	B-DOS
/	JJ	O
20	CD	B-DOS
/	JJ	O
18	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

Continuous	JJ	O
maintenance	NN	O
therapy	NN	O
with	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
is	VBZ	O
instituted	VBN	O
when	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
4,000	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mcL	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
100,000	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mcL	NN	O
.	.	O

SYLVANT	NNP	O
11	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
given	VBN	O
over	IN	O
1	CD	O
hour	NN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
administered	VBD	O
every	DT	B-FREQ
3	CD	I-FREQ
weeks	NNS	O-FREQ
until	IN	O
treatment	NN	O
failure	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Savella	NNP	O
is	VBZ	O
100	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
50	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
.	.	O

Within	IN	O
24	CD	O
to	TO	O
48	CD	O
hours	NNS	O
the	DT	O
volume	NN	O
and	CC	O
concentration	NN	O
of	IN	O
the	DT	O
solution	NN	O
can	MD	O
be	VB	O
increased	VBN	O
until	IN	O
the	DT	O
full	JJ	O
strength	NN	O
pediatric	JJ	O
solution	NN	O
(	(	O
amino	JJ	O
acids	NNS	O
and	CC	O
dextrose	NN	O
)	)	O
is	VBZ	O
given	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
125	CD	B-DOS
to	TO	O
150	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
daily	JJ	B-FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
,	,	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	I-WHO
,	,	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
and	CC	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
7.7	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

Adrenalin®	$	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
mL	NN	O
(	(	O
1:1000	CD	O
)	)	O
epinephrine	NN	O
injection	NN	O
,	,	O
1	CD	B-DOS
mL	JJ	B-UNIT
solution	NN	O-UNIT
in	IN	O
a	DT	O
single	JJ	O
-	:	O
use	NN	O
clear	JJ	O
glass	NN	O
vial	NN	O
and	CC	O
30	CD	B-DOS
mL	JJ	B-UNIT
solution	NN	O-UNIT
in	IN	O
a	DT	O
multiple	JJ	O
-	:	O
dose	JJ	O
amber	JJ	O
glass	NN	O
vial	NN	O
.	.	O

Each	DT	O
actuation	NN	O
of	IN	O
PROVENTIL®	NNP	O
HFA	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
delivers	VBZ	O
108	CD	B-DOS
mcg	NN	B-UNIT
of	IN	O
albuterol	NN	O
sulfate	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
90	CD	B-DOS
mcg	NN	B-UNIT
of	IN	O
albuterol	JJ	O
base	NN	O
)	)	O
from	IN	O
the	DT	O
mouthpiece	NN	O
.	.	O

The	DT	O
maximum	JJ	O
rate	NN	O
at	IN	O
which	WDT	O
dextrose	NN	O
can	MD	O
be	VB	O
infused	VBN	O
without	IN	O
producing	VBG	O
glycosuria	NN	O
is	VBZ	O
0.5	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	O
hour	NN	O
;	:	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
0.8	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
hour	NN	O
,	,	O
about	RB	O
95	CD	O
%	NN	O
of	IN	O
the	DT	O
infused	JJ	O
dextrose	NN	O
is	VBZ	O
retained	VBN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
no	DT	O
more	JJR	O
than	IN	O
36	CD	B-DOS
packets	NNS	B-UNIT
for	IN	O
the	DT	O
6	CD	B-DUR
-	:	O
week	NN	B-DUR
treatment	NN	O
period	NN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
,	,	O
electrolytes	NNS	O
and	CC	O
acid	SYM	O
-	:	O
base	NN	O
needed	VBN	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	B-FREQ
losses	NNS	O
.	.	O

For	IN	O
the	DT	O
prevention	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
,	,	O
the	DT	O
minimum	JJ	O
dose	NN	O
of	IN	O
Alora	NNP	O
that	WDT	O
has	VBZ	O
been	VBN	O
studied	VBN	O
and	CC	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
is	VBZ	O
0.025	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
applied	VBD	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	B-FREQ
weekly	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
BUPHENYL	NNP	O
Tablets	NNP	O
and	CC	O
Powder	NNP	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
urea	JJ	I-WHO
cycle	NN	I-WHO
disorders	NNS	O-WHO
is	VBZ	O
450	CD	B-DOS
-	:	O
600	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
patients	NNS	B-WHO
weighing	VBG	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
20	CD	I-WHO
kg	NN	O-WHO
,	,	O
or	CC	O
9.9	CD	B-DOS
-	:	O
13	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
m²	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
larger	JJR	B-WHO
patients	NNS	O-WHO
.	.	O

Rather	RB	O
than	IN	O
an	DT	O
increase	NN	O
in	IN	O
infusion	NN	O
rate	NN	O
,	,	O
7	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
bolus	NN	O
doses	NNS	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
or	CC	O
a	DT	O
potent	JJ	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
response	NN	O
to	TO	O
signs	NNS	O
of	IN	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
within	IN	O
the	DT	O
last	JJ	O
15	CD	O
minutes	NNS	O
of	IN	O
surgery	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
folic	JJ	O
acid	NNS	O
studied	VBD	O
ranged	VBN	O
from	IN	O
350	CD	B-DOS
to	TO	O
1000	CD	B-DOS
mcg	NN	B-UNIT
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
vitamin	NN	O
B12	NNP	O
was	VBD	O
1000	CD	B-DOS
mcg	NN	B-UNIT
.	.	O

It	PRP	O
has	VBZ	O
usually	RB	O
been	VBN	O
found	VBN	O
that	IN	O
a	DT	O
dosage	NN	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	B-DOS
g	NNS	B-UNIT
per	IN	O
24	CD	O
hours	NNS	O
does	VBZ	O
not	RB	O
produce	VB	O
an	DT	O
increased	JJ	O
effect	NN	O
.	.	O

As	IN	O
an	DT	O
example	NN	O
of	IN	O
the	DT	O
preparation	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
for	IN	O
infusion	NN	O
,	,	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
added	VBD	O
to	TO	O
230	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent	NN	O
provides	VBZ	O
40	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
mL	NNP	O
solution	NN	O
of	IN	O
Alfentanil	NNP	O
.	.	O

The	DT	O
effective	JJ	O
dose	NN	O
resulting	VBG	O
from	IN	O
a	DT	O
370	CD	B-DOS
MBq	NNP	B-UNIT
(	(	O
10	CD	B-DOS
mCi	NN	B-UNIT
)	)	O
dose	NN	O
of	IN	O
Am	NNP	O
yvid	NNP	O
is	VBZ	O
7	CD	B-DOS
mSv	NN	B-UNIT
in	IN	O
an	DT	B-WHO
adult	NN	O-WHO
,	,	O
(	(	O
19	CD	O
x	RB	O
370	CD	O
=	JJ	O
7030	CD	B-DOS
μSv	NNP	B-UNIT
=	VBD	O
7.03	CD	B-DOS
mSv	NN	B-UNIT
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
4.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Generally	RB	O
,	,	O
the	DT	O
ACTIQ	NNP	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
only	RB	O
when	WRB	O
a	DT	O
single	JJ	B-DOS
administration	NN	B-UNIT
of	IN	O
the	DT	O
current	JJ	O
dose	NN	O
fails	NNS	O
to	TO	O
adequately	RB	O
treat	VB	O
the	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
for	IN	O
several	JJ	O
consecutive	JJ	O
episodes	NNS	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
3	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	B-DOS
hr	NNS	B-UNIT

The	DT	O
dose	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
greater	JJR	I-WHO
than	IN	I-WHO
two	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
is	VBZ	O
one	CD	B-DOS
to	TO	O
two	CD	B-DOS
drops	NNS	B-UNIT
in	IN	O
each	DT	O
affected	JJ	O
eye	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
3	CD	I-DUR
months	NNS	O-DUR
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
stable	JJ	I-WHO
coronary	JJ	I-WHO
artery	NN	I-WHO
disease	NN	O-WHO
,	,	O
ACEON	NNP	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
4	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
8	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	JJ	O
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
250	CD	B-DOS
mg	NN	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
in	IN	O
the	DT	O
first	JJ	O
48	CD	O
hours	NNS	O
.	.	O

Growth	NNP	O
hormone	NN	O
deficiency	NN	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	B-FREQ
dose	NN	O
is	VBZ	O
0.18	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	VBD	O
to	TO	O
0.3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
(	(	O
0.9	CD	B-DOS
IU	NNP	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
.	.	O

Sufficient	JJ	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
cover	VB	O
the	DT	O
treatment	NN	O
area	NN	O
,	,	O
including	VBG	O
1	CD	O
centimeter	NN	O
of	IN	O
skin	NN	O
surrounding	VBG	O
the	DT	O
tumor	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
10	CD	B-DOS
-	:	O
80	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
in	IN	O
single	JJ	B-DOS
or	CC	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
;	:	O
the	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
80	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Dosage	NNP	O
reduction	NN	O
of	IN	O
up	IN	O
to	TO	O
50	CD	O
%	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
insufficiency	NN	O-WHO
(	(	O
BUN	NNP	O
≥	VBZ	O
30	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
)	)	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
General	NNP	O
)	)	O
.	.	O

If	IN	O
changes	NNS	O
are	VBP	O
not	RB	O
controlled	VBN	O
after	IN	O
three	CD	B-DOS
bolus	NN	B-UNIT
doses	NNS	O-UNIT
given	VBN	O
over	RP	O
a	DT	O
five	CD	O
minute	NN	O
period	NN	O
,	,	O
a	DT	O
barbiturate	NN	O
,	,	O
vasodilator	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Most	JJS	B-WHO
patients	NNS	O-WHO
will	MD	O
experience	VB	O
an	DT	O
adequate	JJ	O
response	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1.5	CD	B-DOS
to	TO	O
3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

If	IN	O
you	PRP	O
start	VBP	O
to	TO	O
regain	VB	O
weight	NN	O
after	IN	O
you	PRP	O
stop	VBP	O
taking	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
,	,	O
you	PRP	O
may	MD	O
need	VB	O
to	TO	O
start	VB	O
taking	VBG	O
alli	JJ	O
(	(	O
orlistat	JJ	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
again	RB	O
along	IN	O
with	IN	O
your	PRP$	O
diet	JJ	O
and	CC	O
exercise	JJ	O
program	NN	O
.	.	O

Adult	NN	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	B-FREQ
Intake	NNP	O
(	(	O
adults	NNS	B-WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	O
approximately	RB	O
10	CD	B-DOS
IU	NNP	B-UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

Drug	NNP	O
-	:	O
Induced	VBD	O
Edema	NNP	O
:	:	O
Recommended	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	B-DOS
to	TO	O
375	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
acetazolamide	NN	O
once	IN	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
one	CD	B-DUR
or	CC	O
two	CD	B-DUR
days	NNS	O-DUR
,	,	O
alternating	VBG	O
with	IN	O
a	DT	O
day	NN	O
of	IN	O
rest	NN	O
.	.	O

Pediatric	JJ	B-WHO
Patients	NNS	I-WHO
with	IN	I-WHO
a	DT	I-WHO
Body	NNP	I-WHO
Weight	NNP	I-WHO
≥	VBZ	I-WHO
50	CD	I-WHO
kg	NN	O-WHO
:	:	O
Administer	NNP	O
the	DT	O
adult	NN	B-WHO
dose	NN	O
.	.	O

As	IN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
constant	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
intravenous	JJ	O
dextrose	NN	O
must	MD	O
be	VB	O
selected	VBN	O
with	IN	O
caution	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
,	,	I-WHO
particularly	RB	I-WHO
neonates	NNS	I-WHO
and	CC	I-WHO
low	JJ	I-WHO
birth	NN	I-WHO
weight	NN	I-WHO
infants	NNS	O-WHO
,	,	O
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hyperglycemia	NN	O
/	NNP	O
hypoglycemia	NN	O
.	.	O

A	DT	O
2.5	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
of	IN	O
albuterol	NN	O
provided	VBN	O
by	IN	O
a	DT	O
higher	JJR	O
concentration	NN	O
product	NN	O
(	(	O
2.5	CD	B-DOS
mg	NN	B-UNIT
albuterol	NN	O
per	IN	O
3	CD	B-DOS
mL	NN	B-UNIT
)	)	O
may	MD	O
be	VB	O
more	JJR	O
appropriate	JJ	O
for	IN	O
treating	VBG	O
acute	JJ	O
exacerbations	NNS	O
,	,	O
particularly	RB	O
in	IN	O
children	NNS	B-WHO
6	CD	I-WHO
years	NNS	I-WHO
old	JJ	I-WHO
and	CC	I-WHO
above	JJ	O-WHO
.	.	O

An	DT	O
AFINITOR	NNP	O
dose	JJ	O
increase	NN	O
from	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
5	CD	B-DOS
mg	NN	B-UNIT
may	MD	O
be	VB	O
considered	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
tolerance	NN	O
.	.	O

Initial	JJ	O
dosage	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
daily	RB	B-FREQ
in	IN	O
two	CD	B-DOS
to	TO	O
four	CD	B-DOS
doses	NNS	B-UNIT
.	.	O

Turner	NNP	O
Syndrome	NNP	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	B-FREQ
dose	NN	O
is	VBZ	O
0.36	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
not	RB	I-WHO
receiving	VBG	I-WHO
a	DT	I-WHO
diuretic	JJ	O-WHO
is	VBZ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
3.75	CD	B-DOS
mg	NN	B-UNIT
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
.	.	O

Slowly	RB	O
inject	VBP	O
the	DT	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
over	IN	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	O
minute	NN	O
,	,	O
using	VBG	O
the	DT	O
sterile	JJ	O
syringe	NN	O
to	TO	O
direct	VB	O
the	DT	O
solution	NN	O
flow	NN	O
onto	IN	O
the	DT	O
INSIDE	NNP	O
WALL	NNP	O
OF	IN	O
THE	NNP	O
VIAL	NNP	O
.	.	O

Dosage	NNP	O
adjustment	NN	O
of	IN	O
ACTIQ	NNP	O
may	MD	O
be	VB	O
required	VBN	O
in	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
in	IN	O
order	NN	O
to	TO	O
continue	VB	O
to	TO	O
provide	VB	O
adequate	JJ	O
relief	NN	O
of	IN	O
breakthrough	NN	O
pain	NN	O
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
moderate	JJ	O
-	:	O
to	TO	O
-	:	O
severe	JJ	O
vasomotor	NN	O
symptoms	NNS	O
,	,	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
,	,	O
hypogonadism	NN	O
,	,	O
castration	NN	O
,	,	O
or	CC	O
primary	JJ	O
ovarian	JJ	O
failure	NN	O
,	,	O
treatment	NN	O
is	VBZ	O
usually	RB	O
initiated	VBN	O
with	IN	O
Alora	NNP	O
0.05	CD	B-DOS
mg	NN	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
applied	VBD	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	B-FREQ
weekly	RB	O-FREQ
.	.	O

Each	DT	O
mL	NN	O
of	IN	O
the	DT	O
reconstituted	VBN	O
formulation	NN	O
will	MD	O
contain	VB	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
paclitaxel	NN	O
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	B-DOS
50	CD	O-DOS
-	:	O
mg	NN	B-UNIT
capsules	NNS	O-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

A	DT	O
second	JJ	O
6	CD	B-DOS
mg	NNS	B-UNIT
dose	NN	O-UNIT
should	MD	O
only	RB	O
be	VB	O
considered	VBN	O
if	IN	O
some	DT	O
response	NN	O
to	TO	O
a	DT	O
first	JJ	O
injection	NN	O
was	VBD	O
observed	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
9.75	CD	B-DOS
mg	NN	B-UNIT
.	.	O

For	IN	O
most	JJS	B-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
on	IN	I-WHO
intravenous	JJ	I-WHO
nutrition	NN	O-WHO
,	,	O
2.5	CD	B-DOS
grams	NNS	B-UNIT
amino	JJ	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
with	IN	O
dextrose	JJ	O
alone	NNS	O
or	CC	O
with	IN	O
I.V	NNP	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
for	IN	O
200	CD	B-DOS
mg	NNS	B-UNIT
and	CC	O
160	CD	B-DOS
mg	NNS	B-UNIT
are	VBP	O
obtained	VBN	O
only	RB	O
by	IN	O
using	VBG	O
the	DT	O
300	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
400	CD	B-DOS
mg	JJ	B-UNIT
strength	NN	O
vials	NNS	O
for	IN	O
intramuscular	JJ	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
injection	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
ACIPHEX	NNP	O
delayed	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
1	CD	I-WHO
year	NN	I-WHO
to	TO	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
because	IN	O
the	DT	O
lowest	JJS	O
available	JJ	O
tablet	NN	O
strength	NN	O
(	(	O
20	CD	B-DOS
mg	NN	B-UNIT
)	)	O
exceeds	VBZ	O
the	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
.	.	O

AIRDUO	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kyprolis	NNP	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
in	IN	O
Cycle	NNP	O
1	CD	O
on	IN	O
Days	NNS	O
1	CD	O
and	CC	O
2	CD	O
.	.	O

However	RB	O
,	,	O
some	DT	O
investigators	NNS	O
feel	VBP	O
that	IN	O
daily	JJ	B-FREQ
doses	NNS	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	B-DOS
g	NNS	B-UNIT
do	VBP	O
not	RB	O
produce	VB	O
any	DT	O
better	JJR	O
results	NNS	O
than	IN	O
a	DT	O
1	CD	B-DOS
g	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

In	IN	O
trials	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

Usual	NNP	O
dose	VBD	O
5	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dose	NN	O
for	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
is	VBZ	O
one	CD	B-DOS
(	(	O
1	CD	B-DOS
)	)	O
AMRIX	$	O
15	CD	B-DOS
mg	NN	B-UNIT
capsule	NN	O-UNIT
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
titrated	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
15	CD	B-DOS
mg	NN	B-UNIT
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
45	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
based	VBN	O
on	IN	O
glycemic	JJ	O
response	NN	O
as	IN	O
determined	VBN	O
by	IN	O
HbA1c	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ADCIRCA	NNP	O
is	VBZ	O
40	CD	B-DOS
mg	NN	B-UNIT
(	(	O
two	CD	B-DOS
20	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
weighing	VBG	I-WHO
50	CD	I-WHO
kg	NN	I-WHO
or	CC	I-WHO
more	JJR	O-WHO
,	,	O
dosing	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
2	CD	B-DUR
days	NNS	O-DUR
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
,	,	O
with	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
on	IN	O
day	NN	O
8	CD	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hypertension	NN	I-WHO
and	CC	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	B-DOS
mg	JJ	B-UNIT
ALTACE	NNP	O
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
8	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
orally	RB	O
with	IN	O
food	NN	O
and	CC	O
water	NN	O
.	.	O

In	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
patients	NNS	B-WHO
with	IN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
≥	VBD	O-WHO
45	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
required	VBD	O
no	DT	O
dose	JJ	O
adjustments	NNS	O
other	JJ	O
than	IN	O
those	DT	O
recommended	VBN	O
for	IN	O
all	DT	B-WHO
patients	NNS	O-WHO
.	.	O

From	IN	O
this	DT	O
initial	JJ	O
dose	NN	O
,	,	O
closely	RB	O
follow	JJ	O
patients	NNS	O
and	CC	O
change	VB	O
the	DT	O
dosage	NN	O
level	NN	O
until	IN	O
the	DT	O
patient	NN	O
reaches	VBZ	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
using	VBG	O
a	DT	O
single	JJ	B-DOS
ACTIQ	NNP	O
dosage	NN	O
unit	NN	O
per	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
episode	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
On	IN	O
-	:	O
demand	NN	O
Treatment	NNP	O
and	CC	O
Control	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

In	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
it	PRP	O
may	MD	O
be	VB	O
possible	JJ	O
to	TO	O
maintain	VB	O
adequate	JJ	O
remission	NN	O
of	IN	O
lesions	NNS	O
with	IN	O
alternate	JJ	O
day	NN	O
or	CC	O
intermittent	JJ	O
therapy	NN	O
.	.	O

Adding	VBG	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
57.2	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
65.4	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

Withdraw	VB	O
a	DT	O
0.5	CD	B-DOS
mL	NN	B-UNIT
dose	NN	O-UNIT
of	IN	O
the	DT	O
reconstituted	JJ	O
vaccine	NN	O
and	CC	O
inject	JJ	O
intramuscularly	RB	O
.	.	O

Dosage	NN	O
adjustment	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

When	WRB	O
an	DT	O
area	NN	O
of	IN	O
8	CD	O
x	JJ	O
18	CD	O
cm	NN	O
is	VBZ	O
illuminated	VBN	O
,	,	O
the	DT	O
effective	JJ	O
treatment	NN	O
area	NN	O
is	VBZ	O
6	CD	O
x16	JJ	O
cm	NN	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

6	CD	O
-	:	O
16	CD	O
Yrs	NN	O

The	DT	O
risk	NN	O
of	IN	O
administering	VBG	O
methylene	NN	O
blue	NN	O
by	IN	O
non	JJ	O
-	:	O
intravenous	JJ	O
routes	NNS	O
(	(	O
such	JJ	O
as	IN	O
oral	JJ	O
tablets	NNS	O
or	CC	O
by	IN	O
local	JJ	O
injection	NN	O
)	)	O
or	CC	O
in	IN	O
intravenous	JJ	O
doses	NNS	O
much	RB	O
lower	JJR	O
than	IN	O
1	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
kg	NN	O
with	IN	O
Anafranil	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

Flushing	VBG	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
may	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
frequency	NN	O
or	CC	O
severity	NN	O
by	IN	O
pretreatment	NN	O
with	IN	O
aspirin	NN	O
up	RB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
325	CD	B-DOS
mg	NN	B-UNIT
(	(	O
taken	VBN	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
NIASPAN	NNP	O
dose	NN	O
)	)	O
.	.	O

Patients	NNS	O
s	PRP	O
hould	MD	O
be	VB	O
pres	NNS	O
cribed	VBN	O
no	RB	O
more	JJR	O
than	IN	O
36	CD	B-DOS
packets	NNS	B-UNIT
for	IN	O
the	DT	O
16	CD	B-DUR
-	:	O
week	NN	B-DUR
treatment	NN	O
period	NN	O
.	.	O


Changes	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
that	WDT	O
indicate	VBP	O
a	DT	O
response	NN	O
to	TO	O
surgical	JJ	O
stress	NN	O
or	CC	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
may	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
alfentanil	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
4	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
and	CC	O
/	NN	O
or	CC	O
administration	NN	O
of	IN	O
bolus	JJ	O
doses	NNS	O
of	IN	O
7	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
between	IN	I-WHO
4	CD	I-WHO
and	CC	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
for	IN	I-WHO
patients	NNS	I-WHO
13	CD	I-WHO
to	TO	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
with	IN	I-WHO
weight	NN	I-WHO
of	IN	I-WHO
<	$	I-WHO
50	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
twice	RB	B-FREQ
daily	RB	O-FREQ
or	CC	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBD	O
3	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
to	TO	O
a	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
2400	CD	B-DOS
mg	NN	B-UNIT
)	)	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

INJECTION	NN	O
:	:	O
Adults	NNP	B-WHO
-	:	O
One	CD	B-DOS
2	CD	O-DOS
mL	NN	B-UNIT
vial	NN	O-UNIT
(	(	O
60	CD	B-DOS
mg	NN	B-UNIT
)	)	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
;	:	O
may	MD	O
be	VB	O
repeated	VBN	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Therefore	RB	O
,	,	O
ALIMTA	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
patients	NNS	B-WHO
whose	WP$	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
is	VBZ	I-WHO
<	JJ	O-WHO
45	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
using	VBG	O
the	DT	O
standard	NN	O
Cockcroft	NNP	O
and	CC	O
Gault	NNP	O
formula	NN	O
(	(	O
below	IN	O
)	)	O
or	CC	O
GFR	NNP	O
measured	VBN	O
by	IN	O
Tc99m	NNP	O
-	:	O
DPTA	NNP	O
serum	JJ	O
clearance	NN	O
method	NN	O
:	:	O

Admixtures	NNS	O
of	IN	O
3.5	CD	O
to	TO	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
may	MD	O
be	VB	O
infused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

7	CD	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
to	TO	O
two	CD	B-DOS
drops	NNS	B-UNIT
in	IN	O
each	DT	O
affected	JJ	O
eye	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
unable	JJ	I-WHO
to	TO	I-WHO
swallow	VB	I-WHO
whole	JJ	I-WHO
tablets	NNS	O-WHO
,	,	O
Adempas	NNP	O
may	MD	O
be	VB	O
crushed	VBN	O
and	CC	O
mixed	JJ	O
with	IN	O
water	NN	O
or	CC	O
soft	JJ	O
foods	NNS	O
(	(	O
such	JJ	O
as	IN	O
applesauce	NN	O
)	)	O
immediately	RB	O
before	IN	O
administration	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

V	NNP	O
=	VBD	O
1.5	CD	B-DOS
mL	NN	B-UNIT
/	CD	O
min	NN	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
amikacin	JJ	O
sulfate	JJ	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

If	IN	O
erythema	JJ	O
occurs	NNS	O
,	,	O
follow	JJ	O
instructions	NNS	O
outlined	VBN	O
above	IN	O
in	IN	O
the	DT	O
procedures	NNS	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
skin	JJ	I-WHO
types	NNS	I-WHO
I	PRP	O-WHO
,	,	O
II	NNP	O
and	CC	O
III	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
drops	NNS	B-UNIT
in	IN	O
each	DT	O
eye	NN	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
oral	JJ	O
solution	NN	O
can	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
tablets	NNS	O
on	IN	O
a	DT	O
mg	JJ	B-UNIT
-	:	O
per	IN	O
-	:	O
mg	NN	B-UNIT
basis	NN	O
up	RB	O
to	TO	O
the	DT	O
25	CD	B-DOS
mg	NN	B-UNIT
dose	JJ	O-UNIT
level	NN	O
.	.	O

Amiloride	NNP	O
HCl	NNP	O
,	,	O
one	CD	B-DOS
5	CD	O-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
,	,	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
usual	JJ	O
antihypertensive	NN	O
or	CC	O
diuretic	JJ	O
dosage	NN	O
of	IN	O
a	DT	O
kaliuretic	JJ	O
diuretic	NN	O
.	.	O

Growth	NNP	O
hormone	NN	O
deficiency	NN	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	B-FREQ
dose	NN	O
is	VBZ	O
0.18	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	VBD	O
to	TO	O
0.3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
(	(	O
0.90	CD	B-DOS
IU	NNP	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
.	.	O

Adjust	NNP	O
dose	NN	O
at	IN	O
2	CD	B-DUR
week	NN	O-DUR
intervals	NNS	O
as	IN	O
needed	VBN	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	B-DOS
to	TO	O
15	CD	B-DOS
ng	NNS	B-UNIT
/	JJ	O
mL	JJ	O
[	NNP	O
see	VBP	O
Therapeutic	JJ	O
Drug	NNP	O
Monitoring	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
and	CC	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
AMPYRA	NNP	O
is	VBZ	O
one	CD	B-DOS
10	CD	O-DOS
mg	NN	B-UNIT
tablet	NN	O-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Two	CD	B-DOS
to	TO	O
six	CD	B-DOS
inhalations	NNS	B-UNIT
of	IN	O
the	DT	O
vapors	NNS	O
from	IN	O
the	DT	O
capsule	NN	O
are	VBP	O
usually	RB	O
sufficient	JJ	O
to	TO	O
promptly	RB	O
produce	VB	O
therapeutic	JJ	O
effects	NNS	O
.	.	O

Aripiprazole	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
adolescent	JJ	B-WHO
patients	NNS	I-WHO
13	CD	I-WHO
to	TO	I-WHO
17	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
with	IN	I-WHO
schizophrenia	NN	O-WHO
at	IN	O
daily	JJ	B-FREQ
doses	NNS	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
and	CC	O
30	CD	B-DOS
mg	NN	B-UNIT
.	.	O

Apply	VB	O
one	CD	B-DOS
-	:	O
two	CD	B-DOS
drops	NNS	B-UNIT
of	IN	O
VEXOL®	NNP	O
1	CD	O
%	NN	O
Ophthalmic	NNP	O
Suspension	NNP	O
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
throughout	IN	O
the	DT	O
first	JJ	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
is	VBZ	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
as	IN	O
monotherapy	NN	O
or	CC	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
lithium	NN	O
or	CC	O
valproate	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
COMBIVENT®	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
initial	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
leuprolide	JJ	O
acetate	NN	O
for	IN	O
depot	NN	O
suspension	NN	O
3.75	CD	B-DOS
mg	NN	B-UNIT
in	IN	O
combination	NN	O
with	IN	O
norethindrone	JJ	O
acetate	NN	O
5	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
is	VBZ	O
not	RB	O
to	TO	O
exceed	VB	O
six	CD	B-DUR
months	NNS	O-DUR
.	.	O

Children	NNP	B-WHO
weighing	VBG	I-WHO
100	CD	I-WHO
pounds	NNS	I-WHO
or	CC	I-WHO
more	JJR	O-WHO
should	MD	O
receive	VB	O
the	DT	O
adult	NN	B-WHO
dose	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	B-DOS
mg	NN	B-UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
or	CC	O
50	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
6	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
6	CD	I-FREQ
hours	NNS	O-FREQ
;	:	O
or	CC	O
500	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Patients	NNS	B-WHO
well	RB	I-WHO
controlled	VBN	O-WHO
on	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
or	CC	O
twice	VB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
may	MD	O
be	VB	O
maintained	VBN	O
on	IN	O
this	DT	O
regimen	NNS	O
.	.	O

Store	NN	O
solution	NN	O
at	IN	O
20	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Experience	NN	O
with	IN	O
ACEON	NNP	O
is	VBZ	O
limited	VBN	O
in	IN	O
the	DT	O
elderly	JJ	O
at	IN	O
doses	NNS	O
exceeding	VBG	O
8	CD	B-DOS
mg	NN	B-UNIT
.	.	O

For	IN	O
intramuscular	JJ	O
(	(	O
IM	NNP	O
)	)	O
injection	NN	O
only	RB	O
,	,	O
by	IN	O
needle	JJ	O
and	CC	O
syringe	NN	O
(	(	O
5	CD	B-DOS
years	NNS	B-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
)	)	O-WHO
or	CC	O
by	IN	O
PharmaJet®	NNP	O
Stratis®	NNP	O
Needle	NNP	O
-	:	O
Free	JJ	O
Injection	NN	O
System	NNP	O
(	(	O
18	CD	B-WHO
through	IN	I-WHO
64	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
)	)	O
.	.	O

(	(	O
2	CD	O
)	)	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
measure	VB	O
both	DT	O
peak	NN	O
and	CC	O
trough	JJ	O
serum	NN	O
concentrations	NNS	O
intermittently	RB	O
during	IN	O
therapy	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
Dose	NNP	O
Preparation	NNP	O
for	IN	O
Pediatric	NNP	O
Patients*	NNP	O

In	IN	O
patients	NNS	B-WHO
receiving	VBG	I-WHO
ritonavir	NN	O-WHO
for	IN	O
at	IN	B-DUR
least	JJS	I-DUR
one	CD	I-DUR
week	NN	O-DUR
,	,	O
start	VBP	O
ADCIRCA	NNP	O
at	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
adults	NNS	B-WHO
,	,	O
4	CD	B-DOS
drops	NNS	B-UNIT
of	IN	O
the	DT	O
suspension	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
ear	JJ	O
3	CD	B-FREQ
or	CC	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

A	DT	O
3.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
less	RBR	I-WHO
than	IN	I-WHO
1	CD	I-WHO
year	NN	I-WHO
old	JJ	O-WHO
,	,	O
who	WP	O
generally	RB	O
require	VBP	O
a	DT	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

The	DT	O
amount	NN	O
usually	RB	O
administered	VBN	O
is	VBZ	O
500	CD	B-DOS
to	TO	O
1000	CD	B-DOS
mL	NN	B-UNIT
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
aripiprazole	NN	O
is	VBZ	O
10	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

After	IN	O
at	IN	O
least	JJS	O
one	CD	B-DUR
week	NN	O-DUR
following	VBG	O
the	DT	O
initiation	NN	O
of	IN	O
ritonavir	NN	O
,	,	O
resume	VB	O
ADCIRCA	NNP	O
at	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
women	NNS	B-WHO
and	CC	O
either	DT	O
5	CD	B-DOS
or	CC	O
10	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
men	NNS	B-WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
night	NN	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
–	JJ	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
first	JJ	O
24	CD	O
-	:	O
hour	NN	O
dose	NN	O
may	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
;	:	O
however	RB	O
,	,	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
,	,	O
mean	JJ	O
daily	JJ	B-FREQ
doses	NNS	O
above	IN	O
2100	CD	B-DOS
mg	NN	B-UNIT
were	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hypotension	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
mild	JJ	I-WHO
or	CC	I-WHO
moderate	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
Grade	NNP	I-WHO
A	NNP	I-WHO
or	CC	I-WHO
B	NNP	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
and	CC	O
a	DT	O
1	CD	B-DOS
-	:	O
mg	NN	O
starting	VBG	O
dose	NN	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
to	TO	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
currently	RB	O
available	JJ	O
pharmacokinetic	JJ	O
data	NNS	O
do	VBP	O
not	RB	O
justify	VB	O
an	DT	O
absolute	JJ	O
recommendation	NN	O
on	IN	O
dosage	NN	O
reduction	NN	O
to	TO	O
those	DT	O
patients	NNS	O
,	,	O
but	CC	O
it	PRP	O
may	MD	O
be	VB	O
prudent	JJ	O
to	TO	O
use	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
initially	RB	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
ACTIQ	NNP	O
to	TO	O
treat	VB	O
episodes	NNS	O
of	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
is	VBZ	O
always	RB	O
200	CD	B-DOS
mcg	NN	B-UNIT
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
ALESSE	NNP	O
(	(	O
levonorgestrel	NN	O
and	CC	O
ethinyl	VB	O
estradiol	NN	O
)	)	O
-	:	O
28	CD	O
is	VBZ	O
one	CD	B-DOS
pink	NN	B-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
for	IN	O
21	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
,	,	O
followed	VBN	O
by	IN	O
one	CD	B-DOS
lightgreen	NN	B-UNIT
inert	JJ	I-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
for	IN	O
7	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
,	,	O
according	VBG	O
to	TO	O
the	DT	O
prescribed	JJ	O
schedule	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
40	CD	I-WHO
kg	NNS	O-WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
already	RB	I-WHO
stable	JJ	O-WHO
on	IN	O
another	DT	O
oral	JJ	O
antipsychotic	NN	O
(	(	O
and	CC	O
known	VBN	O
to	TO	O
tolerate	VB	O
aripiprazole	NN	O
)	)	O
,	,	O
after	IN	O
the	DT	O
first	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
injection	NN	O
,	,	O
continue	VBP	O
treatment	NN	O
with	IN	O
the	DT	O
antipsychotic	JJ	O
for	IN	O
14	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
to	TO	O
maintain	VB	O
therapeutic	JJ	O
antipsychotic	JJ	O
concentrations	NNS	O
during	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
achieve	VB	I-WHO
optimal	JJ	I-WHO
control	NN	I-WHO
of	IN	I-WHO
tics	NNS	O-WHO
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
mild	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
total	JJ	O
bilirubin	NN	O
greater	JJR	O
than	IN	O
ULN	NNP	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
1.5	CD	O
x	NNS	O
ULN	NNP	O
and	CC	O
aspartate	JJ	O
aminotransferase	NN	O
[	NNP	O
AST	NNP	O
]	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
10	CD	O
x	NNP	O
ULN	NNP	O
)	)	O
,	,	O
no	DT	O
dose	JJ	O
adjustments	NNS	O
are	VBP	O
required	VBN	O
,	,	O
regardless	RB	O
of	IN	O
indication	NN	O
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
try	VB	O
to	TO	O
maintain	VB	O
a	DT	O
significant	JJ	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
depression	NN	O
so	RB	O
as	IN	O
to	TO	O
keep	VB	O
the	DT	O
leukocyte	NN	O
count	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
3000	CD	B-DOS
to	TO	O
3500	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mcL	NN	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
one	CD	O
topical	JJ	O
ophthalmic	JJ	O
product	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
different	JJ	O
products	NNS	O
should	MD	O
be	VB	O
instilled	VBN	O
at	IN	O
least	JJS	O
5	CD	O
minutes	NNS	O
apart	RB	O
.	.	O

Actonel	NNP	O
with	IN	O
Calcium	NNP	O
(	(	O
risedronate	VB	O
sodium	NN	O
with	IN	O
calcium	NN	O
carbonate	NN	O
)	)	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Altoprev	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Postmarketing	VBG	O
experience	NN	O
suggests	VBZ	O
that	IN	O
elderly	JJ	B-WHO
patients	NNS	O-WHO
may	MD	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
complications	NNS	O
of	IN	O
constipation	NN	O
;	:	O
therefore	RB	O
,	,	O
appropriate	JJ	O
caution	NN	O
and	CC	O
follow	VB	O
-	:	O
up	RP	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
alosetron	JJ	O
hydrochloride	NN	O
tablets	NNS	O
are	VBP	O
prescribed	VBN	O
for	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
[	VBP	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

(	(	O
120	CD	B-DOS
mL	NN	B-UNIT
)	)	O
of	IN	O
water	NN	O
or	CC	O
apple	NN	O
juice	NN	O
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Zonalon	NNP	O
(	(	O
doxepin	NN	O
)	)	O
Cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
four	CD	B-FREQ
times	NNS	I-FREQ
each	DT	I-FREQ
day	NN	O-FREQ
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
3	CD	O
to	TO	O
4	CD	O
hour	NN	O
interval	NN	O
between	IN	O
applications	NNS	O
.	.	O

If	IN	O
the	DT	O
5	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
is	VBZ	O
not	RB	O
effective	JJ	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

No	DT	O
additional	JJ	O
benefit	NN	O
was	VBD	O
demonstrated	VBN	O
at	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
10	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
and	CC	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
discontinuations	NNS	O
because	IN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
more	RBR	O
frequent	JJ	O
at	IN	O
higher	JJR	O
doses	NNS	O
[	VBP	O
see	VB	O
FDA	NNP	O
-	:	O
Approved	VBD	O
PATIENT	NNP	O
INFORMATION	NNP	O
for	IN	O
complete	JJ	O
“	NNP	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
”	NNP	O
]	NNP	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
titration	NN	O
should	MD	O
proceed	VB	O
over	IN	O
a	DT	O
7	CD	B-DUR
to	TO	O
14	CD	B-DUR
day	NN	O-DUR
period	NN	O
starting	VBG	O
with	IN	O
30	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
tolerate	VB	O-WHO
25	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
may	MD	O
have	VB	O
their	PRP$	O
dosage	NN	O
reduced	VBN	O
to	TO	O
25	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
DUEXIS	NNP	O
(	(	O
ibuprofen	NN	O
and	CC	O
famotidine	NN	O
)	)	O
800	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
26.6	CD	B-DOS
mg	NN	B-UNIT
is	VBZ	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
administered	VBN	O
orally	RB	O
three	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Dosage	NN	O
and	CC	O
Duration	NNP	O
of	IN	O
ACIPHEX	NNP	O
Delayed	NNP	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
in	IN	O
Adults	NNP	B-WHO
and	CC	I-WHO
Adolescents	NNP	I-WHO
12	CD	I-WHO
Years	NNS	I-WHO
of	IN	I-WHO
Age	NNP	I-WHO
and	CC	I-WHO
Older	JJR	O-WHO

Patients	NNS	B-WHO
whose	WP$	I-WHO
blood	NN	I-WHO
pressures	NNS	I-WHO
are	VBP	I-WHO
not	RB	I-WHO
adequately	RB	I-WHO
controlled	VBN	I-WHO
with	IN	I-WHO
quinapril	JJ	I-WHO
monotherapy	NN	O-WHO
may	MD	O
instead	RB	O
be	VB	O
given	VBN	O
ACCURETIC	NNP	O
10	CD	O
/	NNP	O
12.5	CD	O
or	CC	O
20	CD	O
/	JJ	O
12.5	CD	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
,	,	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	I-WHO
,	,	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
and	CC	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

If	IN	O
at	IN	O
any	DT	O
time	NN	O
,	,	O
the	DT	O
patient	NN	O
has	VBZ	O
symptoms	NNS	O
of	IN	O
hypotension	NN	O
,	,	O
decrease	VB	O
the	DT	O
dosage	NN	O
by	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
taken	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Therapy	NN	O
with	IN	O
NIASPAN	NNP	O
must	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
500mg	CD	O
at	IN	O
bedtime	NN	O
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
side	NN	O
effects	NNS	O
which	WDT	O
may	MD	O
occur	VB	O
during	IN	O
early	JJ	O
therapy	NN	O
.	.	O

Energy	NNP	O
requirements	NNS	O
for	IN	O
children	NNS	B-WHO
between	IN	I-WHO
1	CD	I-WHO
and	CC	I-WHO
7	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
are	VBP	O
approximately	RB	O
75	CD	O
to	TO	O
90	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
for	IN	O
children	NNS	B-WHO
7	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
60	CD	O
to	TO	O
75	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
and	CC	O
for	IN	O
ages	NNS	B-WHO
12	CD	I-WHO
to	TO	I-WHO
18	CD	I-WHO
years	NNS	O-WHO
,	,	O
30	CD	O
to	TO	O
60	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
brucellosis	NN	O
,	,	O
500	CD	B-DOS
mg	NN	B-UNIT
Achromycin	NNP	O
V	NNP	O
(	(	O
Tetracycline	NNP	O
HCl	NNP	O
Capsules	NNP	O
,	,	O
USP	NNP	O
)	)	O
q.i.d	NN	O
.	.	O

The	DT	O
dose	JJ	O
counter	NN	O
window	NN	O
displays	VBZ	O
the	DT	O
number	NN	O
of	IN	O
actuations	NNS	O
(	(	O
inhalations	NNS	O
)	)	O
left	VBD	O
in	IN	O
the	DT	O
inhaler	NN	O
in	IN	O
units	NNS	O
of	IN	O
two	CD	O
(	(	O
e.g	NN	O
,	,	O
60	CD	O
,	,	O
58	CD	O
,	,	O
56	CD	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
irritability	NN	I-WHO
associated	VBN	I-WHO
with	IN	I-WHO
autistic	JJ	I-WHO
disorder	NN	O-WHO
is	VBZ	O
5	CD	B-DOS
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Peak	JJ	O
concentrations	NNS	O
(	(	O
30	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
after	IN	O
injection	NN	O
)	)	O
above	IN	O
35	CD	B-DOS
micrograms	NNS	B-UNIT
per	IN	O
mL	NN	O
and	CC	O
trough	JJ	O
concentrations	NNS	O
(	(	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
next	JJ	O
dose	NN	O
)	)	O
above	IN	O
10	CD	B-DOS
micrograms	NNS	B-UNIT
per	IN	O
mL	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Amiodarone	NNP	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
greater	JJR	O
than	IN	O
3	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
mL	NN	O
in	IN	O
D5W	NNP	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
peripheral	JJ	O
vein	NN	O
phlebitis	NN	O
;	:	O
however	RB	O
,	,	O
concentrations	NNS	O
of	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
or	CC	O
less	JJR	O
appear	JJ	O
to	TO	O
be	VB	O
less	JJR	O
irritating	NN	O
.	.	O

d.	NN	O
For	IN	O
patients	NNS	B-WHO
converting	VBG	I-WHO
from	IN	I-WHO
Actiq	NNP	I-WHO
doses	NNS	O-WHO
of	IN	O
1200	CD	B-DOS
and	CC	O
1600	CD	B-DOS
mcg	NN	B-UNIT
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
200	CD	B-DOS
mcg	NNS	B-UNIT
and	CC	O
400	CD	B-DOS
mcg	JJ	B-UNIT
Abstral	NNP	O
,	,	O
respectively	RB	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

After	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
,	,	O
the	DT	O
maintenance	NN	O
infusion	NN	O
rate	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
min	NN	O
(	(	O
720	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
24	CD	O
hours	NNS	O
)	)	O
should	MD	O
be	VB	O
continued	VBN	O
utilizing	VBG	O
a	DT	O
concentration	NN	O
of	IN	O
1	CD	B-DOS
to	TO	O
6	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
(	(	O
amiodarone	JJ	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
greater	JJR	O
than	IN	O
2	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
mL	NN	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
)	)	O
.	.	O

A	DT	O
5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
one	CD	I-WHO
year	NN	I-WHO
old	JJ	O-WHO
,	,	O
who	WP	O
generally	RB	O
receive	VBP	O
a	DT	O
2	CD	O
to	TO	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

Exogenous	JJ	O
Obesity	NN	O
:	:	O
One	CD	B-DOS
capsule	NN	B-UNIT
at	IN	O
approximately	RB	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
for	IN	O
appetite	JJ	O
control	NN	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
Sumavel	NNP	O
DosePro	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
subcutaneously	RB	O
.	.	O

At	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NN	O
,	,	O
the	DT	O
ACTH	NNP	O
and	CC	O
cortisol	JJ	O
responses	NNS	O
to	TO	O
ACTHREL®	NNP	O
are	VBP	O
prolonged	VBN	O
and	CC	O
remain	VBP	O
elevated	VBN	O
for	IN	O
up	RB	O
to	TO	O
2	CD	O
hours	NNS	O
.	.	O

Instruct	NN	O
patients	NNS	O
not	RB	O
to	TO	O
use	VB	O
more	JJR	O
than	IN	O
4	CD	B-DOS
tablets	NNS	B-UNIT
at	IN	O
one	CD	O
time	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
maintenance	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
MAINTENA	NNP	O
is	VBZ	O
400	CD	B-DOS
mg	NN	B-UNIT
monthly	RB	B-FREQ
(	(	O
no	DT	O
sooner	NN	O
than	IN	O
26	CD	O
days	NNS	O
after	IN	O
the	DT	O
previous	JJ	O
injection	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
hyperaldosteronism	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
by	IN	O
more	RBR	O
definitive	JJ	O
testing	NN	O
procedures	NNS	O
,	,	O
ALDACTONE	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
doses	NNS	O
of	IN	O
100	CD	B-DOS
to	TO	O
400	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
in	IN	O
preparation	NN	O
for	IN	O
surgery	NN	O
.	.	O

Lower	JJR	O
concentrations	NNS	O
(	(	O
0.2	CD	B-DOS
to	TO	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
may	MD	O
be	VB	O
appropriate	JJ	O
for	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
small	JJ	I-WHO
children	NNS	O-WHO
to	TO	O
provide	VB	O
sufficient	JJ	O
volume	NN	O
for	IN	O
infusion	NN	O
.	.	O

The	DT	O
maximum	JJ	O
dosage	NN	O
is	VBZ	O
65	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	VBD	O
or	CC	O
3	CD	B-DOS
g	JJ	B-UNIT
daily	RB	B-FREQ
,	,	O
whichever	WP	O
is	VBZ	O
less	JJR	O
.	.	O

The	DT	O
recommended	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
for	IN	O
patients	NNS	B-WHO
previously	RB	I-WHO
untreated	VBN	I-WHO
with	IN	I-WHO
interferon	NN	O-WHO
is	VBZ	O
24	CD	B-DUR
to	TO	O
48	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

Revised	VBN	O
:	:	O
Jul	NN	O
2014	CD	O

AFREZZA	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
chronic	JJ	I-WHO
lung	NN	I-WHO
disease	NN	O-WHO
because	IN	O
of	IN	O
the	DT	O
risk	NN	O
of	IN	O
acute	JJ	O
bronchospasm	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
.	.	O

The	DT	O
recommended	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
1000	CD	B-DOS
mg	NN	B-UNIT
(	(	O
two	CD	B-DOS
500	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
to	TO	O
2000	CD	B-DOS
mg	NN	B-UNIT
(	(	O
two	CD	B-DOS
1000	CD	O-DOS
mg	JJ	B-UNIT
tablets	NNS	O-UNIT
or	CC	O
four	CD	B-DOS
500	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

(	(	O
5	CD	O
)	)	O
Door	NNP	O
and	CC	O
latches	NNS	O
:	:	O
Patients	NNS	O
should	MD	O
be	VB	O
able	JJ	O
to	TO	O
open	VB	O
the	DT	O
door	NN	O
from	IN	O
the	DT	O
inside	NN	O
with	IN	O
only	JJ	O
slight	JJ	O
pressure	NN	O
to	TO	O
the	DT	O
door	NN	O
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
for	IN	O
use	NN	O
in	IN	O
combination	NN	O
with	IN	O
ritonavir	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
12	CD	B-DOS
mg	NNS	B-UNIT
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
adult	NN	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	O-WHO
.	.	O

Infants	NNS	B-WHO
should	MD	O
receive	VB	O
a	DT	O
1	CD	O
to	TO	O
2	CD	O
hour	NN	O
infusion	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
heart	NN	I-WHO
failure	NN	I-WHO
and	CC	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
ACCUPRIL	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
above	IN	O-WHO
30	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
min	NN	O
and	CC	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
of	IN	O-WHO
10	CD	B-DOS
to	TO	O
30	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
min	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Incremental	JJ	O
Rates	NNS	O
for	IN	O
100	CD	B-DOS
mL	NNS	B-UNIT
ALDURAZYME®	NNP	O
Infusion	NNP	O
(	(	O
For	IN	O
use	NN	O
with	IN	O
Patients	NNS	B-WHO
Weighing	VBG	I-WHO
20	CD	I-WHO
kg	NN	I-WHO
or	CC	I-WHO
Less	NNP	I-WHO
)	)	O-WHO

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
,	,	O
electrolyte	NN	O
and	CC	O
acid	JJ	O
-	:	O
base	NN	O
needs	VBZ	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	B-FREQ
losses	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	B-WHO
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
of	IN	O
AKYNZEO	NNP	O
administered	VBD	O
approximately	RB	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
with	IN	O
dexamethasone	NN	O
12	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
orally	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
chemotherapy	VB	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
8	CD	B-DOS
mg	NNS	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
on	IN	O
days	NNS	O
2	CD	O
to	TO	O
4	CD	O
[	NNS	O
see	VBP	O
Clinical	JJ	O
Studies	NNS	O
,	,	O
Table	JJ	O
5	CD	O
]	NN	O
.	.	O

While	IN	O
there	EX	O
are	VBP	O
no	DT	O
systematic	JJ	O
studies	NNS	O
that	WDT	O
answer	VBP	O
the	DT	O
question	NN	O
of	IN	O
how	WRB	O
long	JJ	O
to	TO	O
continue	VB	O
Anafranil	NNP	O
,	,	O
OCD	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
condition	NN	O
and	CC	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
consider	VB	O
continuation	NN	O
for	IN	O
a	DT	O
responding	JJ	B-WHO
patient	NN	O-WHO
.	.	O

Average	JJ	O
dosage	NN	O
is	VBZ	O
20	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
administering	VBG	O
ALIMTA	NNP	O
concurrently	RB	O
with	IN	O
NSAIDs	NNP	O
to	TO	O
patients	NNS	B-WHO
whose	WP$	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
is	VBZ	I-WHO
<	JJ	O-WHO
80	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
dosage	NN	O
employed	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
simple	NN	O
(	(	O
open	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
ranges	VBZ	O
from	IN	O
250	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
1	CD	B-DOS
g	NN	B-UNIT
of	IN	O
acetazolamide	JJ	O
per	IN	O
24	CD	O
hours	NNS	O
,	,	O
usually	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
amounts	NNS	O
over	IN	O
250	CD	B-DOS
mg	NNS	B-UNIT
.	.	O

For	IN	O
convenience	NN	O
,	,	O
patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
adequately	RB	I-WHO
treated	VBN	O-WHO
with	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
quinapril	NN	O
and	CC	O
25	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
hydrochlorothiazide	NN	O
and	CC	O
experience	NN	O
no	DT	O
significant	JJ	O
electrolyte	NN	O
disturbances	NNS	O
may	MD	O
instead	RB	O
wish	VB	O
to	TO	O
receive	VB	O
ACCURETIC	NNP	O
20	CD	O
/	NN	O
25	CD	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
not	RB	O
exceed	VB	O
6	CD	B-DOS
tablets	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
infants	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
larger	JJR	I-WHO
than	IN	I-WHO
10	CD	I-WHO
kg	NN	O-WHO
,	,	O
the	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
should	MD	O
be	VB	O
up	RB	O
to	TO	O
25	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acids	NNS	O
/	VBP	B-FREQ
day	NN	O-FREQ
for	IN	O
the	DT	O
first	JJ	O
10	CD	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
plus	CC	O
1	CD	B-DOS
to	TO	O
1.25	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	NN	O
for	IN	O
each	DT	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
over	IN	O
10	CD	O
kg	NNS	O
.	.	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
amikacin	JJ	O
sulfate	JJ	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5.0	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

Patients	NNS	B-WHO
previously	RB	I-WHO
receiving	VBG	I-WHO
other	JJ	I-WHO
niacin	JJ	I-WHO
products	NNS	O-WHO
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
the	DT	O
recommended	VBN	O
NIASPAN	NNP	O
titration	NN	O
schedule	NN	O
(	(	O
see	VB	O
Table	NNP	O
11	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
response	NN	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
,	,	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	I-WHO
,	,	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
and	CC	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1.0	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

For	IN	O
doses	NNS	O
above	IN	O
24	CD	B-DOS
units	NNS	B-UNIT
,	,	O
combinations	NNS	O
of	IN	O
different	JJ	O
multiple	JJ	O
cartridges	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O

Oxygen	NN	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
but	CC	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
usual	JJ	O
precautions	NNS	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
respiratory	NN	I-WHO
disease	NN	O-WHO
and	CC	O
CO2	NNP	O
retention	NN	O
.	.	O

Dilute	NNP	O
1	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Adrenalin®	NNP	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
mL	NN	O
(	(	O
1:1000	CD	O
)	)	O
in	IN	O
100	CD	B-DOS
to	TO	O
1000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
an	DT	O
ophthalmic	JJ	O
irrigation	NN	O
fluid	NN	O
to	TO	O
create	VB	O
an	DT	O
epinephrine	JJ	O
concentration	NN	O
of	IN	O
1:100,000	CD	O
to	TO	O
1:1,000,000	CD	O
(	(	O
10	CD	B-DOS
mcg	NN	B-UNIT
/	NN	O
mL	NN	O
to	TO	O
1	CD	B-DOS
mcg	NNS	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
remove	VB	O
the	DT	O
mouthpiece	NN	O
from	IN	O
the	DT	O
mouth	NN	O
and	CC	O
hold	VB	O
the	DT	O
breath	NN	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
possible	JJ	O
,	,	O
up	RB	O
to	TO	O
10	CD	O
seconds	NNS	O
(	(	O
see	VB	O
Figure	NNP	O
6	CD	O
)	)	O
.	.	O

Each	DT	O
100	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
contains	VBZ	O
:	:	O

Figures	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
provide	NN	O
examples	NNS	O
of	IN	O
negative	JJ	O
and	CC	O
positive	JJ	O
scans	NNS	O
.	.	O

AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	B-DOS
injection	NN	B-UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
dosing	NN	O
is	VBZ	O
based	VBN	O
upon	IN	O
the	DT	O
radioactivity	NN	O
determined	VBD	O
using	VBG	O
a	DT	O
suitable	JJ	O
calibration	NN	O
system	NN	O
immediately	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
an	DT	O
initial	JJ	O
titration	NN	O
supply	NN	O
of	IN	O
six	CD	O
200	CD	B-DOS
mcg	NNS	B-UNIT
ACTIQ	NNP	O
units	NNS	O
,	,	O
thus	RB	O
limiting	VBG	O
the	DT	O
number	NN	O
of	IN	O
units	NNS	O
in	IN	O
the	DT	O
home	NN	O
during	IN	O
titration	NN	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
4000	CD	O
calories	NNS	O
and	CC	O
25	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
or	CC	O
more	JJR	O
may	MD	O
be	VB	O
required	VBN	O
daily	RB	B-FREQ
to	TO	O
achieve	VB	O
nitrogen	NN	O
balance	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AGGRENOX	NNP	O
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
given	VBN	O
orally	RB	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
,	,	O
one	CD	B-DOS
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
one	CD	B-DOS
in	IN	O
the	DT	O
evening	NN	O
.	.	O

During	IN	O
titration	NN	O
,	,	O
patients	NNS	O
can	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
multiples	NNS	O
of	IN	O
100	CD	B-DOS
mcg	JJ	B-UNIT
tablets	NNS	O-UNIT
and	CC	O
/	NNP	O
or	CC	O
200	CD	B-DOS
mcg	JJ	B-UNIT
tablets	NNS	O-UNIT
for	IN	O
any	DT	O
single	JJ	O
dose	NN	O
.	.	O

Application	NNP	O
area	NN	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	B-DOS
cm²	NNS	B-UNIT
and	CC	O
no	DT	O
more	JJR	O
than	IN	O
2	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
AMELUZ	NNP	O
(	(	O
one	CD	B-DOS
tube	NN	B-UNIT
)	)	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
one	CD	O
time	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
recommended	VBD	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
should	MD	O
be	VB	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
15000	CD	B-DOS
mg	NNS	B-UNIT
infused	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
one	CD	O
hour	NN	O
followed	VBN	O
by	IN	O
a	DT	O
first	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
5000	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
4	CD	O
hours	NNS	O
and	CC	O
a	DT	O
second	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
10000	CD	B-DOS
mg	NN	B-UNIT
over	IN	O
16	CD	O
hours	NNS	O
(	(	O
See	VB	O
Table	NNP	O
3	CD	O
)	)	O
.	.	O

For	IN	O
Grade	NNP	O
3	CD	O
sensory	NN	O
neuropathy	JJ	O
hold	NN	O
treatment	NN	O
until	IN	O
resolution	NN	O
to	TO	O
Grade	VB	O
1	CD	O
or	CC	O
2	CD	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
dose	JJ	O
reduction	NN	O
for	IN	O
all	DT	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
ABRAXANE	NNP	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Typically	RB	O
,	,	O
the	DT	O
8.5	CD	O
%	NN	O
solution	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
equal	JJ	O
volume	NN	O
with	IN	O
50	CD	O
%	NN	O
or	CC	O
70	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
provide	VB	O
an	DT	O
admixture	NN	O
containing	VBG	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
and	CC	O
25	CD	O
%	NN	O
or	CC	O
35	CD	O
%	NN	O
dextrose	JJ	O
respectively	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TECENTRIQ	NNP	O
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	B-FREQ
3	CD	I-FREQ
weeks	NNS	O-FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

for	IN	O
three	CD	B-DUR
weeks	NNS	O-DUR
should	MD	O
be	VB	O
accompanied	VBN	O
by	IN	O
streptomycin	NN	O
,	,	O
1	CD	B-DOS
gram	NN	B-UNIT
intramuscularly	JJ	O
twice	RB	B-FREQ
daily	RB	O-FREQ
the	DT	O
first	JJ	O
week	NN	B-DUR
and	CC	O
once	RB	B-FREQ
daily	JJ	O-FREQ
the	DT	O
second	JJ	O
week	NN	B-DUR
.	.	O

After	IN	O
dilution	NN	O
in	IN	O
an	DT	O
ophthalmic	JJ	O
irrigating	NN	O
fluid	NN	O
,	,	O
Adrenalin®	NNP	O
may	MD	O
also	RB	O
be	VB	O
injected	VBN	O
intracamerally	RB	O
as	IN	O
a	DT	O
bolus	NN	O
dose	NN	O
of	IN	O
0.1	CD	B-DOS
mL	NN	B-UNIT
at	IN	O
a	DT	O
dilution	NN	O
of	IN	O
1:100,000	CD	O
to	TO	O
1:400,000	CD	O
(	(	O
10	CD	B-DOS
mcg	NN	B-UNIT
/	NN	O
mL	NN	O
to	TO	O
2.5	CD	B-DOS
mcg	NNS	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
fluid	JJ	I-WHO
restrictions	NNS	O-WHO
may	MD	O
only	RB	O
tolerate	VB	O
1	CD	O
to	TO	O
2	CD	O
liters	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACULAR®	NNP	O
ophthalmic	JJ	O
solution	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
for	IN	O
relief	NN	O
of	IN	O
ocular	JJ	O
itching	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
overdosing	VBG	O
during	IN	O
titration	NN	O
,	,	O
patients	NNS	O
should	MD	O
have	VB	O
only	RB	O
one	CD	B-DOS
strength	NN	B-UNIT
of	IN	O
ACTIQ	NNP	O
available	JJ	O
at	IN	O
any	DT	O
one	CD	O
time	NN	O
.	.	O

Diagnostic	JJ	O
Bronchograms	NNS	O
:	:	O
For	IN	O
diagnostic	JJ	O
bronchial	JJ	O
studies	NNS	O
,	,	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
administrations	NNS	B-UNIT
of	IN	O
1	CD	B-DOS
to	TO	O
2	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
2	CD	B-DOS
to	TO	O
4	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
should	MD	O
be	VB	O
given	VBN	O
by	IN	O
nebulization	NN	O
or	CC	O
by	IN	O
instillation	NN	O
intratracheally	RB	O
,	,	O
prior	RB	O
to	TO	O
the	DT	O
procedure	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
weighing	VBG	I-WHO
less	JJR	I-WHO
than	IN	I-WHO
50	CD	I-WHO
kg	NNS	O-WHO
,	,	O
dosing	VBG	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
with	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
after	IN	O
2	CD	O
days	NNS	O
.	.	O

If	IN	O
the	DT	O
dose	NN	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	B-DOS
vial	NN	B-UNIT
of	IN	O
ADYNOVATE	NNP	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
using	VBG	O
the	DT	O
above	JJ	O
steps	NNS	O
.	.	O

The	DT	O
bottom	JJ	O
two	CD	O
arrows	NNS	O
indicate	VBP	O
areas	NNS	O
of	IN	O
decreased	JJ	O
gray	JJ	O
-	:	O
white	JJ	O
contrast	NN	O
with	IN	O
increased	JJ	O
cortical	JJ	O
radioactivity	NN	O
that	WDT	O
is	VBZ	O
comparable	JJ	O
to	TO	O
the	DT	O
radioactivity	NN	O
in	IN	O
the	DT	O
adjacent	JJ	O
white	JJ	O
matter	NN	O
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
Xiidra	NNP	O
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
into	IN	O
each	DT	O
eye	NN	O
using	VBG	O
a	DT	O
single	JJ	B-DOS
-	:	O
use	NN	O
container	NN	O
.	.	O

Administration	NN	O
of	IN	O
Permax	NNP	O
(	(	O
pergolide	JJ	O
mesylate	NN	O
)	)	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
0.05	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Amnesteem	NNP	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	B-DUR
to	TO	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	B-DOS
-	:	O
60	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
single	JJ	B-DOS
doses	NNS	B-UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post	NN	B-WHO
-	:	I-WHO
infarction	NN	I-WHO
patients	NNS	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
shown	VBN	I-WHO
signs	NNS	I-WHO
of	IN	I-WHO
congestive	JJ	I-WHO
failure	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
2.5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
5	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

ALOXI	NNP	O
is	VBZ	O
supplied	VBN	O
ready	JJ	O
for	IN	O
intravenous	JJ	O
administration	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
0.05	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
(	(	O
50	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Parkinson	NNP	O
's	POS	O
Disease	NN	O
:	:	O
Oral	JJ	O
:	:	O
The	DT	O
usual	JJ	O
beginning	NN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
three	CD	B-FREQ
or	CC	O
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
.	.	O

Treatment	NN	O
of	IN	O
patients	NNS	B-WHO
in	IN	I-WHO
the	DT	I-WHO
heavier	JJR	I-WHO
weight	JJ	I-WHO
classes	NNS	O-WHO
should	MD	O
not	RB	O
exceed	VB	O
1.5	CD	B-DOS
gram	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Severe	JJ	O
Infections	NNS	O
:	:	O
4	CD	B-DOS
tablets	NNS	B-UNIT
(	(	O
2	CD	B-DOS
g	NN	B-UNIT
)	)	O
initially	RB	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	B-DOS
tablets	NNS	B-UNIT
(	(	O
1	CD	B-DOS
g	NN	B-UNIT
)	)	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	JJ	O-FREQ
thereafter	RB	O
.	.	O

If	IN	O
after	IN	O
4	CD	B-DUR
weeks	NNS	O-DUR
the	DT	O
dosage	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
but	CC	O
does	VBZ	O
not	RB	O
adequately	RB	O
control	VB	O
IBS	NNP	O
symptoms	NNS	O
,	,	O
then	RB	O
the	DT	O
dosage	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
up	RB	O
to	TO	O
1	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
in	IN	O
patients	NNS	B-WHO
not	RB	I-WHO
on	IN	I-WHO
diuretics	NNS	O-WHO
is	VBZ	O
10	CD	B-DOS
or	CC	O
20	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

ACEON	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
<	VBD	O-WHO
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severely	RB	I-WHO
impaired	JJ	I-WHO
hepatic	JJ	I-WHO
function	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
Class	NNP	I-WHO
C	NNP	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
8	CD	B-DOS
mcg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	B-DOS
mcg	JJ	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
with	IN	O
the	DT	O
dose	NN	O
titrated	VBD	O
upward	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
8	CD	B-DOS
tablets	NNS	B-UNIT
(	(	O
16	CD	B-DOS
mg	NN	B-UNIT
)	)	O
per	IN	O
24	CD	O
hours	NNS	O
.	.	O

and	CC	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2.5	CD	B-DOS
mg	NN	B-UNIT
b.i.d	NN	O
.	.	O

Titration	NN	O
to	TO	O
doses	NNS	O
above	IN	O
90	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
Ancobon	NNP	O
is	VBZ	O
50	CD	B-DOS
to	TO	O
150	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
administered	VBD	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
500	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	B-DOS
hrs	NNS	B-UNIT

Alosetron	NNP	O
hydrochloride	NN	O
tablets	NNS	O
is	VBZ	O
extensively	RB	O
metabolized	VBN	O
by	IN	O
the	DT	O
liver	NN	O
,	,	O
and	CC	O
increased	VBD	O
exposure	NN	O
to	TO	O
alosetron	VB	O
hydrochloride	JJ	O
tablets	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
occur	VB	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

g	NN	O
)	)	O
Place	NN	O
and	CC	O
hold	VB	O
the	DT	O
vial	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
suspension	NN	O
on	IN	O
a	DT	O
hard	JJ	O
surface	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
worse	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
ramipril	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
produce	VB	O
full	JJ	O
therapeutic	JJ	O
levels	NNS	O
of	IN	O
ramiprilat	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
ABRAXANE	NNP	O
to	TO	O
patients	NNS	B-WHO
with	IN	I-WHO
metastatic	JJ	I-WHO
adenocarcinoma	NN	I-WHO
of	IN	I-WHO
the	DT	I-WHO
pancreas	NNS	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
moderate	VBN	I-WHO
to	TO	I-WHO
severe	VB	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
.	.	O

No	DT	O
specific	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
or	CC	O
necessity	NN	O
of	IN	O
dosing	VBG	O
adjustments	NNS	O
in	IN	O
patients	NNS	B-WHO
weighing	VBG	I-WHO
over	IN	I-WHO
100	CD	I-WHO
kg	NNS	O-WHO
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
is	VBZ	O
7	CD	B-DUR
to	TO	O
10	CD	B-DUR
days	NNS	O-DUR
.	.	O

To	TO	O
achieve	VB	O
the	DT	O
required	JJ	O
total	NN	O
mealtime	NN	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
use	VB	O
a	DT	O
combination	NN	O
of	IN	O
4	CD	O
unit	NN	O
,	,	O
8	CD	O
unit	NN	O
and	CC	O
12	CD	O
unit	NN	O
cartridges	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
ADCETRIS	NNP	O
Dosage	NNP	O

Pediatrics	NNS	O
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
(	(	I-WHO
10	CD	I-WHO
to	TO	I-WHO
17	CD	I-WHO
years	NNS	I-WHO
)	)	O-WHO
as	IN	O
monotherapy	NN	O
is	VBZ	O
2	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
with	IN	O
titration	NN	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
after	IN	O
2	CD	O
days	NNS	O
,	,	O
and	CC	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
after	IN	O
2	CD	O
additional	JJ	O
days	NNS	O
.	.	O

8	CD	O

To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
alosetron	NN	O
hydrochloride	NN	O
tablets	NNS	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

For	IN	O
adults	NNS	B-WHO
(	(	I-WHO
≥	JJ	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	B-DOS
mCi	NN	B-UNIT
(	(	O
370	CD	B-DOS
MBq	NNP	B-UNIT
)	)	O
.	.	O

Reconstituted	VBN	O
solutions	NNS	O
retain	VBP	O
their	PRP$	O
physical	JJ	O
and	CC	O
chemical	JJ	O
properties	NNS	O
for	IN	O
3	CD	B-DUR
days	NNS	O-DUR
under	IN	O
refrigeration	NN	O
at	IN	O
2°	CD	O
-	:	O
8°	CD	O
C	NNP	O
(	(	O
36°	CD	O
-	:	O
46°	CD	O
F	NNP	O
)	)	O
,	,	O
or	CC	O
12	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
15°	CD	O
-	:	O
30°	CD	O
C	NNP	O
(	(	O
59°	CD	O
-	:	O
86°	CD	O
F	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMEVIVE®	NNP	O
is	VBZ	O
15	CD	B-DOS
mg	NN	B-UNIT
intramuscularly	RB	O
once	RB	B-FREQ
weekly	JJ	O-FREQ
for	IN	O
12	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

ALLEGRA	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
180	CD	O
and	CC	O
pseudoephendrine	VB	O
hcl	NN	O
240	CD	O
)	)	O
tablets	NNS	B-UNIT
should	MD	O
generally	RB	O
be	VB	O
avoided	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
insufficiency	NN	O-WHO
.	.	O

ARMONAIR	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

Average	JJ	O
daily	JJ	B-FREQ
adult	NN	B-WHO
fluid	NN	O
requirements	NNS	O
are	VBP	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
higher	JJR	O
with	IN	O
losses	NNS	O
from	IN	O
fistula	JJ	O
drainage	NN	O
or	CC	O
in	IN	O
severe	JJ	O
burns	NNS	O
.	.	O

Amoxapine	NNP	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
.	.	O

Multiple	JJ	O
Myeloma	NNP	O
:	:	O
The	DT	O
usual	JJ	O
oral	JJ	O
dose	NN	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
(	(	O
3	CD	B-DOS
tablets	NNS	B-UNIT
)	)	O
daily	RB	B-FREQ
.	.	O

Once	RB	O
opened	VBN	O
,	,	O
Accretropin™	NNP	O
(	(	O
somatropin	JJ	O
injection	NN	O
)	)	O
may	MD	O
be	VB	O
stored	VBN	O
up	IN	B-DUR
to	TO	I-DUR
14	CD	I-DUR
days	NNS	O-DUR
when	WRB	O
refrigerated	VBN	O
[	RB	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
]	NN	O
.	.	O

If	IN	O
agitation	NN	O
warranting	VBG	O
a	DT	O
second	JJ	O
dose	JJ	O
persists	NNS	O
following	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
,	,	O
cumulative	JJ	O
doses	VBZ	O
up	RP	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
may	MD	O
be	VB	O
given	VBN	O
.	.	O

Usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
one	CD	B-DOS
to	TO	O
two	CD	B-DOS
tablets	NNS	B-UNIT
daily	RB	B-FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Initial	JJ	O
dose	NN	O
:	:	O
6	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
as	IN	O
a	DT	O
rapid	JJ	O
intravenous	JJ	O
bolus	NN	O
(	(	O
administered	VBN	O
over	IN	O
a	DT	O
1	CD	O
-	:	O
2	CD	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
12.5	CD	B-DOS
mg	JJ	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

For	IN	O
intramuscular	JJ	O
administration	NN	O
,	,	O
use	VB	O
a	DT	O
needle	JJ	O
long	JJ	O
enough	RB	O
(	(	O
at	IN	O
least	JJS	O
½	JJ	O
inch	NN	O
to	TO	O
5	CD	O
/	NNS	O
8	CD	O
inch	NN	O
)	)	O
to	TO	O
ensure	VB	O
the	DT	O
injection	NN	O
is	VBZ	O
administered	VBN	O
into	IN	O
the	DT	O
muscle	NN	O
.	.	O

AFREZZA	NNP	O
is	VBZ	O
administered	VBN	O
using	VBG	O
a	DT	O
single	JJ	B-DOS
inhalation	NN	B-UNIT
per	IN	O
cartridge	NN	O
.	.	O

Hydrochlorothiazide	NNP	O
can	MD	O
be	VB	O
given	VBN	O
at	IN	O
doses	NNS	O
of	IN	O
12.5	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
when	WRB	O
used	VBN	O
alone	RB	O
.	.	O

There	EX	O
is	VBZ	O
insufficient	JJ	O
data	NNS	O
for	IN	O
dosage	NN	O
recommendation	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
creatinine	JJ	I-WHO
clearance	NN	I-WHO
less	JJR	O-WHO
than	IN	O
10	CD	B-DOS
mL	JJ	B-UNIT
/	NNP	O
min	NN	O
(	(	O
see	VB	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
,	,	O
Heart	NNP	O
Failure	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
and	CC	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
CYSTARAN	NNP	O
in	IN	O
each	DT	O
eye	NN	O
,	,	O
every	DT	O
waking	VBG	O
hour	NN	O
.	.	O

Stability	NN	O
in	IN	O
IV	NNP	O
Fluids	NNP	O
:	:	O
Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	B-DUR
hours	NNS	O-DUR
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

Aminosyn	NNP	O
II	NNP	O
in	IN	O
the	DT	O
2000	CD	B-DOS
mL	NN	B-UNIT
flexible	JJ	O
Pharmacy	NNP	O
Bulk	NNP	O
Package	NNP	O
is	VBZ	O
designed	VBN	O
for	IN	O
use	NN	O
with	IN	O
manual	JJ	O
,	,	O
gravity	NN	O
flow	NN	O
operations	NNS	O
and	CC	O
automated	VBN	O
gravimetric	JJ	O
compounding	NN	O
devices	NNS	O
for	IN	O
preparing	VBG	O
intravenous	JJ	O
nutritional	JJ	O
admixtures	NNS	O
.	.	O

Repeat	JJ	O
administration	NN	O
:	:	O
If	IN	O
conversion	NN	O
of	IN	O
PSVT	NNP	O
does	VBZ	O
not	RB	O
occur	VB	O
within	IN	O
1	CD	O
-	:	O
2	CD	O
minutes	NNS	O
,	,	O
additional	JJ	O
bolus	NN	O
injections	NNS	O
of	IN	O
adenosine	NN	O
can	MD	O
be	VB	O
administered	VBN	O
at	IN	O
incrementally	RB	O
higher	JJR	O
doses	NNS	O
,	,	O
increasing	VBG	O
the	DT	O
amount	NN	O
given	VBN	O
by	IN	O
0.05	CD	B-DOS
to	TO	O
0.1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

(	(	O
See	VB	O
Table	JJ	O
1	CD	O
for	IN	O
weight	NN	O
-	:	O
adjusted	VBN	O
dose	JJ	O
volumes	NNS	O
)	)	O
.	.	O

The	DT	B-WHO
normal	JJ	I-WHO
adult	NN	I-WHO
(	(	I-WHO
70	CD	I-WHO
kg	NN	I-WHO
)	)	O-WHO
dose	NN	O
is	VBZ	O
0.259	CD	B-DOS
-	:	O
0.925	CD	B-DOS
GBq	NNP	B-UNIT
(	(	O
7	CD	B-DOS
-	:	O
25	CD	B-DOS
mCi	NN	B-UNIT
)	)	O
as	IN	O
Tc99m	NNP	O
labeled	VBD	O
leukocytes	NNS	O
by	IN	O
intravenous	JJ	O
injection	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
respond	VB	I-WHO
adequately	RB	O-WHO
to	TO	O
the	DT	O
starting	NN	O
dosage	NN	O
after	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
.	.	O

Attempts	NNS	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
maintain	VB	O
a	DT	O
caloric	JJ	O
intake	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

If	IN	O
the	DT	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
is	VBZ	O
stable	JJ	O
,	,	O
a	DT	O
dosage	NN	O
interval	NN	O
in	IN	O
hours	NNS	O
for	IN	O
the	DT	O
normal	JJ	O
dose	NN	O
can	MD	O
be	VB	O
calculated	VBN	O
by	IN	O
multiplying	VBG	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
by	IN	O
9	CD	O
,	,	O
e.g	NN	O
,	,	O
if	IN	O
the	DT	O
serum	NN	O
creatinine	NN	O
concentration	NN	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
100	CD	B-DOS
mL	NN	B-UNIT
,	,	O
the	DT	O
recommended	VBN	O
single	JJ	B-DOS
dose	NN	B-UNIT
(	(	O
7.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	B-FREQ
18	CD	I-FREQ
hours	NNS	O-FREQ
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
begin	VB	O
a	DT	O
new	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
unless	IN	O
the	DT	O
ANC	NNP	O
is	VBZ	O
≥	JJ	O
1500	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm³	NN	O
,	,	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
>	JJ	O
100000	CD	B-DOS
cells	NNS	B-UNIT
/	JJ	O
mm³	NN	O
,	,	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
≥	JJ	O
45	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommendations	NNS	O
for	IN	O
Starting	VBG	O
Dose	NNP	O
in	IN	O
Patients	NNP	B-WHO
with	IN	I-WHO
Hepatic	NNP	I-WHO
Impairment	NNP	O-WHO

200	CD	B-DOS
mL	NN	B-UNIT
per	IN	O
liter	NN	O
gives	VBZ	O
a	DT	O
solution	NN	O
which	WDT	O
is	VBZ	O
approximately	RB	O
isotonic	JJ	O
and	CC	O
iso	JJ	O
-	:	O
osmotic	JJ	O
with	IN	O
citrated	JJ	O
plasma	NN	O
.	.	O

When	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
are	VBP	O
rising	VBG	O
,	,	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
daily	JJ	B-FREQ
may	MD	O
be	VB	O
instituted	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
QBRELIS	NNP	O
,	,	O
when	WRB	O
used	VBN	O
with	IN	O
diuretics	NNS	O
and	CC	O
(	(	O
usually	RB	O
)	)	O
digitalis	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
for	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
,	,	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Consult	NN	O
with	IN	O
pharmacist	NN	O
.	.	O

The	DT	O
recommended	VBN	O
AMJEVITA	NNP	O
dose	JJ	O
regimen	NNS	O
for	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
Crohn	NNP	I-WHO
's	POS	I-WHO
disease	NN	O-WHO
(	(	O
CD	NN	O
)	)	O
is	VBZ	O
160	CD	B-DOS
mg	NN	B-UNIT
initially	RB	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
given	VBN	O
as	IN	O
four	CD	B-DOS
40	CD	O-DOS
mg	NN	B-UNIT
injections	NNS	O-UNIT
in	IN	O
one	CD	B-DUR
day	NN	O-DUR
or	CC	O
as	IN	O
two	CD	B-DOS
40	CD	O-DOS
mg	NNS	B-UNIT
injections	NNS	O-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
for	IN	O
two	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
)	)	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	B-DOS
mg	NNS	B-UNIT
two	CD	B-DUR
weeks	NNS	O-DUR
later	RB	O
(	(	O
Day	NNP	O
15	CD	O
)	)	O
.	.	O

First	RB	O
,	,	O
initiate	JJ	O
therapy	NN	O
by	IN	O
administering	VBG	O
a	DT	O
normal	JJ	O
dose	NN	O
,	,	O
7.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
,	,	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
.	.	O

The	DT	O
lotion	NN	O
may	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
to	TO	O
the	DT	O
specified	VBN	O
lesions	NNS	O
,	,	O
particularly	RB	O
to	TO	O
those	DT	O
in	IN	O
hairy	JJ	O
areas	NNS	O
,	,	O
two	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
lotion	NN	O
should	MD	O
be	VB	O
rubbed	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
area	NN	O
completely	RB	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
washing	VBG	O
,	,	O
clothing	NN	O
,	,	O
rubbing	VBG	O
,	,	O
etc.until	VB	O
the	DT	O
lotion	NN	O
is	VBZ	O
dried	VBN	O
.	.	O

Apply	NNP	O
gel	VBD	O
approximately	RB	O
1	CD	B-DOS
mm	NNS	B-UNIT
thick	JJ	O
and	CC	O
include	VBP	O
approximately	RB	O
5	CD	B-DOS
mm	NN	B-UNIT
of	IN	O
the	DT	O
surrounding	VBG	O
skin	NN	O
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
in	IN	O
administering	VBG	O
fat	JJ	O
emulsions	NNS	O
to	TO	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
liver	NN	I-WHO
damage	NN	O-WHO
.	.	O

For	IN	O
bolus	RB	O
intravenous	JJ	O
administration	NN	O
,	,	O
prepare	VB	O
a	DT	O
solution	NN	O
containing	VBG	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
of	IN	O
AKOVAZ	NNP	O
(	(	O
ephedrine	JJ	O
sulfate	NN	O
injection	NN	O
)	)	O
:	:	O

The	DT	O
system	NN	O
should	MD	O
be	VB	O
pressed	VBN	O
firmly	RB	O
in	IN	O
place	NN	O
with	IN	O
the	DT	O
palm	NN	O
of	IN	O
the	DT	O
hand	NN	O
for	IN	O
about	IN	O
10	CD	O
seconds	NNS	O
,	,	O
making	VBG	O
sure	JJ	O
there	EX	O
is	VBZ	O
good	JJ	O
contact	NN	O
,	,	O
especially	RB	O
around	IN	O
the	DT	O
edges	NNS	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
require	VBP	I-WHO
treatment	NN	I-WHO
with	IN	I-WHO
a	DT	I-WHO
strong	JJ	I-WHO
CYP3A4	NNP	O-WHO
/	NNP	O
PgP	NNP	O
inducer	NN	O
:	:	O

Approximately	RB	O
60	CD	O
to	TO	O
180	CD	O
mEq	NN	O
of	IN	O
potassium	NN	O
,	,	O
10	CD	O
to	TO	O
30	CD	O
mEq	NN	O
of	IN	O
magnesium	NN	O
,	,	O
and	CC	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
mM	NN	B-UNIT
of	IN	O
phosphate	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
appear	VBP	O
necessary	JJ	O
to	TO	O
achieve	VB	O
optimum	JJ	O
metabolic	JJ	O
response	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	B-WHO
5	CD	I-WHO
kg	NN	I-WHO
to	TO	I-WHO
20	CD	I-WHO
kg	NNS	O-WHO

Withdraw	VB	O
a	DT	O
0.5	CD	B-DOS
Ml	NNP	B-UNIT
dose	NN	O-UNIT
of	IN	O
the	DT	O
combined	JJ	O
vaccines	NNS	O
and	CC	O
inject	JJ	O
intramuscularly	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IRESSA	NNP	O
is	VBZ	O
250	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

During	IN	O
withdrawal	NN	O
,	,	O
some	DT	B-WHO
patients	NNS	O-WHO
may	MD	O
experience	VB	O
symptoms	NNS	O
of	IN	O
systemic	JJ	O
corticosteroid	NN	O
withdrawal	NN	O
;	:	O
e.g	NN	O
.	.	O

In	IN	O
difficult	JJ	O
and	CC	O
complicated	JJ	O
infections	NNS	O
where	WRB	O
treatment	NN	O
beyond	IN	O
10	CD	O
days	NNS	O
is	VBZ	O
considered	VBN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
amikacin	NN	O
should	MD	O
be	VB	O
reevaluated	VBN	O
.	.	O

These	DT	B-WHO
patients	NNS	O-WHO
may	MD	O
be	VB	O
treated	VBN	O
2	CD	B-FREQ
or	CC	O
3	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
week	NN	O-FREQ
,	,	O
as	IN	O
a	DT	O
Type	NN	O
I	PRP	O
patient	VBP	O
.	.	O

Four	CD	B-DOS
cycles	NNS	B-UNIT
of	IN	O
treatment	NN	O
were	VBD	O
administered	VBN	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	B-FREQ
dosage	NN	O
of	IN	O
methyldopa	NN	O
is	VBZ	O
500	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
2	CD	B-DOS
g.	NN	B-UNIT
To	TO	O
minimize	VB	O
the	DT	O
sedation	NN	O
associated	VBN	O
with	IN	O
methyldopa	NN	O
,	,	O
start	JJ	O
dosage	NN	O
increases	NNS	O
in	IN	O
the	DT	O
evening	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
adolescents	NNS	B-WHO
with	IN	I-WHO
ADHD	NNP	I-WHO
who	WP	I-WHO
are	VBP	I-WHO
13	CD	I-WHO
-	:	I-WHO
17	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
are	VBP	I-WHO
either	DT	I-WHO
starting	VBG	I-WHO
treatment	NN	I-WHO
for	IN	I-WHO
the	DT	I-WHO
first	JJ	I-WHO
time	NN	I-WHO
or	CC	I-WHO
switching	VBG	I-WHO
from	IN	I-WHO
another	DT	I-WHO
medication	NN	O-WHO
is	VBZ	O
10	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

If	IN	O
persistent	JJ	O
hypokalemia	NN	O
is	VBZ	O
documented	VBN	O
with	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
then	RB	O
20	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
with	IN	O
careful	JJ	O
monitoring	NN	O
of	IN	O
electrolytes	NNS	O
.	.	O

More	JJR	O
than	IN	O
two	CD	B-DOS
5	CD	O-DOS
mg	NNS	B-UNIT
tablets	NNS	O-UNIT
usually	RB	O
are	VBP	O
not	RB	O
needed	VBN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
little	JJ	O
controlled	JJ	O
experience	NN	O
with	IN	O
such	JJ	O
doses	NNS	O
.	.	O

Nonproteincalories	NNS	O
should	MD	O
be	VB	O
supplied	VBN	O
principally	RB	O
as	IN	O
glucose	NN	O
(	(	O
8	CD	B-DOS
–	RB	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	FW	O
/	NNP	O
min	NN	O
)	)	O
with	IN	O
an	DT	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
added	VBD	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Abstral	NNP	O
is	VBZ	O
always	RB	O
100	CD	B-DOS
mcg	NN	B-UNIT
with	IN	O
the	DT	O
only	JJ	O
exception	NN	O
being	VBG	O
patients	NNS	B-WHO
already	RB	I-WHO
using	VBG	I-WHO
Actiq	NNP	O-WHO
.	.	O

Topical	JJ	O
corticosteroids	NNS	O
are	VBP	O
generally	RB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
from	IN	O
two	CD	B-FREQ
to	TO	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

Avoid	NNP	O
AMBIEN	NNP	O
use	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
as	IN	O
it	PRP	O
may	MD	O
contribute	VB	O
to	TO	O
encephalopathy	VB	O
[	NNP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
schedule	NN	O
for	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
weighing	VBG	I-WHO
100	CD	I-WHO
pounds	NNS	I-WHO
or	CC	I-WHO
less	JJR	O-WHO
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
lb	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBN	O
into	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
lb	NN	O
of	IN	O
body	NN	O
weight	JJ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
or	CC	O
divided	VBN	O
into	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
,	,	O
on	IN	O
subsequent	JJ	O
days	NNS	O
.	.	O

ABILIFY	NNP	O
has	VBZ	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
and	CC	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
a	DT	O
dose	JJ	O
range	NN	O
of	IN	O
10	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
,	,	O
when	WRB	O
administered	VBN	O
as	IN	O
the	DT	O
tablet	NN	O
formulation	NN	O
;	:	O
however	RB	O
,	,	O
doses	VBZ	O
higher	JJR	O
than	IN	O
10	CD	B-DOS
or	CC	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
were	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
10	CD	B-DOS
or	CC	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

PROVERA	NNP	O
tablets	NNS	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
dosages	NNS	O
of	IN	O
5	CD	B-DOS
or	CC	O
10	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
for	IN	O
5	CD	B-DUR
to	TO	O
10	CD	B-DUR
days	NNS	O-DUR
.	.	O

Note	NN	O
:	:	O
The	DT	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
glaucoma	NN	O
and	CC	O
epilepsy	NN	O
differ	NN	O
considerably	RB	O
from	IN	O
those	DT	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
since	IN	O
the	DT	O
first	JJ	O
two	CD	O
conditions	NNS	O
are	VBP	O
not	RB	O
dependent	JJ	O
upon	IN	O
carbonic	JJ	O
anhydrase	NN	O
inhibition	NN	O
in	IN	O
the	DT	O
kidney	NN	O
which	WDT	O
requires	VBZ	O
intermittent	JJ	O
dosage	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
to	TO	O
recover	VB	O
from	IN	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
.	.	O

If	IN	O
desired	VBN	O
,	,	O
only	RB	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
an	DT	O
estimated	VBN	O
daily	JJ	B-FREQ
amino	NN	O
acid	JJ	O
requirement	NN	O
of	IN	O
1.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	NNS	O
can	MD	O
be	VB	O
given	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

3	LS	O
-	:	O
6	CD	O
Yrs	NN	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
above	IN	I-WHO
eight	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
:	:	O
The	DT	O
recommended	JJ	O
dosage	NN	O
schedule	NN	O
for	IN	O
children	NNS	B-WHO
weighing	VBG	I-WHO
45	CD	I-WHO
kg	NN	I-WHO
or	CC	I-WHO
less	JJR	O-WHO
is	VBZ	O
4.4	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBN	O
into	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
2.2	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
daily	JJ	B-FREQ
dose	NN	B-UNIT
or	CC	O
divided	VBN	O
into	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
on	IN	O
subsequent	JJ	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
QUILLIVANT	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	B-WHO
6	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
above	NN	O-WHO
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Epithelial	JJ	O
Ovarian	JJ	O
Cancer	NN	O
:	:	O
One	CD	O
commonly	RB	O
employed	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ovarian	JJ	O
carcinoma	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
daily	NN	B-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
as	IN	O
a	DT	O
single	JJ	O
course	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
6.25	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
women	NNS	B-WHO
and	CC	O
either	DT	O
6.25	CD	B-DOS
or	CC	O
12.5	CD	B-DOS
mg	NN	B-UNIT
for	IN	O
men	NNS	B-WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	B-FREQ
per	IN	I-FREQ
night	NN	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
-	:	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ROZEREM	NNP	O
(	(	O
ramelteon	NN	O
)	)	O
is	VBZ	O
8	CD	B-DOS
mg	NN	B-UNIT
taken	VBN	O
within	IN	O
30	CD	O
minutes	NNS	O
of	IN	O
going	VBG	O
to	TO	O
bed	VB	O
.	.	O

Clinical	JJ	O
studies	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
infusion	NN	O
have	VBP	O
been	VBN	O
conducted	VBN	O
with	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
diluted	VBD	O
to	TO	O
a	DT	O
concentration	NN	O
range	NN	O
of	IN	O
25	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
mL	NN	O
to	TO	O
80	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DuoNeb	NNP	O
(	(	O
ipratropium	JJ	O
bromide	NN	O
and	CC	O
albuterol	VB	O
sulfate	NN	O
)	)	O
is	VBZ	O
one	CD	B-DOS
3	CD	O-DOS
mL	NN	B-UNIT
vial	NN	O-UNIT
administered	VBD	O
4	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
via	IN	O
nebulization	NN	O
with	IN	O
up	IN	O
to	TO	O
2	CD	B-DOS
additional	JJ	O
3	CD	B-DOS
mL	NN	B-UNIT
doses	NNS	O-UNIT
allowed	VBN	O
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
if	IN	O
needed	VBN	O
.	.	O

The	DT	O
diluted	VBN	O
ready	JJ	O
-	:	O
for	IN	O
-	:	O
use	NN	O
admixture	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
up	IN	O
to	TO	O
48	CD	O
hours	NNS	O
at	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
an	DT	O
additional	JJ	O
6	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

No	DT	O
data	NN	O
are	VBP	O
available	JJ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
moderate	JJ	I-WHO
or	CC	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
7	CD	O
%	NN	O
,	,	O
Sulfite	NNP	O
-	:	O
Free	JJ	O
,	,	O
(	(	O
an	DT	O
amino	NN	O
acid	NN	O
injection	NN	O
—	NNP	O
pediatric	JJ	O
formula	NN	O
)	)	O
is	VBZ	O
up	IN	O
to	TO	O
2.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
infants	NNS	B-WHO
up	RB	I-WHO
to	TO	I-WHO
10	CD	I-WHO
kg	NNS	O-WHO
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
Children	NNP	I-WHO
30	CD	I-WHO
kg	NN	I-WHO
(	(	I-WHO
66	CD	I-WHO
lbs	NN	I-WHO
)	)	I-WHO
or	CC	I-WHO
more	JJR	O-WHO
:	:	O
0.3	CD	B-DOS
to	TO	O
0.5	CD	B-DOS
mg	NN	B-UNIT
(	(	O
0.3	CD	B-DOS
mL	NN	B-UNIT
to	TO	O
0.5	CD	B-DOS
mL	NN	B-UNIT
)	)	O
of	IN	O
undiluted	JJ	O
Adrenalin®	NNP	O
administered	VBD	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NN	B-UNIT
(	(	O
0.5	CD	B-DOS
mL	NN	B-UNIT
)	)	O
per	IN	O
injection	NN	O
,	,	O
repeated	VBN	O
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
as	IN	O
necessary	JJ	O
.	.	O

If	IN	O
slower	JJR	O
administration	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
200	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
300	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
10	CD	O
%	NN	O
dextrose	JJ	O
solution	NN	O
and	CC	O
administered	VBN	O
by	IN	O
continuous	JJ	O
drip	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
100	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
this	DT	O
dextrose	JJ	O
solution	NN	O
an	DT	O
hour	NN	O
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
each	DT	O
30	CD	B-DOS
mL	NNS	B-UNIT
vial	JJ	O-UNIT
should	MD	O
be	VB	O
dissolved	VBN	O
with	IN	O
25	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
.	.	O

A	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
dose	NN	O-UNIT
of	IN	O
ACTHREL®	NNP	O
at	IN	O
1	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
ABRAXANE	NNP	O
to	TO	O
patients	NNS	B-WHO
with	IN	I-WHO
total	JJ	I-WHO
bilirubin	NN	I-WHO
greater	JJR	I-WHO
than	IN	I-WHO
5	CD	I-WHO
x	JJ	I-WHO
ULN	NNP	O-WHO
or	CC	O
AST	NNP	O
greater	JJR	O
than	IN	O
10	CD	O
x	JJ	O
ULN	NNP	O
regardless	NN	O
of	IN	O
indication	NN	O
as	IN	O
these	DT	O
patients	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

Dosages	NNS	O
above	IN	O
8	CD	B-DOS
mg	NN	B-UNIT
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
careful	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
and	CC	O
dose	JJ	O
titration	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Concentrations	NNS	O
from	IN	O
40	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
100	CD	B-DOS
mL	NNS	B-UNIT
are	VBP	O
usually	RB	O
necessary	JJ	O
.	.	O

Hoogstraten	NNP	O
et	CC	O
al	NNS	O
have	VBP	O
started	VBN	O
treatment	NN	O
with	IN	O
0.15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
dexamethasone	NN	O
4	CD	B-DOS
mg	NN	B-UNIT
was	VBD	O
given	VBN	O
by	IN	O
mouth	JJ	O
twice	JJ	B-FREQ
daily	JJ	O-FREQ
the	DT	O
day	NN	O
before	IN	O
,	,	O
the	DT	O
day	NN	O
of	IN	O
,	,	O
and	CC	O
the	DT	O
day	NN	O
after	IN	O
ALIMTA	NNP	O
administration	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
dosage	NN	O
of	IN	O
oral	JJ	O
KYTRIL	NNP	O
(	(	O
granisetron	NNP	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
1	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

3	CD	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
insufficiency	NN	O-WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
dosage	NN	O
increases	NNS	O
above	IN	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
should	MD	O
be	VB	O
carefully	RB	O
considered	VBN	O
and	CC	O
,	,	O
if	IN	O
deemed	VBN	O
necessary	JJ	O
,	,	O
implemented	VBN	O
cautiously	RB	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
and	CC	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	B-WHO
taking	VBG	I-WHO
amiodarone	NN	I-WHO
concomitantly	RB	I-WHO
with	IN	I-WHO
lovastatin	NN	O-WHO
,	,	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
,	,	O
Other	JJ	O
drug	NN	O
interactions	NNS	O
)	)	O
.	.	O

For	IN	O
maintenance	NN	O
therapy	NN	O
at	IN	O
dosages	NNS	O
of	IN	O
300	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
less	JJR	O
,	,	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
at	IN	O
bedtime	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Rather	RB	O
than	IN	O
an	DT	O
increase	NN	O
in	IN	O
infusion	NN	O
rate	NN	O
,	,	O
7	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
bolus	NN	O
doses	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
or	CC	O
a	DT	O
potent	JJ	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
response	NN	O
to	TO	O
signs	NNS	O
of	IN	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
within	IN	O
the	DT	O
last	JJ	O
15	CD	O
minutes	NNS	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
of	IN	O
this	DT	O
preparation	NN	O
varies	VBZ	O
from	IN	O
5	CD	B-DOS
to	TO	O
10	CD	B-DOS
mL	NNS	B-UNIT
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	B-DUR
to	TO	O
3	CD	B-DUR
days	NNS	O-DUR
.	.	O

In	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
treated	VBD	O
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
may	MD	O
diminish	VB	O
toward	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
study	NN	O
with	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
,	,	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
a	DT	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
score	NN	I-WHO
ranging	VBG	I-WHO
from	IN	I-WHO
5	CD	I-WHO
to	TO	I-WHO
8	CD	O-WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
of	IN	O
513	CD	B-DOS
mg	NN	B-UNIT
(	(	O
34	CD	B-DOS
mL	NN	B-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
and	CC	O
adult	NN	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
a	DT	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
score	NN	I-WHO
ranging	VBG	I-WHO
from	IN	I-WHO
9	CD	I-WHO
to	TO	I-WHO
12	CD	O-WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
of	IN	O
342	CD	B-DOS
mg	NN	B-UNIT
(	(	O
23	CD	B-DOS
mL	NN	B-UNIT
)	)	O
twice	RB	B-FREQ
daily	JJ	O-FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Hepatic	JJ	O
Insufficiency	NNP	O
)	)	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
infused	VBD	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
45	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
will	MD	O
meet	VB	O
the	DT	O
fluid	NN	O
and	CC	O
amino	NN	O
acid	NN	O
requirements	NNS	O
of	IN	O
the	DT	B-WHO
stable	JJ	I-WHO
adult	NN	I-WHO
patient	NN	O-WHO
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Targretin®	NNP	O
(	(	O
bexarotene	NN	O
)	)	O
capsules	VBZ	O
is	VBZ	O
300	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m2	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
acute	JJ	O
agitation	NN	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
by	IN	O
oral	JJ	O
inhalation	NN	O
,	,	O
using	VBG	O
a	DT	O
single	JJ	B-DOS
-	:	O
use	NN	O
inhaler	NN	O
.	.	O

Pediatric	JJ	B-WHO
Patients	NNS	I-WHO
,	,	I-WHO
other	JJ	I-WHO
than	IN	I-WHO
premature	JJ	I-WHO
infants	NNS	I-WHO
and	CC	I-WHO
neonates	NNS	O-WHO
:	:	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	VBD	O
24	CD	O
hr	NN	O
or	CC	O
150	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m²	NN	O
/	VBD	O
24	CD	O
hr	NN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1500	CD	B-DOS
international	JJ	B-UNIT
units	NNS	O-UNIT
of	IN	O
RIXUBIS	NNP	O
,	,	O
administered	VBD	O
to	TO	O
a	DT	O
20	CD	B-WHO
kg	NN	I-WHO
patient	NN	O-WHO
should	MD	O
be	VB	O
expect	VB	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
peak	NN	O
post	NN	O
-	:	O
infusion	NN	O
factor	NN	O
IX	NNP	O
increase	NN	O
of	IN	O
1500	CD	B-DOS
international	JJ	B-UNIT
units	NNS	O-UNIT
x	VBP	O
{	(	O
[	JJ	O
0.7	CD	B-DOS
IU	NNP	B-UNIT
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	NN	O
}	)	O
/	NNP	O
[	$	O
20	CD	O
kg	NN	O
]	NNP	O
=	VBZ	O
53.6	CD	B-DOS
international	JJ	B-UNIT
units	NNS	O-UNIT
/	VBP	O
dL	NN	O
(	(	O
53.6	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
.	.	O

ERPF	NNP	O
=	VBD	O
8.0	CD	O
x	JJ	O
1.5	CD	O
/	JJ	O
0.02	CD	O
=	JJ	O
600	CD	B-DOS
mL	NN	B-UNIT
/	CD	O
min	NN	O

Approximately	RB	O
60	CD	O
to	TO	O
180	CD	O
mEq	NN	O
of	IN	O
potassium	NN	O
,	,	O
10	CD	O
to	TO	O
30	CD	O
mEq	NN	O
of	IN	O
magnesium	NN	O
,	,	O
and	CC	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
mMol	NN	B-UNIT
of	IN	O
phosphorus	JJ	O
per	IN	B-FREQ
day	NN	O-FREQ
appear	VBP	O
necessary	JJ	O
to	TO	O
achieve	VB	O
optimum	JJ	O
metabolic	JJ	O
response	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
(	(	O
1	CD	B-DOS
tablet	NN	B-UNIT
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
rufinamide	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
with	IN	I-WHO
Lennox	NNP	I-WHO
-	:	I-WHO
Gastaut	NNP	I-WHO
Syndrome	NNP	O-WHO
is	VBZ	O
approximately	RB	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
administered	VBN	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
.	.	O

Following	VBG	O
an	DT	O
anesthetic	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
,	,	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
to	TO	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
maintenance	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
ADVATE	NN	O
Dosing	VBG	O
for	IN	O
Treatment	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O
in	IN	O
Adults	NNP	B-WHO
and	CC	I-WHO
Children	NNP	O-WHO

A	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
is	VBZ	O
0.5	CD	B-DOS
mL	NN	B-UNIT
.	.	O

Doses	NNS	O
of	IN	O
400	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
1000	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
DEPO	NNP	O
-	:	O
PROVERA	NNP	O
Sterile	NNP	O
Aqueous	NNP	O
Suspension	NNP	O
per	IN	B-FREQ
week	NN	O-FREQ
are	VBP	O
recommended	VBN	O
initially	RB	O
.	.	O

Regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ACCURETIC	NNP	O
need	MD	O
not	RB	O
take	VB	O
account	NN	O
of	IN	O
renal	JJ	O
function	NN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
>	JJ	O
30	CD	B-DOS
mL	NN	B-UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	B-DOS
m²	NN	B-UNIT
(	(	O
serum	JJ	O
creatinine	NN	O
roughly	RB	O
≤	$	O
3	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
or	CC	O
265	CD	B-DOS
μmol	JJ	B-UNIT
/	NNP	O
L	NNP	O
)	)	O
.	.	O

Total	JJ	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
TPN	NNP	O
)	)	O
may	MD	O
be	VB	O
started	VBN	O
with	IN	O
10	CD	O
%	NN	O
dextrose	NN	O
added	VBD	O
to	TO	O
the	DT	O
calculated	JJ	O
daily	JJ	B-FREQ
requirement	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
(	(	O
1.5	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
for	IN	O
a	DT	O
metabolically	RB	B-WHO
stable	JJ	I-WHO
patient	NN	I-WHO
)	)	O-WHO
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
is	VBZ	O
8	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
per	IN	O
kg	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

For	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
,	,	O
the	DT	O
dose	NN	O
is	VBZ	O
calculated	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
35	CD	B-DOS
mg	NNS	B-UNIT
for	IN	O
each	DT	O
ten	CD	O
pounds	NNS	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

A	DT	O
patient	NN	B-WHO
who	WP	I-WHO
becomes	VBZ	I-WHO
hypotensive	VBP	I-WHO
at	IN	I-WHO
this	DT	I-WHO
dose	NN	O-WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Flares	NNS	O
During	IN	O
Maintenance	NN	O
:	:	O
If	IN	O
the	DT	O
patient	NN	O
flares	VBZ	O
during	IN	O
maintenance	NN	O
treatment	NN	O
(	(	O
i.e	FW	O
,	,	O
develops	VBZ	O
psoriasis	NN	O
on	IN	O
more	JJR	O
than	IN	O
5	CD	O
percent	NN	O
of	IN	O
the	DT	O
originally	RB	O
involved	VBN	O
areas	NNS	O
of	IN	O
the	DT	O
body	NN	O
)	)	O
his	PRP$	O
maintenance	NN	O
treatment	NN	O
schedule	NN	O
may	MD	O
be	VB	O
changed	VBN	O
to	TO	O
the	DT	O
preceding	VBG	O
maintenance	NN	O
or	CC	O
clearing	NN	O
schedule	NN	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
impaired	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
either	RB	O
by	IN	O
administering	VBG	O
normal	JJ	O
doses	NNS	O
at	IN	O
prolonged	JJ	O
intervals	NNS	O
or	CC	O
by	IN	O
administering	VBG	O
reduced	JJ	O
doses	NNS	O
at	IN	O
a	DT	O
fixed	JJ	O
interval	NN	O
.	.	O

These	DT	O
patients	NNS	O
should	MD	O
continue	VB	O
treatment	NN	O
until	IN	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	B-DOS
cycles	NNS	B-UNIT
,	,	O
disease	NN	O
progression	NN	O
,	,	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

Doses	NNS	O
above	IN	O
1	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
kg	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Increases	NNS	O
above	IN	O
300	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
should	MD	O
be	VB	O
made	VBN	O
only	RB	O
if	IN	O
300	CD	B-DOS
mg	JJ	B-UNIT
daily	NN	B-FREQ
has	VBZ	O
been	VBN	O
ineffective	JJ	O
during	IN	O
a	DT	O
trial	NN	O
period	NN	O
of	IN	O
at	IN	B-DUR
least	JJS	I-DUR
two	CD	I-DUR
weeks	NNS	O-DUR
.	.	O

150	CD	B-DOS
U	NNP	B-UNIT
will	MD	O
facilitate	VB	O
absorption	NN	O
of	IN	O
1000	CD	B-DOS
mL	NN	B-UNIT
or	CC	O
more	JJR	O
of	IN	O
solution	NN	O
.	.	O

Patients	NNS	B-WHO
not	RB	I-WHO
currently	RB	I-WHO
on	IN	I-WHO
NIASPAN	NNP	O-WHO
must	MD	O
start	VB	O
ADVICOR	NNP	O
at	IN	O
the	DT	O
lowest	JJS	O
initial	JJ	O
ADVICOR	NNP	O
dose	NN	O
,	,	O
a	DT	O
single	JJ	B-DOS
500	CD	O-DOS
mg	NN	B-UNIT
/	VBD	O
20	CD	B-DOS
mg	NNS	B-UNIT
tablet	NN	O-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
RA	NNP	O
,	,	O
some	DT	B-WHO
patients	NNS	I-WHO
not	RB	I-WHO
taking	VBG	I-WHO
concomitant	JJ	I-WHO
MTX	NNP	O-WHO
may	MD	O
derive	VB	O
additional	JJ	O
benefit	NN	O
from	IN	O
increasing	VBG	O
the	DT	O
dosing	NN	O
frequency	NN	O
of	IN	O
AMJEVITA	NNP	O
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
week	NN	O-FREQ
.	.	O

In	IN	O
some	DT	O
acute	JJ	O
cases	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
more	JJR	O
satisfactory	JJ	O
to	TO	O
administer	VB	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
500	CD	B-DOS
mg	NN	B-UNIT
followed	VBN	O
by	IN	O
125	CD	B-DOS
mg	NNS	B-UNIT
or	CC	O
250	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
four	CD	I-FREQ
hours	NNS	O-FREQ
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
acne	NN	O
which	WDT	O
,	,	O
in	IN	O
the	DT	O
judgement	NN	O
of	IN	O
the	DT	O
clinician	JJ	O
,	,	O
require	VB	O
long	JJ	O
-	:	O
term	NN	O
treatment	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	B-DOS
gram	JJ	B-UNIT
daily	RB	B-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Instill	NNP	O
one	CD	B-DOS
drop	NN	B-UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
3	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
days	NNS	O-DUR
.	.	O

Ambien	NNP	O
CR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
and	CC	O
should	MD	O
not	RB	O
be	VB	O
readministered	VBN	O
during	IN	O
the	DT	O
same	JJ	O
night	NN	O
.	.	O

Some	DT	B-WHO
patients	NNS	O-WHO
may	MD	O
obtain	VB	O
relief	NN	O
of	IN	O
symptoms	NNS	O
sooner	VBP	O
when	WRB	O
started	VBN	O
on	IN	O
a	DT	O
400	CD	B-DOS
mcg	NN	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
dose	NN	O
of	IN	O
AllerNaze	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
than	IN	O
with	IN	O
200	CD	B-DOS
mcg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

ACAM2000	NNP	O
is	VBZ	O
reconstituted	VBN	O
by	IN	O
addition	NN	O
of	IN	O
0.3	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent	NN	O
to	TO	O
the	DT	O
vial	JJ	O
containing	NN	O
lyophilized	VBN	O
vaccine	NN	O
.	.	O

Table	JJ	O
1	CD	O
summarizes	JJ	O
recommendations	NNS	O
for	IN	O
dose	JJ	O
reduction	NN	O
,	,	O
interruption	NN	O
or	CC	O
discontinuation	NN	O
of	IN	O
AFINITOR	NNP	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Although	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
respond	VBP	O
to	TO	O
a	DT	O
low	JJ	O
dose	NN	O
,	,	O
the	DT	O
optimum	JJ	O
range	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
from	IN	O
375	CD	B-DOS
to	TO	O
1000	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

Administer	RB	O
Flublok	NNP	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
-	:	O
mL	NN	B-UNIT
dose	NN	O-UNIT
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hyperchloremic	JJ	I-WHO
or	CC	I-WHO
other	JJ	I-WHO
metabolic	JJ	I-WHO
acidoses	NNS	O-WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
or	CC	O
lactate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
precursors	NNS	O
.	.	O

After	IN	O
asthma	JJ	O
stability	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
titrate	VB	O
to	TO	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
to	TO	O
reduce	VB	O
the	DT	O
possibility	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
,	,	O
with	IN	O
subsequent	JJ	O
increases	NNS	O
to	TO	O
10	CD	B-DOS
or	CC	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
if	IN	O
needed	VBN	O
.	.	O

This	DT	O
form	NN	O
of	IN	O
administration	NN	O
requires	VBZ	O
very	RB	O
large	JJ	O
volumes	NNS	O
of	IN	O
the	DT	O
solution	NN	O
,	,	O
occasionally	RB	O
as	RB	O
much	JJ	O
as	IN	O
300	CD	B-DOS
mL	NN	B-UNIT
during	IN	O
a	DT	O
single	JJ	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
up	RB	O
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
achieve	VB	I-WHO
optimal	JJ	I-WHO
control	NN	I-WHO
of	IN	I-WHO
tics	NNS	O-WHO
.	.	O

Controlled	VBN	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
failed	VBN	O
to	TO	O
show	VB	O
a	DT	O
clear	JJ	O
benefit	NN	O
with	IN	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
second	JJ	O
6	CD	B-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
have	VBP	I-WHO
failed	VBN	I-WHO
to	TO	I-WHO
respond	VB	I-WHO
to	TO	I-WHO
a	DT	I-WHO
first	JJ	I-WHO
dose	NN	O-WHO
.	.	O

The	DT	O
patient	NN	O
should	MD	O
place	VB	O
the	DT	O
ACTIQ	NNP	O
unit	NN	O
in	IN	O
his	PRP$	O
or	CC	O
her	PRP$	O
mouth	NN	O
between	IN	O
the	DT	O
cheek	NN	O
and	CC	O
lower	JJR	O
gum	NN	O
,	,	O
occasionally	RB	O
moving	VBG	O
the	DT	O
drug	NN	O
matrix	NN	O
from	IN	O
one	CD	O
side	NN	O
to	TO	O
the	DT	O
other	JJ	O
using	VBG	O
the	DT	O
handle	NN	O
.	.	O

Dose	NNP	O
level	NN	O
reductions	NNS	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
adenocarcinoma	NN	O-WHO
of	IN	O
the	DT	O
pancreas	NNS	O
,	,	O
as	IN	O
referenced	VBN	O
in	IN	O
Tables	NNP	O
4	CD	O
and	CC	O
5	CD	O
,	,	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O

Initial	JJ	O
infusion	NN	O
rates	NNS	O
should	MD	O
be	VB	O
slow	JJ	O
,	,	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
the	DT	O
recommended	VBN	O
60	CD	B-DOS
to	TO	O
125	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
hour	NN	O
.	.	O

Discontinue	NNP	O
if	IN	O
patients	NNS	O
are	VBP	O
unable	JJ	O
to	TO	O
tolerate	VB	O
the	DT	O
300	CD	B-DOS
mg	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
dose	VB	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
severely	RB	I-WHO
impaired	JJ	I-WHO
hepatic	JJ	I-WHO
function	NN	I-WHO
(	(	I-WHO
Child	NNP	I-WHO
-	:	I-WHO
Pugh	NNP	I-WHO
Class	NNP	I-WHO
C	NNP	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
8	CD	B-DOS
mcg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
patients	NNS	B-WHO
already	RB	I-WHO
receiving	VBG	I-WHO
a	DT	I-WHO
stable	JJ	I-WHO
dose	NN	I-WHO
of	IN	I-WHO
NIASPAN	NNP	I-WHO
who	WP	I-WHO
require	VBP	I-WHO
further	JJ	I-WHO
LDL	NNP	O-WHO
-	:	O
lowering	NN	O
(	(	O
e.g	UH	O
,	,	O
to	TO	O
achieve	VB	O
NCEP	NNP	O
LDL	NNP	O
-	:	O
C	NNP	O
goals	NNS	O
;	:	O
Table	NNP	O
8	CD	O
)	)	O
,	,	O
the	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
of	IN	O
lovastatin	NN	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
needle	NN	O
will	MD	O
pick	VB	O
up	RP	O
a	DT	O
droplet	NN	O
of	IN	O
vaccine	NN	O
(	(	O
0.0025	CD	B-DOS
mL	NN	B-UNIT
)	)	O
within	IN	O
the	DT	O
fork	NN	O
of	IN	O
the	DT	O
bifurcation	NN	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
requirements	NNS	O
of	IN	O
the	DT	B-WHO
stable	JJ	O-WHO
,	,	O
nonhypermetabolic	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
are	VBP	O
approximately	RB	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
1	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	NN	O
,	,	O
and	CC	O
2500	CD	B-DOS
to	TO	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
1	CD	B-DUR
week	NN	O-DUR
,	,	O
5	CD	B-DOS
mg	NN	B-UNIT
,	,	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
the	DT	O
next	JJ	O
3	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
univasc®	JJ	O
in	IN	O
patients	NNS	B-WHO
not	RB	I-WHO
receiving	VBG	I-WHO
diuretics	NNS	O-WHO
is	VBZ	O
7.5	CD	B-DOS
mg	NN	B-UNIT
,	,	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
meals	NNS	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

If	IN	O
in	IN	O
any	DT	O
cycle	NN	O
the	DT	O
patient	NN	O
starts	VBZ	O
tablets	NNS	O
later	RB	O
than	IN	O
the	DT	O
proper	JJ	O
day	NN	O
,	,	O
she	PRP	O
should	MD	O
protect	VB	O
herself	PRP	O
against	IN	O
pregnancy	NN	O
by	IN	O
using	VBG	O
a	DT	O
nonhormonal	JJ	O
back	NN	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
until	IN	O
she	PRP	O
has	VBZ	O
taken	VBN	O
a	DT	O
pink	JJ	B-UNIT
tablet	NN	O-UNIT
daily	RB	B-FREQ
for	IN	O
7	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
.	.	O

Children	NNS	B-WHO
:	:	O
weighing	VBG	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
45	CD	I-WHO
kg	NNS	O-WHO
,	,	O
2.2	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
60	CD	B-DUR
days	NNS	O-DUR
.	.	O

More	JJR	O
than	IN	O
two	CD	B-DOS
sequential	JJ	B-UNIT
doses	NNS	O-UNIT
of	IN	O
epinephrine	NN	O
should	MD	O
only	RB	O
be	VB	O
administered	VBN	O
under	IN	O
direct	JJ	O
medical	JJ	O
supervision	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACCOLATE	NNP	O
in	IN	O
children	NNS	B-WHO
5	CD	I-WHO
through	IN	I-WHO
11	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
is	VBZ	O
10	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
usual	JJ	O
daily	JJ	B-FREQ
dose	NN	O
is	VBZ	O
250	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
once	RB	B-FREQ
every	DT	I-FREQ
24	CD	I-FREQ
hours	NNS	O-FREQ
or	CC	O
300	CD	B-DOS
mg	NNS	B-UNIT
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
8	CD	O
to	TO	O
12	CD	O
hour	NN	O
intervals	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ALSUMA	NNP	O
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VESIcare	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
ADA	NNP	O
more	JJR	O
than	IN	O
twice	RB	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
35	CD	B-DOS
μmol	JJ	B-UNIT
/	NNP	O
hr	NN	O
/	NNP	O
mL	NN	O
have	VBP	O
occurred	VBN	O
on	IN	O
occasion	NN	O
in	IN	O
several	JJ	B-WHO
patients	NNS	O-WHO
,	,	O
and	CC	O
have	VBP	O
been	VBN	O
maintained	VBN	O
for	IN	O
several	JJ	B-DUR
weeks	NNS	O-DUR
in	IN	O
one	CD	B-WHO
patient	NN	I-WHO
who	WP	I-WHO
received	VBD	O-WHO
twice	RB	B-FREQ
weekly	JJ	O-FREQ
injections	NNS	O
(	(	O
20	CD	B-DOS
U	NNP	B-UNIT
/	NNP	O
kg	FW	O
per	IN	O
dose	NN	O
)	)	O
of	IN	O
ADAGEN®	NNP	O
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
and	CC	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
either	DT	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ENTOCORT	NNP	O
EC	NNP	O
is	VBZ	O
:	:	O
9	CD	B-DOS
mg	NNS	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
8	CD	I-DUR
weeks	NNS	O-DUR
.	.	O

c.	NN	O
For	IN	O
patients	NNS	B-WHO
converting	VBG	I-WHO
from	IN	I-WHO
Actiq	NNP	I-WHO
doses	NNS	O-WHO
of	IN	O
600	CD	B-DOS
and	CC	O
800	CD	B-DOS
mcg	NN	B-UNIT
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
200	CD	B-DOS
mcg	NNS	B-UNIT
and	CC	O
200	CD	B-DOS
mcg	JJ	B-UNIT
Abstral	NNP	O
,	,	O
respectively	RB	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

Careful	JJ	O
increases	VBZ	O
up	IN	O
to	TO	O
300	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
are	VBP	O
indicated	VBN	O
in	IN	O
such	JJ	O
cases	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAPHRIS	NNP	O
is	VBZ	O
5	CD	B-DOS
mg	NN	B-UNIT
given	VBN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

Inject	JJ	O
ADYNOVATE	NNP	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
5	CD	O
minutes	NNS	O
(	(	O
maximum	JJ	O
infusion	NN	O
rate	NN	O
10	CD	B-DOS
mL	NN	B-UNIT
per	IN	O
min	NN	O
)	)	O
.	.	O

AIRDUO	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
one	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
immediately	RB	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
develop	VBP	I-WHO
constipation	NN	O-WHO
or	CC	O
signs	NNS	O
of	IN	O
ischemic	JJ	O
colitis	NN	O
.	.	O

A	DT	O
small	JJ	O
quantity	NN	O
of	IN	O
the	DT	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	B-FREQ
to	TO	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
,	,	O
as	IN	O
required	VBN	O
.	.	O

Additional	JJ	O
separate	JJ	O
doses	NNS	O
of	IN	O
methyldopa	NN	O
or	CC	O
replacement	NN	O
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
with	IN	O
single	JJ	O
entity	NN	O
agents	NNS	O
is	VBZ	O
necessary	JJ	O
until	IN	O
the	DT	O
new	JJ	O
effective	JJ	O
dose	NN	O
ratio	NN	O
is	VBZ	O
re	JJ	O
-	:	O
established	VBN	O
by	IN	O
titration	NN	O
.	.	O

When	WRB	O
acetazolamide	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
anticonvulsants	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
250	CD	B-DOS
mg	JJ	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
existing	VBG	O
medications	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	B-WHO
or	CC	I-WHO
debilitated	JJ	I-WHO
patients	NNS	O-WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
doses	NNS	O
for	IN	O
women	NNS	B-WHO
and	CC	I-WHO
men	NNS	O-WHO
are	VBP	O
different	JJ	O
because	IN	O
zolpidem	JJ	O
clearance	NN	O
is	VBZ	O
lower	RBR	O
in	IN	O
women	NNS	B-WHO
.	.	O

Adults	NNS	B-WHO
and	CC	I-WHO
children	NNS	O-WHO
:	:	O
Thoroughly	RB	O
massage	NN	O
Acticin	NNP	O
(	(	O
permethrin	NN	O
)	)	O
Cream	NNP	O
into	IN	O
the	DT	O
skin	NN	O
from	IN	O
the	DT	O
head	NN	O
to	TO	O
the	DT	O
soles	NNS	O
of	IN	O
the	DT	O
feet	NNS	O
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
up	IN	O
to	TO	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
lb	NN	O
of	IN	O
body	NN	O
weight	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
of	IN	O
quinapril	NN	O
/	NNP	O
hydrochlorothiazide	NN	O
combination	NN	O
therapy	NN	O
using	VBG	O
quinapril	JJ	O
doses	NNS	O
of	IN	O
2.5	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
and	CC	O
hydrochlorothiazide	JJ	O
doses	NNS	O
of	IN	O
6.25	CD	B-DOS
to	TO	O
25	CD	B-DOS
mg	NN	B-UNIT
,	,	O
the	DT	O
antihypertensive	JJ	O
effects	NNS	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
of	IN	O
either	DT	O
component	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
6.5	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

When	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
chemotherapy	NN	O
drugs	NNS	O
,	,	O
the	DT	O
most	RBS	O
commonly	RB	O
used	JJ	O
dosage	NN	O
of	IN	O
doxorubicin	NN	O
is	VBZ	O
40	CD	B-DOS
to	TO	O
60	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
m2	RB	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
intravenous	JJ	B-UNIT
injection	NN	O-UNIT
every	DT	B-FREQ
21	CD	O-FREQ
to	TO	O
28	CD	B-FREQ
days	NNS	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Tourette	NNP	O
's	POS	O
Disorder	NNP	O
is	VBZ	O
5	CD	B-DOS
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Usual	JJ	O
daily	RB	B-FREQ
dose	VBP	O
,	,	O
1	CD	B-DOS
gram	NN	B-UNIT
as	IN	O
500	CD	B-DOS
mg	NN	B-UNIT
b.i.d	NN	O
.	.	O

Although	IN	O
the	DT	O
dosage	NN	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
titration	NN	O
of	IN	O
the	DT	O
individual	JJ	O
ingredients	NNS	O
,	,	O
many	JJ	B-WHO
patients	NNS	O-WHO
will	MD	O
be	VB	O
found	VBN	O
to	TO	O
have	VB	O
an	DT	O
optimal	JJ	O
response	NN	O
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
to	TO	O
100	CD	B-DOS
mg	NNS	B-UNIT
each	DT	O
of	IN	O
spironolactone	NN	O
and	CC	O
hydrochlorothiazide	JJ	O
daily	JJ	B-FREQ
,	,	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
1	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
salmeterol	NN	O
.	.	O

The	DT	O
daily	JJ	B-FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	B-WHO
adult	NN	I-WHO
patient	NN	I-WHO
,	,	I-WHO
not	RB	I-WHO
hypermetabolic	JJ	I-WHO
,	,	I-WHO
in	IN	I-WHO
an	DT	I-WHO
acceptable	JJ	I-WHO
weight	NN	I-WHO
range	NN	I-WHO
and	CC	I-WHO
with	IN	I-WHO
restricted	JJ	I-WHO
physical	JJ	I-WHO
activity	NN	O-WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	B-DOS
to	TO	O
18	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1	CD	B-DOS
to	TO	O
1.5	CD	B-DOS
g	NN	B-UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	B-FREQ
day	NN	O-FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	B-DOS
and	CC	O
3000	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
fluids	NNS	O
.	.	O

Pediatric	JJ	B-WHO
Patients	NNS	I-WHO
with	IN	I-WHO
a	DT	I-WHO
Body	NNP	I-WHO
Weight	NNP	I-WHO
<	VBZ	I-WHO
50	CD	I-WHO
kg	NN	O-WHO
:	:	O

The	DT	O
wick	NN	O
may	MD	O
be	VB	O
removed	VBN	O
after	IN	O
24	CD	O
hours	NNS	O
but	CC	O
the	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
instill	VB	O
5	CD	B-DOS
drops	NNS	B-UNIT
of	IN	O
Acetic	NNP	O
Acid	NNP	O
Otic	NNP	O
Solution	NNP	O
3	CD	B-FREQ
or	CC	O
4	CD	B-FREQ
times	NNS	I-FREQ
daily	JJ	O-FREQ
thereafter	RB	O
,	,	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
indicated	VBN	O
.	.	O

A	DT	O
previously	RB	B-WHO
unvaccinated	JJ	I-WHO
child	NN	I-WHO
12	CD	I-WHO
to	TO	I-WHO
14	CD	I-WHO
months	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
should	MD	O
receive	VB	O
one	CD	B-DOS
dose	NN	B-UNIT
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
followed	VBN	O
by	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
(	(	O
doses	VBZ	O
to	TO	O
be	VB	O
separated	VBN	O
by	IN	O
an	DT	O
interval	NN	O
of	IN	O
8	CD	B-DUR
weeks	NNS	O-DUR
)	)	O
.	.	O

Activase	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
reconstituted	VBN	O
at	IN	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
or	CC	O
further	RB	O
diluted	VBN	O
immediately	RB	O
before	IN	O
administration	NN	O
in	IN	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
yield	VB	O
a	DT	O
concentration	NN	O
of	IN	O
0.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
mL	NN	O
,	,	O
using	VBG	O
either	CC	O
polyvinyl	JJ	O
chloride	NN	O
bags	NNS	O
or	CC	O
glass	NN	O
vials	NNS	O
.	.	O

An	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
250	CD	B-DOS
international	JJ	B-UNIT
unit	NN	O-UNIT
/	NNP	O
kg	NNP	O
(	(	O
50	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
injection	NN	B-UNIT
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ITP	NNP	O
.	.	O

lipid	JJ	O
calories	NNS	O
of	IN	O
100	CD	O
to	TO	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

Dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
or	CC	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
in	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
to	TO	O
support	VB	O
this	DT	O
use	NN	O
of	IN	O
etomidate	NN	O
for	IN	O
longer	JJR	B-WHO
adult	NN	I-WHO
procedures	NNS	O-WHO
or	CC	O
for	IN	O
any	DT	O
procedures	NNS	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	O-WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
discontinued	VBN	O
from	IN	O
those	DT	O
medications	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
either	DT	O
ABILIFY	NNP	O
15	CD	B-DOS
mg	NN	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
or	CC	O
placebo	NN	O
,	,	O
and	CC	O
observed	VBD	O
for	IN	O
relapse	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

In	IN	O
some	DT	B-WHO
patients	NNS	O-WHO
,	,	O
one	CD	B-DOS
inhalation	NN	B-UNIT
every	DT	B-FREQ
4	CD	I-FREQ
hours	NNS	O-FREQ
may	MD	O
be	VB	O
sufficient	JJ	O
.	.	O

AGRIFLUshould	RB	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
0.5	CD	O-DOS
mL	NN	B-UNIT
intramuscular	JJ	O
injection	NN	B-UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
region	NN	O
of	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Recommended	VBN	O
starting	NN	O
doses	NNS	O
,	,	O
based	VBN	O
on	IN	O
clinical	JJ	O
and	CC	O
pharmacokinetic	JJ	O
data	NNS	O
from	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

When	WRB	O
in	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
clinician	NN	O
a	DT	O
lower	JJR	O
initial	JJ	O
dose	NN	O
is	VBZ	O
appropriate	JJ	O
,	,	O
patients	NNS	O
may	MD	O
begin	VB	O
treatment	NN	O
with	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Since	IN	O
improvement	NN	O
in	IN	O
immune	JJ	O
function	NN	O
follows	VBZ	O
correction	NN	O
of	IN	O
metabolic	JJ	O
abnormalities	NNS	O
,	,	O
maintenance	NN	O
dosage	NN	O
in	IN	O
individual	JJ	O
patients	NNS	O
should	MD	O
be	VB	O
aimed	VBN	O
at	IN	O
achieving	VBG	O
the	DT	O
following	JJ	O
biochemical	JJ	O
goals	NNS	O
:	:	O
1	CD	O
)	)	O
maintain	NN	O
plasma	JJ	O
ADA	NNP	O
activity	NN	O
(	(	O
trough	JJ	O
levels	NNS	O
before	IN	O
maintenance	NN	O
injection	NN	O
)	)	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
15	CD	O
-	:	O
35	CD	O
μmol	JJ	O
/	NNP	O
hr	NN	O
/	NNP	O
mL	NN	O
(	(	O
assayed	VBN	O
at	IN	O
37°C	CD	O
)	)	O
;	:	O
and	CC	O
2	CD	O
)	)	O
decline	NN	O
in	IN	O
erythrocyte	JJ	O
dATP	NN	O
to	TO	O
≤	VB	O
0.005	CD	O
-	:	O
0.015	CD	B-DOS
μmol	JJ	B-UNIT
/	NNP	O
mL	NN	O
packed	VBD	O
erythrocytes	NNS	O
,	,	O
or	CC	O
≤	VB	O
1	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
erythrocyte	JJ	O
adenine	NN	O
nucleotide	NN	O
(	(	O
ATP	NNP	O
+	NNP	O
dATP	NN	O
)	)	O
content	NN	O
,	,	O
with	IN	O
a	DT	O
normal	JJ	O
ATP	NNP	O
level	NN	O
,	,	O
as	IN	O
measured	VBN	O
in	IN	O
a	DT	O
pre	NN	O
-	:	O
injection	NN	O
sample	NN	O
.	.	O

See	NNP	O
also	RB	O
Section	NNP	O
on	IN	O
Volume	NN	O
Adjustment	NN	O
:	:	O
Patients	NNS	B-WHO
less	JJR	I-WHO
than	IN	I-WHO
40	CD	I-WHO
kg	NNS	O-WHO
and	CC	O
Requiring	VBG	O
Fluid	NNP	O
Restriction	NNP	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
total	JJ	O
daily	JJ	B-FREQ
doses	NNS	O
greater	JJR	O
than	IN	O
30	CD	B-DOS
mg	NN	B-UNIT
or	CC	O
injections	NNS	O
given	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	B-FREQ
2	CD	I-FREQ
hours	NNS	O-FREQ
have	VBP	O
not	RB	O
been	VBN	O
adequately	RB	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
CAPOTEN	NNP	O
(	(	O
captopril	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
b.i.d	NN	O
.	.	O

Hydrochlorothiazide	NNP	O
doses	VBZ	O
greater	JJR	O
than	IN	O
50	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
10	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
kg	NN	O
at	IN	O
2	CD	B-DUR
-	:	O
week	NN	B-DUR
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
doses	NNS	O
and	CC	O
at	IN	O
4	CD	B-DUR
-	:	O
week	NN	B-DUR
intervals	NNS	O
thereafter	RB	O
.	.	O

For	IN	O
use	NN	O
with	IN	O
local	JJ	O
anesthetic—Epinephrine	NN	O
1:100,000	CD	O
(	(	O
0.01	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
to	TO	O
1:20,000	CD	O
(	(	O
0.05	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
is	VBZ	O
the	DT	O
usual	JJ	O
concentration	NN	O
employed	VBN	O
with	IN	O
local	JJ	O
anesthetics	NNS	O
.	.	O

As	IN	O
Acetadote	NNP	O
is	VBZ	O
hyperosmolar	JJ	O
(	(	O
2600	CD	B-DOS
mOsmol	NN	B-UNIT
/	NNP	O
L	NNP	O
)	)	O
,	,	O
caution	NN	O
is	VBZ	O
advised	VBN	O
when	WRB	O
the	DT	O
diluent	NN	O
volume	NN	O
is	VBZ	O
decreased	VBN	O
as	IN	O
the	DT	O
hyperosmolarity	NN	O
of	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
increased	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	B-DOS
drop	NN	B-UNIT
of	IN	O
ALPHAGAN®	NNP	O
P	NNP	O
(	(	O
brimonidine	JJ	O
tartrate	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
,	,	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
starting	VBG	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
the	DT	O
tablet	NN	O
formulation	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
was	VBD	O
2	CD	B-DOS
mg	NN	B-UNIT
,	,	O
which	WDT	O
was	VBD	O
titrated	VBN	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
after	IN	O
2	CD	O
days	NNS	O
and	CC	O
to	TO	O
the	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
after	IN	O
2	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Schedule	NN	O
Of	IN	O
Exposures	NNS	O
:	:	O
When	WRB	O
patients	NNS	O
have	VBP	O
achieved	VBN	O
95	CD	O
percent	NN	O
clearing	NN	O
,	,	O
or	CC	O
Grade	VBD	O
4	CD	O
response	NN	O
(	(	O
Table	JJ	O
2	CD	O
)	)	O
,	,	O
they	PRP	O
may	MD	O
be	VB	O
placed	VBN	O
on	IN	O
the	DT	O
following	JJ	O
maintenance	NN	O
schedules	NNS	O
(	(	O
M1	NNP	O
–	NNP	O
M4	NNP	O
)	)	O
,	,	O
in	IN	O
sequence	NN	O
.	.	O

Administer	NNP	O
additional	JJ	O
boluses	NNS	O
as	IN	O
needed	VBN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
a	DT	O
total	JJ	O
dosage	NN	O
of	IN	O
50	CD	B-DOS
mg	NN	B-UNIT
.	.	O

ACAM2000	NN	O
should	MD	O
only	RB	O
be	VB	O
reconstituted	VBN	O
with	IN	O
0.3	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
diluent	NN	O
provided	VBD	O
.	.	O

In	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
daily	JJ	B-FREQ
doses	NNS	O
of	IN	O
200	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
prednisolone	NN	O
for	IN	O
a	DT	O
week	NN	B-DUR
followed	VBN	O
by	IN	O
80	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
for	IN	O
1	CD	B-DUR
month	NN	O-DUR
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
(	(	O
4	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
methylprednisolone	NN	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
5	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
prednisolone	NN	O
)	)	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
doses	NNS	O
higher	JJR	O
than	IN	O
800	CD	B-DOS
mcg	NNS	B-UNIT
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
in	IN	O
patients	NNS	B-WHO
.	.	O

For	IN	O
immunocompetent	JJ	B-WHO
patients	NNS	I-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
achieve	VB	I-WHO
parasitic	JJ	I-WHO
clearance	NN	O-WHO
with	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
,	,	O
a	DT	O
repeat	NN	O
course	NN	O
of	IN	O
therapy	NN	O
may	MD	O
be	VB	O
useful	JJ	O
.	.	O

The	DT	O
series	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
primary	JJ	O
immunization	NN	O
course	NN	O
of	IN	O
3	CD	B-DOS
doses	NNS	B-UNIT
administered	VBN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	B-DOS
booster	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
administered	VBN	O
at	IN	O
15	CD	O
-	:	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Increase	NN	O
in	IN	O
increments	NNS	O
of	IN	O
3.1	CD	B-DOS
mg	NNS	B-UNIT
or	CC	O
6.3	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
.	.	O

If	IN	O
such	JJ	O
circumstances	NNS	O
are	VBP	O
suspected	VBN	O
to	TO	O
be	VB	O
present	JJ	O
,	,	O
the	DT	O
initial	JJ	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
1.25	CD	B-DOS
mg	JJ	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.2	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
Normosol®	NNP	O
M	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
(	(	O
or	CC	O
Plasma	NNP	O
-	:	O
Lyte	NN	O
56	CD	O
Injection	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Water	NNP	O
)	)	O
Normosol®	NNP	O
R	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
(	(	O
or	CC	O
Plasma	NNP	O
-	:	O
Lyte	NN	O
148	CD	O
Injection	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Water	NNP	O
)	)	O

As	IN	O
with	IN	O
adults	NNS	B-WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
25	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
and	CC	O
should	MD	O
be	VB	O
gradually	RB	O
increased	VBN	O
(	(	O
also	RB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
with	IN	O
meals	NNS	O
to	TO	O
reduce	VB	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
as	IN	O
tolerated	VBN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
daily	JJ	B-FREQ
maximum	NN	O-FREQ
of	IN	O
3	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBD	O
or	CC	O
100	CD	B-DOS
mg	NN	B-UNIT
,	,	O
whichever	WP	O
is	VBZ	O
smaller	JJR	O
.	.	O

Two	CD	B-DUR
weeks	NNS	O-DUR
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
begin	VB	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
40	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
other	JJ	I-FREQ
week	NN	O-FREQ
.	.	O

The	DT	O
optimal	JJ	O
interval	NN	O
before	IN	O
retreatment	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
defined	VBN	O
for	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
have	VBP	I-WHO
not	RB	I-WHO
completed	VBN	I-WHO
skeletal	JJ	I-WHO
growth	NN	O-WHO
.	.	O

NIASPAN	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
significant	JJ	I-WHO
or	CC	I-WHO
unexplained	JJ	I-WHO
hepatic	JJ	I-WHO
dysfunction	NN	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
by	IN	O
all	DT	O
routes	NNS	O
of	IN	O
administration	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Instill	NNP	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
prior	RB	O
to	TO	O
operating	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosages	NNS	O
for	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
for	IN	O
patients	NNS	B-WHO
aged	VBN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	I-WHO
are	VBP	I-WHO
based	VBN	I-WHO
upon	IN	I-WHO
patients	NNS	I-WHO
'	POS	I-WHO
asthma	JJ	I-WHO
severity	NN	O-WHO
.	.	O

Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
week	NN	O-FREQ
for	IN	O
a	DT	O
full	JJ	O
16	CD	B-DUR
weeks	NNS	O-DUR
to	TO	O
a	DT	O
defined	VBN	O
treatment	NN	O
area	NN	O
on	IN	O
the	DT	O
face	NN	O
or	CC	O
scalp	NN	O
(	(	O
but	CC	O
not	RB	O
both	DT	O
concurrently	RB	O
)	)	O
.	.	O

NIASPAN	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
renal	JJ	I-WHO
insufficiency	NN	O-WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
range	NN	O
is	VBZ	O
2.5	CD	B-DOS
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
or	CC	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Incremental	JJ	O
Rates	NNS	O
for	IN	O
250	CD	B-DOS
mL	NNS	B-UNIT
ALDURAZYME®	NNP	O
Infusion	NNP	O
(	(	O
For	IN	O
use	NN	O
with	IN	O
Patients	NNS	B-WHO
Weighing	VBG	I-WHO
Greater	NNP	I-WHO
than	IN	I-WHO
20	CD	I-WHO
kg	NNS	I-WHO
)	)	O-WHO

Patients	NNS	B-WHO
with	IN	I-WHO
erythrodermic	JJ	I-WHO
psoriasis	NN	O-WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
special	JJ	O
attention	NN	O
because	IN	O
pre	JJ	O
-	:	O
existing	VBG	O
erythema	NN	O
may	MD	O
obscure	VB	O
observations	NNS	O
of	IN	O
possible	JJ	O
treatment	NN	O
-	:	O
related	JJ	O
phototoxic	NN	O
erythema	NN	O
.	.	O

Two	CD	B-DUR
weeks	NNS	O-DUR
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
continue	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
40	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
other	JJ	I-FREQ
week	NN	O-FREQ
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

THE	DT	O
100	CD	B-DOS
mg	NN	B-UNIT
VIALS	NNP	O
DO	NNP	O
NOT	NNP	O
CONTAIN	NNP	O
VACUUM	NNP	O
.	.	O

15	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
500	CD	B-DOS
mg	JJ	B-UNIT
tablet	NN	O-UNIT
:	:	O
white	JJ	O
to	TO	O
off	VB	O
-	:	O
white	JJ	O
,	,	O
oblong	JJ	O
,	,	O
film	NN	O
-	:	O
coated	VBN	O
tablet	NN	O
with	IN	O
“	JJ	O
4833M	CD	O
”	NN	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
“	$	O
15	CD	O
/	$	O
500	CD	O
”	NN	O
on	IN	O
the	DT	O
other	JJ	O
,	,	O
available	JJ	O
in	IN	O
:	:	O

In	IN	O
other	JJ	O
indications	NNS	O
initial	JJ	O
dosage	NN	O
will	MD	O
vary	VB	O
from	IN	O
10	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NN	B-UNIT
of	IN	O
methylprednisolone	NN	O
depending	VBG	O
on	IN	O
the	DT	O
clinical	JJ	O
problem	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Available	JJ	O
evidence	NN	O
suggests	VBZ	O
about	IN	O
one	CD	O
third	NN	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	B-WHO
with	IN	I-WHO
multiple	JJ	I-WHO
myeloma	NN	O-WHO
show	NN	O
a	DT	O
favorable	JJ	O
response	NN	O
to	TO	O
the	DT	O
drug	NN	O
.	.	O

One	CD	O
regimen	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
courses	NNS	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
0.25	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
4	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
(	(	O
or	CC	O
,	,	O
0.20	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
5	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
)	)	O
for	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBP	O
/	JJ	O
course	NN	O
.	.	O

Usage	NN	O
in	IN	O
Children	NNP	B-WHO
:	:	O
Clinical	JJ	O
data	NNS	O
to	TO	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
in	IN	O
patients	NNS	B-WHO
under	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
are	VBP	I-WHO
not	RB	I-WHO
presently	RB	I-WHO
available	JJ	O-WHO
.	.	O

Consider	VB	O
G	NNP	O
-	:	O
CSF	NNP	O
prophylaxis	NN	O
for	IN	O
subsequent	JJ	O
cycles	NNS	O
in	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
experience	VBP	I-WHO
Grade	NNP	I-WHO
3	CD	I-WHO
or	CC	I-WHO
4	CD	I-WHO
neutropenia	NN	O-WHO
in	IN	O
the	DT	O
previous	JJ	O
cycle	NN	O
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
due	JJ	O
to	TO	O
menopause	VB	O
.	.	O

g	NN	O
)	)	O
If	IN	O
the	DT	O
injection	NN	O
is	VBZ	O
not	RB	O
performed	VBN	O
immediately	RB	O
after	IN	O
reconstitution	NN	O
keep	VB	O
the	DT	O
vial	NN	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
shake	VB	O
the	DT	O
vial	JJ	O
vigorously	RB	O
for	IN	O
at	IN	O
least	JJS	O
60	CD	O
seconds	NNS	O
to	TO	O
re	VB	O
-	:	O
suspend	NN	O
prior	RB	O
to	TO	O
injection	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
data	NNS	O
with	IN	O
this	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	B-WHO
receiving	VBG	I-WHO
strong	JJ	I-WHO
CYP3A4	NNP	O-WHO
/	NNP	O
PgP	NNP	O
inducers	NNS	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
intolerable	JJ	O
headaches	NNS	O
during	IN	O
initial	JJ	O
treatment	NN	O
,	,	O
switch	VB	O
to	TO	O
one	CD	B-DOS
capsule	NN	B-UNIT
at	IN	O
bedtime	NN	O
and	CC	O
low	JJ	O
-	:	O
dose	NN	O
aspirin	NN	O
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
=	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	NN	O
Desired	NNP	O
Factor	NNP	O
VIII	NNP	O
rise	NN	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
x	VBZ	O
0.5	CD	B-DOS
(	(	O
IU	NNP	O
/	NNP	O
kg	FW	O
per	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O

Ophthalmologic	NNP	O
use	NN	O
(	(	O
for	IN	O
producing	VBG	O
conjunctival	JJ	O
decongestion	NN	O
,	,	O
to	TO	O
control	VB	O
hemorrhage	NN	O
,	,	O
produce	VBP	O
mydriasis	NN	O
and	CC	O
reduce	VB	O
intraocular	JJ	O
pressure	NN	O
)	)	O
—Use	VBZ	O
a	DT	O
concentration	NN	O
of	IN	O
1:10,000	CD	O
(	(	O
0.1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
to	TO	O
1:1,000	CD	O
(	(	O
1	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Hypertension	NN	O
:	:	O
For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hypertension	NN	I-WHO
and	CC	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	B-DOS
mg	NN	B-UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
ALTABAX	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
up	IN	O
to	TO	O
100	CD	B-DOS
cm²	NN	B-UNIT
in	IN	O
total	JJ	O
area	NN	O
in	IN	O
adults	NNS	B-WHO
or	CC	O
2	CD	O
%	NN	O
total	JJ	O
body	NN	O
surface	NN	O
area	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
aged	VBD	I-WHO
9	CD	I-WHO
months	NNS	I-WHO
or	CC	I-WHO
older	JJR	O-WHO
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
5	CD	B-DUR
days	NNS	O-DUR
.	.	O

ADVAIR	NNP	O
HFA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
body	NN	I-WHO
weight	NN	I-WHO
greater	JJR	I-WHO
than	IN	I-WHO
20	CD	I-WHO
kg	NNS	O-WHO
should	MD	O
receive	VB	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
250	CD	B-DOS
mL	NN	B-UNIT
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Altoprev	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphorus	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	B-DOS
mM	NN	B-UNIT
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	B-DOS
tablet	NN	B-UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
symptoms	NNS	O
of	IN	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
due	JJ	O
to	TO	O
menopause	VB	O
.	.	O

Single	NNP	B-DOS
Dose	NNP	B-UNIT
-	:	O
Actidose®	NN	O
with	IN	O
Sorbitol	NNP	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
recurrent	JJ	I-WHO
Grade	NNP	I-WHO
4	CD	I-WHO
neutropenia	NN	O-WHO
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
G	NNP	O
-	:	O
CSF	NNP	O
prophylaxis	NN	O
,	,	O
consider	VB	O
discontinuation	NN	O
or	CC	O
dose	JJ	O
reduction	NN	O
of	IN	O
ADCETRIS	NNP	O
to	TO	O
1.2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
or	CC	O
withdrawals	NNS	O
because	IN	O
of	IN	O
adverse	JJ	O
events	NNS	O
in	IN	O
elderly	JJ	B-WHO
patients	NNS	O-WHO
.	.	O

Usual	JJ	O
pediatric	JJ	O
dose	NN	O
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
4	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
,	,	O
then	RB	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
the	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	JJ	O
Usual	NNP	O
adult	NN	B-WHO
dose	NN	O
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
200	CD	B-DOS
mg	NNS	B-UNIT
,	,	O
then	RB	O
100	CD	B-DOS
mg	NNS	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	B-DOS
mg	NNS	B-UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
patient	NN	O
begins	VBZ	O
her	PRP$	O
next	JJ	O
and	CC	O
all	DT	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
tablets	NNS	O
on	IN	O
the	DT	O
day	NN	O
after	IN	O
taking	VBG	O
her	PRP$	O
last	JJ	O
light	JJ	O
-	:	O
green	JJ	O
tablet	NN	O
.	.	O

Dosage	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
is	VBZ	O
usually	RB	O
prescribed	VBN	O
on	IN	O
a	DT	O
g	NN	O
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
basis	NN	O
,	,	O
with	IN	O
adjustments	NNS	O
for	IN	O
patient	JJ	O
age	NN	O
as	IN	O
follows	VBZ	O
:	:	O
ages	NNS	B-WHO
1	CD	I-WHO
to	TO	I-WHO
3	CD	I-WHO
years	NNS	O-WHO
,	,	O
2	CD	B-DOS
to	TO	O
2.5	CD	B-DOS
g	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
4	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	O-WHO
,	,	O
2	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
13	CD	I-WHO
to	TO	I-WHO
15	CD	I-WHO
years	NNS	O-WHO
,	,	O
1.7	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
ages	VBZ	B-WHO
16	CD	I-WHO
and	CC	I-WHO
above	RB	O-WHO
,	,	O
1.5	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
,	,	O
if	IN	O
needed	VBN	O
,	,	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
increments	NNS	O
.	.	O

Methotrexate	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
or	CC	O
intramuscularly	RB	O
in	IN	O
doses	NNS	O
of	IN	O
15	CD	B-DOS
to	TO	O
30	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
for	IN	O
a	DT	O
five	CD	B-DUR
-	:	O
day	NN	B-DUR
course	NN	O
.	.	O

Telephone	CD	O
1	CD	O
-	:	O
866­792	CD	O
-	:	O
5172	CD	O
.	.	O

The	DT	O
published	VBN	O
medical	JJ	O
literature	NN	O
does	VBZ	O
not	RB	O
indicate	VB	O
that	IN	O
the	DT	O
dose	NN	O
of	IN	O
acetylcysteine	NN	O
in	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hepatic	JJ	I-WHO
impairment	NN	O-WHO
should	MD	O
be	VB	O
reduced	VBN	O
.	.	O

ABILIFY	NNP	O
MAINTENA	NNP	O
comes	VBZ	O
in	IN	O
two	CD	O
types	NNS	O
of	IN	O
kits	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
HYZAAR	NNP	O
is	VBZ	O
50	CD	B-DOS
/	JJ	O
12.5	CD	B-DOS
(	(	O
losartan	JJ	O
50	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
hydrochlorothiazide	RB	O
12.5	CD	B-DOS
mg	NN	B-UNIT
)	)	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Syphilis	NN	O
of	IN	O
more	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
:	:	O
Patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
allergic	JJ	I-WHO
to	TO	I-WHO
penicillin	VB	O-WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
doxycycline	JJ	O
100	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
4	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

For	IN	O
children	NNS	B-WHO
over	IN	I-WHO
8	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
mg	NN	B-UNIT
per	IN	O
kg	NN	O
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
up	IN	O
to	TO	O
the	DT	O
adult	NN	B-WHO
dose	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
concomitant	JJ	I-WHO
use	NN	O-WHO
of	IN	O
CYP3A4	NNP	O
inhibitors	NNS	O
,	,	O
CYP2D6	NNP	O
inhibitors	NNS	O
or	CC	O
CYP3A4	NNP	O
inducers	NNS	O
for	IN	O
less	JJR	O
than	IN	O
14	CD	O
days	NNS	O
.	.	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
If	IN	O
AGENERASE	NNP	O
and	CC	O
ritonavir	NN	O
are	VBP	O
used	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
:	:	O
AGENERASE	$	O
1,200	CD	B-DOS
mg	NN	B-UNIT
with	IN	O
ritonavir	JJ	O
200	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
or	CC	O
AGENERASE	$	O
600	CD	B-DOS
mg	NN	B-UNIT
with	IN	O
ritonavir	JJ	O
100	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

One	CD	O
regimen	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
courses	NNS	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
0.25	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
4	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
(	(	O
or	CC	O
,	,	O
0.2	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
for	IN	O
5	CD	B-DUR
consecutive	JJ	I-DUR
days	NNS	O-DUR
)	)	O
for	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	VBP	O
/	JJ	O
course	NN	O
.	.	O

Since	IN	O
methyldopa	NN	O
is	VBZ	O
largely	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
,	,	O
patients	NNS	B-WHO
with	IN	I-WHO
impaired	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
may	MD	O
respond	VB	O
to	TO	O
smaller	JJR	O
doses	NNS	O
.	.	O

In	IN	O
children	NNS	B-WHO
6	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
,	,	O
start	VBP	O
with	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
or	CC	O
twice	JJ	B-FREQ
daily	RB	O-FREQ
;	:	O
daily	JJ	B-FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
respond	VB	I-WHO
adequately	RB	O-WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	B-WHO
requiring	VBG	I-WHO
a	DT	I-WHO
concomitant	NN	I-WHO
strong	JJ	I-WHO
CYP3A4	NNP	I-WHO
inducer	NN	O-WHO
is	VBZ	O
9	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	B-FREQ
daily	JJ	O-FREQ
[	NNP	O
see	VBP	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
given	VBN	O
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

If	IN	O
the	DT	O
400	CD	B-DOS
mcg	NN	B-UNIT
dose	NN	O-UNIT
is	VBZ	O
used	VBN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
given	VBN	O
either	CC	O
as	IN	O
a	DT	O
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
dosage	NN	O
(	(	O
4	CD	B-DOS
sprays	NNS	B-UNIT
in	IN	O
each	DT	O
nostril	NN	O
)	)	O
or	CC	O
divided	VBN	O
into	IN	O
two	CD	B-DOS
daily	JJ	B-FREQ
doses	NNS	B-UNIT
of	IN	O
two	CD	B-DOS
sprays	NNS	B-UNIT
/	VBP	O
nostril	JJ	O
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

One	CD	O
study	NN	O
by	IN	O
Alexanian	NNP	O
et	NN	O
al	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
prednisone	NN	O
significantly	RB	O
improves	VBZ	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
multiple	JJ	I-WHO
myeloma	NNS	I-WHO
who	WP	I-WHO
achieve	VBP	I-WHO
palliation	NN	O-WHO
.	.	O

For	IN	O
prevention	NN	O
of	IN	O
bleeding	VBG	O
episodes	NNS	O
,	,	O
doses	NNS	O
between	IN	O
20	CD	B-DOS
to	TO	O
40	CD	B-DOS
International	NNP	B-UNIT
Units	NNS	O-UNIT
of	IN	O
Factor	NNP	O
VIII	NNP	O
per	IN	O
kg	NN	O
body	NN	O
weight	JJ	O
every	DT	B-FREQ
other	JJ	I-FREQ
day	NN	O-FREQ
(	(	O
3	CD	B-FREQ
to	TO	O
4	CD	B-FREQ
times	NNS	I-FREQ
weekly	RB	O-FREQ
)	)	O
may	MD	O
be	VB	O
utilized	VBN	O
.	.	O

A	DT	O
fluid	JJ	O
intake	NN	O
sufficient	NN	O
to	TO	O
yield	VB	O
a	DT	O
daily	JJ	B-FREQ
urinary	JJ	O
output	NN	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
liters	NNS	O
in	IN	O
adults	NNS	B-WHO
and	CC	O
the	DT	O
maintenance	NN	O
of	IN	O
a	DT	O
neutral	JJ	O
or	CC	O
,	,	O
preferably	RB	O
,	,	O
slightly	RB	O
alkaline	JJ	O
urine	NN	O
are	VBP	O
desirable	JJ	O
.	.	O

Bottles	NNS	O
of	IN	O
60	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
155	CD	O
-	:	O
60	CD	O
Bottles	NNS	O
of	IN	O
180	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
155	CD	O
-	:	O
18	CD	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
dosage	NN	O
interruption	NN	O
or	CC	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
rebound	NN	O
in	IN	O
platelet	NN	O
count	NN	O
is	VBZ	O
variable	JJ	O
,	,	O
but	CC	O
platelet	NN	O
counts	NNS	O
typically	RB	O
will	MD	O
start	VB	O
to	TO	O
rise	VB	O
within	IN	O
4	CD	O
days	NNS	O
and	CC	O
return	NN	O
to	TO	O
baseline	NN	O
levels	NNS	O
in	IN	O
one	CD	B-DUR
to	TO	O
two	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
possibly	RB	O
rebounding	VBG	O
above	IN	O
baseline	NN	O
values	NNS	O
.	.	O

Refer	NN	O
to	TO	O
Table	VB	O
1	CD	O
for	IN	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	NN	O
and	CC	O
ADDERALL	NNP	O
XR	NNP	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
ALDACTONE	NNP	O
25	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
if	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
potassium	NN	O
is	VBZ	O
≤	JJ	O
5.0	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
≤	JJ	O
2.5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
dL	NN	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
dextrose	NN	O
in	IN	O
the	DT	O
final	JJ	O
admixture	NN	O
is	VBZ	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
simultaneous	JJ	O
administration	NN	O
of	IN	O
lipid	JJ	O
emulsion	NN	O
is	VBZ	O
recommended	VBN	O
both	RB	O
as	IN	O
a	DT	O
calorie	NN	O
source	NN	O
and	CC	O
to	TO	O
attenuate	VB	O
the	DT	O
potentially	RB	O
irritating	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
hypertonic	JJ	O
nutritional	JJ	O
admixture	NN	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
and	CC	O
a	DT	O
sterile	JJ	O
1	CD	B-DOS
mL	NN	B-UNIT
syringe	NN	O
fitted	VBN	O
with	IN	O
a	DT	O
25	CD	O
gauge	NN	O
x	NN	O
5	CD	O
/	JJ	O
8	CD	O
”	NN	O
needle	NN	O
(	(	O
provided	VBN	O
)	)	O
,	,	O
draw	VBZ	O
up	RP	O
0.3	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
diluent	NN	O
and	CC	O
transfer	VB	O
the	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
vaccine	NN	O
vial	NN	O
.	.	O

A	DT	O
semipermeable	JJ	O
dressing	NN	O
is	VBZ	O
one	CD	O
that	WDT	O
allows	VBZ	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
air	NN	O
but	CC	O
does	VBZ	O
not	RB	O
allow	VB	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
fluids	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
15	CD	O
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
or	CC	O
one	CD	B-DOS
tablet	NN	B-UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
25	CD	O
two	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
.	.	O

Dosage	NN	O
adjustments	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
should	MD	O
occur	VB	O
gradually	RB	O
,	,	O
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	B-DUR
week	NN	O-DUR
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Pediatric	JJ	B-WHO
Patients	NNS	O-WHO
:	:	O
For	IN	O
adolescents	NNS	B-WHO
(	(	I-WHO
13	CD	I-WHO
to	TO	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	B-DOS
50	CD	O-DOS
-	:	O
mg	NN	B-UNIT
capsules	NNS	O-UNIT
)	)	O
twice	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Each	DT	O
Adrenaclick	NNP	O
contains	VBZ	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
of	IN	O
epinephrine	NN	O
for	IN	O
single	JJ	O
use	NN	O
injection	NN	O
.	.	O

No	DT	O
more	JJR	O
than	IN	O
one	CD	B-DOS
packet	NN	B-UNIT
of	IN	O
Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
contiguous	JJ	O
treatment	NN	O
area	NN	O
at	IN	O
each	DT	O
application	NN	O
.	.	O

Therefore	RB	O
,	,	O
for	IN	O
infusions	NNS	O
longer	JJR	O
than	IN	O
1	CD	O
hour	NN	O
,	,	O
amiodarone	NN	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
mL	NN	O
unless	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
is	VBZ	O
used	VBN	O
(	(	O
See	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
Postmarketing	NNP	O
Reports	NNP	O
)	)	O
.	.	O

Dose	NNP	O
(	(	O
International	NNP	O
Unit	NNP	O
)	)	O
=	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	NN	O
Desired	NNP	O
Factor	NNP	O
VIII	NNP	O
Rise	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
x	VBZ	O
0.5	CD	B-DOS
(	(	O
IU	NNP	O
/	NNP	O
kg	FW	O
per	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O

In	IN	O
circumstances	NNS	O
of	IN	O
rapid	JJ	O
ascent	NN	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
rescue	NN	O
or	CC	O
military	JJ	O
operations	NNS	O
,	,	O
the	DT	O
higher	JJR	O
dose	JJ	O
level	NN	O
of	IN	O
1000	CD	B-DOS
mg	NN	B-UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Tyzeka	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
600	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
taken	VBN	O
orally	RB	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
a	DT	O
600	CD	B-DOS
mcg	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
the	DT	O
next	JJ	O
titration	NN	O
step	NN	O
is	VBZ	O
800	CD	B-DOS
mcg	NN	B-UNIT
.	.	O

There	EX	O
are	VBP	O
two	CD	B-DOS
aripiprazole	JJ	B-UNIT
formulations	NNS	O-UNIT
for	IN	O
intramuscular	JJ	O
use	NN	O
with	IN	O
different	JJ	O
dosages	NNS	O
,	,	O
dosing	VBG	O
frequencies	NNS	O
,	,	O
and	CC	O
indications	NNS	O
.	.	O

Preparation	NN	O
and	CC	O
Storage	NN	O
of	IN	O
Parenteral	JJ	O
Solution	NN	O
:	:	O
Each	DT	O
500	CD	B-DOS
mg	NN	B-UNIT
vial	JJ	O-UNIT
containing	VBG	O
sterile	JJ	O
acetazolamide	JJ	O
sodium	NN	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
at	IN	O
least	JJS	O
5	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
four	CD	B-DOS
episodes	NNS	B-UNIT
of	IN	O
breakthrough	NN	O
pain	NN	O
are	VBP	O
experienced	VBN	O
per	IN	O
day	NN	O
,	,	O
re	VB	O
-	:	O
evaluate	VB	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
long	JJ	O
-	:	O
acting	VBG	O
opioid	NN	O
used	VBN	O
for	IN	O
persistent	JJ	O
underlying	JJ	O
cancer	NN	O
pain	NN	O
.	.	O

Patients	NNS	B-WHO
who	WP	I-WHO
tolerate	VBP	O-WHO
25	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
may	MD	O
have	VB	O
their	PRP$	O
dosage	NN	O
increased	VBD	O
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
as	IN	O
clinically	RB	O
indicated	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
25	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
reconstituted	JJ	O
E	NNP	O
-	:	O
Z	NNP	O
-	:	O
HD	NN	O
for	IN	O
adults	NNS	B-WHO
and	CC	I-WHO
pediatric	JJ	I-WHO
patients	NNS	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
and	CC	I-WHO
older	JJR	O-WHO
is	VBZ	O
between	IN	O
65	CD	B-DOS
and	CC	O
135	CD	B-DOS
mL	NN	B-UNIT
given	VBN	O
orally	RB	O
(	(	O
155	CD	B-DOS
to	TO	O
321	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
barium	NN	O
sulfate	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Pediatric	NNP	B-WHO
<	NN	I-WHO
Patients	NNS	O-WHO
:	:	O
For	IN	O
children	NNS	B-WHO
and	CC	I-WHO
adolescents	NNS	I-WHO
6	CD	I-WHO
-	:	I-WHO
15	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
two	CD	B-DOS
inhalations	NNS	B-UNIT
may	MD	O
be	VB	O
administered	VBN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
1	CD	B-DOS
mg.	NN	B-UNIT
Higher	JJR	O
doses	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

Adult	NN	B-WHO
patients	NNS	I-WHO
whose	WP$	I-WHO
disease	NN	I-WHO
is	VBZ	I-WHO
very	RB	I-WHO
severe	JJ	I-WHO
with	IN	I-WHO
scarring	NN	O-WHO
or	CC	O
is	VBZ	O
primarily	RB	O
manifested	VBN	O
on	IN	O
the	DT	O
trunk	NN	O
may	MD	O
require	VB	O
dose	NN	O
adjustments	NNS	O
up	IN	O
to	TO	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

Usual	JJ	O
daily	RB	B-FREQ
dose	VBP	O
,	,	O
10	CD	B-DOS
to	TO	O
20	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
lb	NN	O
(	(	O
25	CD	B-DOS
to	TO	O
50	CD	B-DOS
mg	NNS	B-UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
divided	VBN	O
in	IN	O
four	CD	B-DOS
equal	JJ	B-UNIT
doses	NNS	O-UNIT
.	.	O

Repeat	JJ	O
administration	NN	O
:	:	O
If	IN	O
the	DT	O
first	JJ	O
dose	NN	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
elimination	NN	O
of	IN	O
the	DT	O
supraventricular	JJ	O
tachycardia	NN	O
within	IN	O
1	CD	O
-	:	O
2	CD	O
minutes	NNS	O
,	,	O
12	CD	B-DOS
mg	NN	B-UNIT
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
rapid	JJ	O
intravenous	JJ	O
bolus	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
RAPIVAB	NNP	O
in	IN	O
adult	NN	B-WHO
patients	NNS	I-WHO
18	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
or	CC	I-WHO
older	JJR	I-WHO
with	IN	I-WHO
acute	NN	I-WHO
uncomplicated	JJ	I-WHO
influenza	NN	O-WHO
is	VBZ	O
a	DT	O
single	JJ	B-DOS
600	CD	O-DOS
mg	NN	B-UNIT
dose	NN	O-UNIT
,	,	O
administered	VBN	O
via	IN	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
15	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
.	.	O

XTAMPZA	NN	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
,	,	O
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
,	,	O
and	CC	O
must	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

ADIPEX	NNP	O
-	:	O
P®	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	B-WHO
patients	NNS	I-WHO
≤	VBP	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

When	WRB	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
is	VBZ	O
given	VBN	O
with	IN	O
antihypertensives	NNS	O
other	JJ	O
than	IN	O
thiazides	NNS	O
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
methyldopa	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
500	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
these	DT	O
other	JJ	O
agents	NNS	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
to	TO	O
effect	NN	O
a	DT	O
smooth	JJ	O
transition	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
18.8	CD	B-DOS
mg	JJ	B-UNIT
daily	JJ	B-FREQ
for	IN	O
patients	NNS	B-WHO
6	CD	I-WHO
to	TO	I-WHO
12	CD	I-WHO
years	NNS	O-WHO
,	,	O
and	CC	O
12.5	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
for	IN	O
patients	NNS	B-WHO
13	CD	I-WHO
to	TO	I-WHO
17	CD	I-WHO
years	NNS	O-WHO
[	RB	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
Clinical	NNP	O
Studies	NNP	O
]	NNP	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
doses	NNS	O
of	IN	O
40	CD	B-DOS
–	JJ	O
80	CD	B-DOS
mg	NN	B-UNIT
and	CC	O
divided	VBD	O
doses	NNS	O
give	VB	O
a	DT	O
somewhat	RB	O
greater	JJR	O
effect	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

ADVAIR	NNP	O
DISKUS	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	B-DOS
inhalation	NN	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
AGRYLIN	NNP	O
is	VBZ	O
0.5	CD	B-DOS
mg	NN	B-UNIT
four	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
or	CC	O
1	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proven	NN	O
dapsone	NN	O
-	:	O
resistant	JJ	O
leprosy	NN	O
,	,	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
100	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
antileprosy	JJ	O
drugs	NNS	O
for	IN	O
3	CD	O
years	NNS	O
,	,	O
followed	VBN	O
by	IN	O
monotherapy	NN	O
with	IN	O
100	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
daily	RB	B-FREQ
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
kept	VBN	O
small	JJ	O
,	,	O
using	VBG	O
0.5	CD	B-DOS
to	TO	O
2	CD	B-DOS
mL	NN	B-UNIT
(	(	O
preferably	RB	O
1	CD	B-DOS
mL	NNS	B-UNIT
maximum	JJ	O
)	)	O
for	IN	O
each	DT	O
injection	NN	O
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
single	JJ	O
treatment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	B-DOS
mL	NNS	B-UNIT
.	.	O

Therefore	RB	O
,	,	O
if	IN	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
,	,	O
patients	NNS	O
should	MD	O
then	RB	O
be	VB	O
titrated	VBN	O
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
until	IN	O
an	DT	O
effective	JJ	O
dose	NN	O
,	,	O
usually	RB	O
20	CD	B-DOS
to	TO	O
40	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
equally	RB	B-UNIT
divided	JJ	I-UNIT
doses	NNS	O-UNIT
,	,	O
is	VBZ	O
reached	VBN	O
or	CC	O
undesirable	JJ	O
hypotension	NN	O
,	,	O
orthostatis	NN	O
,	,	O
or	CC	O
azotemia	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
prohibit	NN	O
reaching	VBG	O
this	DT	O
dose	NN	O
.	.	O

Alupent	NNP	O
(	(	O
metaproterenol	JJ	O
sulfate	NN	O
USP	NNP	O
)	)	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
children	NNS	B-WHO
under	IN	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
.	.	O

The	DT	O
lower	JJR	O
dosage	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
patients	NNS	B-WHO
with	IN	I-WHO
inadequate	JJ	I-WHO
marrow	NN	I-WHO
reserves	NNS	I-WHO
due	JJ	I-WHO
to	TO	I-WHO
old	JJ	I-WHO
age	NN	O-WHO
,	,	O
or	CC	O
prior	RB	O
therapy	NN	O
,	,	O
or	CC	O
neoplastic	JJ	O
marrow	NN	O
infiltration	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
who	WP	I-WHO
do	VBP	I-WHO
not	RB	I-WHO
respond	VB	I-WHO
adequately	RB	O-WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
3	CD	B-DUR
-	:	O
4	CD	B-DUR
weeks	NNS	O-DUR
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
doses	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
7	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

ACTHREL®	NNP	O
is	VBZ	O
to	TO	O
be	VB	O
reconstituted	VBN	O
aseptically	RB	O
with	IN	O
2	CD	B-DOS
mL	NNS	B-UNIT
of	IN	O
Sodium	NNP	O
Chloride	NNP	O
injection	NN	O
,	,	O
USP	NNP	O
(	(	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
)	)	O
,	,	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
use	NN	O
by	IN	O
injecting	VBG	O
2	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
the	DT	O
saline	JJ	O
diluent	NN	O
into	IN	O
the	DT	O
lyophilized	JJ	O
drug	NN	O
product	NN	O
cake	NN	O
.	.	O

Dividing	VBG	O
the	DT	O
dose	NN	O
(	(	O
40	CD	B-DOS
mg	NN	B-UNIT
)	)	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
day	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
is	VBZ	O
0.5	CD	B-DOS
to	TO	O
1.0	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
two	CD	B-DOS
divided	JJ	B-UNIT
doses	NNS	O-UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	B-DUR
to	TO	O
20	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Actigall	NNP	O
for	IN	O
gallstone	NN	O
prevention	NN	O
in	IN	O
patients	NNS	B-WHO
undergoing	VBG	I-WHO
rapid	JJ	I-WHO
weight	JJ	I-WHO
loss	NN	O-WHO
is	VBZ	O
600	CD	B-DOS
mg	JJ	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
(	(	O
300	CD	B-DOS
mg	NN	B-UNIT
b.i.d	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
target	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	B-DOS
or	CC	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
administered	VBD	O
on	IN	O
a	DT	O
once	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
schedule	NN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
doses	NNS	O
for	IN	O
adults	NNS	B-WHO
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
heart	NN	I-WHO
failure	NN	I-WHO
and	CC	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	B-DOS
mg	JJ	B-UNIT
ALTACE	NNP	O
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

For	IN	O
cardiac	JJ	O
resuscitation	NN	O
-	:	O
A	DT	O
dose	NN	O
of	IN	O
0.5	CD	B-DOS
mL	NN	B-UNIT
(	(	O
0.5	CD	B-DOS
mg	NN	B-UNIT
)	)	O
diluted	VBD	O
to	TO	O
10	CD	B-DOS
mL	NN	B-UNIT
with	IN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
can	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
or	CC	O
intracardially	RB	O
to	TO	O
restore	VB	O
myocardial	JJ	O
contrac	NN	O
-	:	O
tility	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
1.25	CD	B-DOS
mg	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
and	CC	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2.5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
depending	VBG	O
on	IN	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	B-DOS
g	NNS	B-UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

1	CD	B-DOS
mg	NN	B-UNIT

For	IN	O
conjunctivitis	NN	O
and	CC	O
other	JJ	O
superficial	JJ	O
ocular	JJ	O
infections	NNS	O
:	:	O
Instill	NNP	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
drops	NNS	B-UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
every	DT	B-FREQ
two	CD	O-FREQ
to	TO	O
three	CD	B-FREQ
hours	NNS	O-FREQ
initially	RB	O
.	.	O

Methyldopa	NNP	O
is	VBZ	O
largely	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
and	CC	O
patients	NNS	B-WHO
with	IN	I-WHO
impaired	JJ	I-WHO
renal	JJ	I-WHO
function	NN	O-WHO
may	MD	O
respond	VB	O
to	TO	O
smaller	JJR	O
doses	NNS	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post	NN	B-WHO
-	:	I-WHO
myocardial	JJ	I-WHO
infarction	NN	I-WHO
patients	NNS	I-WHO
who	WP	I-WHO
have	VBP	I-WHO
shown	VBN	I-WHO
signs	NNS	I-WHO
of	IN	I-WHO
congestive	JJ	I-WHO
heart	NN	I-WHO
failure	NN	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
is	VBZ	O
2.5	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
(	(	O
5	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

Instill	NNP	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
2	CD	O
or	CC	O
3	CD	O
minutes	NNS	O
before	IN	O
removal	NN	O
of	IN	O
stitches	NNS	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	B-WHO
should	MD	O
take	VB	O
a	DT	O
maximum	NN	O
of	IN	O
two	CD	B-DOS
doses	NNS	B-UNIT
of	IN	O
ACTIQ	NNP	O
for	IN	O
any	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
.	.	O

The	DT	O
suggested	JJ	O
amino	NN	O
acid	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
children	NNS	B-WHO
between	IN	I-WHO
4	CD	I-WHO
and	CC	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
is	VBZ	O
2	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
for	IN	O
13	CD	B-WHO
to	TO	I-WHO
15	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
1.7	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
;	:	O
and	CC	O
for	IN	O
16	CD	B-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
above	IN	O-WHO
,	,	O
1.5	CD	B-DOS
g	NN	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
Striant	NNP	O
is	VBZ	O
the	DT	O
application	NN	O
of	IN	O
one	CD	B-DOS
buccal	JJ	B-UNIT
system	NN	O-UNIT
(	(	O
30	CD	B-DOS
mg	NN	B-UNIT
)	)	O
to	TO	O
the	DT	O
gum	JJ	O
region	NN	O
twice	RB	B-FREQ
daily	RB	O-FREQ
;	:	O
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
about	IN	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
.	.	O

Effective	JJ	O
dosage	NN	O
of	IN	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
one	CD	O
patient	NN	O
to	TO	O
another	DT	O
.	.	O

When	WRB	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
given	VBN	O
with	IN	O
antihypertensives	NNS	O
other	JJ	O
than	IN	O
thiazides	NNS	O
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
500	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
;	:	O
when	WRB	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
added	VBN	O
to	TO	O
a	DT	O
thiazide	NN	O
,	,	O
the	DT	O
dosage	NN	O
of	IN	O
thiazide	NN	O
need	MD	O
not	RB	O
be	VB	O
changed	VBN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	B-DOS
,	,	O
40	CD	B-DOS
,	,	O
or	CC	O
60	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Syphilis	NNP	B-WHO
–	VBD	I-WHO
early	JJ	O-WHO
:	:	O
Patients	NNS	B-WHO
who	WP	I-WHO
are	VBP	I-WHO
allergic	JJ	I-WHO
to	TO	I-WHO
penicillin	VB	O-WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
doxycycline	JJ	O
100	CD	B-DOS
mg	NN	B-UNIT
by	IN	O
mouth	NN	O
twice	RB	B-FREQ
-	:	I-FREQ
a	DT	I-FREQ
-	:	I-FREQ
day	NN	O-FREQ
for	IN	O
2	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
0.9	CD	B-DOS
mg	NN	B-UNIT
/	NN	O
kg	NN	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
90	CD	B-DOS
mg	JJ	B-UNIT
total	NN	O
dose	NN	O
)	)	O
,	,	O
with	IN	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
dose	NN	O
administered	VBD	O
as	IN	O
an	DT	O
initial	JJ	O
intravenous	JJ	O
bolus	NN	O
over	IN	O
1	CD	O
minute	NN	O
and	CC	O
the	DT	O
remainder	NN	O
infused	VBD	O
over	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Solutions	NNS	O
containing	VBG	O
3.5	CD	O
to	TO	O
5	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
coinfused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Generally	RB	O
,	,	O
these	DT	O
decrements	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
prednisone	NN	O
or	CC	O
its	PRP$	O
equivalent	NN	O
.	.	O

The	DT	O
recommended	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
of	IN	O
Oxtellar	NNP	O
XR®	NNP	O
is	VBZ	O
1200	CD	B-DOS
mg	NN	B-UNIT
to	TO	O
2400	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
.	.	O

Initial	JJ	O
infusion	NN	O
rates	NNS	O
should	MD	O
be	VB	O
slow	JJ	O
,	,	O
generally	RB	O
20	CD	B-DOS
to	TO	O
30	CD	B-DOS
mL	NNS	B-UNIT
/	JJ	O
hour	NN	O
for	IN	O
the	DT	O
first	JJ	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
CLARINEX	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
Extended	NNP	O
Release	NNP	O
Tablets	NNP	O
is	VBZ	O
1	CD	B-DOS
tablet	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
administered	VBN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
more	RBR	I-WHO
severe	JJ	I-WHO
renal	JJ	I-WHO
impairment	NN	O-WHO
,	,	O
loop	NN	O
diuretics	NNS	O
are	VBP	O
preferred	VBN	O
to	TO	O
thiazides	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
PERFOROMIST	NNP	O
(	(	O
formoterol	VB	O
fumarate	NN	O
)	)	O
Inhalation	NNP	O
Solution	NNP	O
is	VBZ	O
one	CD	B-DOS
20	CD	O-DOS
mcg	NN	B-UNIT
unit	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
administered	VBN	O
twice	RB	B-FREQ
daily	JJ	O-FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
by	IN	O
nebulization	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
a	DT	O
single	JJ	B-DOS
capsule	NN	B-UNIT
should	MD	O
not	RB	O
be	VB	O
divided	VBN	O
.	.	O

Initiate	NNP	O
dosing	NN	O
at	IN	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
1	CD	B-DUR
week	NN	O-DUR
,	,	O
5	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
for	IN	O
the	DT	O
next	JJ	O
3	CD	B-DUR
weeks	NNS	O-DUR
,	,	O
and	CC	O
then	RB	O
increase	VB	O
as	IN	O
tolerated	JJ	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
2	CD	B-DOS
to	TO	O
15	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Dosing	VBG	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
skin	JJ	I-WHO
types	NNS	I-WHO
IV	NNP	O-WHO
,	,	O
V	NNP	O
and	CC	O
VI	NNP	O
may	MD	O
be	VB	O
treated	VBN	O
2	CD	B-FREQ
or	CC	O
3	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
week	NN	O-FREQ
.	.	O

Although	IN	O
nitrogen	NN	O
requirements	NNS	O
may	MD	O
be	VB	O
higher	JJR	O
in	IN	O
severely	RB	B-WHO
hypercatabolic	JJ	I-WHO
or	CC	I-WHO
depleted	JJ	I-WHO
patients	NNS	O-WHO
,	,	O
provision	NN	O
of	IN	O
additional	JJ	O
nitrogen	NN	O
may	MD	O
not	RB	O
be	VB	O
possible	JJ	O
due	JJ	O
to	TO	O
fluid	VB	O
intake	VB	O
limits	NNS	O
,	,	O
nitrogen	NN	O
,	,	O
or	CC	O
glucose	JJ	O
intolerance	NN	O
.	.	O

COVERA	NNP	O
-	:	O
HS	NN	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Silenor	NNP	O
(	(	O
doxepin	JJ	O
tablets	NNS	O
)	)	O
for	IN	O
adults	NNS	B-WHO
is	VBZ	O
6	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
.	.	O

A	DT	O
previously	RB	B-WHO
unvaccinated	JJ	I-WHO
infant	NN	I-WHO
,	,	I-WHO
7	CD	I-WHO
to	TO	I-WHO
11	CD	I-WHO
months	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
,	,	O
should	MD	O
receive	VB	O
as	IN	O
primary	JJ	O
immunizations	NNS	O
,	,	O
two	CD	B-DOS
doses	NNS	B-UNIT
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
at	IN	O
8	CD	B-DUR
-	:	O
week	NN	B-DUR
intervals	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Uncomplicated	VBN	O
urethral	JJ	O
,	,	O
endocervical	JJ	O
or	CC	O
rectal	JJ	O
infections	NNS	O
in	IN	O
adults	NNS	B-WHO
caused	VBN	O
by	IN	O
Chlamydiatrachomatis	NN	O
:	:	O
500	CD	B-DOS
mg	NN	B-UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
four	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
for	IN	O
at	IN	B-DUR
least	JJS	I-DUR
seven	CD	I-DUR
days	NNS	O-DUR
.	.	O

Initial	JJ	O
dose	NN	O
:	:	O
Give	VB	O
0.05	CD	B-DOS
to	TO	O
0.1	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
as	IN	O
a	DT	O
rapid	JJ	O
IV	NNP	O
bolus	NN	O
given	VBN	O
either	CC	O
centrally	RB	O
or	CC	O
peripherally	RB	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
and	CC	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
either	DT	O
2	CD	B-DOS
or	CC	O
3	CD	B-DOS
equally	RB	B-UNIT
-	:	O
divided	VBN	I-UNIT
doses	NNS	O-UNIT
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
.	.	O

0.14	CD	B-DOS
(	(	O
mg	NN	B-UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
)	)	O
x	FW	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
/	FW	O
Adenoscan	JJ	O
concentration	NN	O
(	(	O
3mg	CD	B-DOS
/	NNP	O
mL	NN	O
)	)	O
=	VBZ	O
Infusion	NNP	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
min	NN	O
)	)	O

Nonprotein	NNP	O
calories	NNS	O
should	MD	O
constitute	VB	O
approximately	RB	O
100	CD	O
to	TO	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

An	DT	O
example	NN	O
of	IN	O
a	DT	O
5	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
week	NN	O-FREQ
application	NN	O
schedule	NN	O
is	VBZ	O
to	TO	O
apply	VB	O
Aldara	NNP	O
Cream	NNP	O
,	,	O
once	RB	B-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
,	,	O
Monday	NNP	O
through	IN	O
Friday	NNP	O
.	.	O

Atralin	NNP	O
Gel	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
,	,	O
before	IN	O
bedtime	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
a	DT	O
thin	JJ	O
layer	NN	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
.	.	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1.5	CD	B-DOS
Joules	NNS	B-UNIT
/	JJ	O
cm²	NN	B-UNIT
at	IN	O
each	DT	O
treatment	NN	O
unless	IN	O
erythema	NN	O
occurs	NNS	O
.	.	O

This	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

Therefore	RB	O
,	,	O
ACCURETIC	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
.	.	O

In	IN	O
children	NNS	B-WHO
with	IN	I-WHO
ADHD	NNP	I-WHO
who	WP	I-WHO
are	VBP	I-WHO
6	CD	I-WHO
-	:	I-WHO
12	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
and	CC	I-WHO
are	VBP	I-WHO
either	DT	I-WHO
starting	VBG	I-WHO
treatment	NN	I-WHO
for	IN	I-WHO
the	DT	I-WHO
first	JJ	I-WHO
time	NN	I-WHO
or	CC	I-WHO
switching	VBG	I-WHO
from	IN	I-WHO
another	DT	I-WHO
medication	NN	O-WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
once	RB	B-FREQ
daily	RB	O-FREQ
in	IN	O
the	DT	O
morning	NN	O
;	:	O
daily	JJ	B-FREQ
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	B-DOS
mg	NNS	B-UNIT
or	CC	O
10	CD	B-DOS
mg	NN	B-UNIT
at	IN	O
weekly	JJ	B-FREQ
intervals	NNS	O-FREQ
.	.	O

Calculate	VB	O
the	DT	O
amount	NN	O
of	IN	O
reconstituted	VBN	O
(	(	O
4	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
)	)	O
AmBisome	NNP	O
to	TO	O
be	VB	O
further	RB	O
diluted	VBN	O
.	.	O

0	CD	B-DOS

Adjust	NNP	O
dose	NN	O
at	IN	O
2	CD	B-DUR
week	NN	O-DUR
intervals	NNS	O
as	IN	O
needed	VBN	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	B-DOS
to	TO	O
15	CD	B-DOS
ng	NNS	B-UNIT
/	JJ	O
mL	JJ	O
[	NNP	O
see	VBP	O
Therapeutic	JJ	O
Drug	NNP	O
Monitoring	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
and	CC	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	B-DOS
mg	NN	B-UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	B-DOS
mg	NN	B-UNIT
every	DT	B-FREQ
12	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	B-DOS
mg	JJ	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
in	IN	O
these	DT	B-WHO
patients	NNS	O-WHO
is	VBZ	O
6.25	CD	B-DOS
mg	NN	B-UNIT
once	RB	B-FREQ
daily	JJ	O-FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
FAMVIR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
herpes	NNS	O
labialis	NN	O
is	VBZ	O
1500	CD	B-DOS
mg	NN	B-UNIT
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
.	.	O

Geriatric	JJ	B-WHO
patients	NNS	O-WHO
may	MD	O
require	VB	O
reduced	JJ	O
doses	NNS	O
of	IN	O
etomidate	NN	O
.	.	O

In	IN	O
patients	NNS	B-WHO
taking	VBG	I-WHO
cyclosporin	JJ	I-WHO
concomitantly	RB	I-WHO
with	IN	I-WHO
ALTOCOR™	NNP	O-WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
of	IN	O
ALTOCOR™	NNP	O
(	(	O
lovastatin	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
.	.	O

Aminosyn	RB	O
7	CD	O
%	NN	O
,	,	O
8.5	CD	O
%	NN	O
or	CC	O
10	CD	O
%	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
sterile	JJ	O
water	NN	O
for	IN	O
injection	NN	O
or	CC	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
achieve	VB	O
a	DT	O
final	JJ	O
amino	NN	O
acid	JJ	O
concentration	NN	O
of	IN	O
3.5	CD	O
,	,	O
4.25	CD	O
or	CC	O
5	CD	O
%	NN	O
for	IN	O
peripheral	JJ	O
administration	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	B-WHO
oral	JJ	O
dose	NN	O
is	VBZ	O
1	CD	B-DOS
gram	NN	B-UNIT
AMOXIL	NNP	O
and	CC	O
30	CD	B-DOS
mg	NN	B-UNIT
lansoprazole	NN	O
,	,	O
each	DT	O
given	VBN	O
three	CD	B-FREQ
times	NNS	I-FREQ
daily	RB	O-FREQ
(	(	O
every	DT	B-FREQ
8	CD	I-FREQ
hours	NNS	O-FREQ
)	)	O
for	IN	O
14	CD	B-DUR
days	NNS	O-DUR
.	.	O

Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	B-DUR
hours	NNS	O-DUR
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	B-DOS
and	CC	O
5	CD	B-DOS
mg	NN	B-UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

For	IN	O
adults	NNS	B-WHO
(	(	I-WHO
≥	JJ	I-WHO
16	CD	I-WHO
years	NNS	I-WHO
of	IN	I-WHO
age	NN	I-WHO
)	)	O-WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	B-DOS
mCi	NN	B-UNIT
(	(	O
370	CD	B-DOS
MBq	NNP	B-UNIT
)	)	O
[	VBD	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

For	IN	O
Control	NNP	O
of	IN	O
Hypertension	NNP	O
:	:	O
The	DT	B-WHO
adult	NN	O-WHO
initial	JJ	O
dose	NN	O
of	IN	O
MICROZIDE	NNP	O
(	(	O
hydrochlorothiazide	JJ	O
capsule	NN	O
)	)	O
is	VBZ	O
one	CD	B-DOS
capsule	NN	B-UNIT
given	VBN	O
once	RB	B-FREQ
daily	JJ	O-FREQ
whether	IN	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensives	NNS	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	B-FREQ
maintenance	NN	O
dose	NN	O
of	IN	O
PURINETHOL	NNP	O
is	VBZ	O
1.5	CD	B-DOS
to	TO	O
2.5	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	JJ	O
/	JJ	B-FREQ
day	NN	O-FREQ
as	IN	O
a	DT	O
single	JJ	B-DOS
dose	NN	B-UNIT
.	.	O

As	IN	O
an	DT	O
example	NN	O
of	IN	O
the	DT	O
preparation	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfentanil	NN	O
)	)	O
for	IN	O
infusion	NN	O
,	,	O
20	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
added	VBD	O
to	TO	O
230	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
diluent	NN	O
provides	VBZ	O
40	CD	B-DOS
mcg	NN	B-UNIT
/	NNP	O
mL	NNP	O
solution	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
.	.	O

5	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
400	CD	B-DOS
mg	NN	B-UNIT
:	:	O
The	DT	O
usual	JJ	O
adult	NN	B-WHO
dose	NN	O
is	VBZ	O
one	CD	B-DOS
or	CC	O
two	CD	B-DOS
tablets	NNS	B-UNIT
every	DT	B-FREQ
four	CD	O-FREQ
to	TO	O
six	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Adults	NNS	B-WHO
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
2	CD	B-DOS
inhalations	NNS	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	B-FREQ
dose	NN	O
of	IN	O
1	CD	B-DOS
mg	NN	B-UNIT
.	.	O

Clinical	JJ	O
studies	NNS	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
infusion	NN	O
have	VBP	O
been	VBN	O
conducted	VBN	O
with	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
diluted	VBD	O
to	TO	O
a	DT	O
concentration	NN	O
range	NN	O
of	IN	O
25	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
mL	NN	O
to	TO	O
80	CD	B-DOS
mcg	NNS	B-UNIT
/	JJ	O
mL	NN	O
.	.	O

Osserman	NNP	O
and	CC	O
Takatsuki	NNP	O
have	VBP	O
used	VBN	O
an	DT	O
initial	JJ	O
course	NN	O
of	IN	O
10	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	B-FREQ
day	NN	O-FREQ
for	IN	O
7	CD	B-DUR
to	TO	O
10	CD	B-DUR
days	NNS	O-DUR
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
can	MD	O
vary	VB	O
from	IN	O
as	RB	O
much	JJ	O
as	IN	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
to	TO	O
as	RB	O
little	JJ	O
as	IN	O
1	CD	B-DOS
or	CC	O
2	CD	B-DOS
drops	NNS	B-UNIT
twice	RB	B-FREQ
a	DT	I-FREQ
week	NN	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	B-DOS
-	:	O
60	CD	B-DOS
mg	JJ	B-UNIT
/	NNP	B-FREQ
day	NN	O-FREQ
,	,	O
in	IN	O
single	JJ	B-DOS
doses	NNS	B-UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

A	DT	O
lower	JJR	O
starting	VBG	O
dose	NN	O
of	IN	O
2.5	CD	B-DOS
mg	JJ	B-UNIT
two	CD	B-FREQ
or	CC	O
three	CD	B-FREQ
times	NNS	I-FREQ
a	DT	I-FREQ
day	NN	O-FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
frail	NN	B-WHO
elderly	RB	O-WHO
.	.	O

Patients	NNS	B-WHO
with	IN	I-WHO
creatinine	JJ	I-WHO
clearance	NN	O-WHO
between	IN	O
10	CD	B-DOS
and	CC	O
49	CD	B-DOS
ml	NN	B-UNIT
/	NNP	O
min	NN	O
may	MD	O
be	VB	O
given	VBN	O
half	NN	O
of	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
at	IN	O
the	DT	O
usual	JJ	O
dosage	NN	O
interval	NN	O
,	,	O
or	CC	O
the	DT	O
normal	JJ	O
recommended	VBD	O
dose	NN	O
at	IN	O
twice	RB	O
the	DT	O
usual	JJ	O
dosage	NN	O
interval	NN	O
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	O
duration	NN	O
of	IN	O
Soma	NNP	O
Compound	NNP	O
(	(	O
carisoprodol	NN	O
and	CC	O
aspirin	NN	O
)	)	O
use	NN	O
is	VBZ	O
up	RP	O
to	TO	O
two	CD	B-DUR
or	CC	O
three	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

Two	CD	B-DOS
to	TO	O
four	CD	B-DOS
mL	NN	B-UNIT
of	IN	O
Ethiodol	NNP	O
(	(	O
ethiodized	VBN	O
oil	NN	O
)	)	O
injected	VBD	O
into	IN	O
the	DT	O
upper	JJ	O
extremity	NN	O
will	MD	O
suffice	VB	O
to	TO	O
demonstrate	VB	O
the	DT	O
axillary	JJ	O
and	CC	O
supraclavicular	JJ	O
nodes	NNS	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
40	CD	B-DOS
to	TO	O
120	CD	B-DOS
mg	NNS	B-UNIT
per	IN	B-FREQ
day	NN	O-FREQ
.	.	O

Control	NN	O
of	IN	O
pain	NN	O
can	MD	O
be	VB	O
maintained	VBN	O
in	IN	O
most	JJS	B-WHO
patients	NNS	O-WHO
with	IN	O
400	CD	B-DOS
to	TO	O
800	CD	B-DOS
mg	NNS	B-UNIT
daily	RB	B-FREQ
.	.	O

The	DT	O
maximum	JJ	B-FREQ
daily	JJ	O-FREQ
dose	NN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
was	VBD	O
45	CD	B-DOS
mcg	NN	B-UNIT
(	(	O
5	CD	B-DOS
mcg	RB	B-UNIT
9	CD	B-FREQ
times	NNS	I-FREQ
per	IN	I-FREQ
day	NN	O-FREQ
)	)	O
.	.	O

Limited	JJ	O
storage	NN	O
periods	NNS	O
at	IN	O
15°	CD	O
to	TO	O
30°C	CD	O
(	(	O
59°	CD	O
to	TO	O
86°F	CD	O
)	)	O
are	VBP	O
acceptable	JJ	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
hypogammaglobulinemia	NN	O-WHO
and	CC	O
/	NN	O
or	CC	O
recurrent	JJ	O
bacterial	JJ	O
infections	NNS	O
due	JJ	O
to	TO	O
B	NNP	O
-	:	O
cell	NN	O
Chronic	NNP	O
Lymphocytic	NNP	O
Leukemia	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
400	CD	B-DOS
mg	NNS	B-UNIT
/	JJ	O
kg	NN	O
every	DT	B-FREQ
3	CD	O-FREQ
to	TO	O
4	CD	B-FREQ
weeks	NNS	O-FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

Because	IN	O
steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
concentrations	NNS	O
are	VBP	O
approximated	VBN	O
in	IN	O
1	CD	B-DUR
day	NN	O-DUR
,	,	O
ARYMO	NNP	O
ER	NNP	O
dosage	NN	O
adjustments	NNS	O
may	MD	O
be	VB	O
done	VBN	O
every	DT	B-FREQ
1	CD	O-FREQ
to	TO	O
2	CD	B-FREQ
days	NNS	O-FREQ
.	.	O

10	CD	B-DOS
mg	NN	B-UNIT
/	VBD	O
400	CD	B-DOS
mg	NN	B-UNIT
:	:	O
The	DT	O
usual	JJ	O
adult	NN	B-WHO
dosage	NN	O
is	VBZ	O
one	CD	B-DOS
tablet	NN	B-UNIT
every	DT	B-FREQ
four	CD	O-FREQ
to	TO	O
six	CD	B-FREQ
hours	NNS	O-FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

They	PRP	O
report	VBP	O
that	IN	O
maximal	JJ	O
suppression	NN	O
of	IN	O
the	DT	O
leukocyte	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
occurs	VBZ	O
within	IN	O
3	CD	B-DUR
to	TO	O
5	CD	B-DUR
weeks	NNS	O-DUR
and	CC	O
recovery	NN	O
within	IN	O
4	CD	B-DUR
to	TO	O
8	CD	B-DUR
weeks	NNS	O-DUR
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	B-DOS
to	TO	O
250	CD	B-DOS
grams	NNS	B-UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	B-DOS
mL	NN	B-UNIT
,	,	O
administered	VBN	O
from	IN	O
containers	NNS	O
containing	VBG	O
250	CD	B-DOS
or	CC	O
500	CD	B-DOS
mL	NN	B-UNIT
.	.	O

Thereafter	RB	O
,	,	O
schedule	NN	O
injections	NNS	O
every	DT	B-FREQ
6	CD	I-FREQ
months	NNS	O-FREQ
from	IN	O
the	DT	O
date	NN	O
of	IN	O
the	DT	O
last	JJ	O
injection	NN	O
.	.	O

For	IN	O
patients	NNS	B-WHO
with	IN	I-WHO
a	DT	I-WHO
first	JJ	I-WHO
episode	NN	I-WHO
of	IN	I-WHO
idiopathic	JJ	I-WHO
DVT	NNP	O-WHO
or	CC	O
PE	NNP	O
,	,	O
warfarin	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
at	IN	O
least	JJS	O
6	CD	B-DUR
to	TO	O
12	CD	B-DUR
months	NNS	O-DUR
.	.	O

This	DT	O
medication	NN	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	B-FREQ
every	DT	I-FREQ
3	CD	I-FREQ
months	NNS	O-FREQ
.	.	O

Haloperidol	NNP	O
decanoate	NN	O
is	VBZ	O
usually	RB	O
administered	VBN	O
monthly	RB	O
or	CC	O
every	DT	B-FREQ
4	CD	I-FREQ
weeks	NNS	O-FREQ
.	.	O

Retreatment	NN	O
with	IN	O
XEOMIN	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	B-FREQ
three	CD	I-FREQ
months	NNS	O-FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	B-WHO
,	,	O
following	VBG	O
an	DT	O
8	CD	B-DUR
week	NN	O-DUR
course	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
treatment	NN	O
for	IN	O
active	JJ	O
disease	NN	O
and	CC	O
once	RB	O
the	DT	O
patient	NN	O
’	NNP	O
s	NN	O
symptoms	NNS	O
are	VBP	O
controlled	VBN	O
(	(	O
CDAI	NNP	O
less	JJR	O
than	IN	O
150	CD	O
)	)	O
,	,	O
is	VBZ	O
ENTOCORT	NNP	O
EC	NNP	O
6	CD	B-DOS
mg	NN	B-UNIT
orally	RB	O
once	RB	B-FREQ
daily	JJ	O-FREQ
for	IN	O
maintenance	NN	O
of	IN	O
clinical	JJ	O
remission	NN	O
up	RB	B-DUR
to	TO	I-DUR
3	CD	I-DUR
months	NNS	O-DUR
.	.	O

Monitor	NNP	O
hemoglobin	NN	O
levels	NNS	O
at	IN	O
least	JJS	O
every	DT	B-FREQ
2	CD	I-FREQ
weeks	NNS	O-FREQ
until	IN	O
stable	JJ	O
,	,	O
then	RB	O
monitor	NN	O
at	IN	O
least	JJS	O
monthly	JJ	O
.	.	O

An	DT	O
infant	JJ	B-WHO
2	CD	I-WHO
to	TO	I-WHO
10	CD	I-WHO
months	NNS	I-WHO
of	IN	I-WHO
age	NN	O-WHO
should	MD	O
receive	VB	O
three	CD	B-DOS
doses	NNS	B-UNIT
of	IN	O
a	DT	O
product	NN	O
containing	VBG	O
PRP	NNP	O
-	:	O
OMPC	NN	O
.	.	O

Periostat®	NNP	O
(	(	O
doxycycline	JJ	O
hyclate	NN	O
)	)	O
20	CD	B-DOS
mg	JJ	B-UNIT
twice	RB	B-FREQ
daily	RB	O-FREQ
as	IN	O
an	DT	O
adjunct	NN	O
following	VBG	O
scaling	NN	O
and	CC	O
root	NN	O
planing	NN	O
may	MD	O
be	VB	O
administered	VBN	O
for	IN	O
up	IN	B-DUR
to	TO	I-DUR
9	CD	I-DUR
months	NNS	O-DUR
.	.	O

Pigmentation	NN	O
may	MD	O
begin	VB	O
after	IN	O
a	DT	B-DUR
few	JJ	I-DUR
weeks	NNS	O-DUR
but	CC	O
significant	JJ	O
repigmentation	NN	O
may	MD	O
require	VB	O
6	CD	O
to	TO	O
9	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Prolia	NNP	O
is	VBZ	O
60	CD	B-DOS
mg	NN	B-UNIT
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	B-DOS
subcutaneous	JJ	B-UNIT
injection	NN	O-UNIT
once	RB	B-FREQ
every	DT	I-FREQ
6	CD	I-FREQ
months	NNS	O-FREQ
.	.	O
